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i 
Abstract 
Cell salvage involves the recycling of a patient’s own blood shed during or after an 
operation. The procedure is mainly used in the specialties of orthopaedics, cardiac 
and obstetrics where high volumes of blood loss are expected. The cell salvage 
process can therefore obviate the need for a patient to require a blood transfusion 
using donated (allogeneic) blood. 
This thesis examines the cost impacts of cell salvage on overall NHS costs in 
primary total hip replacement surgery. It compares data for three hospital sites in 
England; one an extensive user of cell salvage and two sites that do not utilise cell 
salvage. The thesis adopts a novel approach in sub-dividing the activity into HRGs 
(Healthcare Resource Groups) and considers the related allogeneic blood and cell 
salvage costs from both a financial and an economic perspective. The thesis 
concludes that recent procedural changes and the adoption of published blood 
management guidance can reduce the need for a patient to require an allogeneic 
blood transfusion. These changes render both intra-operative and post-operative cell 
salvage unnecessary to support most primary total hip replacement operations. 
This thesis recommends further comparative studies in surgery that are associated 
with higher potential blood loss to assess the financial and economic impacts of 
intra-operative cell salvage in a less predictable operating environment. 
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Chapter 1. Introduction and Background 
1.1 Introduction 
Cell salvage is a surgical technique whereby a patient’s shed blood is collected using 
a drainage system during or after an operation. The blood is then filtered, and the 
blood cells washed to remove debris. The filtered blood is then reinfused into the 
patient. It is claimed (e.g. Waters et al (2007) and Carless et al (2010)) that utilising 
cell salvage will reduce the need for a patient to have a blood transfusion using 
donated (allogeneic) blood from a blood donor. A transfusion using a patient’s own 
blood is termed an ‘autologous transfusion’; this term is often shortened to 
‘autotransfusion’ in the US. 
This chapter will: 
• Introduce the technique of utilising allogeneic blood transfusions and outline 
their use and application; 
• Introduce the differing interpretations of costs associated with allogeneic 
blood from a financial and economic perspective; 
• Describe the role of NHS Blood & Transplant (NHSBT) and its predecessor 
organisations in the development of the blood transfusion service, primarily 
in England; 
• Outline the English healthcare financial tariff system and the impact of the 
internal market for allogeneic blood on the hospital blood costs; 
• Highlight the potential alternatives to allogeneic blood transfusions and their 
development and support across the National Health Service (NHS) along 
with other allogeneic blood avoiding techniques; 
• Introduce the technique of cell salvage, its development and application in the 
total hip replacement surgery environment. 
 
2 
1.2 Challenges of Cell Salvage as Subject to Analyse 
The researcher’s background is as a Chartered Public Finance Accountant who 
has worked in a number of London hospitals as a management accountant and, 
from 1998 to 2013, in various roles at NHSBT. Until 2017 he was also a regular 
blood donor and saw at first hand the changes in the blood donor environment 
since first donating blood in 1980. In the early 1980s, a clinician (doctor or 
nurse) had to be present at a blood donation session. By the early 2000s only a 
registered phlebotomist needed to be present to insert the needle to draw the 
donor’s blood. 
Managing the finances of the blood bank budgets in two hospitals gave the 
researcher an insight into issues such as stock management of allogeneic blood 
and the costs associated with its use. It was not until the researcher joined 
NHSBT in 1998 that he became aware that ways of avoiding a transfusion were 
possible. The national directive ‘Better Blood Transfusion’ (BBT1) had recently 
been published (para 1.11) which recommended that cell salvage be considered 
and adopted by individual Hospital Transfusion Committees (HTCs).  The 
researcher then began to think through and discuss the potential financial impacts 
of cell salvage from differing NHS backgrounds. In April 1999 the NHSBT 
charge for an allogeneic unit was virtually doubled to around £80 per unit; 
reflecting the cost of rolling out leucodepletion (the removal of the white cells 
from donated blood, para 1.14). The discussions with clinicians included the 
significant potential savings that could accrue to hospitals from avoiding an 
allogeneic transfusion. These discussions held a resonance with the researcher 
who saw the ‘text book’ ideas of internal charging mechanisms he had learned 
while training for his accountancy exams. There was, however, a wider public-
sector dimension with NHSBT effectively levying an internal charge that also 
included transfer prices such as VAT and national insurance. There were 
additionally costs that donors incurred and potential costs to the wider society by 
loss of productive time that the donor would generate by donating blood. The 
donors would also derive satisfaction of providing a ‘gift of life’; this element 
was also relevant and needed to be included in the discussions. 
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This combination of potentially competing interests within the NHS and the 
wider society sparked the researcher’s interest and it was clear that there were 
competing approaches from both a financial and economic perspective. Given he 
had a young family around 2000/2001 it was several years before he could 
devote sufficient time to pursuing this interest in investigating the issues in depth. 
1.3 Approach to Studying Cell Salvage 
The researcher had been involved in rudimentary specialty costing analysis work 
in his time as a management accountant up to 1998 and kept in touch with 
developments via his continuing professional development programme. In 2004 a 
Cochrane Review (Carless et al (2004)) noted the level of bias in most of the 
published reviews on cell salvage. The researcher felt that a study with more 
academic rigour would circumvent the challenges and perceptions of bias that 
Carless et al (2004) highlighted. This, in turn, would lead to additional credibility 
and a wider debate. 
The researcher also felt that the financial discussions around the costs of cell 
salvage were too narrow and felt it would be advantageous to approach the 
costing work from a fresh angle. Healthcare Resource Groups (HRGs-a measure 
of classifying procedures into groups requiring similar levels of resource input) 
had been rolled out across NHS trusts as part of the English NHS tariff-based 
system. The researcher felt that HRG information could be utilised to minimise 
the allegations of selection bias and add more confidence on homogeneity and 
cross hospital comparison. This comparison had not been undertaken previously 
in any study on cell salvage.  
Academic support was required, as the researcher felt his background as an 
accountant would need a health economics input. He felt that a project to 
understand the costs of cell salvage across the NHS would bring new knowledge 
to allow a wider debate and support the understanding of its impact in a wider, 
rather than local hospital-based, setting. The academic support would be a base 
for the extensive collaborative research and information gathering that would be 
required. NHSBT and the hospital trusts focus on financial issues relating to 
blood (both allogeneic and salvaged) from a resource perspective, rather than 
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from a wider economic perspective. The study therefore needed to encapsulate 
both interpretations in order to address the challenges from both a professional 
accounting and an academic perspective. 
Cell salvage was an area that was indirectly related to the researcher’s day job 
and, at the time of commencement (2008), the vast majority of discussion 
favoured the roll out of cell salvage programmes. An academic study from a new 
and wider angle therefore seemed opportune. 
1.4 Allogeneic Blood and Blood Transfusions 
Blood comprises several components. The main components, according to the 
Department of Health (DH) website ‘NHS Choices’ (accessed 27 March 2014), are: 
• Red Cells. Red cells transport oxygen around the body and prevent the patient 
becoming anaemic; this is where oxygen levels are depleted, slowing down 
the function of the various organs. 
• Platelets. Platelets are blood cells that work to ensuring there is sufficient 
clotting of the blood when a patient is bleeding. Increasingly platelets are 
collected by a specific donation process known as ‘apheresis’. The alternative 
is for ‘pooled platelets’ where, on average, four blood donations will have the 
platelets extracted to form one adult therapeutic dose of platelets. 
• Plasma. Plasma is mainly water carrying proteins, electrolytes and other 
clotting agents. 
• White cells. White cells are cells of the immune system, used to fight 
infections. Following research into variant Creutzfeldt–Jakob disease (vCJD) 
in the late 1990s, the white cells are now removed from allogeneic blood. 
This process, known as leucodepletion, contributed significantly to the 
increased costs of blood collection and processing from 1998. 
An ‘average adult’ will have approximately 5.0 litres of blood circulating in their 
body. This will vary according to the person’s weight/size. In the UK, a typical blood 
donation requires around 470 mls of blood being taken. Information material 
produced for blood donors in the UK highlights that the maximum amount of blood 
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donated will be 13% of circulating blood by volume (see ‘How the Body Replaces 
Blood’ on www.blood.co.uk accessed 28 Oct 2014). 
The prime reason for an allogeneic blood transfusion during and after surgery is to 
treat anaemia (NHS Choices website accessed 27 March 2014), resulting from 
insufficient oxygen carrying red cells circulating in the body. Anaemia can be caused 
by blood loss (this is the main reason in the surgical environment), a medical 
condition such as various types of cancers, or a specific condition such as sickle cell 
anaemia. 
There are also a number of other issues that relate to infections such as malaria or a 
toxin overload such as alcohol poisoning that can be treated with an allogeneic blood 
transfusion. 
There is an ethical issue in attempting to assess the effectiveness of allogeneic blood 
as no clinician would wish to refuse a transfusion of allogeneic blood to a sick 
patient to make the comparison of benefits from having/not having an allogeneic 
transfusion. Beliaev et al (2011) circumvented this issue by undertaking a 
retrospective study comparing the outcomes of 103 Jehovah’s Witness (JW) patients 
who refused allogeneic transfusions against the same number of patients who had 
received transfusions. The authors concluded that, inter alia, mortality was reduced 
by 94% with an allogeneic transfusion. The authors stressed that the study was not a 
randomised control trial (RCT) but highlighted that “it would be unethical to conduct 
a(n) RCT in patients with severe anaemia to investigate an effect of (allogeneic) 
transfusion(s) on mortality”. The relationship between transfused blood and 
treatment of anaemia is therefore not disputed. 
Blood donor recruitment campaigns around the world highlight that blood donation, 
along with organ donation, is ‘the gift of life’ (US Red Cross website 
http://www.redcross.org/what-we-do/blood-donation accessed 28 Oct 2014). In a 
medical environment, this is true as there is no alternative to allogeneic blood. An 
article in the Guardian newspaper by James Meikle (24 May 2013) on permanent 
blood donation clinics sums this up succinctly by quoting the NHSBT Medical 
Director saying, “We expect to see an increase in demand for blood over the next 10 
years as a result of an ageing population requiring more complex procedures such as 
joint replacements and cancer therapies”. There are no alternatives for a cancer 
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patient who requires an allogeneic blood transfusion; however, there are techniques 
available to minimise allogeneic blood transfusions in joint replacements. 
NHSBT is responsible for the collection, processing, testing, storage and issue of 
allogeneic blood and related components in England. It is one of the few remaining 
Special Health Authorities following several reorganisations across the English NHS. 
1.5 World Health Organisation Resolution on Allogeneic Blood 
The World Health Organisation WHO 63.12 (2010) Adopted Resolution urges 
member states to establish and maintain the capacity, safety and quality of donated 
blood products. It also stresses member states should “promote the availability of 
transfusion alternatives including, where appropriate, autologous transfusion and 
patient blood management”. The directive additionally stresses that “before surgery 
every reasonable measure should be taken to minimise the patient’s blood loss and to 
harness and optimise the patient-specific physiological tolerance of anaemia”. The 
report effectively views the provision of allogeneic blood and avoidance techniques 
as equal responses to the management of anaemia during and after surgery. 
The issues behind this overarching statement by the WHO Adopted Resolution will 
be covered in this introductory chapter. 
1.6 Allogeneic Blood Journey – From Donor to Patient 
The journey ‘from vein to vein’; from donor to patient, is shown in figure 1 below. 
When a donor donates, his/her blood is drained into a PVC bag. This has a built-in 
filter with tubing leading to a second bag. When the filter is activated at the 
processing centre, the blood will filter into the second bag. Both bags will have a 
unique bar code identifying the donor. All this is linked to NHSBT’s PULSE IT and 
blood tracking system. 
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Figure 1. The Allogeneic Blood Journey 
 
NHSBT relies on a complex logistical infrastructure to transport the allogeneic blood 
around the country. In the Birmingham area, for example, the allogeneic blood is 
collected from the various sessions in cool boxes and taken to a stock holding unit in 
Edgbaston, South Birmingham, where the blood is then stored, awaiting additional 
blood from other sessions in, for instance, Coventry. Once all deliveries have been 
received, the blood (up to 500 units) is transported in a refrigerated container lorry to 
the Filton Blood Centre, near Bristol. This may be between 3.00 a.m. to 5.00 a.m. in 
the morning following the day of the donations. The blood bags then enter the 
production cycle, which commences by draining the blood into a separate blood bag 
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and using a centrifuge to separate the contents into its constituent elements. The 
associated test tube samples will be tested by automated analysers. In the event of 
any positive test result or irregularity arising the blood bag can be isolated in the 
quarantine area while further tests on the samples are undertaken. 
Throughout the cycle the blood is never exposed to the atmosphere, ensuring it 
maintains the required ‘shelf life’ of up to 35 days (NHSBT website accessed 28 
October 2014). The process is now highly automated and the recent NHSBT strategy 
has been to focus the processing and testing functions at Manchester, Filton and 
Colindale in North London. Testing functions (using the three test tubes) can be 
undertaken separately from the processing functions and the NHSBT contingency 
plans allow testing to be undertaken additionally at Newcastle and Sheffield if 
required. 
Once an allogeneic unit has passed through the process described in figure 1 the 
majority remains in stock at one of the three main NHSBT centres (Filton, Colindale 
or Manchester). Further stocks are dispatched to satellite centres such as Cambridge, 
Sheffield and Plymouth. The rationale being that no English hospital is more than 
two hours’ drive from a stockholding of allogeneic blood. 
1.7 Disadvantages of Allogeneic Blood Transfusions 
An allogeneic blood transfusion is still a foreign body entering a patient. There is 
never a perfect blood match. Various ‘foreign’ antibodies will be absorbed by a 
patient who has recently undergone surgery and allergic reactions can develop (see 
the American Cancer Society www.cancer.org website, accessed 28 October 2014). A 
BBC report entitled ‘Blood Donors ‘Passing on Hepatitis E’’ (28 July 2014) 
highlighted a study in the Lancet that reported 1 in 3,000 blood donations were 
contaminated with the Hepatitis E virus (HEV). While HEV is not a life-threatening 
condition it would not, however, support a patient’s speedy recovery if s/he received 
a contaminated donation. The British Liver Trust website www.britishlivertrust.org 
(accessed 13 Aug 2014) noted that the impact of HEV is relatively mild unless the 
patient has a pre-existing liver problem or is pregnant. 
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Cost is cited as a disadvantage. An allogeneic unit was priced at £122 in 2017/18 
with the median usage for an NHS hospital being around 6,000 units in a year. The 
split is approximately 2:1 for medical use of allogeneic blood over surgical 
requirements (see para 1.10).  
There is always the risk of matching an allogeneic unit with the wrong patient and 
invoking adverse reactions through incompatible blood; this is classed as an NHS 
‘never event’. The Serious Hazards of Transfusion (SHOT) report for 2012 reported 
the relative risks of major morbidity as being 46.5 per million of blood components 
issued. The corresponding figure for mortality was 3.1 per million components used. 
Additionally, there is also still the theoretical risk of vCJD noted in the SHOT report 
and the cost associated with the removal of the white cells from allogeneic blood 
through the leucodepletion process (para 1.4); the indications are that the white cells 
are the carriers of vCJD. The theoretical risk remains even after the implementation 
of the leucodepletion process. 
Nearly every country in the world has at least one organisation responsible for the 
collection of allogeneic blood from donors. Not widely publicised is the fact that 
many countries will refuse to accept blood from donors who have lived in the UK for 
a period between 1980 and 1996. This is due to the potential risk that donors are still 
incubating vCJD. Restrictions vary from country to country. The Republic of Ireland, 
for instance, refuses donations from anyone who has lived for more than one year in 
the UK (see www.giveblood.ie/become_a_donor, accessed 18 March 2017). 
Australia and New Zealand are even more restrictive: potential donors are refused if 
they have spent over six months at any time living in the UK, France or the Republic 
of Ireland (see www.nzblood.co.nz/give_blood and www.donateblood.com.au, 
accessed 18 March 2017). While there is still no test to detect whether a donor is 
incubating vCJD the avoidance of an allogeneic transfusion would prevent any 
potential spread. 
Although shortages of allogeneic blood are now rare, there is still a risk that they 
might occur. In periods of lower demand, e.g. around Christmas and the summer 
holiday season, the average age of the allogeneic blood issued to hospitals will tend 
to be older as stocks are run down more slowly. Older blood will have depleted more 
oxygen than fresher allogeneic blood. Some studies have shown (e.g. Sanders et al 
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(2011)) that there is a strong correlation between older blood (defined in the study as 
over 14 days old) and longer post-operative length of stay. NHSBT ensures the blood 
issued to hospitals is significantly below the 35-day threshold. As a result of the 
recent investments in infrastructure and stock management systems, the issued blood 
is rarely over 14 days old. The exact age of the blood issued will vary in relation to 
stock levels and current demand. Stock levels were published weekly on 
www.blood.co.uk with a key performance indicator being the number of days of 
stock of each blood type held. In February 2015, the average stock level for O+ and 
A+ (the two most common types covering two-thirds of the population) was just 
under seven days. This information is now not regularly available on the National 
Blood Service website since the level of public interest in national stocks of 
allogeneic blood has waned.  
More recently Waters (2013) has highlighted that more emphasis should be placed on 
the patient’s bleeding rather than the allogeneic transfusion. His editorial in the US 
publication ‘Transfusion’ noted that recent evidence is “…showing that many 
(allogeneic) transfusions provide no benefit to the recipient”. Older, more ill, patients 
will require more transfused blood as they cannot withstand blood loss as effectively 
as younger, fitter patients. The implication, according to Waters (2013), is that the 
blood loss may be the main contributor to an increased length of stay, rather than the 
allogeneic transfusion given. 
An article in the British Medical Journal, Goodnough and Murphy (2014) 
commented similarly to Waters (2013), noting 48% of hip replacement patients were 
inappropriately transfused in 2007. This is consistent with a survey at the 
Gloucestershire Hospitals NHS Foundation Trust (Joy and Bennet (2012)) that 
recorded the corresponding figure at 46%. These studies effectively questioned the 
requirement for a high proportion of surgical blood transfusions. The disadvantage 
lies in the associated cost of the unnecessary allogeneic blood transfused. 
1.8 History of Blood Transfusions 
This section will briefly outline the development of blood transfusions over the past 
century and examine the changing trends in blood usage. The focus of the study will 
be on England as, from May 2016, all Welsh allogeneic blood requirements became 
the responsibility of the Welsh Blood Service, based in Cardiff. 
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This historical section is mainly summarised from Thomas et al’s (2005) ‘A Manual 
for Blood Conservation’ and NHSBT’s published literature on www.blood.co.uk. 
Allogeneic blood transfusions were first attempted, with limited success, in the late 
1800s. In 1900 Karl Landsteiner discovered the ABO blood grouping system that 
identified the different blood groups, allowing further research into allogeneic blood 
transfusions, especially into the compatibility of the various types. During World War 
One US surgeons developed the use of anti-coagulants to prevent donated blood 
clotting. This led to the idea of developing blood ‘depots’ in strategic locations 
however the standards of storage were not sufficient to maintain the quality of the 
donated blood, provoking adverse reactions that led to the ‘depot’ system falling out 
of favour. 
The first civilian unremunerated donor panel was developed in Camberwell, South 
London, in 1921 by Percy Lane Oliver. When a hospital needed blood, they would 
contact Oliver, who would liaise with the donor to go to the hospital. The idea of a 
‘blood bank’ was still in its infancy and further attempts to develop this were 
introduced during the Spanish Civil War from 1936. 
Necessity, due to the Second World War, forced through plans to centralise blood 
collection and allow its speedy passage to wherever it was required. This proved a 
success and the National Blood Transfusion Service in England & Wales was set up 
in 1946 with the American Association of Blood Banks following in 1947. 
NHSBT was formed in 2004 and existed previously as the National Blood Service. 
Prior to 1994 the responsibility for the supply of allogeneic blood lay with the 14 
English regional health authorities and the Welsh Blood Service. 
Today, the approach to collecting blood from donors in the UK has changed little 
from the early 1950s. Blood donors are still unremunerated and there remains a high 
level of altruistic feelings recorded in donor surveys. An article in The Economist (16 
February 2011) entitled ‘Blood, Not Money’ noted, “Blood donors are stalwarts of 
the voluntary sector” and suggested that there were two main reasons for giving 
blood. These are either for altruistic reasons or so that donors, themselves, may 
benefit from receiving future allogeneic blood transfusions; effectively giving now to 
allow them to receive in the future. 
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Donors have the option of donating in city centre locations (‘static sites’), in 
donation sessions in community venues such as village halls, at the workplace or 
other locations using NHSBT’s fleet of ‘bloodmobiles’. These are articulated lorries 
that hold up to six donor beds to allow donations in any location large enough to 
accommodate the lorries. 
1.9 Application of Allogeneic Blood Transfusions 
Allogeneic blood is used in the three environments of medical, surgery and 
obstetrics. This thesis will focus on the use of blood in the surgical environment 
where blood loss volumes are higher. Within the medical environment there is 
currently no alternative for allogeneic blood for treatment of conditions relating to 
anaemia. Cell salvage cannot therefore be used as a treatment. Synthetic blood is a 
number of years’ away, but some developments are happening. For instance, the 
Scottish Centre for Regenerative Medicine (SCRM) has announced a funding 
package to continue research into the manufacture of blood via stem cells. The plans 
are for “…the process to be scalable for manufacture on a commercial scale, with the 
first in-man trial taking place by late 2016” (SCRM website http://www.crm.ed.ac.uk 
accessed 14 January 2016). At May 2018 there was no update on this trial. An 
additional development was announced on 24 March 2017 by the University of 
Bristol. This was publicised as “Discovery Enables ‘Mass Produced Blood’”. See 
www.bbc.co.uk/news/health-39354627, accessed 24 March 2017. 
Within obstetrics the most common area requiring blood transfusions is caesarean 
sections. There is high blood loss and any blood sparing drugs are not used in order 
to prevent any issues with the unborn child. 
Within surgery, allogeneic blood usage has fallen markedly over the past 10 years 
(para 1.10). Developments in more minimally invasive surgical techniques that result 
in less blood loss and initiatives such as the DH ‘Better Blood Transfusion’ (BBT) 
programme have led to a fall in allogeneic blood usage across the UK (para 1.13). 
The first BBT initiative in 1998 championed the use and development of cell 
salvage. 
Older surgical patients are more likely to require an allogeneic blood transfusion. A 
survey undertaken on patients who received transfusions in the North East of 
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England estimated the average age of a recipient of allogeneic blood as being 62.7 
years’ old (Wells et al (2002)). 
The key measure for anaemia is the haemoglobin (Hb) level, measured in grams per 
litre (g/l) of blood. The World Health Organisation (WHO) indicator is that patients 
have sufficient iron levels (i.e. they are not anaemic) when they fall above the 
thresholds in Table 1 below: 
Table 1. Haemoglobin Levels Indicating Preparedness for Surgery  
 Hb Level 
Less Than 
Males 130 g/L 
Females 120 g/L 
Source: WHO indicators of anaemia 
Drugs are now widely administered to minimise blood loss in surgery and lower the 
requirements for an allogeneic blood transfusion. Tranexamic acid is a drug endorsed 
by the DH as the recommended anti-fibrinolytic (blood clotting) agent. The increased 
use of tranexamic acid has had a significant impact on cell salvage usage. The Chief 
Executive Officer of the cell salvage machine manufacturer, Haemonetics, Brian 
Concannon, was quoted in the US investors’ website ‘Seeking Alpha’ as saying, 
“..we’re now seeing a trend that is working against the use of OrthoPat disposables; 
the growing use of tranexamic acid…that obviates the need for transfusion for some 
orthopaedic procedures” (29 July 2013 investor conference call). The notes further 
quote the Haemonetics Chief Finance Officer (Chris Lindop), in relation to the post-
operative cell saver OrthoPat machine, as saying, “OrthoPat disposables revenue of 
$6 million was down 10% in the quarter. The increased use of tranexamic acid and 
lower transfusion triggers by hospital customers are the market challenges for 
OrthoPat”. In the same article Haemonetics noted that forecast revenues would be 
lower, but they planned to issue a new machine, the ‘OrthoPat Advance’ and that 
“…We expect benefits from introducing the OrthoPat Advance will be more than 
offset by these market declines and our expectations reflect this trend”. Tranexamic 
acid costs approximately £1-£2 per dosage and therefore has the public 
acknowledgement of Haemonetics that its use is decreasing associated cell salvage 
product sales. The OrthoPat Advance has undergone clinical trials but is still not 
advertised (14 February 2018) on the Haemonetics website. 
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Haemonetics still advertise the OrthoPat cell salvage machine. Appendix 1 shows a 
copy of the advertising material that highlights allogeneic blood has “a price of up to 
1,400 USD”. This price is quoted in various peer reviewed academic studies. 
There is a rough rule of thumb that a unit of allogeneic blood may improve the 
patient’s Hb level by 10 g/L (McClelland (2007) page 8) though there is no definitive 
study in this area. Contrary to general beliefs, 60% of allogeneic blood is given to 
patients on the ward while they are recovering after their operation (Thomas et al 
2005), rather than in the operating theatre. Hb levels are monitored and clinicians 
often prescribe two allogeneic units if the patient’s Hb level falls below a 
‘transfusion trigger’ point of 80 g/L. Basing the allogeneic transfusion on a specific 
point is now discouraged (Better Blood Transfusion initiatives and UK Patient Blood 
Management guidance). Clinicians are encouraged to view the state of the patient’s 
health holistically and e.g. a fit male of around 55 years could generally withstand a 
temporarily low Hb level without the need for an allogeneic transfusion (e.g. Shander 
et al (2012)). 
1.10 Allogeneic Blood Marketing/Collection and Usage in England 
Male blood donors can donate blood up to four times a year, while female donors can 
donate up to three times a year (www.blood.co.uk). NHSBT has a national marketing 
function, focusing on recruiting and retaining donors. The ‘village hall’ approach, 
where a collection team spends a day in a rural community building to collect a small 
volume of donations (as few as 15-20) is dwindling. The strategy is now based on 
quick throughput of a high volume of donors to collect at least 80 units in a single 
donation session. The researcher donated at a blood donation session on 30 October 
2014 in Torquay. Donor slots were available for 5 ¾ hours in order to achieve the 
session target of collecting 115 units. These sessions will often be open in the 
evening to catch donors on their way home from work. Communications and session 
bookings are supported by call centres run by the outsourcing company, 
Teleperformance. Modern social media shares details of the local donation session 
availability. This approach can be intensified or relaxed to meet the demand patterns 
and ensure that NHSBT’s national target of eight days of blood stocks is maintained. 
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A recent NHSBT initiative has been to focus on the ‘class of 96’. These are young 
donors who, in 2014, were at least 17 years’ old. They are eligible to give blood and 
were born after the changes in legislation on the treatment of meat following the 
vCJD issues in the 1980s and 1990s. The theoretical risk of their allogeneic blood 
being potentially tainted by vCJD noted previously does not therefore apply to 
younger donors due to the changed legislation affecting the handling and preparation 
of raw meat for sale. Initiatives such as the ‘class of 96’ are costly. In terms of both 
targeting and collection the ‘churn’ rate is relatively constant, and the long-term 
strategy is to recruit and retain younger donors who will be invited to donate more 
often. This cohort of the ‘class of 96’ donors is being followed as part of an internal 
study by NHSBT. 
Figure 2 below shows the number of allogeneic blood units collected along with the 
number of allogeneic units issued to hospitals. 
Figure 2. Supply of Allogeneic Blood to Hospitals in England 
 
Source: Supplied from NHSBT Corporate Communications January 2018 
The volume of allogeneic issues has experienced a marked decline since 2000 when 
the volume of allogeneic issues was in the region of 2.2m units. This decrease in 
volume of allogeneic issues is due to several reasons: 
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• Less invasive surgery. The advances in e.g. keyhole and micro surgery have 
lowered the requirement for large incisions and, consequently a lower 
intraoperative blood loss. 
• Improved stock management and operation scheduling at hospitals. 
Allogeneic blood is often kept in the hospital blood bank and is not issued 
until it is required in the operating theatre or post-operatively in the recovery 
unit or on the ward. Previously a short notice cancellation of a theatre list 
would have resulted in a number of allogeneic units being discarded as they 
had already been issued out to the theatre. 
• Application of BBT initiatives and the move to patient blood management 
(paras 1.11 and 1.12) has resulted in more appropriate use of blood. This 
would include the impact of cell salvage. 
• Use of drugs such as tranexamic acid (para 1.9) 
• More advanced blood testing equipment requiring less blood to be taken in 
hospital to undertake a portfolio of tests. 
• No research has been undertaken but it has been suggested the significant rise 
in the price of allogeneic blood from 1998-2008 acted as a catalyst to 
encourage better hospital blood bank stock management and more sparing 
use of allogeneic blood in hospitals (Murphy 2013). 
The phenomenon of falling demand for allogeneic blood is not confined to the UK. 
An article by Matthew L Wald in the New York Times (22 August 2014) entitled 
‘Blood Industry Shrinks as Transfusions Decline’ notes that allogeneic blood usage 
fell by ‘almost one third over the last five years’. The article notes a number of the 
points above, but also refers to revised recommendations from such organisation as 
the US Society of Thoracic Surgeons not to give an allogeneic transfusion until the 
Hb level falls to less than 70 g/l. 
NHSBT is actively involved in estimating allogeneic blood requirements that 
therefore translate into collection plans. The overall totals noted in Figure 2 above 
need to be further analysed. Figure 3 below was supplied by NHSBT and analyses 
the estimated blood usage over the main specialties. One key feature is the decrease 
in surgical usage from the 40.7% estimated by Wells et al (2002) against 30.3% in 
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the 2012 NHSBT study. A rough calculation of the decrease in allogeneic units is 
shown in Table 2 below. 
Figure 3. Analysis of Allogeneic Hospital Blood Use Supplied by NHSBT 
 
Source. Supplied from NHSBT Demand Planning Team 
Table 2. Impact on Allogeneic Requirements of Decrease in Surgical Usage  
Year Total Allogeneic Blood Issued 
(000s) 
Percent Surgical Notional Surgical 
Volume (000s) 
2002/03 2,200 40.7% 895 
2011/12 1,830 30.3% 554 
Decrease 370  341 
Source: NHSBT; note figures exclude South/Mid Wales, Scotland and N. Ireland 
The difference in Table 2 is stark. Over 90% of the overall calculated decrease in 
allogeneic blood issued (341/370) is due to the fall in surgical usage. At a cost of 
£122 per unit the decrease in the overall hospital expenditure on allogeneic blood is 
approximately £41.6m (341,000 x £122). 
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The cost of allogeneic blood and the internal market in the NHS will be introduced in 
para 1.23 and 1.24. Discussions with clinicians and finance staff in NHS trusts 
pointed to the relatively easy savings to be made in their trust’s blood budget by 
avoiding the use of allogeneic blood. The 2009 McKinsey NHS Productivity Review 
(see: www.nhshistory.net/mckinsey%20report.pdf, accessed 25 January 2015) 
concluded that around 21% savings had been made in blood products by NHS Trusts 
between 1997 and 2009. This was the 13th highest saving in the survey of 75 areas 
undertaken by McKinsey (page 37 of PowerPoint presentation). The workings in this 
study were not published widely and were released in the form of a PowerPoint 
presentation following a Freedom of Information Act request by the Daily Mail in 
May 2010. The report findings were, however, consistent with discussions with users 
and the notional calculation above. 
Trusts can therefore make savings in their allogeneic blood budgets by lower than 
planned blood usage but NHSBT fixed costs will remain. This impact on NHSBT 
and the overall NHS expenditure will be examined in Chapter 6. 
1.11 Better Blood Transfusion (BBT) Initiatives 
Although there is an internal market for allogeneic blood, the National 
Commissioning Group for blood and blood products (NCG-see para 1.23) maintains 
collaboration between the NHS organisations to derive the average cost and hence 
price charged per allogeneic unit. The three initiatives, commencing in 1998, were 
developed jointly by the four home nations. The main aims were to: 
• Avoid the unnecessary use of blood transfusions. The publications stressed 
there was always a risk of contamination or mix up of the blood group. 
Reducing the number of transfusions reduced the overall level of risk. It was 
felt that the ‘quick wins’ to reduce the volume of transfused blood required 
(pre-operative patient assessment, patient positioning, less invasive surgery 
etc.) were sufficiently developed to allow the individual Hospital Transfusion 
Committees/Teams to audit usage. 
• Secure appropriate and cost-effective provision of blood transfusion and 
alternatives in surgical care. Specifically mentioned in BBT1 was ‘(Trusts 
to) develop a blood conservation strategy including …alternatives to donor 
blood such as perioperative cell salvage’. 
19 
• Ensure patients who are likely to receive a blood transfusion are informed of 
their choices. Specific mention was made on disseminating information on 
‘alternatives available’. References were also made to ‘managing Jehovah’s 
Witnesses’. Jehovah’s Witnesses believe that shed blood is unclean and will 
stipulate that they are not to be given allogeneic blood. A proportion of 
Jehovah’s Witnesses will, however, accept cell salvage as the blood is still 
part of a circuit and has not therefore actually been lost by the patient. 
BBT3 (2007) referred to the NHSBT supported website: 
www.transfusionguidelines.org.uk. This (four country) website made reference to 
two little-used alternatives to blood transfusion using autologous (patient’s own) 
blood: 
• Pre-operative autologous donation (PAD), para 6.1.1. of the Transfusion 
Handbook. This is where a patient ‘banks’ some of his/her blood over two-
three weeks prior to the operation. Studies have shown that this lowers the 
patient’s Hb levels markedly with the patient subsequently presenting for 
surgery in an anaemic condition. They may therefore require allogeneic blood 
in addition to that which has been banked. The British Committee for 
Standards in Haematology (2007) recommend its use in only exceptional 
circumstances. 
• Acute Normovolaemic Haemodilution, (ANH) para 6.1.4. of the Transfusion 
Handbook. Once the patient is anaesthetised, several units of blood are 
collected in the anaesthetic room. The patient is transfused with crystalloids 
until surgical haemostasis (bleeding stops) is achieved then post-operatively 
the patient’s own blood is reinfused. ANH was popular in the US, especially 
for cardiac surgery which often involved high volumes of blood loss. In 
recent years, surgical advances have reduced blood loss, thereby decreasing 
its requirement. The UK health bodies do not encourage this technique and 
the Transfusion Guidelines website states ‘the safety of ANH remains 
unclear’. 
There have been no additional BBT initiatives since BBT3 in 2007. The UK Cell 
Salvage Action Group (CSAG) has taken over the role of encouraging the 
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appropriate use of blood and the promotion of blood sparing activities such as cell 
salvage. 
1.12 International Patient Blood Management (PBM) Initiative 
A recently developed concept, effectively extending the BBT initiatives, is Patient 
Blood Management (PBM). Shander and Javidroozi (2012) define this as an 
initiative to “improve patient outcomes while reducing the use of allogeneic blood, 
through multitudes of strategies relying on optimising RBC (red blood cell) mass, 
preventing blood loss and optimising the physiologic response to anaemia”. Some of 
the ‘strategies’ are basic, such as ensuring the patient is well positioned and kept 
warm during surgery, and that the patient has followed a basic exercise programme 
to be fit and well before surgery. At the other end of the scale would be cell salvage; 
relying on a trained member of staff to operate equipment to recycle a patient’s own 
blood. Shander & Javidroozi (2012) recommend the combined use of all the 
strategies to maximise the benefits of minimising the risk of having an allogeneic 
transfusion. 
PBM was formally cascaded to hospital trusts by NHS England in June 2014 (see 
appendix 3). The document, issued by the National Clinical Director of Pathology 
(NBTC (2014)), defined PBM as “an evidence-based, multidisciplinary approach to 
optimising the care of patients who might need transfusion. It encompasses measures 
to avoid transfusion such as anaemia management without transfusion, cell salvage 
and the use of anti-fibrinolytic drugs to reduce bleeding as well as restrictive 
transfusion”. The document quoted inappropriate use of, inter alia, allogeneic blood 
at a rate of 15-20%. Specific recommendations include: 
• Enhanced training in avoiding unnecessary blood transfusions e.g. to 
transfuse one allogeneic unit at a time and view the impact rather than 
transfusing two units immediately.  
• Preoperative management of anaemia to ensure the patient is above the World 
Health Organisation definitions of Hb levels >130g/l for men and >120 g/l for 
women (Table 1 above) prior to commencing surgery. 
• Use of cell salvage for appropriate procedures and pharmacologic agents to 
reduce blood loss, e.g. tranexamic acid. 
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The American Association of Blood Banks (AABB) is also implementing its own 
PBM programme and hosted a national awareness week in November 2014, followed 
up by a similar initiative in the corresponding weeks in November 2015 and 2016. 
The AABB’s definition of PBM is the same as the NHS England version (see 
www.aabb.org/pbm accessed 19 January 2016). 
The June 2014 document above referred to a 2013 survey of all English NHS trusts. 
The survey summarised various findings including ‘… patchy use of intraoperative 
cell salvage, for example 55% of Trusts use it for orthopaedic surgery’. It was 
impossible to reconcile this percentage to the approximate 40% cell salvage 
utilisation calculated for England in the cell salvage consumables survey discussed in 
para 1.14 below. The comment, when associated with the other survey findings, has a 
negative slant. The assertion is that more cell salvage should be considered since cell 
salvage is highlighted as a key measure to avoid allogeneic transfusions. 
1.13 Methodology of Cell Salvage as an Alternative to An Allogeneic Blood 
Transfusion 
Cell salvage collects a patient’s shed blood during or after surgery. In the early years 
of development of cell salvage the blood would immediately be reinfused back into 
the patient. Developments in techniques and mechanical applications allow the shed 
blood to be washed prior to reinfusion and there are now two types of equipment 
available. These offer the options of: 
• Intra-operative cell salvage (ICS). This is where the shed blood is collected, 
washed and immediately reinfused back into the patient during surgery. This 
is the more common type of cell salvage and is used across the various 
surgical specialties. 
• Post-operative cell salvage (POCS). The post-operative shed blood is 
collected, washed and reinfused back into the patient after the operation is 
completed. The actual shed blood collection and continuous reinfusion will 
carry on for up to six hours after the operation. This technique is mainly used 
for hip and knee surgery, as a tourniquet would often be used to minimise 
blood loss during the operation. The suction device will be placed in situ 
prior to the tourniquet being released. 
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Figure 4. Intraoperative Cell Salvage Circulation 
 
Source. Above diagram provided by UKCSAG 
The principle for cell washing is broadly similar for both intraoperative and post-
operative techniques. Shed blood is filtered to remove debris and collected in a 
reservoir (see above). It is already anticoagulated with heparin or citrate to stop 
clotting. Once sufficient blood is collected in the reservoir it is released into a bowl 
to be processed (depending on manufacture the volume may be 55ml, 125ml or 
225ml). The majority of machines will spin (process) the bowl and the centrifugal 
process will trap the oxygen carrying red cells to generate highly oxygen-
concentrated blood to be re-infused. Additionally, blood laden swabs used on the 
patient can be washed out in saline and poured into the reservoir. 
The cycle can be repeated during the operation when each bowl is full. A full bowl is 
preferable to partial bowls. The decision to open the reservoir is often a matter of 
judgement by the operator. The locally held, non-scientific view at the Royal 
Cornwall Hospitals is that the colour and texture of the salvaged blood in the 
reservoir should look like a blackcurrant drink and resemble a smoothie, rather than 
Ribena, indicating there is a high concentration of red blood cells. If this is the case, 
then the contents of the reservoir can be released. This judgement call effectively 
assesses the haematocrit levels; this is the volume of red cells in the blood. The 
higher the volume of red cells, the thicker the blood. Newer cell salvage machines 
will use a light scanner to assess the haematocrit levels and give a more accurate 
indication when a reinfusion of blood can take place. 
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The final ‘packed red cells’ will then be reinfused into the patient. The cycle can be 
repeated for the duration of the operation if necessary. With some patients, who are 
expected to have high blood loss the clinician may feel it safer to keep some 
allogeneic units on ‘stand by’, e.g. in a cool box in the operating theatre. 
The decision whether to salvage will be made by the clinician. Many hospitals will 
have information leaflets for patients who may request the use of a cell saver to 
minimise the chances of requiring an allogeneic blood transfusion. 
As noted in para 1.4 the prime reason for undertaking an allogeneic transfusion is to 
keep the patient’s Hb levels as high as possible to maximise the level of oxygen in 
the blood. These levels will be depleted in an operation and the cell salvage process 
will minimise this depletion. Used in conjunction with other blood sparing 
techniques the patient’s Hb level will be maintained as high as possible. The 
patient’s Hb level will be monitored regularly and allogeneic blood may be 
prescribed if the level does not start to rise. 
To circumvent the issue of trying to isolate the contribution of cell salvage against 
other blood sparing techniques, this thesis will undertake a comparison between three 
sites; only one of which uses cell salvage, but the other two sites describe themselves 
as assiduous proponents of PBM. The hypothesis is therefore that the respective 
differences in allogeneic blood utilisation and hence the allogeneic blood costs will 
be attributable to the utilisation (or non-utilisation) of cell salvage. 
Cell salvage is accepted as a highly safe technique. In the UK, it is only used in 
hospitals where there is an ample supply of available allogeneic blood, should it be 
required. Hussain (2010) succinctly sums this up, stating if there is a problem with 
the operation of cell salvage during the operation then the clinician can stop the 
process and give allogeneic blood instead. This would suffice for any patient, except 
Jehovah’s Witness patients who refuse allogeneic blood (paras 1.11 and 1.17). 
1.14 Evolution and Usage of Cell Salvage in the UK 
Thomas (2005) states ‘The first use of blood salvage was reported (in 1818) by 
James Blundell for the treatment of postpartum haemorrhage’. This involved 
collecting the blood and injecting it back into the patient.  
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Landsteiner’s discovery of blood grouping (para 1.8) developed more interest in 
allogeneic transfusions and consequently interest in cell salvage waned. It was not 
until research at the Mayo Clinic in the US in the 1960s that interest increased when 
systems to salvage spilt blood were developed. This coincided with the US 
involvement in the Vietnam War and studies found that salvaged blood contributed to 
lower requirements for allogeneic blood. Thomas (2005) believes that these 
rudimentary attempts at salvaging severe trauma cases from the battlefield sowed the 
seeds of development in the civilian surgery we see today. 
Cell salvage is now utilised, to a varying degree, in most countries in the world. 
Some basic systems such as the EAT (emergency autotransfusion) SET, developed in 
Nigeria may be the difference between life and death in cases of postpartum 
haemorrhage where the nearest hospital may be 100km away and no allogeneic 
blood is available. The EAT SET is a hand operated suction pump that filters shed 
blood and re-infuses it immediately. It can therefore be used without electricity, often 
outdoors, in an emergency setting. www.kumatoo.com/dr_oviemo_ovadje.html 
accessed 28 October 2014. 
In the developed countries, four multi-national companies dominate the market for 
both allogeneic donation and cell salvage related equipment. These are: 
• Cobe/Terumo (Japan) 
• Fresenius (Germany) 
• Haemonetics (USA) 
• Sorin (Italy). 
A 2011 survey by the UK Cell Salvage Action Group (para 1.16) found the most 
widely used intra-operative machines are the Sorin Electa and the Haemonetics Cell 
Saver 5 (CS5). The main post-operative device is the Haemonetics OrthoPat cell 
saver, which can also be used intraoperatively. At the time of the collection of the 
data (2010/11) the Royal Cornwall Hospital Trust used seven Haemonetics 
OrthoPats, three Sorin Electas and two Haemonetics Cell Saver 5s. 
The cost of the equipment is usually bound by commercial confidentiality. Generally, 
the equipment will cost in the region of up to £15,000 including VAT. The 
consumables (in the US confusingly termed ‘disposables’), mainly the reservoir, 
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filter and the tubing, cost c. £68 per operation for the Electa and are significantly 
more expensive (c. £170) for the OrthoPat. These costs are negotiated charges from 
the suppliers at the Royal Cornwall Hospitals. There will be some additional costs 
(see NICE Costing Report 2015 for the implementation of NICE Guidelines NG24) 
for heparin (£21.20) and saline (£4.20). 
1.15 NHSBT Supported Collaborative Work on Cell Salvage 
NHSBT actively supports blood conservation measures and is a host organisation for 
the UK Cell Salvage Action Group (CSAG, introduced in para 1.11 above). NHSBT 
has also supported the NHS ‘Better Blood Transfusion’ (BBT) initiatives that 
commenced in 1998 to encourage the ‘safe and appropriate use of blood’ (para 1.11). 
Being part of the NHS, it is in NHSBT’s interests to achieve stability in allogeneic 
blood usage. This helps the organisation to assess hospitals’ future allogeneic blood 
requirements and convert these requirements into collection targets nationally. 
The primary role of the CSAG is to encourage the development of cell salvage in 
conjunction with other blood avoidance techniques. The group is comprised of 
hospital users (medical, scientific and theatre staff) and representatives from the UK 
Blood Services. Although there is an internal market for blood, most of the 
organisations, except for private hospitals, are part of the public-sector NHS. 
Collaboration on blood sparing initiatives will ensure more certain demand planning 
which, in turn, will translate to potentially lower blood collection targets and 
consequent lower collection and marketing costs to recruit and retain allogeneic 
blood donors. 
Responsibilities for data collection, follow up of the BBT initiatives (para 1.11) and 
estimations associated with the impact of cell salvage were therefore allocated to the 
CSAG, which was set up in 2006. The ‘four country’ representatives on CSAG will 
then report to the individual blood organisations, e.g. the England representative 
reports to NHSBT’s Patient Blood Management Steering Group. 
NHSBT International is a division of NHSBT primarily concerned with developing 
international collaborations and benchmarking initiatives to enhance the efficiency of 
the service. The basic process from blood donation through to hospital issue is 
broadly similar in most countries with the responsibility being held within one or 
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more large centralised management units. A set of comparative key performance 
indicators (KPIs) has therefore been developed, comparing, for example, the number 
of allogeneic donations per member of collection staff employed. Comparative costs 
obviously vary due to exchange rates and the relative purchasing power of 
currencies, so the focus is on assessing the non-financial units of measurement. In 
the event of severe shortages of allogeneic blood (e.g. in national emergencies), 
member countries of the European Blood Alliance (EBA) have arrangements to 
supply allogeneic blood across borders. The UK is a partner in this arrangement but 
is not in a position to ‘export’ UK blood due to the potential risk of vCJD 
contamination. 
The EBA was approached in 2007 as part of the preliminary work for this thesis. A 
brief questionnaire was issued, and a summary of the member consultation responses 
is shown in appendix 5. Broadly it showed interest in cell salvage in a number of 
member countries. The response from the Bavarian/German blood service was 
particularly thought-provoking with the view that, since the supply of allogeneic 
blood was safe and plentiful, there was little incentive to assess and develop 
alternatives (see comments in appendix 5). 
The 2007 EBA survey noted a wide-ranging enthusiasm for cell salvage from 
member countries. The EBA has since expanded its membership and, in January 
2014, the EBA Chair was approached with the request to re-run the survey. The 
Chair stated that members were too busy and that interest in cell salvage had now 
waned around Europe. Consequently, the request was refused. This did not come as a 
great surprise given the vast majority of publications (see analysis in the literature 
review) relate to the UK or US and not across Europe. 
The roles and responsibilities of NHSBT do not therefore stop at managing the 
supply of allogeneic blood. It provides support for CSAG which, through its related 
work, encourages alternatives and the efficacious use of allogeneic blood. 
1.16 Utilisation of Cell Salvage in the UK 
Both utilisation and usage of cell salvage are difficult to assess. Companies do not 
wish to reveal their sales levels for commercial reasons. We are therefore reliant on 
surveys and general discussions. The 2011 CSAG survey on ICS approached known 
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hospital cell salvage users. As a rough guide this was approximately 40% of English 
NHS hospital trusts, with a much higher percentage in Scotland and Wales. The 
response rate was a little disappointing at around 44%. One key question related to 
the number of consumables used in ICS. The responses are shown in the graph 
below: 
Figure 5. Intraoperative Cell Salvage Consumables Used in the UK 
 
Source. 2011 CSAG Study. 
The above information, reproduced from the 2011 survey, estimates the ICS usage at 
approximately 8,325 operations per annum for the 71 respondents. The basic 
calculation is shown in Table 3 below: 
Table 3. Estimate of the Number of Consumables Used in the UK in 2010/11  
Usage p.a. <50 51-100 101-150 151-200 201-250 >250 Unknown Total 
Estimated Mean 25 75 125 175 225 275 125 — 
Number of 
Hospitals 
25 10 5 6 20 1 4 71 
Estimated Usage 625 750 625 1,050 4,500 275 500 8,325 
Table 3 therefore estimates the mean annual usage per hospital for ICS at 117 
operations (8,325/71). It was highlighted to the survey author that the total number of 
organisations in the graph (71) did not tally with the number of overall respondents 
in the questionnaire (53). The response was that the graph referred to sites, so a two-
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site trust would be treated as two entities in the graph but as one respondent in the 
44% overall response rate. 
This anomaly aside, the indications are that the estimated ICS annual usage is low. 
One would expect the respondents in the questionnaire to be the more enthusiastic 
proponents of ICS and therefore the implication is that the overall usage across 
(especially) England is still relatively low. A second graph summarised in Table 4 
below notes the respondents had the use of 209 ICS machines. A crude average, by 
dividing the estimated number of operations (8,325) by the 209 machines gives an 
average machine usage of 40 operations per annum. With 71 organisations, this 
averages at about three machines per organisation (209/71). 
Table 4. Analysis by Machine Type 
Equipment Type Number 
Sorin Electa 91 
Haemonetics CS5 63 
Fresenius CATS 19 
Cobe Brat 12 
Haemonetics OrthoPat 15 
Haemonetics Cardiopats 6 
Medtronic Autologic 3 
Total 209 
Note. The OrthoPat is a dual intra-operative and post-operative machine and, in the survey, used 
intra-operatively 
The crude calculation of derived activity from table 4 above is effectively the best 
information available, given there is no central NHS wide procurement database of 
NHS organisations’ equipment purchases. The equipment may also have been 
purchased and provided free of charge by the local Jehovah’s Witness community 
(para 1.17). The calculation therefore equates to an individual machine being 
utilised, on average, less than once a week (40 times per annum). This assumes that 
only one consumable set is used per operation so there is no wastage. It is arguable 
that low usage of cell salvage implies efficiency and sparing use of the consumables 
only where they are utilised to avoid an allogeneic blood transfusion. One cannot 
really take machine utilisation as an indicator. From an accounting perspective, if the 
average cost of consumables is £100 and two units of allogeneic blood (rounded to 
£250) are avoided then, ‘ceteris paribus’ this equates to a cost avoidance of £6,000 
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((£250 – £100) x 40) per annum. A brand-new cell saver may cost approximately 
£15,000, making the payback period 2.5 years on a very low usage. This is the 
general argument purported by the sales representatives of the main manufacturing 
companies. The promotional material for the Sorin Xtra states “the average total cost 
of transfusing a unit of homologous RBCs (alternative US term for allogeneic units 
of blood) as $1,158” (appendix 1), quoting Shander et al (2008) and thereby 
implying that using the machine would avoid these costs. It ignores issues such as: 
• Training costs. Training a cohort of around 15 operating department 
practitioners (ODPs) from scratch may cost more than £5,000. This level of 
training cost for the ODPs may be difficult to justify when total cell salvage 
usage may only be 120 operations per annum. 
• Retaining the practical experience. 120 operations spread equally over 15 
ODPs would equate to eight operations each per year. There is an argument 
that, to be most effective, ODPs (and surgeons) should have more ‘flying 
hours’. 
• Transfusion rates. A high cell salvage rate may be combined with a high 
allogeneic transfusion rate. This may imply inefficiencies in the blood 
management process in patient treatment (Joy and Bennet (2012)). 
While the CSAG have promoted the benefits of cell salvage, the utilisation rate is 
relatively low. In 2010/11 210 NHS hospitals in England requested at least 2,500 
units of allogeneic blood from NHSBT (NHSBT activity information). The 2011 
CSAG survey results indicated that a high proportion of English hospitals have either 
not demonstrated an active interest in the development of cell salvage or are not 
utilising it. It is this gap in the knowledge of the ‘customer’ that the CSAG are trying 
to assess and therefore influence change. 
Pulling the crude ratios from the questionnaire is not an exact science, although it 
does point to a potential for a gap in the market and the potential for companies to 
sell additional cell saver machines to new customers. Alternatively, there are some 
organisations that do not utilise cell salvage as they feel it is not cost effective. There 
are some, but not many, articles that point to this. For instance, Attaran et al (2010) 
argue that their study in “routine cardiac surgery” identified no lower allogeneic 
blood usage when cell salvage was used and when it was not. They argued that the 
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cost of operating the cell savers effectively generated a loss. These issues will be 
discussed in the literature review. The approach to the cost effectiveness of cell 
salvage from all perspectives will be undertaken in subsequent chapters. 
1.17 Jehovah’s Witness Beliefs and Support for Cell Salvage 
A key belief of a Jehovah’s Witness (JW) member is that their life is contained 
within their blood. There are a number of biblical passages quoted on the JW website 
highlighting members’ belief in forbidding the use of blood, e.g. Genesis 9:4 “The 
one thing you must not eat is meat with blood still in it; I forbid this because life is in 
the blood”. Additionally Acts 15:28, 29: “You are to abstain from …blood.. If you 
keep yourselves free from these things you will be doing right”. (see www.jw.org 
accessed 18 January 2016). 
Many JW members will therefore refuse allogeneic transfusions and the JW website 
highlights this refusal as being a religious rather than a medical issue. For many JW 
members, however, intraoperative cell salvage is acceptable as the blood has not 
been spilt, since the blood remains in a circuit connected to the body. Many JW 
communities in the UK have funded the purchase of a cell saver machine for their 
local hospital. This will be used in the event of a JW patient requesting it. Local 
arrangements may vary but the machines would be made available to all patients 
regardless of their beliefs. 
JW patients will identify themselves as requesting ‘no blood’ at their pre-operative 
assessment (para 1.19). Arrangements will be made for a cell saver machine to be 
made available if the JW patient requests it. Each NHS hospital has a JW liaison 
officer who can advise and ensure the patient’s requirements are met. Antifibrinolytic 
drugs such as tranexamic acid (see para 1.9) are also utilised by JW patients. 
JW members are prominent in supporting initiatives to avoid allogeneic blood 
transfusions and the umbrella JW organisation in the US actively highlights the 
consideration of alternatives to allogeneic transfusions, including intraoperative cell 
salvage. In the south west of England, the joint NHSBT/ University of Bristol MSc 
in Transfusion and Transplantation Science course includes a training session from 
the local JW representative as part of the wider approach to transfusion medicine. 
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1.18 Low Utilisation of Cell Salvage 
Advocates of cell salvage have been promoting the technique as an alternative to an 
allogeneic blood transfusion since the 1990s with many articles highlighting 
significant savings. A detailed critique will be undertaken in the literature review, 
however many articles (not just on cell salvage) can achieve publication citing costs 
that are often based on average costs. A common misconception in the UK is to quote 
savings associated with lower length of stay (LOS), e.g. Dixon et al (2005). The cost 
of a hospital stay may average out at £300 per in-patient day. A study may cite a 
particular procedure that would reduce LOS by one day, so the study would quote a 
saving of £300 a day per patient if the procedure were adopted. In practice the saving 
would be minimal since, in the short term, virtually all hospital costs are fixed and 
the savings in avoiding one in-patient day would mainly be in patient meals and 
other accommodation costs. 
Earlier studies would often cite a 1:1 relationship in using cell salvage so that the use 
of a cell saver would avoid the use of (say) two allogeneic units (Crotty (2006)). 
‘Ceteris paribus’ the savings quoted would be cited as: 
Table 5. Basic Calculation of Savings Avoiding One Allogeneic Blood Transfusion per Week  
 Cell 
Salvage 
£’000 
Allogeneic 
Costs 
£’000 
Blood Costs Avoided (2.7 units per operation per week)  17.5 
Consumables 4.7  
Training 4.5  
Electricity 0.2  
Capital Charges 1.0  
Maintenance 0.5  
Sub total  10.9 
Saving  6.6 
Source: Table reproduced from HFMA publication ‘Healthcare Finance’ September 2010 
The savings in Table 5, while focusing on the marginal savings, may not be 
realisable. One would need to be certain that at least one patient a week was 
definitely going to require an allogeneic transfusion. The identification of this one 
patient would be difficult so, for instance, to allow one patient a day to avoid an 
allogeneic blood transfusion may require salvaging five patients in a list thereby 
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requiring five sets of consumables. This would then make using cell salvage more 
expensive than utilising allogeneic blood if four out of the five patients would not 
have required an allogeneic transfusion anyway. It is this level of uncertainty that has 
not been highlighted. Some hospitals, e.g. the Royal Cornwall Hospitals Truro that 
forms the basis of this study, attempt to salvage all patients and rely on negotiating a 
better price for using a high volume of consumables. With this level of subjectivity, 
the cost of ensuring the high volumes of cell salvage may be viewed as prohibitive, 
especially when compared to the financial benefits of tranexamic acid that even the 
makers of cell salvage equipment acknowledge (para 1.9). 
Other challenges facing cell salvage are: 
• The UK CSAG has a list of users but there is no guarantee that it is complete 
nor is there a more reliable indicator of usage. There is therefore a difficulty 
in developing convincing cases for or against its use when it is only a small 
pocket of enthusiastic proponents who regularly contribute to the debate. 
• Discussions with hospital staff cite a lowering in emphasis in cell salvage in 
the BBT series (para 1.11). BBT1 (1998) explicitly cited cell salvage as a 
concept for hospitals to develop and quoted Morriston Hospital, Swansea, as 
an exemplar site. Moving forward to BBT3 (2007) and there is little mention 
of cell salvage. The perception is therefore that the profile of cell salvage has 
fallen. 
• There is a possible political issue that has been raised in general discussions 
with some clinicians. Blood donors feel very altruistic about donating blood 
(see paras 1.8 and 6.13) and the act of donating is packaged as a ‘gift of life’. 
If it were widely circulated that there is a high level of unnecessary 
allogeneic transfusions in surgery due to the availability of cell salvage and 
other blood avoidance techniques, would this have an impact on the number 
of donors willing to donate? This may then require further expenditure on 
marketing to recruit and retain the donors. The assertion has been put forward 
(in confidence) that this altruism needs to be retained for NHSBT to react to 
future uncertainties in the blood supply chain.  
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1.19 Enhanced Recovery Pathways 
NHS Hospital trusts are now expected to follow the Enhanced Recovery Pathway 
(ERP) programme to ensure the patient is adequately prepared for the surgery. (See: 
http://webarchive.nationalarchives.gov.uk/20130107105354/http://www.dh.gov.uk/en
/Healthcare/Electivecare/Enhancedrecovery/DH_117433 Accessed on 19 October 
2015.) 
The ERP programme was implemented across the NHS from 2008 onwards. The 
examples on the, now archived, website highlight the reduced length of stay by ‘as 
much as 10 days for colorectal procedures and 4 to 5 days for hip and knee 
replacements’. The programme noted areas of benefit by optimising the patient prior 
to surgery using the pre-operative assessments. Additionally, the therapy support 
(physiotherapists and occupational therapists) before and after the operation was 
cited as a contributory factor. 
There are a number of examples of best practice in ERP programmes, all of which 
commence with the pre-operative assessment; a standard template form from 
Abertawe Bro Morgannwg Trust (ABM) is attached as appendix 6. These 
assessments are generally undertaken by a nurse and the results will form the 
judgement on whether to go ahead with the operation or refer the patient back to the 
GP for further assessment. A common referral back would be if the patient is 
anaemic i.e. their Hb levels are below the recommended WHO levels of 120g/L for 
women and 130g/L for men. 
In 2011 Torbay and South Devon NHS Foundation Trust undertook a collaborative 
project with the orthopaedic implant manufacturer, Biomet, to develop the Rapid 
Recovery orthopaedics programme at Torbay Hospital in Torquay. Here, patients will 
initially have their pre-operative assessment if clinicians have decided surgery is 
appropriate. The ERP programme is specifically targeted at total hip replacement 
surgery. The researcher discussed the procedure with Torbay Hospital staff in 2014 
who ‘walked through’ the process with the researcher. 
At Torbay Hospital, if the patient is deemed fit enough to undergo an operation s/he 
is invited to a ‘joint school’ along with the patient’s immediate carer. This ‘joint 
school’, held about two weeks prior to the scheduled operation, comprises an 
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education session, watching a video and a series of exercises and tasks with the 
physiotherapist and occupational therapist. The patient will then practice and work 
on the exercises at home. The expression used locally is ‘pre-habilitation’; to be 
effectively fit for the operation and ready for the recovery process. 
After the operation, the aim is to get the patient up and about as early as possible, 
subject to no adverse psychological impacts. The day of the week is irrelevant as the 
therapists work over a seven-day week. The patient is likely to be seen by the 
physiotherapist twice in a day with the aim to establish the patient’s independence 
and mobility as early as possible. This will encompass exercises and techniques to 
enhance mobility using aids (e.g. frames/sticks) and ensuring the patient is able to 
tackle stairs. These are the criteria to assess the patient’s rehabilitation along with 
pain control. There are also specific exercises to strengthen muscles and develop the 
movement in the hip joint. Crucially the patient is taught to get in and out of bed 
unaided. 
Alongside this work the occupational therapist (OT) is assessing the patient’s 
rehabilitation from an independence perspective, e.g. s/he will have met the patient at 
the joint school and assessed the height of the furniture in the patient’s house by 
undertaking a home visit. Many of the patients live alone and their independence will 
therefore already have been assessed prior to taking the decision to discharge. 
The decision to discharge is made jointly by the nursing and therapy staff, based on 
their professional judgment. Comorbidities are assessed and, where appropriate, 
medical staff will be consulted. The process at South Devon is mapped out in the 
flowchart below. 
The key objective is to get the patient mobile as early as time permits. The age range 
of patients undergoing this type of operation is getting wider (National Joint Registry 
Annual Report 2013). A younger patient with few or no comorbidities would expect 
to recover more quickly. With a rigorous pre-operative assessment, the patient’s iron 
levels will be optimised, lowering the likelihood of requiring an allogeneic 
transfusion. Older patients who are likely to have other comorbidities will be 
therefore more likely to require a blood transfusion as their iron levels may be more 
volatile, e.g. the pre-operative nutrients may not have as much beneficial impact. 
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Figure 6 below maps out the main pathway ‘walk through’ of a typical Rapid 
Recovery programme. 
Figure 6. Enhanced Recovery Treatment Flow 
 
Although the Department of Health guidance on the ERP programme has now been 
archived, the indications are that all hospitals are not fully adhering to the 
programme. The English NHS organisation responsible for regulating NHS 
Foundation Trusts was Monitor (renamed NHS Improvement from April 2016). A 
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report produced in October 2015, “Helping NHS Providers Improve Productivity in 
Elective Care” compares length of stay for, inter alia, elective primary hip 
replacement surgery at a number of sites in England and around the world. The sites 
were chosen by Monitor “because they are regarded as delivering high quality care 
by …the British Orthopaedic Association”. The average length of stay quoted in the 
document for the selected English hospitals is 5.1 days. Two of the selected NHS 
organisations in this thesis have 5.1 and 5.2 days’ average length of stay. Chapter 6 
will discuss the length of stay but the Monitor report gives an additional level of 
assurance that two of the researcher’s chosen sites virtually achieved the Monitor 
average more than four years prior to the Monitor report being published. 
 
1.20 Choice of Speciality to Study Cell Salvage Applications 
Cell salvage is mainly utilised in cardiac and orthopaedic surgery. It was decided to 
focus on assessing the cost effectiveness of cell salvage in orthopaedics due to the 
lower level of variability in orthopaedics compared to cardiac. Outcomes are more 
predictable since there are fewer potential complications and therefore costs 
associated with blood usage will be more visible. The key aspect is to isolate the 
impacts on the patient if an allogeneic blood transfusion was or was not required. 
Chapter 5 will introduce the utilisation of HRGs (Healthcare Resource Groups). 
These group together similar procedures within a specialty and report on activity and 
costs of the HRG. They are used within the NHS as a tariff-based funding allocation 
mechanism but can also be used to grade the severity of the operation or the patient 
comorbidities. With having a small number of HRGs to compare then elective total 
hip replacement was a logical choice within orthopaedics. This was also consistent 
with Carless et al’s (2004 and 2010) Cochrane Review that recommended 
comparative trials of cell salvage in orthopaedics. Additionally, the comments in the 
Guardian newspaper by the NHSBT Medical Director on joint replacements were 
noted (para 1.4). She had previously given NHSBT approval to support this study 
and approved the audit documentation from one of the study sites to allow the release 
of the activity information for analysis and comparison. 
The information collected in the three centres is more detailed than in the published 
studies assessed in the literature review. Most studies use the generic term ‘total hip 
replacement (THR)’ rather than analysing activity at HRG level. This study will 
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therefore add additional rigour to the analysis and aims to minimise the variability 
associated with studies focusing on the wider category of ‘THR’ rather than the more 
detailed ‘HRGs’ where figure 11 notes the variation in the tariff price for the HRGs. 
Finally, using orthopaedics allows the assessment of both intra-operative and post-
operative cell salvage usage as the Royal Cornwall Hospitals uses both types, 
including the OrthoPat which was highlighted in the discussions with the 
Haemonetics manufacturer (para 1.9). These discussions were significant in that they 
alerted the researcher to the issue of the expensive consumables. This would have a 
significant impact on the decision whether or not to transfuse allogeneic blood due to 
the cost of consumables. 
The comment on ‘patchy’ use of cell salvage in orthopaedics in the National Blood 
Transfusion Committee (NBTC 2014) report on Patient Blood Management also 
needs pursuing (para 1.12). Two of the sites analysed in this thesis are particularly 
vehement in their view that cell salvage is not cost-effective in elective primary hip 
replacement surgery. They would therefore argue that the absence of cell salvage 
may be advantageous and the term ‘patchy’ implies an argument which justifies not 
utilising cell salvage. The conclusions of this thesis can therefore be shared with the 
NBTC to inform discussions on the efficacy of cell salvage within orthopaedics. 
Finally, with Trusts adhering to the Enhanced Recovery Pathway programme 
(para 1.19) in orthopaedics it can be reasonably assumed that the majority of pre-
operative assessments have been undertaken. This will lower the level of subjectivity 
by minimising the requirement to use cell salvage to correct any omissions in patient 
assessment planning. As far as possible there will be a straight comparison between 
cell salvage and allogeneic blood transfusions. 
The decision to focus on hip surgery is primarily due to the level of activity 
undertaken in each area (table 6 below). There were three times as many elective hip 
procedures as knee procedures recorded by HRG in England in 2013/14 and the hip 
activity had increased against the comparative data in 2012/13 with the knee activity 
falling slightly. Changes in blood practice, as a result of blood saving initiatives, 
were therefore likely to have a higher impact in hip procedures, thereby influencing 
the choice of area to study. 
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Table 6. Comparison of HRG Procedures in England — Hips v. Knees  
 2012/13 2013/14 Percentage Increase 
Procedure Number Cost £m Number Cost £m Number Cost 
Knee Procedures 19,635 81.5 19,065 84.2 -2.9% 3.3% 
Hip Procedures 61,308 420.1 63,631 449.1 3.3% 6.9% 
Source. Analysis of reference cost returns; Department of Health 
Aligned to the high number of hip procedures was the relatively high perception of 
health improvement by the patient questionnaires in the PROMs (patient recorded 
outcome measures) surveys. More recent statistics for 2012/13 (9 April 2015 
publication) now show 96% of hip replacement patients reported an improvement. 
The regularly high PROMs measure implies a successful outcome to the operation, 
thereby allowing more certainty in assuming the operations were successful. The 
National Joint Registry Annual Report for 2013 noted 92% of elective primary hip 
replacement patients were cited as having the primary indication for surgery being 
osteoarthritis. The inference is that the operation relieves the symptoms and 
debilitating factors associated with osteoarthritis. 
The choice to focus on total hip replacement surgery therefore minimises the level of 
variability. The proportion of successful surgery is very high. A low variability will 
improve the ability to identify differences when making comparisons. This issue will 
be discussed in Chapter 4. 
Patient reported outcome measures (PROMs) data above notes the high success rate 
of the operations. This supports the idea of using total hip replacement surgery as the 
outcome, thereby using the comparator of allogeneic blood required. 
1.21 Total Hip Replacement Operations 
The NHS Choices website (accessed 18 November 2015) highlights both types of 
arthritis (osteoarthritis and rheumatoid arthritis) as being the principal reason for hip 
surgery being required. The website also notes the other main reason being hip 
fracture ‘during a fall or similar accident’. 
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Lambden (2015) states that 95% of people aged over 60 years of age develop 
arthritic changes in one or more joints. Arthritis can affect all joints but the most 
common are hips and knees. The diagrams below show the difference between a 
normal hip joint where the head of femur (the ‘ball’ on top of the thigh bone) fits into 
the pelvis socket (the cup-shaped acetabulum). The cartilage, which acts as a 
lubricant, prevents the bones rubbing and grinding together. Osteoarthritis occurs 
when the cartilage gets worn away. Rheumatoid arthritis arises when the body’s 
immune system mistakenly attacks the joint lining. The results are similar to 
osteoarthritis, with the joint getting damaged over time. 
Figure 7. Normal Hip Joint 
 
Figure 8. Arthritic Hip Joint 
 
The above diagrams were reproduced with the permission of the UCLH Foundation Trust, London. 
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Initial treatment for both types of arthritis is to control the pain and swelling via the 
administration of drugs along with an exercise programme to support mobility and 
encourage weight loss. If this is not successful, the decision would be taken to 
undertake a total hip replacement operation. This is where a metal stem is inserted 
into the femur. On the end of the stem is a ball which fits into a replacement 
acetabulum cup. The picture below shows an image of the successful operation. 
Figure 9. Successful Total Hip Replacement 
 
Above image reproduced from West of England Academic Health Science Network Photo library 
1.22 NHS Trust Financial Regime in England 
Hospitals are evolving into more commercially orientated entities. Since 2009 there 
has been a move to develop Service Line Reporting and Management (SLR) within 
NHS trusts. The application of the concept can vary across trusts but, broadly, the 
medical and surgical specialties will be segregated into business units with income 
and expenditure identified to each unit. Against imposed savings targets, costs and 
income are regularly reviewed with the focus on the ‘profitability’ of each business 
unit (see Service Line Management in www.gov.uk, accessed 25 January 2015). A 
typical general hospital will use over 5,000 allogeneic blood units per annum with 
the largest teaching hospitals using over 25,000 units, costing over £3m. Most 
hospitals now charge out their blood costs to the relevant specialties/business units 
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and some patient level costing systems are sufficiently sophisticated to charge the 
blood costs down to individual patient level, e.g. Guy’s and St Thomas Hospital 
NHS Foundation Trust and University Hospital Southampton NHS Foundation Trust. 
There have been significant developments in costing of services across the NHS over 
the past 15 to 20 years. The English NHS system operates on a tariff system whereby 
trusts are reimbursed for the costs of providing treatment via a single payment 
system applicable to all trusts. The tariff is essentially a price list of services (HFMA 
Briefing July 2012). The majority of these services are grouped into healthcare 
resource groups (HRGs). These are ‘the currency used to collate the costs of 
procedures/diagnoses into common groupings to which prices can be applied’ 
(HFMA/CIPFA definition October 2015). Each HRG is assigned a price and this is 
the income the trust will receive for performing the HRG. There is therefore the 
incentive to control costs, given the income per HRG is fixed, in order to increase the 
‘profitability’ under SLR. At a basic level, avoiding allogeneic blood use will, 
‘ceteris paribus’, increase the profit as the patient will still be treated and the trust 
will avoid paying the £122 for each unit of allogeneic blood. 
1.23 Allogeneic Blood Prices 
The price NHSBT charges for allogeneic blood each financial year is agreed in 
discussion with a panel of hospital users and representatives from the Department of 
Health (the ‘National Commissioning Group for Blood’-the NCG), the notification 
letter on prices is shown in appendix 2. NHSBT’s prices for blood and blood 
components are designed to reflect the cost over a particular level of activity. The 
changes in price of a unit of allogeneic blood over the past decade are shown in 
Figure 10 below. 
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Figure 10. Allogeneic Unit Price Since 2008 (unadjusted for price inflation) 
 
Source. Supplied from NHSBT Demand Planning Team 
Table 10 highlights the sharp fall in the price to 2010 and the subsequent small 
reductions. The relative price (after taking pay and price inflation into account) of the 
allogeneic blood has therefore fallen significantly over the past decade. The gradual 
reduction in the price reflects the decreased costs of the operation of NHSBT due to 
the fall in demand for allogeneic blood of approximately 33% between 2002/3 to 
2017/17 (figure 2). Since 2005 NHSBT has been reviewing its property portfolio and 
focusing investment on a smaller number of centres while, at the same time, 
enhancing its transport infrastructure. There have also been a significant number of 
staff redundancies, thereby reducing NHSBT’s cost base in the longer term and 
allowing the real terms fall in the price over the past nine years. 
There is an argument that, if the fall in allogeneic blood usage did not occur in 
surgical specialties, there would be a greater chance of national blood shortages. This 
would have required wide-scale, and expensive, campaigns to recruit and retain more 
blood donors. This would be costly and the benefits of the price falls in Figure 10 
would not be likely to have occurred. 
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1.24 Allogeneic Blood Transfusions and the Impact on the English NHS Tariff 
System 
As noted earlier, NHSBT sells blood at £122 per unit to hospitals. All blood products 
supplied by NHSBT are charged for and the prices are set to recover the full cost of 
NHSBT’s operations. In 2010/11 approximately £308m came from the supply of 
allogeneic blood and components (NHSBT annual accounts 2010/11, para 6.11). This 
procedure to recover costs via the internal market is consistent with the NHS tariff 
system where there is a price list for services provided by NHS organisations. Within 
NHS hospital trusts, the individual HRG price (Table 7 below) is fixed for the year, 
based on the average cost of all hospitals providing the HRG in England. This overall 
average cost is the basis of the tariff price for the HRG. The price will be adjusted by 
an average ‘market forces factor’ percentage to reflect areas of higher costs e.g. 
London. This tariff-based system is referred to as ‘Payment by Results (PbR)’. 
It is therefore relatively simple to identify the proportion of allogeneic blood costs in 
relation to the income received for undertaking the HRG. The coding of the HRG is 
undertaken by the hospital’s specialist clinical coders. The standard NHS ‘grouper’ 
software will automatically identify a ‘base HRG’ and utilise the procedures that 
have been recorded to assign the most relevant HRG code. 
Figure 11 below is reproduced from the HFMA’s July 2012 briefing on PbR and 
notes the variation in HRG prices for elective hip replacement. All the clinical coding 
is undertaken retrospectively in hospitals. The diagram notes that all patients present 
with previously diagnosed osteoarthritis. The HB12C classification refers to the basic 
condition of a major hip procedure without any complications or comorbidities 
(‘CC’). A CC is then introduced (in this case hypertension) and the grouper software 
will identify the HRG as HB12B; which is a major hip procedure with CC. This 
revised coding will generate additional income for the Trust of £138 per operation. 
Similarly, the HB12A, which has a major CC of dehydration, will attract a 
significantly higher level of income in recognition of the additional input the patient 
will require. 
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Figure 11. Impact of Clinical Coding on Trust Income – Elective Hip Replacement 
 
Assuming two units of allogeneic blood were required for the HRGs in Figure 11, the 
proportion of allogeneic blood costs in relation to HRG income would be shown in 
Table 7 below: 
Table 7. Proportion of Allogeneic Blood Costs to Income in NHS Hospitals  
HRG: HB12A HB12B HB12C 
 Maj Hip Procedure 
with Major CC 
Maj Hip Procedure 
with CC 
Maj Hip Procedure 
without CC 
Two Allogeneic Units £244 £244 £244 
HRG Tariff 2012/13 £8,305 £6,021 £5,382 
Proportion 3.0% 4.1% 4.5% 
Note. CC=Complications and Comorbidities 
It should be noted that table 7 outlines an indicative position consistent with a 
financial ‘make v buy’ question. The HRG is effectively a national average cost and 
therefore not used in decision making. Blood costs at hospital specialty level will be 
absorbed into the tariff price and averaged out nationally. Avoiding allogeneic blood 
usage will leave the hospital with more potential funds as the charges from NHSBT 
will be obviously lower. The funding mechanism combined with the internal market 
for allogeneic blood therefore encourages a hospital to avoid allogeneic blood 
charges. 
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1.25 Summary of Chapter 1 
This chapter has examined the history and development of allogeneic blood 
transfusions. It has introduced the role of NHSBT in ensuring the provision of 
allogeneic blood to (mainly NHS) hospitals in England and briefly highlighted the 
transfer price mechanism that operates. 
There are significant disadvantages in undergoing an allogeneic transfusion and more 
recent studies highlight the inappropriate usage. Allogeneic blood usage has fallen 
significantly over the past decade. NHSBT does not operate in a commercial 
environment and savings in hospital allogeneic blood usage would eventually lead to 
price reductions though there may be a few years’ lead time for the fixed costs (those 
costs that do not vary with activity) to be released from the NHSBT cost portfolio.  
The process of cell salvage has been outlined in this chapter and the assertion is that 
its utilisation will avoid or minimise the requirements for an allogeneic transfusion 
being required in surgery. Proponents of cell salvage point to cost savings. Most 
publications do not focus on the detail of how these ‘cost savings’ are realised. The 
longer-term view is that the demand for allogeneic blood will increase, and 
transfusion avoidance techniques adopted within Patient Blood Management 
(including cell salvage) will be crucial in ensuring allogeneic blood usage is 
minimised to allow for its utilisation where no alternative exists. Cell salvage is one 
tool in the Patient Blood Management armoury and combined strategies may have 
contributed to the falling demand for blood in the surgical environment over the past 
decade. 
Para 1.2 introduced the challenge of the differing theories around costing from a 
financial and economic perspective. Most accountants working in the NHS would be 
focused on their revenue budgets, being part of a financial analysis from an NHS 
organisational perspective. An economist would undertake an evaluation based on 
welfare economics (Mogyorosy and Smith (2005)), being concerned with “the 
impact of any decisions (changes) from a societal perspective”. 
The next chapter will investigate the theoretical aspects of ‘costs’ and ‘savings’ with 
particular reference to the NHS internal market for allogeneic blood.  
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Chapter 2. Financial & Economic Costing-Allogeneic Blood 
Transfusions and Cell Salvage 
2.1 Background 
The literature review will highlight a number of inconsistencies in the interpretation 
of costs associated with both allogeneic and autologous blood transfusions. This has 
been compounded by the cost of an allogeneic blood transfusion claimed by 
manufacturers’ advertising literature. Sorin, manufacturers of the Electa cell salvage 
machine, claim the use of allogeneic blood costs $1,158 per unit and Haemonetics, 
manufacturers of the OrthoPat cell salvage machine, claim the allogeneic blood costs 
“more than $1,400 per unit” (appendix 1). If these high stated costs are correct the 
incentive to avoid an allogeneic unit is significant. 
 
The actual amount charged for an allogeneic unit by NHSBT in England is £122. 
Cost is defined by Horngren et al (2015) as “the resource required to make, do or buy 
a commodity”. This cost is the charge from NHSBT to hospitals (both NHS and 
private); this £122 charge has been relatively unchanged in cash terms from the early 
2000’s. This section will therefore explore the concepts of costs from both a financial 
and an economic approach. The starting point in most of the UK literature is the 
price of an allogeneic unit of blood in the internal market for allogeneic blood within 
the English NHS. The analysis will commence by outlining the relevant costs 
relating to blood transfusions from both a financial and economic viewpoint. 
2.2 Financial Analysis 
Horngren et al (2015) initially assign costs as being direct or indirect costs. 
• Direct Costs. “Those costs that are related to a particular cost object or 
product and can be traced to it in an economically feasible (cost-effective) 
way”. Horngren et al (2015) also notes the technique of cost tracing, being 
the identification and assignment of costs. Direct costs in the hospital surgery 
setting would include the cost of allogeneic blood, cell salvage operating 
costs and consumables. 
• Indirect Costs. These are other costs that are related to the particular cost 
objective but cannot be traced to it in an economically feasible (cost 
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effective) way. These costs are often apportioned using a particular “cost 
allocation method”. In the NHS, these are often termed ‘overhead costs’. The 
operation of the hospital blood bank, internal portering service, ODP training 
and depreciation of the cell salvage machines would be relevant to the full 
costing of blood transfusions. 
 
There are similar cost classifications at NHSBT. It should be noted that NHS 
accounting conventions report costs as gross, including VAT, where this is not 
reclaimable and also employers’ national insurance and pension costs. NHS costs fall 
into two main overall categories. These are: 
• Fixed Costs. Those costs that ‘stay unchanged over stated ranges in the 
volume of production’ (Wood and Sangster (2005) page 658). 
• Variable Costs. These costs vary with output levels and, according to Wood 
and Sangster (2005), ‘variable costs are usually taken to be in direct 
proportion to volume’ (page 658). The charge for allogeneic blood 
transfusions would therefore be a variable cost for the hospital. Cell salvage 
consumables would also fall within this category. 
 
Avoiding an allogeneic blood transfusion will therefore generate a relatively 
substantial saving in the hospital budget (being a product of the number of allogeneic 
units avoided multiplied by £122) with ‘ceteris paribus’ the income received via the 
NHS tariff system being unchanged for the procedure. This saving is consistent with 
Table 8 that notes the costs avoided in hospital budgets utilising cell salvage. The 
key difference is, however, that NHSBT is obviously part of the NHS and therefore 
payment for allogeneic ‘blood costs’ at hospital level are viewed as ‘income’ to 
NHSBT. Most academic studies ignore this point that the £122 is an internal NHS 
transfer price. Table 8 below illustrates the issue if two units of allogeneic blood are 
avoided in an operation utilising cell salvage with consumable costs of £92 per unit. 
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Table 8. Cost/Income in the Provision of Allogeneic Blood  
 NHS 
Trust 
Level 
NHSBT 
Level 
NHS 
Aggregate 
 £ £ £ 
Hospital avoids 2 units -244  -244 
NHSBT income ‘loss’  244 244 
Additional consumables (Royal Cornwall Hospitals 
Electa costs including heparin/saline for illustration) 
92 - 92 
NHSBT avoiding variable costs (2 x £18)  -36 -36 
(Decrease)/Increase in Costs to NHS in Short Term -152 208 56 
 
In the short term, under the NHS internal market for allogeneic blood, there is 
therefore an additional net cost of £56 to the NHS, associated with avoiding two 
allogeneic units utilising cell salvage. This is effectively the cell salvage cost being 
offset by the NHSBT variable cost of producing the units of allogeneic blood. 
NHSBT’s variable costs are primarily the costs of the blood bag used to collect the 
blood from donors. In practice the hospital-based cost would be higher (e.g. 
including the costs of cell salvage training) however Table 8 highlights that the 
respective costs should not be viewed in isolation. NHSBT has responded to the fall 
in demand for allogeneic blood by centralising its services to remove its fixed costs. 
By working in isolation, the hospital therefore increases the short-term costs to the 
NHS. The charges for the allogeneic blood avoided by the hospital translate to an 
immediate offsetting loss of income for NHSBT. NHSBT attempts to mitigate this 
loss of income by requesting information on forecast usage via the National 
Commissioning Group for Blood and modelling demand over the forthcoming years 
to estimate the overall cost requirements. It is against this backdrop of falling activity 
that the progressive reorganisations have led to three main blood centres being 
established in England with smaller centres such as Plymouth being effectively 
stockholding units of blood products receiving daily top ups of products from Filton. 
 
The £122 transfer price is therefore the average cost of one unit of allogeneic blood 
provided by NHSBT from the three main centres. Unlike many other manufacturing 
organisations there is no alternative allogeneic blood product available. To avoid the 
charge the hospitals therefore need to develop alternatives to the ‘traditional’ 
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allogeneic blood transfusion for patient care. Cell salvage is an established 
alternative to allogeneic blood transfusions in a number of patient specialties. This 
therefore allows a comparison for ‘make v buy’ decisions. The ‘make v buy’ 
decision becomes more favourable with cell salvage when high volumes of blood 
loss are forecast. Horngren et al (2015) identify the concept of differential costs 
where the consumable costs are unchanged irrespective of the volume of shed blood 
collected and recycled. The cell salvage machine can keep recycling the shed blood 
until clotting is achieved. This therefore allows a higher equivalent unit of recycled 
blood compared to allogeneic blood to be salvaged where necessary. 
 
Horngren et al (2015) also highlight the “concept of relevance” stressing the focus 
should be on “a manager selecting a course of action based on its future expected 
results”. This approach should therefore exclude capital costs of the cell salvage 
equipment as these capital costs have already been incurred. Arguably the equipment 
is supplied using the ‘razorblade model’ where a relatively cheap purchase of a piece 
of equipment is then followed up by repeated purchases of associated consumables. 
Hospital departmental budgets are, however, likely to be charged the depreciation 
costs of the equipment. These charges will be levied regardless of activity since 
depreciation is regarded as a fixed cost. 
 
From a financial perspective allogeneic blood and cell salvage related costs within 
hospitals and are therefore a combination of actual direct costs and internal transfer 
prices. All charges include VAT and other transfer costs, where levied; being 
consistent with NHS accounting requirements. This significantly adds to the cost 
profile of NHSBT and therefore, by implication, a proportion of the £122 charge per 
allogeneic unit of blood includes VAT. This transfer price is rarely highlighted in 
published articles. The analysis in chapters 6 and 7 will extract the transfer costs 
from the £122 charge and the other costs to facilitate a direct comparison between 
the costs of cell salvage v allogeneic blood; consistent with a ‘make v buy’ decision. 
 
Within hospitals the ‘Blood Bank’ is still a feature in Pathology Departments. Often 
a separate cost centre, the Blood Bank Manager will book in allogeneic blood 
deliveries and maintain the storage facility in a cool room. Stocks will be monitored, 
and additional orders placed for allogeneic units when required. National blood stock 
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management initiatives developed and led by NHSBT over the past 20 years have 
had significant impacts on the size of the hospital blood bank and the volume of 
allogeneic blood held at the hospital. The ‘Online Blood Ordering System’ (OBOS) 
automatically manages the hospital stock and reorders from the local blood 
centre/stock holding unit. At the same time the OBOS system will automatically 
reassign blood stocks nationally to ensure the average age of the blood stock is 
uniform across the country. The impact on allogeneic wastage has been significant. 
From a financial perspective the size and costs incurred by the hospital blood bank 
are now significantly lower and continue to fall. Often the Blood Bank Manager role 
is now combined with additional duties and performed by a less experienced member 
of staff. This obviously has an impact on the blood related costs reported in the 
hospital. 
2.3 Economic Analysis 
An economist will view the costs associated with allogeneic blood from a wider 
opportunity cost perspective (Mogyorosy and Smith (2005)). The cost of using the 
allogeneic blood is obviously relevant. Wider costs e.g. including the donor’s travel 
costs and associated expenses of getting to and from the donation session are also 
relevant as these costs could be utilised by the donor on an alternative. Similarly, a 
donor may take time off work to donate. This may have impacts on pay and outputs. 
 
Opportunity cost measures a particular course of action (e.g. donating blood) in 
terms of opportunities foregone. Arguably this issue may become subjective; many 
donors derive satisfaction from donating blood which generates a ‘feel good’ state of 
mind (see the reference to ‘The Economist’ para 1.8 with donated blood being 
regarded as being the ‘gift of life’). Donors may place a greater value on these 
altruistic feelings than the actual costs they incur. A detailed discussion on this issue 
is beyond the scope of this thesis but the associated donor costs can be viewed as 
directly relevant and therefore an element of the comparison. 
 
Drummond et al (2015) (page 62) note the development of guidelines for the analysis 
and presentation of results using standardised categories. The main features were 
grouped into a ‘reference case’ and the features are highlighted in table 9 below. The 
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potential relevance to allogeneic blood transfusions and cell salvage for each of the 
elements is also noted in table 9. 
 
Table 9. Standardisation of Reporting of Studies in Economic Evaluation in Healthcare (Drummond 
et al (2015)) 
Element Relevance to Cell Salvage 
1. 1. Adopt a societal perspective. Relevant-impact on donor’s time, productivity 
and opportunity cost in donating blood. 
1. 2. Estimates to incorporate benefits and harms. Relevant-Statistical comparisons of datasets 
relating to allogeneic, salvaged blood and no 
transfusions can be undertaken. There are very 
few “harms” associated with allogeneic blood 
(SHOT report) and the vast majority of these 
harms relate to human error. 
3. Mortality and morbidity consequences should 
be combined using QALYS. 
Partially relevant. HRG codes can standardise 
comorbidity estimates and length of stay (LOS) 
can be compared across sites. QALY approach 
not relevant as the comparison is not on whether 
or not to operate. 
4. Effectiveness estimates from best designed and 
least biased sources should be used. 
Relevant. Literature review notes allegations of 
bias (e.g. Carless et al (2010)). Common datasets 
utilised to minimise this issue. 
5. Costs to include healthcare services, patient 
and caregiver time and costs of non-health 
impacts. 
Relevant. Consistent with societal perspective 
and costs incurred by blood donor. 
6. Comparison should be made with existing 
practice and (if necessary) a viable low-cost 
alternative. 
Relevant. Undertaking a three-way comparison 
between a cell salvage site and two sites who do 
not salvage in total hip replacement surgery. 
7. Discounting of costs should be undertaken. Not directly relevant. Overall outcome of surgery 
is not directly contingent on the decision to use 
allogeneic blood or an alternative. Can, however, 
compare allogeneic blood costs directly with cell 
salvage without the need to discount since time 
periods are not crossed. Can also investigate 
capital costs of machine acquisition from a 
financial and an economic perspective to 
determine whether any significant difference in 
impacts. 
8. One way and multiway sensitivity analysis (for 
important parameters e.g. tolerance to falls in 
haemoglobin levels) should be undertaken. 
Relevant. Datasets on e.g. patients’ pre-operative 
Hb levels are pertinent to comparing approaches 
to utilising allogeneic blood, cell salvage or 
neither option. 
9. Composition of incremental cost effectiveness 
ratios should be made with those for other 
relevant interventions. 
Not directly relevant. As for “7” above.  
 
The economic costs associated with cell salvage and allogeneic blood in the 
comparisons should therefore be just the relevant elements. These can be analysed 
over the same headings as for the financial analysis. 
 
• Direct Costs. Drummond et al (2015) classes these costs as those 
“unambiguously attributable to the treatment or programme in question” 
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(page 238). Direct costs relating to allogeneic blood/cell salvage in the 
hospital surgery setting would include the cost of allogeneic blood, cell 
salvage operating costs/consumables and cross matching of blood. 
• Indirect Costs. Drummond et al (2015) note that the favoured option is to 
utilise marginal analysis to identify costs that change if there were a change 
to the overall programme. This is particularly relevant to allogeneic blood 
transfusion and cell salvage. The costs incurred by the hospital blood bank 
may change if there were more or less allogeneic blood transfusions. 
 
Both types of costs can then be sub-divided into: 
• Fixed Costs. Nechyba (2011) defines a fixed cost as “an economic cost that 
remains unchanged regardless of how much output is produced” (page 1188). 
In relation to allogeneic blood transfusions/cell salvage these are mainly 
confined to the performance of costs at NHSBT. Staffing costs at NHSBT are 
generally viewed as the main fixed cost with the majority of staff on 
permanent contracts, having also accrued long periods of employment and 
pension benefits. It is likely these costs would remain unchanged for the 
following two years. 
• Variable Costs. Nechyba (2011) defines a variable cost as a “cost that 
changes as the quantity produced changes” (page 1194). An allogeneic unit of 
blood, utilised in surgery, would be a variable cost in a hospital setting via the 
internal market (para 1.23) along with the consumables associated with 
utilising cell salvage. 
 
The above definitions from both an accountant’s and an economist’s (Horngren and 
Nechyba) perspective are very similar. Both Horngren et al (2015) and Drummond et 
al (2015) refer to ‘cost-effectiveness’; this is defined by Kobelt (2013) as “the 
efficient use of scarce resources” (page 3) and Drummond et al (2015) as where 
“(costs) are related to a single, common effect which may differ in magnitude 
between the alternative programmes”. Kobelt (2013) elaborates by asking the 
question “is an additional benefit worth an additional cost?”; both questions imply 
there should be a decision made to justify whether or not to incur an additional cost. 
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The operation of the NHS internal market has an impact on the decision making and 
focus on costs. The tariff funding for HRGs in para 1.24 is based on an average cost 
basis (i.e. a mix of direct, indirect, fixed and variable costs). This average cost is 
calculated by aggregating hospital apportioned costs to individual HRGs. These 
HRG costs and activity are then consolidated across all English hospitals to derive 
the average costs per HRG. Implicit in this HRG cost, and hence tariff price, will be 
the cost of allogeneic blood. Some hospitals may have elaborate patient level costing 
systems that identify allogeneic blood costs to patient and hence HRG; others may 
just undertake a simple apportionment exercise. These costing methodologies will 
feed into the NHS wide consolidated HRG cost information at a national level and 
the national average cost per HRG calculated. Avoiding a transfusion will therefore, 
‘ceteris paribus’, lower the costs to be identified to the specific HRG at hospital level 
and, in the short term, therefore potentially generate a surplus given the tariff price 
per HRG is fixed. 
 
As noted in table 8 above, aggregating both the costs and the avoided costs would, in 
the short term, cause an imbalance. Allogeneic blood costs in primary hip 
replacement operations are variable for hospitals, but there is an approximate 6:1 
split between fixed and variable costs at NHSBT level (table 71, page 176). Timings 
to match demand for allogeneic blood with supply are therefore crucial. To 
circumvent this issue, the National Commissioning Group for Blood (para 1.23) 
meets to agree forecast volumes and prices annually. Arguably this is a market 
imperfection and perfect competition would ultimately generate an equilibrium price 
and quantity. The recent trends are towards a steadily declining demand for 
allogeneic blood and NHSBT is gradually decreasing its cost base to reflect the 
decreased demand. In recent years, the price (average cost) of a unit of allogeneic 
blood has remained steady or fallen slightly, this is mainly a consequence of the 
reduction in fixed costs by NHSBT closing or substantially reducing its scale of 
operations in Leeds, Birmingham, Southampton, Oxford, Plymouth and Brentwood. 
Para 1.4 noted that the longer-term outlook is still for an upturn in allogeneic blood 
requirements. It is planned that this upturn can be accommodated across a smaller 
number of centres supported by enhanced logistics to deliver the allogeneic blood to 
its required location. 
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2.4.  Comparison of Perspectives 
Overall both financial and economic costs are relevant. From a financial analysis 
perspective budgetary issues relating to allogeneic blood and cell salvage would need 
to be highlighted and the overall (holistic) economic impacts could be described in 
an economic analysis. The choice of methodology of the economic analysis would 
need to be established and the next section will examine the main options/techniques 
available. 
 
Morris et al (2007) noted: “Average cost data obscure potentially important issues 
with respect to the technical efficiency of providers”. The ‘make v buy’ assertion 
effectively assumes that an allogeneic transfusion is required, and this can be 
replaced by cell salvage. What the ‘make v buy’ assertion omits is any verification 
that the approach to deciding whether or not the decision to undertake an allogeneic 
transfusion is based on a uniform set of comparable characteristics. The focus on the 
£122 and calculations of potential units avoided may make cell salvage seem 
attractive. The calculations are, however, built on average costs that can distract from 
the actual costs incurred or avoided. Morris et al (2007) recommend a three-point 
analysis involving: 
• “Identify and describe the changes…in resource use that are associated with 
the options to be evaluated”. The questions would therefore be whether or not 
to utilise an allogeneic transfusion, cell salvage, both (if necessary) or neither. 
• “Quantify, in physical units, those changes in resource use”. This would 
obviously involve the number of allogeneic units utilised along with the cell 
salvage usage where utilised. 
• “Value those resources”. Costs (adjusted depending on financial analysis or 
economic analysis) can be identified relating to the relevant option utilised. 
This approach can be utilised to incorporate both financial and economic approaches. 
The issue on achieving uniformity of the need for an allogeneic transfusion will be 
addressed in chapter 5 (Methods). 
2.4.1. Types of Economic Evaluation 
 
Drummond et al (2015) note that “the purpose of any type of economic evaluation is 
to inform decisions about which of the alternative courses of action available ought 
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to be recommended….for specific groups of patients”. The alternatives available in 
this analysis are whether or not to utilise cell salvage in a primary total hip 
replacement operation to reduce the likelihood of the patient requiring an allogeneic 
blood transfusion. The costs of operating the cell salvage systems can then be 
compared to the savings in allogeneic blood usage associated with the lower 
allogeneic transfusion rate. Primary total hip replacement surgery was chosen for this 
study (paras 1.20) as the outcomes are highly successful and 
complications/comorbidities are unlikely to be a factor of whether or not a patient 
had or did not have an allogeneic blood transfusion. 
 
Both Drummond et al (2015) and Kobelt (2013) detail a number of approaches to 
economic evaluation: 
 
Cost Effectiveness Analysis 
 
This analyses the costs and impacts of the treatment within the same setting. 
Drummond et al (2015) use the example of comparing renal dialysis with kidney 
transplantation. The “outcome of interest” is life years gained allowing the collection 
of cost data for the two alternatives and calculation of e.g. life years gained per 
£1,000 spent on each alternative. 
 
This type of analysis would be partially relevant to a comparison of costs of 
allogeneic and salvaged blood. Reference is made in studies in the literature review 
of an association between a patient’s length of stay (LOS) and whether s/he had or 
did not have an allogeneic blood transfusion. This discussion has tailed off in recent 
years. This study will compare LOS across the three chosen sites to establish whether 
there is a likely impact on LOS by having an allogeneic blood transfusion. 
 
Cost Minimisation Analysis 
 
There is a specific variant of cost effectiveness analysis where, according to 
Drummond et al (2015), the “consequences of two or more treatments or 
programmes (are) broadly equivalent, so the difference between them reduces to a 
comparison of costs”. The ‘treatment’ or ‘programme’ in this thesis is utilising, or 
not utilising, cell salvage, with a potentially increased allogeneic blood transfusion 
requirement, in a successful primary total hip replacement operation (the outcome). 
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Kobelt (2013) highlights a similar interpretation citing an example of the costs 
associated with administering two medicines to achieve the same outcome. This 
therefore allows the limitation of the study to costs alone. 
 
Cost Utility Analysis 
 
This is another variation of cost effectiveness analysis to study the consequences of 
the health intervention. The study utilises a generic measure of health gain (the 
positive impact of the intervention) such as a QALY (quality adjusted life year). This 
can therefore be used to compare different programmes of healthcare. 
Given this study focuses on alternatives for allogeneic blood usage within primary 
total hip replacement surgery the concept of a health gain comparison is not directly 
relevant. As noted in chapter 1 the key aim of an allogeneic blood transfusion/cell 
salvage is to maximise the patient’s post-operative Hb level after surgery. This will 
speed up recovery. Analysis by QALY or another form of cost utility analysis would 
not therefore support the comparison as it is not comparing different programmes of 
healthcare. Instead the analysis will concentrate on a particular set of costs associated 
with attempting to minimise the use of allogeneic blood. 
 
Cost Benefit Analysis 
 
This approach, according to Kobelt (2013) “measures costs and benefits in monetary 
units and computes a net pecuniary loss/gain”. This requires the impacts of a 
particular course of action to be converted into monetary terms. A number of the 
earlier studies (e.g. Thomas et al (2001)) attempted this approach on total knee 
replacement surgery, citing the impact of the longer length of stay (LOS) associated 
with allogeneic blood transfusions. It was argued that this longer LOS generated 
additional costs e.g. additional accommodation and support costs. The literature 
review discusses other studies that adopt this approach noting, however, that most of 
the costs cited are fixed costs and are therefore not directly relevant to the discussion. 
 
The LOS issue is still, however, pertinent. If the analysis in this study concludes, 
‘ceteris paribus’, that increased LOS is likely to be driven by a patient having an 
allogeneic blood transfusion then an element of the support cost would be relevant to 
incorporate into the cost comparison i.e. avoiding this cost would be a further 
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benefit. A cost benefit analysis approach should therefore not be discounted at this 
early stage. 
 
2.4.2. Choice of Approach for Economic Comparison 
 
Given the focus is on one particular treatment and the comparison is being made 
between allogeneic blood requirements and cell salvage, a cost minimisation study 
on the costs of cell salvage is likely to be the most appropriate approach. LOS issues 
should be investigated to determine whether this analysis should be extended to a 
cost benefit analysis  
2.5  Health Technology Assessment (HTA) 
The World Health Organisation defines a health technology as “the application of 
organized knowledge and skills in the form of devices, medicines, vaccines, 
procedures and systems developed to solve a health problem and improve quality of 
lives” (http://www.who.int/health-technology-assessment/about/healthtechnology/en/ 
accessed 6 October 2017). The “health problem” in this thesis is the requirement to 
increase the patient’s post-operative Hb levels in order to facilitate a quicker 
recovery and hence support as early a discharge from hospital as possible. The 
choice is therefore whether or not to use cell salvage as a ‘device’ to avoid using an 
allogeneic blood transfusion. 
 
An HTA is defined by the WHO (EB134/30) as “the systematic evaluation of 
properties, effects and/or impacts of health technologies and interventions. It covers 
both the direct, intended consequences of technologies and interventions and their 
indirect, unintended consequences”. The WHO list various examples of when HTAs 
may be used to support decision making; these include “supporting decisions on 
diagnostic and medical equipment”. 
 
The application of cell salvage as a means of avoiding an allogeneic blood 
transfusion therefore falls within the criteria of an HTA.  
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2.6  Type of Analysis to Adopt 
Given so many of the cost concepts are interrelated the decision was taken to 
examine the costs associated with allogeneic blood and cell salvage from both a 
financial and economic perspective. Discussions with NHS accountants note their 
focus on the ‘make v buy’ approach. This is highly relevant but, from an economic 
cost perspective, omits questions on the efficacy of using either process when the ‘do 
nothing’ approach of not adopting either an allogeneic transfusion or utilising cell 
salvage may be an option. Additionally, an economic analysis would take a more 
holistic approach across the NHS and examine the related donor and societal costs 
that are rarely covered in the published literature. Separate ‘pools’ of costs to 
differentiate between financial and economic approaches can therefore be utilised. 
2.7 Treatment of Capital Expenditure 
Capital costs have a broadly similar definition from both a financial and an economic 
perspective. From a financial approach Horngren et al (2015) note capital budgeting 
is “the process of making long-run planning decisions for investments in projects”. 
Drummond et al (2015) define capital from an economic analysis perspective as “the 
costs to purchase…major assets required by the programme; generally equipment 
and land”. Both definitions note the issue of timing of the relevant expenditure. This 
timing is longer term and often involves ‘up front’ payments with the expectancy of 
a stream of benefits accruing over a number of years. 
 
An economic approach would consider two elements associated with capital 
expenditure. There is an opportunity cost of the organisation’s funds being tied up in 
the asset. This is usually accounted for by discounting the cash flows associated with 
the asset as it is being used. The second element is the depreciation of the asset over 
time. This represents the ‘wearing out’ of the asset through use or obsolescence. 
Drummond et al (2015) recommend treating capital costs through the ‘equivalent 
annual cost’ method. This method smooths out the two elements over the life of the 
asset. 
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A financial approach will similarly attempt to identify the capital costs over the life 
of the asset. This is undertaken through depreciation where the capital cost is spread 
over and therefore charged to the financial years the asset is in use. NHS accounting 
requirements do not now require any discounting for a comparable opportunity cost 
charge.  Depreciation is generally calculated on a straight-line basis. A typical cell 
salvage machine would cost around £15,000 including VAT. Many machines will 
last at least ten years, so the depreciation charge would be c. £1,500 per year. This 
cost in a hospital would generally be charged to the hospital department’s operating 
budget. An apportionment would be required to identify the element of the £1,500 
depreciation charge relating to primary total hip replacement surgery since the 
machine would also be utilised in other surgical procedures. 
 
At NHSBT the identification of the costs associated with the capital assets utilised on 
allogeneic blood is more challenging. This will encompass elements of buildings, 
machinery and ‘intangible’ assets such as software. An estimate of the depreciation 
costs can be extracted from the notes to the audited accounts. The equivalent annual 
cost element will not be appropriate since the many hundreds of assets will have 
varying lives and depreciation methods however an estimate of the opportunity cost 
element in an economic evaluation can also be derived by reference to calculated 
depreciation charge, representing the decrease in the overall balance sheet value. 
 
The calculations for the capital elements from both a financial and economic 
perspective will therefore be very similar. An adjustment for the transfer price charge 
for VAT will be also be required in the economic analysis. 
2.8  Summary of Chapter 2 
A brief comparison of the Financial and Economic perspective is summarised in 
table 10 below. There is no ‘right’ or ‘wrong’ approach. The hospital accountant will 
focus on a particular set of circumstances and assumptions within the blood related 
costs and contract income. This focus will be different to the income and cost focus 
from the accountants at NHSBT. All these costs and sales income are within the NHS 
and some of these cancel out. Additionally, the majority of non-pay costs include 
VAT and other transfer payments such as national insurance. From an economic 
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perspective the wider cost impacts can be considered. These may include donor costs 
that are not recompensed or potentially lost production costs where the donor is 
given time off work to donate. 
Table 10. Summary of Relevant Cost Concepts 
Issue Financial Analysis-Horngren et al (2015) Economic Analysis-Drummond et 
al (2015) 
Focus Expected future costs arising from a particular 
course of action. 
Same. Costs of allogeneic blood 
Emphasis Focus will be on the costs that differ according 
to various courses of action e.g. cell salvage v 
allogeneic blood. 
As above. 
Common 
Costs 
Common costs e.g. hospital blood bank costs 
are excluded but transfer payments are relevant 
for budgetary purposes. 
Transfer payments excluded 
(includes VAT that is levied across 
most non-pay expenditure in the 
NHS). 
Sunk Costs Sunk costs (past costs) are excluded but 
depreciation still utilised in NHS accounts. 
Excluded as not a relevant cost. 
Wider 
Costs 
Societal and wider non- hospital costs not 
included. 
Include societal costs e.g. donor 
travel costs, environmental costs, 
lost productivity/time off work. 
Capital 
Expenditure 
Relevant from NHSBT perspective, given 
depreciation is included in £122 charge for an 
allogeneic unit. Reflects the accounting 
‘accruals concept’. 
Relevant, reflecting the opportunity 
cost of funds being tied up in the 
assets. 
 
Chapter 3 will develop the research question to consider the approach to the differing 
perspectives of costs highlighted in this chapter.  
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Chapter 3. Development of Research Question 
3.1 Introduction 
The Literature Review will highlight the divergence and subjectivity of studies in the 
costs associated with cell salvage. The manufacturers (para 2.1) continue to imply 
significant savings can be made within a hospital when utilising cell salvage to 
replace an allogeneic blood transfusion. Chapter 2 noted the substantial differences 
between a financial and economic approach to the costs within the NHS internal 
market for allogeneic blood; the differing transfer prices and costs can significantly 
distort the position. 
This chapter therefore outlines the development of the research question to 
incorporate the issues associated with ‘costs’ and the application of these ‘costs’ 
relating to cell salvage along with the impact of cell salvage on the allogeneic blood 
requirements. 
3.2. Research Aim/Challenges 
A brief background to the development of the researcher’s interest in cell salvage 
was included in para 1.2. The challenges on undertaking the research were further 
exacerbated when he was made redundant from NHSBT in October 2013. This 
significantly held back the progression of the thesis as finding and settling into a new 
job became the priority. The researcher secured employment in the Finance 
Department at South Devon Healthcare Foundation Trust, Torquay in January 2014. 
This allowed access back into the NHS wide information systems, access to which 
had been suspended in October 2013. Work on the thesis recommenced in 2014 
when it was time to take stock of how the research was developing. 
The main association for accountants working in the NHS is the Healthcare Financial 
Management Association (HFMA). The researcher had previously written two 
articles on avoiding blood transfusions in the HFMA’s monthly publication 
‘Healthcare Finance’ in 2005 and 2010, however there was little interest generated in 
the healthcare finance community. Discussions with colleagues at NHS Trusts 
elicited the general response that the savings generated by cell salvage appeared 
relatively small. The accountants were looking for more and the emphasis was on 
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wider NHS costing initiatives to achieve the savings being demanded by initiatives 
such as the 2010 Nicholson Challenge in the English NHS. 
The 2010 HFMA article drew on the experiences of the researcher’s trip to Pittsburgh 
to meet Dr Jon Waters, a leading proponent of avoiding allogeneic blood 
transfusions. Dr Waters stressed the importance of the recovery plans and highlighted 
the interrelationships between many initiatives running concurrently. He stressed that 
the operation day of the week was important for relatively routine operations to 
ensure most of the patients were sufficiently recovered to go home by the weekend. 
Tuesday surgery at Pittsburgh was traditionally the day for relatively minor 
orthopaedic operations to be undertaken so most patients would be home by Friday 
afternoon. 
The researcher believes the impact of cell salvage goes much wider than savings in 
hospital blood budgets, with most hospital accountants focusing on the direct budgets 
as he did in his early days in London. There are few economic analysis studies taking 
a holistic view of the financial impacts (including transfer prices such as VAT and 
national insurance) across the whole area of blood transfusions from donor to patient. 
This study gives the opportunity to research the overall impact of cell salvage and 
will inform discussions over the wider development of the emerging concept of 
Patient Blood Management (PBM). The researcher’s thoughts have developed 
significantly since his published article (Crotty (2006)) where, in hindsight, the 
analysis was simplistic. 
Furthermore, the researcher notes the variation in the resources required to undertake 
a total hip replacement operation (para 1.24 above) using HRG coding to indicate the 
relative differences. This variation is likely to affect allogeneic blood requirements. 
To the best of the researcher’s knowledge no study on the application of cell salvage 
in total hip replacement studies has made an assessment based on HRG 
classification. A study based on this enhanced level of detail will allow an additional 
level of confidence that the cohorts of patients are readily comparable and minimise 
the potential variation caused by those patients e.g. a group of patients may require 
relatively more invasive surgery due to additional complications and comorbidities. 
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3.3 Statement of Research Question and Objectives of Thesis 
This study aims to assess whether the utilisation of cell salvage in total hip 
replacement surgery will support overall reductions in allogeneic blood costs from 
both a financial and economic perspective. It will therefore assess the wider costs 
associated with allogeneic blood transfusions, including costs associated with blood 
donors and NHS wide costs. Cell salvage will also be assessed to verify whether it is 
cost effective in reducing the requirements (and hence demand) for allogeneic blood 
and thereby reducing costs across the NHS and the wider society. 
As noted in chapter 2 the choice of specialty is likely to lend itself to a cost 
minimisation study. This is defined by Kobelt (2013) as being applied “when two or 
more health care interventions have the same outcomes”. Kobelt (2013) quoted the 
example of a comparison of the cost of alternative drugs being appropriate to 
utilising a cost minimisation study. With cell salvage, there is an effective choice 
between using cell salvage to avoid an allogeneic transfusion, in the case of the 
Royal Cornwall Hospitals NHS Trust, or with South Manchester University 
Foundation Trust and the SOC (the Specialist Elective Orthopaedic Centre that 
remains anonymised in this study) not using cell salvage in orthopaedics. South 
Manchester utilise cell salvage in cardiac operations but believe that they can be 
equally assiduous in patient blood management without the need to salvage 
orthopaedic patients. 
This cost minimisation approach has an added complication of including an internal 
recharging mechanism for allogeneic blood combined with alternative methods of 
avoiding allogeneic transfusions. The challenges associated with attempting to 
isolate the individual impact of the various allogeneic blood avoidance methods are 
highlighted in para 5.5. 
Para 2.4 noted that, if length of stay (LOS) is likely to be a consequence of an 
allogeneic blood transfusion then a cost benefit analysis may be more appropriate. 
LOS will therefore be included in the analysis (para 3.3.3 below). 
Additionally, there are even fewer studies that make comparisons between the 
different types of cell salvage machines available for use. Dusik et al (2014) state in 
their review of publications, “No studies directly compared transfusion rates among 
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cell salvage systems”. This thesis has extracted information from two different 
salvage systems (intraoperative and post-operative cell salvage) and a comparison of 
the information relating to the two systems’ use will be undertaken. Preliminary work 
undertaken indicated that the running costs of the OrthoPat cell saver machine were 
significantly more expensive than other cell salvage machines. The Haemonetics 
investor conference call comments (para 1.9 above) were quite pertinent and 
reinforced the researcher’s motivation to accommodate a comparison of cell salvage 
machines. 
The research question was therefore developed in discussions with clinicians across a 
number of hospitals. The common theme of the discussions was the often-quoted 
remark by clinicians “the best transfusion is no transfusion” (Daniels and Bromilow 
(2014) quoted but widely discussed since the 1990’s) and “transfusion has risks but 
bleeding to death is fatal” (Thomas (2005) page 35)). All means possible should 
therefore be used to minimise the likelihood of a patient requiring an allogeneic 
blood transfusion in surgery in accordance with the Department of Health (DH) 
‘Better Blood Transfusion’ (BBT) initiatives of 1998, 2002 and 2007. 
The research question was therefore finalised as:  
“Is cell salvage an appropriate method of blood conservation to support the 
reduction in costs associated with the collection and utilisation of allogeneic 
blood?”  
The question therefore allows the interrelationship between cell salvage and other 
blood avoidance techniques to be examined, as well as the wider analysis with costs 
at hospitals, NHSBT and costs associated with the donation process, including the 
donor costs. In the UK, in common with most countries, blood donors are 
unremunerated. The choice of the word “appropriate” was deliberate as this word 
was used to stress that consideration should be given to alternatives to an allogeneic 
transfusion “where appropriate and available”. The second BBT initiative in 2002 
was titled “Appropriate Use of Blood” with the third BBT initiative in 2007 entitled 
“Safe and Appropriate Use of Blood”. The term therefore spanned both the 
allogeneic usage and the alternatives. The term, along with “inappropriate use of 
blood” was also stressed in the Patient Blood Management Guidance issued in June 
2014. The adjective “appropriate” is defined by the Cambridge English Dictionary as 
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“suitable or right for a particular situation”. The term is therefore apt in the context 
of deciding when to administer an allogeneic blood transfusion where the clinician 
needs to decide on the basis of a number of issues that can be both subjective (e.g. 
the patient states they are feeling ‘unwell’) or more certain (e.g. the most recent Hb 
level). 
The research question will be answered by addressing the following three 
overarching objectives: 
3.3.1. Establish the homogeneity of the patient cohorts selected in order to minimise 
allegations of bias and compare patient data between sites that use and do not 
use cell salvage. This will support a valid comparison between the three sites. 
3.3.2. Evaluate the cost impacts of cell salvage against using allogeneic blood from 
both a financial and an economic perspective; 
3.3.3. Investigate other possible factors that may impact on comparison across sites 
such as preparation for surgery and length of stay. 
3.4 Summary of Chapter 3 
The differing approaches relating to the financial and economic analysis are highly 
relevant. An accountant in a hospital would view the comparison between utilising 
cell salvage to avoid an allogeneic blood transfusion as a ‘make v buy’ discussion 
where, all other things being equal, the hospital as a separate entity would benefit 
financially if the cost of operating cell salvage in an operation is less than the cost of 
the allogeneic blood purchased from NHSBT. The accountant at NHSBT would see 
the sales level fall with a fall in allogeneic blood usage. At the same time there is no 
guarantee that cell salvage or allogeneic blood is being utilised optimally with the 
concomitant impact on the level of costs incurred within the respective organisations. 
To the best of the author’s knowledge no study has been undertaken to compare the 
overall impact of a mix of allogeneic blood and cell salvage together while, at the 
same time, investigating the efficacy of whether either type of transfusion is required 
at all. 
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Chapter 4. Literature Review 
4.1 Introduction 
This chapter will focus on the published literature and will highlight the differing 
approaches to studies in cell salvage. The aim will be to generate sufficient 
information to support the work involved in developing the answer to the research 
question “Is cell salvage an appropriate method of blood conservation to support the 
reduction in costs associated with the collection and utilisation of allogeneic 
blood?”. 
Chapter 2 noted the alternative aspects of financial and economic analysis in relation 
to allogeneic blood and cell salvage. This literature review will consider the main 
selected studies from both aspects. ‘Cost’ is obviously a key attribute in the studies. 
However, this term can be interpreted in a number of different ways in studies. The 
aim of this chapter is to identify and highlight the differences in interpretations of 
costs and activity associated with cell salvage. This will form the basis for the 
information gathering at the three centres performing the total hip replacement 
operations. 
Prior to developing the literature review, the researcher discussed the draft research 
question with a consultant anaesthetist at Abertawe Bro Morgannwg (ABM) 
University Health Board. His views were particularly thought provoking to the 
researcher. He stressed to the researcher that the ‘costs’ associated with a patient’s 
treatment not only included direct and indirect costs (highlighted in para 2.2) but the 
wider societal costs also includes unquantifiable costs. This could be the anxiety of 
knowing a loved one is in hospital and the general lower productivity of relatives of 
working age who may take time off from work to visit. This issue is especially 
relevant to allogeneic blood transfusions where the mean age of the patients 
receiving an allogeneic transfusion is 62.7 years’ old (para 1.9) and the partner may 
be around the same age with a higher likelihood of facing transport challenges in 
getting to the hospital to visit. The longer a patient is in hospital the more stress is 
therefore heaped on friends and relatives. The consultant anaesthetist stressed that 
length of stay should therefore be a key aspect of the study. This could act as an 
indicator of the general stress and anxiety levels impacting on others. 
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Discussions with colleagues at NHSBT noted potential issues around the NHS 
internal market and that the true ‘saving’ of avoiding allogeneic blood would accrue 
across NHS organisations (table 8). The researcher had a further discussion with the 
Welsh Lead on the UK Cell Salvage Action Group. She drew the researcher’s 
attention to the costs associated with training of staff to use the cell salvage 
machines. These were a short term logistical cost but, in time, these would tail off as 
more staff were trained. 
At the hospital level the researcher had spoken to a number of blood bank managers. 
All were adamant that the NHS internal market could provide an incentive to reduce 
the cost of allogeneic blood in hospitals. There was a cynical view from one blood 
bank manager that lower NHSBT allogeneic blood issues would result in an increase 
in the price of an allogeneic unit to maintain overall cost recovery, but the price fall 
highlighted in figure 10, along with gradually decreasing allogeneic blood usage, is 
reassurance that this concern was unfounded. 
The different perceptions of costs tended to muddy the waters. A significant 
challenge was to keep the study focused on cell salvage and attempt to isolate the 
impact of cell salvage on costs associated with the collection and utilisation of 
allogeneic blood. Not all costs highlighted were directly relevant to the discussions 
and this review will consider the efficacy and relevance of the costs. 
Chapter 1 introduced the main concepts behind the provision of allogeneic blood and 
noted that the conditions for an economic analysis were appropriate to undertake a 
cost minimisation study; as highlighted by Kobelt (2013) where there are alternative 
treatments, but the outcomes are the same. Kobelt specifically refers to (page 36) 
“technical improvements in procedures, (that) can lead to fundamental changes to 
cost structures without affecting outcomes”. One would expect a similar (successful) 
outcome to the operation with the technical improvement being the adoption of cell 
salvage to minimise the allogeneic blood requirements. The requirement would be 
whether the patient needed an allogeneic transfusion or, as an alternative, cell 
salvage; the blood requirement combinations would therefore be: 
• patient has an allogeneic blood transfusion. 
• adoption of cell salvage as an alternative to an allogeneic blood transfusion. 
• a combination of a transfusion utilising both allogeneic and salvaged blood. 
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• no transfusion at all with no cell salvage. 
4.2 Objectives of Chapter 4 
The key aim, as described in the research question, will be to identify the relevant 
financial and economic costs of cell salvage and its impacts on minimising 
allogeneic blood usage. This chapter therefore builds on the logic behind the 
development of the research question and reviews the literature associated with cell 
salvage and other aspects of allogeneic blood costs associated with answering the 
research question. It explores the differing views of authors, where the approaches 
and conclusions can contradict each other or where it could be argued the 
conclusions are based on logic that may not stand up to scrutiny or may be overtaken 
by developments. 
Costs associated with an allogeneic blood transfusion can be grouped into four main 
headings: 
• Hospital associated costs. The main element is the actual charge from 
NHSBT for a unit of blood (£122). Overall there are 23 different blood 
groups with over 400 antigenic differences (substances that can produce a 
specific immune response or reaction). The majority of human blood falls 
into six main groups. A patient undergoing an operation that will be likely to 
require an allogeneic blood transfusion will have his/her own blood ‘cross 
matched’ to test any incompatibilities between the antigenic differences. This 
test is undertaken by hospital haematology staff and the cost of this cross 
matching is borne by the hospital. Over the past ten years, there has been a 
move to electronic cross matching (ECM) where the results are available 
within minutes. This is adequate for c. 70% of all patients. Where a more 
detailed assessment is required the estimates on the cost vary but, in general; 
a cross match will cost approximately £10-£20. Additional costs will include 
the operation of the ‘Blood Bank’-the secure area that stores the allogeneic 
blood and, depending on the size of the hospital and the volume of allogeneic 
blood required, will have at least one member of staff responsible for 
allogeneic blood issues. Where cell salvage is utilised, these costs are 
incurred by the hospitals in the form of the equipment costs (capital costs and 
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running costs) and the consumable costs (mainly the reservoir, the tubes/filter 
and the anticoagulant). These costs are generally included in the published 
articles on cell salvage. 
• Cell salvage equipment manufacturers costs. It is assumed that costs are 
recovered in the companies’ pricing structures for the sale of 
equipment/consumables. In the US, especially, some manufacturers supply 
the equipment for no charge and recover their costs via charging for the 
consumables. In the UK, value added tax (VAT) is levied on all charges for 
equipment/consumables; this is not reclaimable by hospitals. 
• NHS Blood & Transplant (NHSBT) costs. NHSBT recover costs by levying a 
charge of £122 per unit of allogeneic blood (‘red cells’). This was the 
uniform price charged for 2011/12, being held fixed for subsequent years, 
irrespective of the number of units requested, to all hospitals (both NHS and 
non-NHS). The price reflects the cost of the whole NHSBT operation from 
recruiting donors through to blood collection and the processing/testing 
environment to issuing the blood to the hospitals plus all the NHSBT 
overheads. The £122 charge includes transfer prices such as employers’ 
national insurance contributions and VAT. HMRC class VAT as an ‘exempt 
supply’ for healthcare in the UK; as such, the VAT incurred on purchases of 
goods cannot be reclaimed by the NHS, except in specific circumstances. The 
calculations in this thesis will always include VAT and will be adjusted, 
where necessary, within chapter 6. 
• Societal Costs. This is a more subjective issue. The donors will give up their 
time to donate blood. There is an opportunity cost involved since the donors 
may lose pay through having to take time off work. If their pay is not 
deducted, then the employer will effectively be making good the loss. Either 
way, productivity falls. Alternatively, if, e.g. the donor takes a half day off as 
paid holiday s/he would be forgoing approximately 90 minutes of benefits 
derived from leisure by going to donate blood. There is also an environmental 
impact relating to the carbon emissions from the donor’s journey to/from the 
donation location. 
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Underpinning all the analysis will be the differences in interpretation between 
financial and economic analysis as highlighted in chapter 2. 
4.3 Methods 
The start point in the electronic search for information was undertaken by entering 
the terms ‘cell salvage’ or ‘autotransfusion’ (a US shortened form of ‘autologous 
transfusion’ and often used interchangeably with the term ‘cell salvage’) into the 
Eduserv Athens search engine. These accessed databases of publications including: 
• Allied & Complementary Medicine 
• British Nursing Index 
• CINAHL 
• EMBASE 
• Health Business Elite 
• Health Management Information Consortium 
• Medline 
• PsycINFO 
As noted in para 3.2 the author was made redundant from NHSBT in 2013, this 
slowed down the progression of the thesis as finding and settling into a new job 
became the priority. The search was therefore undertaken in two stages. The original 
search was undertaken to the end of 2011 however it was felt that this may omit 
more recent relevant articles. In 2014 it was therefore felt advisable to update the 
review to cover the additional two years to the end of 2013. In both cases the same 
search criteria was adopted. 
A flowchart of the methodology is shown in figure 12 below: 
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Figure 12. Literature Review Flow 
 
 
Tables 11 to 15 below have been derived from a Microsoft Excel pivot table analysis. 
A pivot table is a data summarisation tool that can automatically sift, sort and 
summarise spreadsheet data into a separate table according to the criteria stipulated. 
Summary information relating to each of the 142 articles selected was inserted into 
an Excel spreadsheet and table 11 below summarises the extraction of the data by 
country of origin and year of publication where the studies were undertaken. 
Discussions and investigation into cell salvage have been focused on publications 
from the US and the UK. 
Table 11. Breakdown of Articles’ Country of Origin 
Year UK US Rest of 
World 
Total 
2006 5 2 2 9 
2007 4 2 4 10 
2008 4 6 3 13 
2009 7 6 5 18 
2010 16 8 5 29 
2011 9 5 5 19 
2012 10 8 7 25 
2013 9 5 5 19 
Total 64 42 36 142 
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Further sub-dividing these publications by specialty highlights the difference in 
emphasis in the studies between the UK and the US. This is shown in table 12 below. 
Table 12. Breakdown by Specialty 
Specialty UK US Rest of 
World 
Total 
Orthopaedics 10 11 9 30 
Cardiac/Cardiothoracic 8 11 10 29 
Obstetrics & Gynae 23 2 1 26 
Cross Specialty 13 8 10 31 
Other/General 10 10 6 26 
Total 64 42 36 142 
 
Analysing the information by article type by country of origin again highlights the 
dominance of the discussion between the UK/US. This trend may be changing 
slightly with slightly more articles being produced from other countries. It is 
therefore difficult to identify the usage of cell salvage across countries and whether 
the number of articles is a factor of usage or individual’s aspirations. The most recent 
Council of Europe report (2013) on the ‘Collection, Testing and Use of Blood and 
Blood Components in Europe’ does not survey cell salvage usage in member states. 
As such there are few current assessments of the utilisation of cell salvage across 
countries. 
Table 13. Breakdown of Articles by Type/Country of Origin 
Country 
Full 
Article 
Conf 
Abstract Other Total 
UK 36 20 8 64 
US 29 11 2 42 
Rest of World 22 8 6 36 
Total 87 39 16 142 
4.4 Studies Considering Financial Impact 
Each of the articles was reviewed and classed into a category to indicate the level of 
discussion relating to financial impacts. The criteria adopted was to take all 142 
articles and group them into: 
Low-no reference or passing general reference to the cost of operating the cell 
salvage machine or cost of allogeneic blood-no indications of costs that could be 
avoided. There was little allogeneic blood activity information reported to therefore 
estimate costs. 
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Medium-Made more specific references to operating costs or impact of allogeneic 
blood costs in the study or some allogeneic blood activity information that would 
enable an estimate of the blood costs to be derived. 
High-Incorporated costs and financial impacts in the conclusion or there was 
adequate allogeneic blood activity information to generate more detailed blood cost 
estimates and draw conclusions. 
The criteria were, by the nature of the studies, subjective. The focus was initially on 
the studies that could allow the comparison of costs. Other studies were also 
accessed as examples to illustrate issues and make comparisons. Very few studies 
utilised any cost-effectiveness techniques or economic analysis. This criterion was 
therefore not used as a category to differentiate between the studies. Tables 11 to 13 
above were therefore re-analysed in the Excel pivot table and summarised in table 14 
below. 
Table 14. Breakdown of Articles by Specialty and Cost Relevance 
Specialty\Relevance High Medium Low Total 
Orthopaedics 15 7 8 30 
Cardiac/Cardiothoracic 7 3 19 29 
Obstetrics & Gynae 4 9 13 26 
Cross Specialty 8 2 21 31 
Other/General 6 4 16 26 
Total 40 25 77 142 
 
The focus of the financial discussions is therefore on orthopaedics. 31 out of the 40 
‘high’ categories are from the UK and US. The obstetrics and gynaecology total of 
26 is one of the highest in the grouping; however, the 2010 publications were 
dominated by exchanges in correspondence in the publication, Anaesthesia, on 
hypotension in child birth and the impact of cell salvage. This made only slight 
references to costs in relation to the operation of the cell salvage filters used.  
4.5 Main Reference Work-Carless et al (2004) and (2010) 
The main published reference work is the Cochrane Collaboration’s “Cell Salvage 
for Minimising Perioperative Allogeneic Blood Transfusion (Review)” authored by 
Carless et al (2004) with an update in 2010. Both studies undertook a meta-analysis 
of the publications relating to studies in cell salvage worldwide. Their specific search 
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criteria identified allogeneic blood transfusion trials and randomised controlled trials 
(RCTs). They noted that there was little advance in the debate on costs. Some of their 
conclusions e.g. on orthopaedics, were virtually unchanged over the six-year 
intervening period between 2004-2010. Carless et al (2010) commented on the 
studies that took the ‘traditional’ approach to a cell salvage cost comparison. 
Generally, a hospital would randomly select patients to have cell salvage in a 
particular type of operation and compare the results against a similar cohort that had 
the same operation in the hospital but did not have cell salvage. 
Carless et al (2010) assessed RCTs comparing allogeneic usage with cell salvage 
published between 1978 and 2008. They were critical on the low number (6) of non-
English language studies (page 12) and bought in a level of doubt over the 
comparability. They then asserted (page 15) that “technologies such as cell salvage 
have been introduced without firm evidence to support their use”. This seems to be 
contradictory with the next comment relating to a 2006 Health Technology 
Assessment (HTA) (Davies et al 2006), this pointed to significant savings by using 
cell salvage. It is not clear whether Carless et al (2010) are critical of the HTA report. 
What is clear is the level of subjectivity and divided opinion across the discussion. 
Carless et al (2010) noted the potential bias in studies such as Thomas et al (2001). 
This was also raised by Vamvakas and Blajchman (2001) who pointed to ethical 
considerations where patients cannot be randomly allocated not to receive a blood 
transfusion. There would therefore be a tendency to try to avoid giving post-
operative allogeneic units to the cell salvage group of patients while feeling more 
relaxed about giving allogeneic units to the cohort without cell salvage. As noted in 
chapter 1 this was one of the reasons for the researcher developing a multi-site study 
to compare information from sites that used or did not use cell salvage in order to 
ensure this potential for bias is minimised. Given the variation in allogeneic 
transfusion rates the comparative study needed to be undertaken between sites with 
low rates of transfusion in order that a ‘baseline’ transfusion rate for the procedure 
could be derived. The comparative work would then isolate the costs associated with 
cell salvage. An article by Joy and Bennett (2012) was published that calculated the 
allogeneic transfusion rate for total hip replacement operations at 27% at the 
Gloucestershire Hospitals Foundation Trust. This is another variation on the theme of 
bias. Introducing cell salvage at Gloucestershire would be likely to reduce the 
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volumes of allogeneic blood required. On the face of it cell salvage would then be 
banded a success but Joy and Bennett (2012) point to the high rate of ‘inappropriate’ 
transfusions (>50%). If the blood management policy at the Royal Gloucestershire 
was enhanced to utilise fewer allogeneic units, savings in allogeneic blood usage 
would gradually accrue with little or no outlay. 
The debate over ethical considerations has evolved over recent years. Catling (2009) 
noted that “the ethics of randomising patients to receive donor blood when they 
could chose (sic) autologous blood should be considered” in commenting on points 
raised in Geoghegan et al (2009). Catling (2009)’s reply to her letter noted that this is 
an issue that could be put to the relevant hospital ethics’ committee. This issue over 
patient choice is key; Carless et al noted (page 6) the very high risk of selection bias 
in the studies and therefore the potential conflict between assigning a patient in a 
study to be in an allogeneic blood group i.e. not being given the opportunity to refuse 
allogeneic blood. 
The conclusion to Carless et al (2010) article is hardly a ringing endorsement of cell 
salvage: “the use of washed cell salvage appears justified in orthopaedic surgery”. 
The implication is that cell salvage is cost effective but their recommendation, 
unchanged from 2004, remained that “the principal need is for large, 
methodologically rigorous comparative trials to assess the (inter alia) cost 
effectiveness of cell salvage in different surgical procedures”. Disadvantages in using 
cell salvage were highlighted but Carless et al’s conclusions were that no advantages 
were statistically significant. They also highlighted that the difference in hospital 
length of stay was not statistically significant when comparing cell salvage with 
allogeneic blood. Their conclusions focused on the negative and did not consider 
costs in detail though they referred to costs that in some studies were not included 
e.g. the operator costs or the actual cell salvage kit itself. Davies et al (2006) was 
quoted noting the net benefit of using cell salvage in an operation as being within the 
range £112 to £359. These were the only detailed costs referred to in Carless et al 
(2010). 
Carless et al (2010) sum up their analysis by stating, “The majority of trials were of 
poor quality” and of most concern was that “only one trial reported a method of 
concealing treatment allocation that was judged to be adequate”. These (relatively 
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scathing) comments were noted and borne in mind by the researcher for the 
comparative studies to be undertaken. Given no patient allocation was required (all 
orthopaedic patients were planned to be salvaged at the Royal Cornwall Hospitals 
and none at South Manchester or the SOC) this thesis will circumvent the allegation 
of potential bias on patient selection. Additionally, the allocation of the patient to the 
relevant HRG (para 1.24) is automatically undertaken post-operatively via the 
national HRG grouper software that identifies the patient to a specific HRG code. 
This code is allocated utilising the individual procedure codes assigned by the 
clinical coders who act independently of the whole surgical process. 
A number of articles highlight the potential disadvantages of cell salvage but state 
that, on balance, the advantages of avoiding an allogeneic transfusion outweigh the 
disadvantages. Liumbruno et al (2011) highlighted a more recently discussed 
disadvantage of having an allogeneic blood transfusion; the increased risk of 
alloimmunization. This is where the patient’s blood effectively becomes immune to 
the benefits of the allogeneic blood. Recycling as much of the patient’s own blood as 
possible would minimise the requirement to use allogeneic blood. They stress the 
advantages of cell salvage far outweigh the disadvantages and focus on 
alloimmunization as the main disadvantage of having the allogeneic blood 
transfusion. This article (page 2251) showed a level of subjectivity by including a 
caveat “although to the knowledge of the authors..” that “most likely the risk of 
maternal alloimmunization by allogeneic blood transfusion is much greater than that 
caused by fetal RBCs”. The authors also noted, “evidence from comparative studies 
is still lacking”. The key recommendation was that patients at higher risk of 
haemorrhage should be targeted with CS. On a related issue, Hussain (2010) stresses 
that, where there is an indication of any adverse issue e.g. increased blood loss then 
the simple solution is to stop the cell salvage and give an allogeneic transfusion. This 
can be undertaken in minutes. Some hospitals take several allogeneic units from the 
blood bank and keep them in a cool box in the operating theatre as a safeguard. If the 
units are not required, then they are returned to the blood bank. 
On a related issue para 1.9 notes the administration of tranexamic acid as a method 
of slowing down the blood loss. A Cochrane Review, Perel et al (2013) concluded 
that “tranexamic acid reduces the probability that a patient will receive a blood 
transfusion by around 30%”. This review was undertaken on studies relating to 
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“emergency or urgent” surgery. Arguably the volume of blood loss may be higher in 
emergency cases (also pre-operative Hb levels would not have been managed) but 
the total is indicative of how tranexamic acid has impacted on the discussions on 
allogeneic transfusions and the effect it has on manufacturers of cell salvage 
equipment (para 1.9). Tranexamic acid is now included on the World Health 
Organisation’s (WHO) Model List of Essential Medicines. Essential medicines are 
“those that satisfy the primary health needs of the population” and “are intended to 
be available within the context of functioning health systems at all times” (WHO 
website www.who.int accessed 8 November 2015). The main proposal for the 
inclusion came from Dr Paul Carless in 2008 who saw the benefits of combining a 
number of blood avoidance techniques. It is interesting to note that little cross 
reference is made to combining allogeneic blood avoidance techniques in Carless et 
al (2010). 
On balance, Carless et al (2010) were highly critical of the studies they reviewed. 
They did not consider the background of the significant decline in the use of 
allogeneic blood in the period 2001 to 2010 (para 1.10). A number of the authors 
whose work was critiqued by Carless et al were most probably significant 
contributors to developing systems to avoid the unnecessary use of allogeneic blood, 
thereby providing a benefit to the population. This issue is not recognised in Carless 
et al (2010) where the authors could have addressed and highlighted the fall in 
overall usage in their analysis. Carless et al (2010) could therefore have shown a 
degree of empathy, highlighting that the publicity around the articles may well have 
contributed to the success by the UK NHS bodies in increasing the number of 
operations and, at the same time, decreasing the surgical use of allogeneic blood. 
Carless et al (2010) were consistent with other studies in that they did not 
differentiate between the financial and economic costs. Their plain language 
summary notes “the financial costs associated with providing a safe and reliable 
blood product are escalating”. It is unlikely that the authors were deliberately 
differentiating between ‘financial’ and ‘economic’ costings in this context. 
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4.6  Discussions Post Carless et al (2004) 
Since 2004 the main author of articles proposing expansions in cell salvage and other 
blood sparing techniques is Dr Jon H Waters from the University of Pittsburgh 
Medical Centre (UPMC). Waters et al (2007) points to significant savings resulting 
from paying for less blood utilised and the resultant shorter LOS associated with not 
having an allogeneic blood transfusion. There is a wider debate on whether or not an 
allogeneic blood transfusion contributes to a longer LOS. This is cited in the 
conclusion, but no attempt is made in the article to justify the assertion. Waters et al 
(2007) include staff costs that are viewed as a necessity such as three ODP staff 
dedicated to operating the five machines used in the study; other articles such as 
Brown (2010) also take this view and allocate costs. The key assumption is that 
“…every cell salvage unit would replace an allogeneic unit” (page 871). This is a 
sweeping assumption and may only apply to systems such as the OrthoPat machine; 
this will re-infuse the patient after his/her operation. Since the blood has been 
collected and washed then there is the obvious incentive to re-infuse the patient 
anyway. There is a higher probability that, if cell salvage was not undertaken, an 
allogeneic transfusion may be required but there is no ‘one for one’ theoretical 
replacement. This has the effect of increasing the perceived savings reported.  Dixon 
et al (2004) also adopted this approach, citing intra-operative cell salvage avoiding c. 
410,000 units of allogeneic blood with a saving of c. £100 per unit i.e. £41m. 
It is interesting to note that the majority of UK studies assume the operator of the 
equipment will not be in addition to the usual complement of staff. This contradicts 
the detailed calculations undertaken by Waters et al (2007) who included dedicated 
staff to manage the cell salvage equipment. Discussions with members of the UK 
Cell Salvage Action Group elicit the unanimous view that no additional staff are 
required, and the training provided in-house and by the manufacturers is sufficient 
for the needs of the existing staff to cope with the workload. 
Later in the 2000’s there was wider discussion in the use of cell salvage in 
Obstetrics. As noted in chapter 1 there has been a marked move in allogeneic blood 
usage from surgical to medical. The proportion of allogeneic blood utilised in 
obstetrics has remained fairly static at around 5% (NHSBT surveys). This has, most 
likely, stimulated the discussion of the application of cell salvage in caesarean 
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sections where blood loss can be relatively high but predictable. The analysis of the 
articles by year and specialty is shown in table 15 below: 
Table 15. Breakdown by Specialty by Year 
Specialty 2006 2007 2008 2009 2010 2011 2012 2013 Total 
Orthopaedics 2 3 1 4 4 2 8 6 30 
Cardiac/Cardiothoracic 1 2 7 6 3 4 4 2 29 
Obstetrics & Gynae  1 2 4 8 3 4 4 26 
Cross Specialty 5 4 3 - 3 5 5 6 31 
Other/General 1 - - 4 11 5 4 1 26 
Grand Total 9 10 13 18 29 19 25 19 142 
 
The discussions around cell salvage in Obstetrics peaked in 2010. There is currently 
(2018) a large-scale, multi-site, cell salvage study in obstetrics (the ‘Salvo’ study) 
being undertaken across the UK. In part, this was undertaken as an impact of the 
earlier discussions and wider debate in the obstetrics field. This was originally a two-
year study that was originally intended to complete in 2015. The study timescales 
were significantly extended due to the need for a more even split of data between cell 
salvage and non-cell salvaged activity. The initial publication from the study, Khan et 
al (2017) noted there was “modest evidence for an effect of routine use of cell 
salvage during caesarean section on donor blood transfusion”. 
4.7 ‘High’ Rated Articles 
The articles rated ‘high’ in para 4.4. are summarised below: 
Table 16. ‘High’ Rated Articles 
Ref 
First 
Author Year Country Specialty 
Article 
Type 
Summary of Discussion 
A04 Samnaliev  2013 US Paeds Full 
CS cheapest when compared 
to allogeneic and pre-deposit 
and combinations. 
A05 Solomon 2013 
South 
Africa Obstetrics Full 
Converted salvaged blood to 
equivalent allogeneic units. 
Concluded very little 
difference. 
A06 Bigsby  2013 UK Orthopaedics Full 
Estimated volume of 
allogeneic blood needed to 
replace salvaged blood. 
Concluded cell salvage cost 
effective. 
A16 Canan 2013 US Orthopaedics Full 
CS not cost effective in single 
level lumbar decompression 
and fusion surgery. 
A19 Offierski. 2013 Canada Orthopaedics Conf Abs Compared allogeneic 
80 
Ref 
First 
Author Year Country Specialty 
Article 
Type 
Summary of Discussion 
transfusion requirements after 
introduction of tranexamic 
acid. Concluded allogeneic 
requirements fell. 
A23 Odak  2013 UK Orthopaedics Full 
Assessed the theoretical fall in 
Hb levels if cell salvage was 
not adopted and estimated the 
cost of allogeneic blood 
required to alleviate the fall. 
A29 Brearton 2012 UK Obstetrics Full 
Estimated the number of 
allogeneic units avoided by 
using cell salvage. Concluded 
small savings were possible. 
A36 Rao  2012 US Orthopaedics Full 
Compared notional volumes 
of blood avoided. Savings in 
THR. 
A41 Munoz  2012 Spain Orthopaedics Conf Abs 
Concluded that LOS one day 
longer if a patient had an 
allogeneic transfusion. 
2 Kelleher 2011 UK Cardiac Full 
QA aspects to increase Hb 
levels and decrease reliance 
on allogeneic blood. 
3 Frank 2011 US General/Cross Editorial 
Introduced additional costs to 
be included. 
4 Liumbruno 2011 US Obstetrics Full 
Cites risks of immunity to 
benefits of allogeneic blood 
and cost impact.  
5 Portsmore 2011 UK Emergency Conf Abs 
Focus on trauma/massive 
haemorrhage. Indicates cell 
salvage cost effective with 
larger volumes of blood loss. 
7 Buckley 2011 UK AAA Conf Abs 
Average reduction of 1 unit of 
allogeneic blood per operation 
where cell salvage utilised. 
8 Thurer 2011 US General/Cross Conf Abs 
Significant reduction in 
transfusion rate and costs with 
CS. Stressed the combination 
of blood avoidance 
techniques. 
13 Yarham 2011 UK Evaluation Full 
Evaluation of Sorin Electa 
machine. Stresses the 
disadvantages of allogeneic 
transfusions. 
14 Attaran 2011 UK Cardiac Full 
Challenged use of cell salvage 
in routine cardiac surgery. 
Argued differences between 
allogeneic v cell salvage not 
significant. Pointed to intraop 
cell salvage potentially 
offsetting falls in Hb. 
16 Waldron 2011 UK Obstetrics Conf Abs 
Obstetric study noting savings 
of £220 per operation using 
CS. 
17 Butchart 2011 UK Orthopaedics Conf Abs 
Noted potential tail off in 
usage of CS. 
19 Ubee 2011 UK Urology Full 
Small sample study pointing 
to savings in blood costs and 
lower LOS associated with 
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Ref 
First 
Author Year Country Specialty 
Article 
Type 
Summary of Discussion 
CS. 
22.1 Waters 2010 US Orthopaedics Conf Abs 
Significant variation in 
transfusion rates between 
surgeons. LOS higher with 
allogeneic transfusions. 
22.2 Thurer 2010 US Orthopaedics Conf Abs 
Same surgeons involved in 
TKR ops in 2007 (no CS) and 
2009 (with CS). Allogeneic 
transfusions fell by 33%. 
22.3 Waters 2010 US Orthopaedics Conf Abs 
Discussed variations in blood 
usage between surgeons and 
questioned whether cell 
salvage was beneficial in 
THRs.  
23 Jaben 2010 US General/Cross Conf Abs 
Studied long term survival 
rates following surgery where 
a transfusion was needed. 
Found the lower the 
transfusion rate the longer 
survival. 
25 Spahn 2010 
Multi 
Nat Orthopaedics Full 
Large analysis of studies, 
many of which had different 
criteria. Looked at anaemia 
and concluded cell salvage 
generally reduced the need for 
allogeneic transfusion. 
27 Brown 2010 US Trauma Full 
Study of trauma patients with 
and without CS. External 
perfusionist dedicated to cell 
salvage costed into cell 
salvage group. 
50 Vieira SD 2009 Brazil Cardiac Conf Abs 
Assess likelihood of 
allogeneic transfusion with 
having cell salvage. 
51 Savvidou 2009 Greece Orthopaedics Full 
Small study. Costs used a 
“local price” for allogeneic 
unit of €450. Twice as likely 
to have allogeneic transfusion 
w/out CS. 
55 Staber M 2009 UK Orthopaedics Conf Abs 
Mix of elective and 
emergency. Average of 2.8 
allogeneic units transfused. 
58 
Scannell 
B.P. 2009 US Orthopaedics Full 
Study of acetabular fracture 
patients. Lower LOS when 
cell salvage used; cell salvage 
cheaper if >= 2 allogeneic 
units required. 
66 
Markovic 
M 2009 Serbia Cardiovascular Full 
Study of ruptured AAA 
patients. cell salvage does not 
need to wait for cross match; 
more cost effective when >3 
allogeneic units required. 
71 Klein A 2008 UK Cardiac Full 
Study of routine cardiac 
surgery patients. Half group 
selected for CS-noted little 
difference in transfusion rates. 
80 Tawfick W 2008 Ireland AAA Full Study spanning nine years. 
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Ref 
First 
Author Year Country Specialty 
Article 
Type 
Summary of Discussion 
Based on average costs. 
Ignored potential 
improvements over the study 
period. 
81 Freedman J 2008 Canada Orth/Cardiac Full 
Appointment of Transfusion 
Co-ordinators achieved a fall 
in allogeneic usage. Used 
average costs to measure 
savings in reduced LOS. 
91 Waters J 2007 US General/Cross Full 
Estimated the costs for a 
hospital to set up a cell 
salvage programme. 
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Blanchette 
C 2007 US Orthopaedics Full 
Multi-site study. Concluded 
that cell salvage reduced the 
probability of needing an 
allogeneic transfusion. 
101 Bird C 2006 UK General/Cross Full 
Basic ‘opinion’ style article 
highlighting most Trusts 
spend between £1m and £4m 
on allogeneic blood. Ignores 
medical/surgical split. 
102 Phillips SD 2006 UK Liver Tx Full 
Large-scale liver transplant 
study. Associated low pre-op 
Hb with higher rate of 
allogeneic transfusion. 
Concluded staffing costs 
associated with cell salvage 
would breakeven at 80 cases 
per year. 
103 Davies L 2006 UK General/Cross Full 
HTA. Assessed a number of 
allogeneic blood avoidance 
techniques. Highlighted role 
and cost impact at NHSBT 
and need for consistent 
application of costs to 
facilitate accurate 
comparisons.  
105 Crotty B 2006 UK General/Cross Full 
Basic comparison of running 
costs associated with cell 
salvage and assuming 2.6 
allogeneic units avoided each 
time cell salvage is utilised. 
 
The selected articles in table 16 were chosen due to their focus on the financial 
impacts. A theme that emerged in 2012/13 was the calculation of equivalent units of 
allogeneic blood that may have been required if cell salvage was not utilised. The 
newer versions of the cell salvage machines will now record the volumes of blood 
shed and salvaged blood reinfused. Solomon et al (2013), Bigsby et al (2013), 
Brearton et al (2012) and Rao et al (2013) all adopted this approach; converting the 
volumes reinfused to equivalent units of allogeneic blood. They then compared these 
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equivalent units at a particular cost per allogeneic unit against the cost of operating 
the cell salvage machines. Solomon et al (2013) noted there was little difference in 
the derived costs but stressed that there were other benefits such as addressing issues 
of the non-availability of allogeneic blood. This study was undertaken in South 
Africa where allogeneic blood supply may not be constantly available as in the 
Europe/US. Bigsby et al (2013) and Odak et al (2013) utilised McClelland’s (2007) 
rule of thumb of one allogeneic unit raising Hb levels by 10 g/l (para 1.9). The 
‘transfusion trigger’ is assumed to be a post-operative Hb level of 80 g/l. By 
calculating the mean blood loss from the information generated in the cell salvage 
machines the notional units of allogeneic blood required can be calculated. Both 
these studies were based on acetabular fracture and separately concluded that cell 
salvage was cost effective. Both studies, however, calculated notional amounts of 
allogeneic blood avoided. Patients’ blood loss tolerance can differ markedly; and 
younger, fitter patients can withstand greater falls in their Hb levels than older 
patients (para 1.9). The idea of a notional allogeneic blood requirement based on a 
fall in Hb levels is a relatively new argument and may be open to differences of 
opinion. The implication is that the financial costs rather than economic costs were 
incorporated in the analysis though this was not made clear by any of the authors. 
Rao et al (2013) noted a pertinent point that the majority of blood loss in total hip 
replacement operations was intraoperatively (i.e. during the operation). The study 
included the OrthoPat cell saver that can be utilised to collect both intraoperative and 
post-operative blood loss. The operating cost of this machine is significantly more 
expensive than the single intraoperative machines. This would raise a question on the 
efficacy of using the OrthoPat compared to other, cheaper, machines in intraoperative 
cell salvage since the OrthoPat has no ‘collect first’ option available. The ‘collect 
first’ option would allow the termination of the cell salvage process if it was looking 
unlikely to recover an adequate level of shed blood. Again, this may be an indication 
of the challenges that Haemonetics are facing with falling sales (para 1.9). 
There are other theoretical studies undertaken; Samnaliev (2013) concluded cell 
salvage in the US in paediatric surgery was, on a sliding scale, the cheapest 
compared to pre-deposit or allogeneic transfusions. The study utilised a 
“mathematical decision tree of hypothetical identical control groups” and calculated 
the lifetime costs avoided by assigning probabilities and costs associated with 
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reactions or infections caused by an allogeneic blood transfusion. The analysis 
seemed simplistic and verged on the sensational. The article’s opening statement was 
“red blood cells are a scarce resource with demand outstripping supply”. In some 
lesser developed countries, this may be the case but in developed countries there is 
now rarely any shortage of allogeneic blood. The last time there was any shortage of 
allogeneic blood in the UK was in 1994. 
Canan et al (2013) also highlighted the combination of cell salvage and allogeneic 
blood transfusion where it is difficult to assess the benefits attributable to each of the 
two elements. Canan et al (2013) however conclude that, in single level lumbar spine 
surgery, cell salvage is “unnecessary” and “not cost effective”. They did however 
recommend further research be undertaken to identify patients who would be likely 
to benefit from undergoing cell salvage rather than salvaging all patients in a list. 
Tranexamic acid was highlighted in a poster by Offierski et al (2013) who noted that, 
prior to 2009, the allogeneic transfusion rate in total hip replacements at Niagara 
hospital was 19%. With the introduction of tranexamic acid, the transfusion rate 
dropped to 11%; primarily due to higher rates of Hb levels being maintained. As 
noted in para 1.9 tranexamic acid appears to significantly lower the allogeneic 
transfusion rate. This can therefore cloud the comparisons and potentially distort the 
contribution made by cell salvage to minimising allogeneic blood transfusions in 
surgery. 
The trend towards highlighting the impact of cell salvage on length of stay has tailed 
off recently. Munoz et al (2012) highlighted that LOS was one day longer if a patient 
had an allogeneic transfusion. The assertion was that the post-operative allogeneic 
transfusion would be required because the patient was not recovering as quickly due 
to a lower Hb level. The allogeneic transfusion is therefore an indicator of how the 
patient is recovering rather than being a contributor towards the increasing LOS. By 
using cell salvage the chances of an allogeneic transfusion are lowered as the Hb fall 
would be ameliorated. 
The studies mainly related to retrospective analysis of data under the auspices of a 
service development thereby not requiring any ethical clearance from the relevant 
hospital ethics’ committee. Kelleher (2011), based at the Royal Brompton Hospital in 
London, adopted this approach, analysing data for over 7,000 cardiac patients 
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between 2001 and 2007. An interesting aspect of the study was that Kelleher noted 
how “operator behaviour” and “progressive machine deterioration” affected the 
intermediate results (and hence the measurement of cost impacts). Carless et al 
(2010) did not refer to these types of issues that would be unlikely to become 
apparent in a traditional short-term comparative study. A long term, more dynamic, 
study therefore highlighted these two significant principles. Chapter 6 of this thesis 
will note that the researcher has circumvented this issue by taking a snapshot of 
activity over a relatively short period and only used one centre utilising cell salvage. 
This centre now (2018) has a rigorous training regime that ensures all theatre staff 
are trained to operate the equipment. Additionally, there are service contracts in place 
to ensure all machines are regularly maintained and tested. 
Waters (2011) undertook a similar study to Kelleher et al (2011). Waters (2011) led a 
review of almost 20,000 operations in 12 hospitals in the West Pennsylvania area. 
His conclusions were that cell salvage was not cost effective in all cases. This was 
based on the c.16,500 patients of the 20,000 who received cell salvage. The study 
was published in the October 2011 edition of the publication ‘Transfusion’ and the 
conclusions were critiqued in the introduction by the editor, Dr Steven Frank. Frank 
(2011) highlighted that stand by set up costs were not included in the costings; he 
then used average costs to demonstrate a point that, where only low volumes of shed 
blood were recovered, and the patient did not need an allogeneic transfusion anyway, 
it may therefore have been more cost effective not to have used cell salvage and rely 
on an allogenic transfusion where necessary. This is one of the issues that was 
considered in the Royal Cornwall Hospital study where, as far as possible, all shed 
blood is collected. When utilising the Sorin Electa the shed blood can be collected in 
a reservoir allowing time to decide if there is sufficient salvaged blood available to 
reinfuse. The ‘collect first’ option costs c. £50 regardless of whether or not the blood 
is reinfused. 
The articles by Kelleher et al (2011) and Waters (2011)/Frank (2011) highlight, in 
differing ways, the difficulties in adhering to the Carless criteria for randomised 
controlled trials (RCTs). High volume salvage with well-maintained machinery is 
required to ensure sufficient allogeneic blood is avoided to cover the 
capital/maintenance costs along with the operator/consumable costs. This would 
therefore minimise the allogeneic blood costs. A related issue is that there is also a 
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base level of knowledge and skills that the operator (generally a nurse or an ODP) 
needs to acquire and maintain. Though an individual group of cases may not generate 
savings they contribute, indirectly, to developing the skills of the operators. Frank’s 
(2011) assertion to be more selective on adopting cell salvage may provide savings 
but there still needs to be a critical mass of work to develop and maintain the 
operators’ skills and provide a range of training opportunities. 
The Carless implication that RCTs should be adopted may, in practice, not be the 
most efficient methodology.  The operators would need to have the requisite ‘flying 
hours’ of experience and the machinery would need to be sufficiently utilised to 
perform at an optimum rate. 
Staff training issues are also highlighted by Buckley et al (2011) and Thurer et al 
(2011). Buckley et al (2011) studied the reasons why cell salvage was not adopted for 
patients undergoing elective abdominal aortic surgery. In 44% of cases cell salvage 
was not used. In 81% of these cases the reason cited was the lack of trained staff. 
Their study noted that average allogeneic transfusion requirements were 
approximately one unit higher per operation where cell salvage was not used. They 
argued that the cost of investment in staff is key to developing a successful cell 
salvage programme. Thurer et al (2011) noted that “successful interventions to 
reduce transfusion are either multidisciplinary …and multimodality (utilising many 
techniques)”. They studied an initiative in orthopaedics to reduce the “transfusion 
trigger” (the patients’ Hb level indicating iron levels are falling too rapidly) and 
discontinue the use of pre-operative autologous donation (PAD, para 1.11) while, at 
the same time, introducing cell salvage. They observed that allogeneic transfusions 
fell from 44% within the six-month period prior to the change, to 25% in the six-
month period after the change. They concluded that it would be difficult to assess 
which procedural change (the change in the transfusion trigger, the move away from 
PAD or the introduction of cell salvage) contributed the most towards the reduction 
in allogeneic usage. These two studies emphasise the aspect that it is difficult to 
assess the contribution of cell salvage in isolation. The team at the Royal Cornwall 
Hospitals also reiterate the message that, in their view, cell salvage is only one of the 
‘tools in the armoury’ and most of the benefits of avoiding an allogeneic transfusion 
accrue when as many blood avoidance techniques as possible are running together. 
This argument is consistent with the Patient Blood Management approach (para 
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1.12). An earlier study by Thurer et al (2010) noted a significant reduction in the 
allogeneic transfusion rate (from 39.5% to 26.5%) when a cell salvage programme 
was introduced by the same orthopaedic surgeons undertaking total knee replacement 
surgery. Though there was no evidence of bias two of the authors (including R. L. 
Thurer) disclosed commercial interests with the cell salvage equipment 
manufacturer, Haemonetics. 
One interesting conclusion emerged from a large-scale retrospective multi-site study 
undertaken in the US (Blanchette et al (2007)). Patients with non-Medicaid insurance 
(primarily private or employer provided health insurance) had a lower risk of having 
an allogeneic blood transfusion than a patient funded by Medicare. Given patients 
funded by Medicare are older, this conclusion is not new. The older a person is, then 
the more likely they are to have an operation making it more likely that a transfusion 
will be required. Blanchette et al (2007) concluded that cell salvage resulted in the 
probability of a lower allogeneic transfusion and there was significant variability in 
its application in spinal surgery. They stressed the variability in approaches with 
some hospitals being enthusiastic about adopting a range of blood sparing techniques 
and others that were not. They additionally speculated that the varying levels of 
enthusiasm may be due to reasons “…associated with cost, potential adverse effects 
or lack of strong clinical evidence”. The first and third reasons are still pertinent 
today. 
The theme of clinicians’ willingness to utilise cell salvage techniques and their 
perceived impact on reducing LOS by speeding up the recovery process was 
highlighted in two conference abstracts in volume 50 of the publication 
‘Transfusion’. Waters et al (2010a and b) noted the massive variation in transfusion 
and readmission rates with LOS not appearing to correlate with whether a patient had 
or did not have an allogeneic transfusion in total hip replacements. The authors 
concluded that the results were unclear and “…might pose a challenge to future 
efforts to standardise RBC (red blood cell) transfusion practice”. What is novel is the 
issue of readmission rates being raised. Readmissions for primary total hip 
replacement surgery due to transfusion issues are rare; Waters et al (2010a) quoted a 
readmission rate of 6.2% with an allogeneic transfusion v 0.8% without a 
transfusion. The reasons for the readmissions in the UK are mainly due to wound 
problems with the 10th National Joint Registry estimating readmissions at 7.6% using 
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Patient Reported Outcomes Measures (PROMS) rather than anything due to blood 
transfusions so this assertion may not reflect any causality.  
Waters et al (2010b) led on the same theme of variation but based this on a survey of 
surgeons in total knee replacements and total hip replacements. The key reason for a 
transfusion was if the surgeon felt the patient was anaemic (para 1.4). This was 
generally indicated at an Hb level of <80 g/l and there was a strong correlation 
between a lower pre-operative Hb level and a patient requiring an allogeneic 
transfusion. Waters et al (2010b) noted that by post-operative day 2 the patients who 
had used PAD had a lower Hb level than those that had not; thereby increasing the 
chances of requiring an allogeneic transfusion. The above two articles were 
conference abstracts and were difficult for the reader to assess the impact of the 
detail. There was a common theme in that it was accepted that the higher the Hb 
level the less likely the patient would require an allogeneic transfusion (or cell 
salvage). The articles do not, however, give any indication of how many surgeons 
were invited to answer the questionnaire; instead focusing on the responses of the 17 
who took part. The timing of this coincided with the analysis of the activity of c. 
1,100 patients undergoing total hip and knee replacement surgery. There is therefore 
the possibility of bias with the 17 respondents being potentially more likely to be 
enthusiastic about blood avoidance techniques than a non-respondent. Given no 
reference is made to the total number of potential respondents this could affect the 
consistency of the responses to the reported views on anaemia. Waters et al (2010b) 
conclude “Cell salvage might not be beneficial in THR (total hip replacement)”. 
Based on the evidence this seems an over-generalization. It does, however, add a 
further level of interest to whether the analysis in this thesis could support the debate 
by developing a mechanism to breakdown the overarching term ‘total hip 
replacement’. The aim would be to identify whether there is an equal spread of 
allogeneic blood over more or less intensive total hip replacement operations. 
As noted earlier the primary reason for an allogeneic transfusion is to increase the 
patients Hb levels. Spahn (2010) undertook an analysis of studies comparing various 
patient factors such as age, pre-and post-operative Hb rates and transfusion rates in 
hip or knee studies. The analysis included a number of the comparative factors 
developed in chapter 5. Spahn (2010)’s focus on pre-operative Hb levels identified 
levels below 120 g/l for females and 130 g/l for males as being “unmet medical 
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need” as defined by the World Health Organisation. His conclusion to the study was 
unequivocal “Anaemia in the orthopaedic perioperative setting was frequent and was 
associated with increased ABT (allogeneic blood transfusion) rates and with adverse 
clinical outcomes”. Spahn (2010)’s analysis could be criticised in that there was not a 
common dataset of factors to undertake the comparisons e.g. some studies had a 
gender split, others did not, some had an age breakdown, others omitted this. Though 
the conclusion was based on a wide number of studies it again fell foul of Carless et 
al’s (2004 and 2010) classification of the “methodological rigour” requirement. 
A similar conclusion to Spahn (2010) was noted by Jaben et al (2010). This study 
followed up patients who had received a transfusion between 1991-1998. It 
concluded that the smaller the volume of allogeneic blood utilised the better the 
survival rates. Factors such as age, gender and LOS were incorporated into the model 
with the Charlson co-morbidity index. This area is quite subjective. It could be 
argued that one would expect this outcome given there would be a tendency for 
sicker patients to have a higher allogeneic blood transfusion requirement. There was 
also no analysis of patients who had the same operations but no allogeneic blood 
transfusion. The article, however, indicates the complexity of the challenges and 
level of variability in the patients; thereby increasing the likelihood of any 
conclusions attracting criticism. 
Some of the studies attempted to evaluate where the use of cell salvage would work 
out cheaper compared to using units of allogeneic blood. Varney & Guest (2003) 
estimated that, where an allogeneic transfusion was required, an average 2.7 units 
would be utilised. This average crossed all specialties and was therefore indicative in 
2003. Table 2 (page 17) highlights the significant changes in the split between 
medical and surgical requirements for allogeneic blood. Combining this with the c. 
33% fall in the number of allogeneic units issued between 2003 (2.25m units issued) 
and 2017 (1.51m units) would imply that the average of 2.7 units may now be 
significantly lower. Scannell et al (2009) noted that cell salvage is cheaper if two or 
more allogeneic units were required in acetabular fracture (where the femur is forced 
into the pelvis). This study was retrospective, and the article compared the price of 
allogeneic blood and a “flat rate transfusion fee” against the “flat rate fee” for using 
cell salvage. This was a US study and would therefore have utilised the published 
price lists for charging via a Health Maintenance Organisation (HMO) or via an 
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insurance company. Scannell et al (2009) made a major caveat that, in practice, 
patients were not formally pre-selected to have either cell salvage or an allogeneic 
transfusion. It can often be a combination of the two; and the authors noted that there 
was “no formal protocol for blood transfusion at our institution”. Effectively the two 
units that were required to breakeven on cell salvage costs was therefore only a 
notional amount and could not be used as a definitive target. LOS was quoted in a 
different way from other studies. The authors noted that patients having cell salvage 
were likely to be in intensive care for a longer period implying they were more 
severely injured so there was a potential bias in allocating those patients to have cell 
salvage. Waldron et al (2011) undertook a similar approach in obstetrics citing the 
NICE guidelines in interventional procedures guidance (IPG) 144. Out of 100 
patients in their sample, eight needed allogeneic transfusions, totalling 50 allogeneic 
units. They assumed that the potential cost saving was the difference between the 
cost of operating the cell salvage machine and the cost of allogeneic blood. Waldron 
et al (2011) assumed that all of these 50 allogeneic units could be avoided if cell 
salvage were utilised. This would not necessarily be the case and the basic cost 
comparison was arguably too simplistic. 
A similar type of study in Serbia was undertaken by Markovic et al (2009). This 
compared 90 prospective patients who underwent abdominal aortic aneurysm (AAA) 
surgery utilising cell salvage against 90 consecutive patients who underwent the 
same operations prior to the hospital introducing cell salvage. The authors noted that 
ruptured abdominal aortic aneurysms (RAAAs) involved high blood loss, cell 
salvage would therefore need to be utilised quickly. Given the hospital did not use 
electronic cross matching (ECM, para 4.2) there would be a delay of 30-60 minutes 
before an allogeneic transfusion could be administered. This would be a significant 
distortion and, effectively, give cell salvage a head start with the patients in the 
allogeneic blood group needing to be stabilised to stem the blood flow. This was 
therefore likely to make the comparison between the two groups disparate. Most UK 
hospitals would utilise ECM thereby allowing an allogeneic transfusion within 
minutes. Markovic et al (2009) calculated the breakeven point as three units of 
allogeneic blood. This analysis only compared the costs of the cell salvage 
consumables against the costs of three allogeneic units. It did not include the capital 
costs of the cell salvage machine, the operating costs or the costs of training. To 
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include these factors in the analysis would take the comparison to over four units as a 
breakeven point in a financial analysis. Portsmore et al (2011) highlighted that the 
breakeven level (i.e. the point when cell salvage was cost effective) was when over 
250-500 mls of blood was salvaged. This is the equivalent of up to approximately 
three allogeneic units.  
One factor noted in Markovic et al (2009) was that the cost of an allogeneic unit was 
€46.30 (2005 price level). A study in Greece by Savvidou et al (2009) used the cost 
as being €450 per unit. It is unclear what year’s price level was adopted but there is 
an almost 10-fold variation in the cost. This illustrates the difficulty in undertaking 
the international comparisons. The costs may not reflect actual costs incurred but 
may be pitched at a notional level to influence usage. The Greek price in question 
was “..determined by the Greek ministry of health and applied in a public urban 
hospital” (page 203). The massive variation and notional prices may therefore make 
one hospital (or country’s) approach to costs skew the conclusions against or in 
favour of cell salvage. In Savvidou et al’s (2009) case the conclusion, using a similar 
notional cost of €370 for cell salvage, made the case that “the cell saving technique is 
cost-effective in a European Union country”. This statement assumes the cost base 
and costing assumptions of each country are similar. This assumption would be open 
to debate. The above issue is significant given the international discussions and, 
again, was not an issue considered by Carless et al in either 2004 or 2010. Shander et 
al (2010) highlight this issue and urge caution when comparing prices between 
countries. 
Klein et al (2008) focused on first time coronary artery bypass graft (CABG) and 
cardiac valve surgery. The authors critiqued and noted weaknesses in earlier studies 
and believed these could be circumvented by using a study of elective 
CABGs/cardiac valve surgery. These accounted for the majority of elective cardiac 
surgery at Papworth Hospital, where the study was based. The authors quoted 
Carless et al (2004) stating they would undertake a cost benefit analysis. 
Klein et al (2008) concluded that the incidence and volume of post-operative 
bleeding was lower within the cell salvage group. The patients undergoing cell 
salvage would receive the reinfusion in ICU immediately after the operation. The 
authors noted that the post-operative Hb levels were similar on admission to ICU but 
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were higher (10.4 v 10.1 g/dl) for the cell salvage group 24 hours after. The authors 
did not investigate this difference stating (page 1494) “our study was not powered to 
detect haemoglobin concentration between groups”. It is disappointing that the 
authors did not pursue this element; they noted that there was a marked reduction in 
the number of allogeneic units given to the cell salvage patients in ICU after six 
hours. They concluded that cell salvage “may reduce the demand for blood products 
during cardiac surgery” but this came at an increased cost. 
Costs were presented in a table with little breakdown or analysis. The operating room 
cost difference of c. $9,100 for a cell salvage patient v c. $8,700 for a non-cell 
salvage patient were not explained. The difference may be a function of the cost of 
consumables and the cost of an ODP (Operating Department Practitioner) dedicated 
to cell salvage. Similarly, the corresponding costs of c. $4,300 v $4,100 for the ICU 
costs are not explained. The “cell salvage equipment” cost is shown in a separate line 
in the table. The cost of the “ward stay” was reported as being just over $100 cheaper 
for the cell salvage group. Overall, the authors concluded the average cost for a 
patient utilising cell salvage was $17,785 against $17,046 without cell salvage.  
Though Klein et al (2008) banded their study a “cost benefit analysis”, the 
comparison was effectively an analysis of average costs that were not classified into 
fixed/variable or direct/indirect (paras 2.2 and 2.3). As such, the authors could leave 
themselves open to criticism of their findings. They did stress, however, that this 
study was undertaken on a relatively “routine” procedure and cell salvage could 
prove more cost effective in more involved cardiac procedures. Significantly, the 
authors pointed to the “public health implications” of the costs associated with 
collecting and making donated blood available. There are few studies that highlight 
this issue and the authors overall conclusion was that, even though they calculated 
cell salvage was more expensive than allogeneic blood, it would offset the costs 
generated by the blood institutions. This is one of the key areas of investigation in 
this thesis. Klein et al (2008) are contradicted by Attaran et al (2011) who viewed the 
‘collect first’ principle without reinfusion as incurring a ‘loss’ rather than being 
deemed a potential ‘insurance policy’. Their retrospective study highlighted a 
transfusion rate of 35.6% where cell salvage was not used against 30.3% where cell 
salvage was utilised. They concluded there was no significant difference in the 
number of allogeneic units transfused for patients that had, or did not have, cell 
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salvage. It was unclear in the article when Hb readings were taken; they could have 
been taken after a reinfusion of salvaged blood. If this were the case, then the authors 
would not have identified the beneficial impacts of cell salvage. 
A study based in Ontario, Freedman et al (2008), examined the whole approach to 
blood conservation rather than just cell salvage individually. They concluded that cell 
salvage was one of the four main contributors to blood conservation; the other three 
being education, PAD (pre-operative autologous donation-see para 1.11) and EPO 
(Erythropoietin-this stimulates the production of red blood cells in the bone marrow). 
Costs were rounded to the nearest $m and the net savings in the blood conservation 
programme were grouped into: 
Table 17. Blood Conservation Savings in Ontario 
Ref Category Saving 
$m 
1 Reduction in allogeneic blood costs 8.6 
2 Reduction in LOS 5.3 
3 Reduced work in hospital transfusion 
laboratories and nursing units 
0.7 
 Forecast Saving 14.6 
 
The third element, staffing costs, had not been considered in this thesis methodology. 
The authors estimated the savings in time associated with the technologists/nurses 
not needing to undertake tests in the laboratory, take blood from patients for testing, 
blood stock management etc. These tasks are often the responsibility of a number of 
hospital staff and it is highly doubtful, especially in the short to medium term, that 
the staffing costs could be removed as the staff would still be required to perform 
other duties. Staff would need to be on a contract similar to a ‘zero hours’ basis to be 
reactive to the peaks and troughs of work requirements. In reality having a large 
number of staff in a hospital on these types of contracts would be viewed as too 
risky. 
Similarly, an average saving of $1,000 a day for the shorter LOS was used. Again, 
the majority of hospital-based costs are fixed in the short to medium term. Virtually 
none of these costs would be realisable until after a significant time had elapsed. 
They may, however, increase capacity and free up space for additional use. Using 
similar logic, the reduction in allogeneic blood costs may be a direct (and variable) 
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cost for the hospital but there will be fixed costs that will remain for the blood 
collection institution. 
Overall, the cost of running the programme in Ontario was $1.8m. It is impossible to 
examine the breakdown of the costs from the information available. Given 23 
transfusion co-ordinators were appointed these costs may be in the region of $1m. 
This would not leave much funding left for cell salvage; assuming $150 for 
consumables then the balance of costs would fund c. 5,300 sets of consumables with 
no funds left for PAD, EPO or education. Though the conclusions seem optimistic, 
the costs and benefits do not seem to be realistic or realisable. 
A number of the articles extracted from the literature review search referred to the 
generally lower LOS in patients who have not had an allogeneic transfusion in 
addition to those quoted earlier. LOS at the three sites in this study will be discussed 
more fully in chapter 6. It is difficult to make a judgement on whether the LOS is 
increased by a patient having an allogeneic transfusion. The transfusion may be seen 
as being a symptom of the patient recovering more slowly and hence staying in 
hospital longer. Ubee (2011) asserts the improved LOS in the cell salvage group was 
“..probably attributable to the fact that circulating volume and Hb levels were better 
maintained at near optimum levels through the perioperative period..”. He further 
suggests that the allogeneic transfusions were given post-operatively, therefore 
taking some time to take effect, implying an increased chance of a higher LOS. Dunn 
et al (2010) pointed to a fall in LOS of 3 days in radical cystectomy when the service 
was centralised in Exeter using cell salvage against the average LOS prior to 
centralisation. What is not clear is how other factors due to centralisation of the 
service e.g. staff availability, enhanced training, working practices, specialist 
equipment availability etc., impacted on the LOS rather than any positive impacts of 
cell salvage. Phillips et al (2006) arrived at broadly the same conclusion with a 
reduced LOS of 2.8 days. They highlighted the use of both cell salvage and 
tranexamic acid impacted favourably on the Hb levels. They then asserted, “the 
savings attributable to the reduced LOS by avoiding transfusion was £756 per 
patient, or 2.8 days at £270 per day”. This £270 is an average cost developed by 
apportioning all types of costs, both fixed and variable, into an average cost per in-
patient day. The majority of this cost is unlikely to be avoided if the LOS was 
shortened. Again, with Phillips et al (2006), there was no attempt at answering the 
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assertion that, the more ill the patient, the more likely s/he would be to require an 
allogeneic transfusion and therefore the more likely they would be to stay in hospital 
longer to be observed as well as the recovery period taking longer. 
A 2011 NHS initiative in England ‘Innovation, Health and Wealth’ cited the 
Conquest Hospital, East Sussex’s short length of stay. What was not highlighted in 
the publication was the assertion by Royal Cornwall Hospital staff that some of the 
Conquest patients were discharged into residential accommodation, managed by the 
Conquest Hospital. Patients continued their recovery in a non-hospital environment 
thereby shortening hospital LOS; but still under NHS care. For the purposes of this 
study, it was therefore felt advisable to investigate any differences in discharge 
patterns in the three sites prior to undertaking any costing work on LOS (chapter 6). 
This would minimise subjective issues of differing measurements of LOS. 
On a related note, Tawfick et al (2008) stressed the shorter LOS and used average 
hospital in patient costs to highlight savings by using cell salvage in AAA surgery. 
Patients were allocated to the salvage group if a skilled operative was available. If 
none were available, then an allogeneic transfusion was the only option. This would 
leave the study open to bias e.g. cell salvage support would be less likely at 
weekends where the majority of admissions would be emergencies. Additionally, the 
study was undertaken over a nine-year period up to June 2006. It is likely that there 
were advances in surgical techniques, changes in the surgeons’ experience, 
approaches to patient management etc over the period making the comparison of 
blood usage open to distortion by these factors. This lengthy duration convinced the 
researcher to have a short window to extract details of consecutive patients 
undergoing surgery. 
Overall Carless et al (2010) concluded that the LOS with cell salvage was “not 
statistically significantly reduced compared to control”. The articles quoted above 
exhibit a varying level of bias (a common theme in the Carless report) in that they 
assert the absence of an allogeneic transfusion is the reason for the lower LOS. This 
argument is not conclusive and, when tagged to average costs, can lead to a 
significantly distorted financial conclusion. 
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One associated issue with LOS is that any fall would potentially free up time for 
nursing staff. In the current climate of patient safety and ‘safe staffing levels’ there 
would (‘ceteris paribus’) be a favourable movement in the staffing ratios. 
Given the duration of this thesis the researcher felt it prudent to update the literature 
search to cover the period from January 2014 to December 2016. The other 
parameters remained unchanged. The search was undertaken in January 2017 using 
the NHS Athens system. This generated a number of duplicates and these were 
manually excluded with 29 being selected for consideration. A summary of the main 
issues is shown in note format in appendix 7. Orthopaedics was still the most 
common specialty, followed by Obstetrics. Some of the articles continued to convert 
salvaged blood to equivalent units e.g. Bellam et al (2014). The consumables costs 
were also relatively low; however, the conclusion was that the success factor was 
avoiding the allogeneic transfusion rather than comparing costs. It was noticeable 
that the adoption of this equivalent unit calculation tailed off after 2014 as more 
cross referencing to ‘Patient Blood Management’ was highlighted e.g. Pendry et al 
(2015). 
Training was also emphasised as part of the international Patient Blood Management 
initiative with Yeung et al (2016) highlighting that regular use of cell salvage keeps 
“the team up to date with the skills required”. Allied to this was the noting of the 
difficulties in predicting which patient will benefit from cell salvage (e.g. Tio et al 
(2016)) and how this impacts on costs if a high number of patients are salvaged. Son 
et al’s (2014) study in obstetrics noted “…cell salvage set up appears to be cost 
effective only when reinfused, but clinical characteristics cannot predict accurately 
which women will require reinfusion of cell salvaged blood”.  
Overall the more recent articles still tend to be more in favour of cell salvage and its 
impact on costs however there is more reference to other blood-sparing techniques 
being used together. This is the essence of Patient Blood Management and the recent 
literature implies clinicians are bearing the issues in mind. 
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4.8 Training Issues 
Konstantinou (2011) used the relatively high transfer price of allogeneic blood in 
Greece to demonstrate that cell salvage was not cost effective unless more than two 
allogeneic units were required.  This study used a simplistic cost model, assuming 
the volume of blood reinfused was a like for like substitute for allogeneic blood. This 
is not the case as allogeneic blood contains anticoagulants and the active red cells 
gradually diminish over time. Allogeneic blood is generally at least a week old when 
utilised in a transfusion, salvaged blood is therefore a much richer product requiring 
less volume than allogeneic blood to provide the same Hb benefits. 
Training costs are highlighted by the US Society for the Advancement of Blood 
Medicine (SABM) in so far as they are classed as being a ‘generic cost’. Very few of 
the articles accessed in this review focus on cell salvage training. Training costs will 
be relevant, but a more dynamic model would assert that these costs would decrease 
over the medium term as all staff will be trained. (Waters (2010b) notes that lack of 
education in cell salvage is a reason for inconsistency in use and variation in 
transfusion rates). In the UK, Grainger et al (2008) detailed the training sources and 
packages available. In time the wider adoption of the techniques would mean most 
ODPs, theatre nurses and surgeons had cell salvage in their skillset only therefore 
requiring cheaper and less time-consuming refresher training. 
The level of skills can impact on the conclusions. Bridgens et al (2007) compared a 
group of 47 revision hip arthroplasty operations using cell salvage with a control 
group of 47 operations without using cell salvage. Allogeneic blood usage was 
significantly higher in the control group (mean of 6.4 allogeneic units v 2.6 units). 
The authors noted, however that “(the operations) were not well matched for the 
operating surgeon because the operations in the control group took place when fewer 
arthroplasty fellows were on staff (shift)”. An associated difficulty is that revision 
hip operations are becoming more infrequent as the primary (i.e. the first) hip 
replacements are lasting significantly longer and are more reliable than hip 
replacement operations undertaken 20-30 years’ ago. Bridgens et al (2007)’s study 
was undertaken between 1999 and 2003 implying a low volume of throughput with 
an increased likelihood of less experienced staff being available. This is borne out by 
the quote. It is also interesting to note that this article was not picked up by Carless et 
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al (2010) in their study. There was potential for bias in the study that one would have 
expected Carless et al (2010) to identify and highlight. 
The concept of Patient Blood Management (PBM), where a more holistic view is 
taken of the various blood-sparing techniques, was introduced in para 1.12. Again, 
this is consistent with the Royal Cornwall Hospital view of cell salvage being just 
one of the ‘tools in the armoury’.  It remains to be seen whether PBM will initiate a 
change in emphasis on studies to e.g. trying to isolate the benefits of cell salvage 
while ignoring other opportunities to avoid a transfusion. An article by Shaz et al 
(2013) noted that PBM’s goals should be to “improve patient care and quality while 
reducing spending”. It is interesting to note that one of the article’s co-authors was 
Dr Jon Waters; who, as noted earlier, wrote prolifically and specifically about cell 
salvage through the mid-late 2000’s, post Carless 2004. 
Additional issues on potential bias in a way not highlighted by Carless et al are 
noticeable in Yarham et al (2011). The Sorin Xtra (the updated Electa, now in use at 
the Royal Cornwall Hospitals) was evaluated at the Essex Cardiothoracic Centre. 
The price of an allogeneic unit was inflated by the group and screen test (to 
determine blood group and Rh) and the cost of cross matching (the check for 
antibodies). These two tests are often undertaken on patients anyway and, 
additionally, an electronic cross match is significantly cheaper than the £30.54 
quoted in the article. Furthermore, an evaluation of the machine should have 
included the energy requirements (and hence an accurate assessment of the potential 
running costs) of the machine. This was not supplied nor was a cost of consumables. 
It was interesting to note at the end of the article that it was stated the Sorin Xtra 
could be used post-operatively as a direct competitor to the Haemonetics OrthoPat 
cell salvage machine that was the established market leader in post-operative cell 
salvage. 
An issue experienced at the Royal Cornwall Hospitals where, when protocols on cell 
salvage are relaxed, was mirrored in the Queen Elizabeth Hospital, King’s Lynn. 
Butchart and Abdy (2011) noted an increase and then a decline in cell salvage usage 
in orthopaedics over the period 2004 to 2010. They noted that “this did not correlate 
with increased donor transfusion” i.e. allogeneic blood usage. The implication was 
that cell salvage was not required to avoid an allogeneic transfusion. The authors, 
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however, stated that record keeping was incomplete and “the majority (of entries) 
had significant information missing”. 
4.9 Societal and Wider Economic Costs 
Little consideration has been given to the wider costs associated with blood donation 
and how these would be avoided if the demand for allogeneic blood fell due to an 
uptake in blood avoidance techniques. The main UK article is Varney & Guest 
(2003) that attempted to derive a total cost for the supply of a unit of allogeneic 
blood. A Canadian article (Amin et al (2004)) was similar in that it attempted to 
measure the blood donor’s opportunity cost. This study used an average wage to 
calculate a notional cost irrespective of whether the donor was part of the labour 
force or if they were taking time off work. 
A US article, “The Cost of Blood: Multidisciplinary Consensus Conference for a 
Standard Methodology” (2003) attempted to segregate all costs associated with 
allogeneic blood from the recruitment of donors through to the assessment of the 
allogeneic “transfusion outcome”. This article was based on a symposium held in 
2003 by the US Society for the Advancement of Blood Medicine (SABM) and does 
not have a quoted author though the address for correspondence was to Dr Aryeh 
Shander (para 1.16). The article attempted to identify and categorise the costs rather 
than undertake a study to assess and quantify them. It highlighted “lost donor wages” 
and “lost productivity borne by the donors’ employers”. Costs relating to donor travel 
were not included and Varney & Guest’s (2003) costs were dismissed as “costs 
incurred by a nationalised system are not likely to apply to the rest of the world; thus, 
the generalizability of their estimate is limited”. Arguably this is a simplistic view, 
regardless of the overarching national blood collection system. Donors will still be 
required and there will be an associated costs and opportunity costs. 
The Consensus document only scratched the surface and did not initiate any detailed 
discussion in this area. Shander et al (2007) followed up with a paper entitled 
“Estimating the Cost of Blood: Past, Present and Future Directions”. The authors led 
a working group to standardise an estimate of the costs associated with blood. They 
pointed out that their work was still in progress and needed much more refinement. 
They estimated that the cost of an allogeneic unit was c. $1,400 with the implication 
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that the estimate could rise with the incorporation of additional costs such as donors’ 
costs, lost productivity and the “cost of treating transfusion transmitted disease”. 
This cost of $1,400 is the cost highlighted in the OrthoPat marketing material 
discussed in para 1.9. It is interesting to note that a Google search of the terms 
“societal costs of blood transfusion” or using replacement words/expressions such as 
“society” and “associated with” did not pull out any results (search undertaken and 
refreshed on 2 February 2016). Shander et al (2007) costs of c $1,400 have been 
revisited in Shander et al (2008) at $1,158 and Shander et al (2010) quoting a range 
between $522 and $1,183.  
Varney & Guest’s (2003) study was far more in-depth than the Consensus document 
and subsequent studies by Shander, assessing the occupation of the donor and if they 
were giving up time from work to donate. Additionally, other costs not borne by 
NHSBT (e.g. travel expenses to attend a donation session) were also considered. 
These costs were considered relevant to the whole allogeneic donation process and 
therefore the Varney & Guest (2003) study was re-visited as part of the Methods 
chapter 5 in order to update the costs.  
The impact on NHSBT’s costs due to an expansion in cell salvage was highlighted 
by Phillips SJ et al (2006). This article and Davies et al (2006) are the only 
references found that makes any detailed reference to the impacts on the costs at the 
relevant blood collection organisation. Davies et al (2006) noted that, at the time, the 
demand for allogeneic blood had fallen. Due to the nature of the high level of fixed 
costs they asserted the fall in demand actually drove up the price of a unit to maintain 
the ‘cost = price’ maxim and allow NHSBT to plan to recover all its costs and break 
even. Given the significant changes in the structure of the costs in NHSBT since 
2006, a reassessment of this assertion seemed opportune.   
4.10 Summary of Chapter 4 
Overall, there are difficulties and inconsistencies in highlighting the benefits of cell 
salvage due to: 
• The perception that it would be unethical for a clinician to withdraw an 
established blood avoidance technique (e.g. withdraw tranexamic acid or a 
course of iron tablets) just to isolate the benefits of cell salvage. Tse (2011) 
101 
additionally notes the difficulties in isolating the effectiveness of individual 
blood-sparing techniques when a number of them are used together. 
• No study made verifiable attempts to undertake any comparison between the 
differences between a financial and an economic appraisal (para 2.8). As such 
it is difficult to draw any robust conclusions over cell salvage supporting the 
reduction in costs associated with the collection and utilisation of allogeneic 
blood. 
• All studies have differing populations, differing judgements and differing 
working practices making it difficult to derive an objective comparison. The 
application of cell salvage in different specialties is likely to have different 
conclusions. It is significant that Waters (2010b) appears to have altered his 
view over the application of cell salvage in orthopaedics (para 4.7). Given 
Carless et al (2004 and 2010) state “the use of washed cell salvage appears 
justified in orthopaedic surgery” there is some irony that the leading 
proponent of cell salvage is now heading towards the other end of the 
spectrum of opinion with cell salvage in orthopaedics. 
• Carless et al’s (2010) conclusions changed little in the six years between their 
two reports. Their views were highly critical of most studies and did not 
address the key point that most studies reported a fall in the allogeneic blood 
requirements when a cell salvage programme was introduced. This would 
have a benefit to society that Carless et al (2010) did not encompass in their 
analysis. 
• Given the paucity of detailed costing and activity information in this area, it 
was felt that the true ‘costs’ of any developments in cell salvage would need 
to incorporate an up to date estimate of the wider costs to society of donating 
blood. Additionally, these ‘costs’ needed to be developed from both a 
financial and an economic evaluation standpoint. No studies considered the 
difference in interpretation between the two perspectives. 
• There will be time lags between the recent announcements on Patient Blood 
Management and the studies the announcements may initiate. This thesis is 
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therefore well-placed to contribute to the role of cell salvage in the 
discussions. 
• There was a marked change in the approach to the studies in 2012 and 2013. 
More studies were examining cell salvage in the wider hospital blood 
management context rather than the earlier ‘traditional’ approach to isolate 
costs associated with cell salvage and comparing these against the estimated 
volume and cost of allogeneic blood avoided. Associated with this was the 
trend to convert the salvaged/reinfused blood into equivalent units of 
allogeneic blood and attributing costs to the calculated units. This seems 
likely to have been initiated by newer pieces of cell salvage equipment that 
can capture information relating to volumes of blood salvaged and reinfused. 
McClelland’s (2007) formula of one allogeneic unit to raise the Hb level by 
10g/l is therefore quick and easy to attach to the volumes. In practice the 
volumes derived are notional and do not indicate whether the reinfusion is 
appropriate to the individual patient or whether an allogeneic transfusion 
would have been required anyway. The most recent literature search, up to 
December 2016, noted fewer studies adopting this approach and enthusiasm 
for this interpretation may be wearing off. 
In conclusion, the articles highlight that there is much more support for cell salvage 
than dissentient views though this difference should be viewed with caution. It may 
be that those holding unfavourable views just do not participate in discussions or 
utilise cell salvage equipment. The Patient Blood Management discussions raise the 
profile of avoiding allogeneic blood transfusions; but it is up to the individual 
organisations and the enthusiasm of individuals within these organisations to decide 
if they wish to utilise cell salvage in surgery. 
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Chapter 5. Methods 
5.1 Introduction 
The literature review highlighted three separate key factors that have had (and 
continue to have) an impact on the objectivity of a study into the financial impacts of 
cell salvage: 
• Carless et al (2004 and 2010)’s issues on the high level of bias in studies 
and the consequent recommendation to develop a large-scale comparative 
approach to a study on cell salvage. 
• The lack of emphasis placed on approaches to costs from both a financial 
and economic perspective. 
• The isolation of the impact of cell salvage when other blood avoidance 
techniques are running concurrently. Few studies (with the exception of 
Thurer (2011) and Phillips SJ et al (2006)) considered this issue. 
Discussions with clinicians from a number of hospitals (para 5.4 below) 
stressed the potential benefits of cell salvage to avoid allogeneic blood 
transfusions. Some clinicians highlighted however that, with some 
operations, the benefits of allogeneic blood avoidance could be replicated 
by simply dispensing a packet of iron tablets in the two weeks prior to 
surgery. 
The above recommendation from the clinicians on iron tablets was partly said in jest 
and not based on literature. However, the message was that a viable comparison of 
patients undergoing or not undergoing cell salvage needed to address the above 
factors in order to establish a baseline set of viable comparative data. 
A preliminary literature search in 2009 gave an indication of the level of discussion 
around the hospital-based costs. The researcher initially felt the challenge would be 
relatively straightforward and the work would primarily involve a simple ‘make v 
buy’ type comparative study building on his previous research (Crotty (2006)). It was 
soon apparent that answering the research question would be a significant challenge. 
In particular, there were a number of significant, confounding factors, highlighted in 
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the literature review. These would potentially distort the outcome of results, and 
therefore conclusions on costs, at hospital level leading to assertions of potential 
bias. These confounding factors included: 
• Level and quality of patient preparation for the surgery. 
• How invasive the total hip replacement operation was and any 
associated patient comorbidities. These would consume a greater 
amount of resource and potentially require more allogeneic blood. 
• Day of week of surgery that may potentially impact on the patient’s 
recovery programme when recovering over the weekend. This, in 
turn, may therefore affect the patient’s length of stay for primary total 
hip replacement surgery. 
• The quality of the financial information reported. 
The researcher felt that the priority was to avoid the investigations falling foul of the 
criticisms of Carless et al (2004 and 2010). At the same time, the researcher should 
undertake a “large, methodologically rigorous” (para 4.5) study to study the costs 
and follow the spirit of the Carless et al (2004 and 2010) conclusions. 
This chapter starts with a background of the key issues associated with the choice of 
data to extract in order to ensure the impacts of cell salvage are isolated and 
measurable. The chapter subsequently describes the approach to be employed and 
then highlights the organisational and personal challenges in collecting the data. An 
overall summary of the comparative information datasets requested is shown in table 
18 below. 
Table 18. Summary of Comparative Information Datasets Requested 
Information Required Purpose Method of Collection 
Patient identifier Extract relevant data for 
primary total hip replacement 
operations from hospital 
patient systems. 
Information Department 
extract information by 
operation code. 
HRG code Categorise patient into level of 
invasiveness/severity of 
operation. 
Lookup table generated by 
relevant Information 
Department 
Pre-operative Hb level Record patient’s iron level 
prior to the operation. 
Indication of ‘preparedness’ 
for operation. 
Manually extracted from 
patient record. 
Lowest post-operative Hb Record patient’s iron level Manually extracted from 
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Information Required Purpose Method of Collection 
level after the operation. Indication 
of how well patient has 
managed the trauma. 
patient record. 
Patients date of birth/gender To test for patient 
homogeneity in age/gender 
across the three sites. 
 
Manually extracted from 
patient record.  
Date of operation/date of 
discharge. 
To test for any day of week 
association and calculate 
length of stay. 
Manually extracted from 
patient record. Spreadsheet 
formulae would calculate 
the relevant day of week 
and the length of stay. 
Consultant/Firm Extract comparisons of 
allogeneic blood usage for 
internal discussion. 
Manually extracted from 
patient record. 
If allogeneic transfusion how 
much allogeneic blood 
transfused? 
To isolate number of 
allogeneic transfusions and the 
volume of allogeneic blood 
required. 
Manually extracted from 
patient record. 
At the Royal Cornwall 
Hospitals, for each patient, 
verify if cell salvage used 
and if shed blood reinfused 
To quantify utilisation of cell 
salvage and estimate 
associated costs. Allow 
comparison of different types 
of machine utilised. 
Manually extracted from 
patient record. 
 
The main focus on studies in the literature review is on the impact of cell salvage on 
minimising allogeneic blood transfusions. This thesis builds on ideas generated from 
the literature review and comments received from clinicians. It adopts a more holistic 
approach by undertaking a multi-site comparison of patients who have not had an 
allogeneic blood transfusion in primary total hip replacement surgery. This compares 
one organisation (the Royal Cornwall Hospitals NHS Trust) that uses cell salvage 
against two organisations (University Hospital of South Manchester NHS Trust and a 
specialist orthopaedic centre) that do not utilise cell salvage in primary total hip 
replacement surgery. The objective was to establish the baseline of patient data that 
could be readily compared over a number of sites; only then introducing cell salvage 
into the discussion. The key challenges to be addressed are summarised in table 19 
below. 
Table 19. Information Required to Compare Pre-Operative Activity Data 
Challenges Addressed by: 
Potential bias in selection Take a series of consecutive patients at a site where cell 
salvage utilised for total hip replacement. Compare these 
against a series of consecutive patients at  two sites where no 
cell salvage is utilised.  
Homogeneity of patients Statistically verify the different patient cohorts are 
homogeneous using age and gender. 
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Challenges Addressed by: 
Difficulty in isolating 
impact of cell salvage 
from other blood saving 
techniques 
Patients need to be homogenous and pre-operative statistics 
should indicate adequate preparation for the operation. Clarify 
with the selected centres they adopt best practice under Better 
Blood Transfusion and subsequently Patient Blood 
Management techniques. 
Preparedness of patients 
for surgery  
Collect and statistically test pre-operative Hb reading. 
Homogeneity of surgery Obtain patient healthcare resource group (HRG) codes to 
analyse the total hip replacement operation in more detail. This 
level of detail has not previously been adopted in a cell salvage 
study. 
Operation Day Experiences at UPMC Pittsburgh indicate operations 
undertaken earlier in the week have an impact on patient 
length of stay. 
 
The approach to gather the information in table 19 would allow the researcher to: 
• Establish the level of age and gender homogeneity in the groups of patients 
and develop a strong indication of the preparedness of the patients for 
surgery. The less prepared the patient the more likely there would be a need 
for an allogeneic blood transfusion. 
• Establish if the patient comorbidities are uniformly distributed in each of 
the chosen sites. The more severe the surgery the more likely an allogeneic 
blood transfusion will be required. By extracting and comparing the 
relevant healthcare resource group (HRG) category a comparison could be 
made on the severity of the surgery and associated treatment. If the profile 
of the HRGs was similar across the sites, then patient comorbidities could 
be discounted as a factor in influencing differences in allogeneic blood 
transfusion rates. 
• Identify whether any other factors may explain differences in transfusion 
rates. 
If the three patient cohorts are homogenous this will support a direct comparison 
between the pre-and post-operative patient data across the three sites. Comparisons 
can then be undertaken between patients who have had their blood reinfused at the 
Royal Cornwall Hospitals, utilising cell salvage, with the other two sites where cell 
salvage is not utilised. ‘Ceteris paribus’; the differences in the post-operative 
statistics would be caused by lower allogeneic transfusions at the Royal Cornwall 
Hospitals resulting from the utilisation of reinfused blood from adopting cell salvage. 
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Further comparisons on patients who have had allogeneic transfusions can 
subsequently be extracted. The key aim, therefore, is to establish this ‘baseline’ 
where the same profile of procedures is undertaken on a set of homogeneous patients 
over three organisations. Once this baseline is established the focus can move to 
answering the research question: 
Is cell salvage an appropriate method of blood conservation to support the reduction 
in costs associated with the collection and utilisation of allogeneic blood? 
This chapter highlights the information required and the approach to answering the 
research question. It is crucial therefore to, as far as possible, isolate the impact and 
cost of cell salvage from the other allogeneic blood avoidance techniques that are 
running concurrently across the three sites. This strategy has been omitted from most 
of the studies discussed in chapter 4. 
5.2 Objectives of Study 
This approach differs significantly from the majority of other studies noted in the 
literature review. In particular, it adopts a novel approach in assessing the costs 
associated with cell salvage in relation to:  
• The varying resource inputs required to achieve a successful operation and 
the associated severity of the primary hip replacement surgery. This is 
highlighted by analysing HRG activity information that can classify the 
operations and treatment into varying levels of resource requirements and 
costs. All other studies only focus on the generic term ‘primary hip 
replacement surgery’. To the best of the researcher’s knowledge no other 
study has studied primary hip replacement surgery in this level of detail by 
utilising HRGs. This will therefore facilitate an additional method of 
comparison between hospitals. A Google search on the terms ‘hip 
replacement surgery’ and ‘cell salvage’ and ‘HRG’ with no date 
restrictions, undertaken on 10 April 2016, only gave 19 ‘hits’. None of 
these references were directly relevant to this thesis.  
• Segregating the impact of enhanced recovery pathway programmes (para 
1.19) such as identifying the potential impact of weekend discharges on 
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patient length of stay and the adequacy of the pre-operative assessments by 
comparing patients’ haemoglobin (Hb) levels. Additionally, the analysis 
should address the length of stay differences by comparing patients who 
have not had an allogeneic blood transfusion or had their salvaged blood 
reinfused. This generates a ‘baseline’ of comparative data that will not be 
affected by the impacts of allogeneic blood transfusions or re-infused blood 
(the ‘yellow route’ in figure 15 on page 128). 
• Addressing one of the key recommendations of Carless et al (2004 and 
2010) on developing a large-scale comparative approach to a study on cell 
salvage. Additionally, with the Royal Cornwall Hospitals collecting 
information relating to patients who did not have their blood reinfused, 
there is the ability to extract some intra-hospital comparisons. This can 
provide additional reassurance that the three centres’ operational 
procedures are uniform, allowing a further comparison with the cell salvage 
patient cohort. 
• Segregating the costs and undertaking comparisons from both a financial 
and an economic approach. 
In late 2009 the researcher secured funding from NHSBT trust funds to visit the 
University of Pittsburgh Medical Centre (UPMC), Pennsylvania, USA. This is the 
hospital where the author of a number of cell salvage articles, Dr Jon Waters, is 
based and this gave the researcher an opportunity to see the environment where Dr 
Waters based most of his studies and articles. The researcher spent four days with 
clinicians, seeing cell salvage in the surgical environment and shadowing members 
of staff. At first hand the operating procedures were similar to those the researcher 
had observed in operating theatres at the Morriston Hospital, Swansea. The main 
difference was that, at Pittsburgh, there were dedicated operating department 
practitioners (ODPs) who moved between operating theatres to manage the operation 
of cell salvage equipment. 
The overall objectives of the study to answer the research question can be 
summarised as undertaking a comparison that minimises potential allegations of bias 
in order to: 
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5.2.1 Establish the homogeneity of the patient cohorts selected in order to 
minimise allegations of bias and compare patient data between sites that use and 
do not use cell salvage. This will support a valid comparison between the three 
sites. 
5.2.2 Evaluate the cost impacts of cell salvage against using allogeneic blood 
from both a financial and an economic perspective; 
5.2.3 Investigate other possible factors that may impact on comparison across 
sites such as preparation for surgery and length of stay. 
Data to underpin these objectives is therefore crucial to ensure valid comparisons 
between patients and across different sites are undertaken. The data from all three 
sites would be a consecutive series of patient details extracted from the patient 
admission system. This information would then be supplemented by additional data 
held in the respective departments. 
5.3  Overall Approach to Analysis 
The approach was planned as: 
5.3.1 Extract the main activity data by site for elective primary total hip 
replacement patients and identify the reasoning behind generating the particular 
results, grouping these by: 
• Pre-operative indicators for elective patients who have not had an 
allogeneic transfusion by hospital site. 
• Compare post-operative indicators for the non-transfused (or non-
transfused and non-reinfused at Royal Cornwall Hospitals) group. 
• Analysis of length of stay (LOS) for patients who have not had an 
allogeneic blood transfusion to estimate the underlying mean length 
of stay at each site without being influenced by any allogeneic blood 
impacts. 
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• These pre- and post-operative indicators will therefore generate a 
series of ‘baseline’ comparisons not affected by the impact of 
allogeneic transfusions. 
• Patients with a LOS over 14 days would be excluded in order to 
minimise any distortions. A longer LOS may imply difficulties in 
discharging the patient or other complications arising. This excluded 
20 patients in table 20 below: 
Table 20. Elective Patients with Length of Stay >14 days and Excluded from Analysis 
Hospital/ 
Category 
South 
Manchester 
Royal 
Cornwall 
Specialist 
Orthopaedic 
Centre 
Totals 
Number of Records 153 218 147 518 
Records Excluded 5 5 10 20 
Number of Records for 
Analysis 
148 213 137 498 
 
5.3.2 Undertake statistical comparisons with the data extracted, subsequently 
comparing results where allogeneic blood transfusions are undertaken. 
5.3.3 For the Royal Cornwall Hospitals, only, generate comparative information on 
the use of cell salvage (180 from a total of 213 patients) and especially where the 
blood was reinfused (104 from the 180 patients who were salvaged).  
5.3.4 Derive estimates of expenditure associated with cell salvage and allogeneic 
blood usage. 
5.3.5 Outline the calculations from NHSBT and the estimated costs attributable to 
the blood donation process (costs incurred by blood donors but not recompensed) 
and derived societal costs. 
5.3.6 Estimate a unit cost of blood requirements (allogeneic and/or salvaged) per 
operation. This will include an estimate of the associated societal cost. Transfer 
prices can also be calculated and, where necessary, excluded from the analysis for a 
comparison from both a financial and an economic perspective. 
5.3.7 The analysis plan was based on discussions with clinicians in 2008/09 and 
reference to articles in the literature review. The information requirements were then 
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developed in conjunction with the clinicians’ assessments on what datasets would 
provide the researcher with the requisite information to undertake comparisons 
across sites. 
5.4 Dealing with Challenges in Acquiring Information 
The researcher had access to the NHSBT costs and activity information. As 
highlighted earlier the main stumbling block was the collection of the 
hospital/patient data. The finalised schedule of hospital information requirements in 
table 18 was agreed in early 2010. Consultants from the three hospitals below were 
keen to support the work: 
• Abertawe Bro Morgannwg (ABM) University Health Board. 
• Guy’s Hospital London. 
• Oxford University Hospitals NHS Trust. 
Morriston Hospital, part of Abertawe Bro Morgannwg (ABM) University Health 
Board, agreed to commence the pilot of the information gathering in March 2010. A 
list of patients who had undergone primary total hip replacement operations was to 
be generated. The relevant information would then be accessed from the patient 
record system using the patient identification number. The intention was for a 
foundation level doctor to undertake the extraction of the information and the 
researcher to develop it into a service evaluation for the Hospital Transfusion 
Committee (HTC). The researcher would receive the information suitably 
anonymised thereby not requiring any local Ethics’ Committee approval. Several 
foundation level doctors expressed an interest to the lead consultant but were put off 
by the Morriston information systems requiring each patient record to be accessed 
individually and the data manually transferred to a spreadsheet. The researcher was 
advised to wait until August 2010, to await the next post rotation. Again, however, 
interest from the new cohort of junior doctors waned and in early 2011 the researcher 
agreed with the lead consultant that Morriston was unable to collect the required 
information. 
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In mid-2010 the researcher met with a consultant orthopaedic surgeon at Guy’s 
Hospital in London. The surgeon was keen to introduce the elements in table 18 into 
Guy’s and agreed to take the request to the Orthopaedics Management Board of the 
Trust in late 2010. The Management Board, following liaison with the Information 
Technology Department, did not feel it appropriate to support the request citing the 
significant volume of work that would be required to collect the information. The 
researcher offered to be placed on an honorary contract and be supervised by the 
surgeon. It was pointed out that the information needed to be extracted by individual 
patient (this issue was similar to the issues at Morriston Hospital); this would be time 
consuming and the researcher would need to be constantly supervised to ensure no 
individual patient could be identified. This was viewed as unworkable by the 
Orthopaedics Management Board at Guy’s. 
By early 2011 the researcher was also not getting positive messages from the Oxford 
University Hospitals Trust. Again, the initial enthusiasm waned as the same issues 
emerged with collection of data and the researcher had to discount Oxford as a 
potential site on which to base his study. 
The researcher was then introduced to the Spire private hospital in Bristol. The 
Pathology manager kept most of the information in table 18 however these were only 
readily available for patients who had received an allogeneic blood transfusion. New 
salvage machines had recently been acquired and these could record the majority of 
the relevant information. Key data on allogeneic transfusions and the HRG code 
were not recorded. This was a further disappointment, but it was a short move in the 
right direction to note that the information could actually be generated. 
The researcher was almost at a point of giving up. He realised, in harsh reality, the 
issues of potential bias evolving that Carless et al (2004 and 2010) had highlighted. 
The idea of a large-scale cross-site comparative study seemed very challenging to co-
ordinate if there was not the enthusiasm and resource to gather a common set of data 
within each particular site. At the same time, the researcher needed to overcome the 
significant obstacles of data gathering and managing the associated patient 
confidentiality. 
In September 2010, the researcher succeeded in getting an article published in the 
Healthcare Financial Management Association (HFMA)’s monthly publication 
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‘Healthcare Finance’. This related to a joint project on costs associated with cell 
salvage undertaken with the Welsh Blood Service’s Cell Salvage Coordinator. The 
title of the article, chosen by the editor with a recycling emphasis, was “When Blood 
Turns Green”. This did not create any stir in the world of cell salvage but proved 
useful in providing a crucial introduction in 2011. In March 2011, the researcher read 
an article on preparedness for surgery in the Health Service Journal by an 
anaesthetist at the Royal Devon & Exeter (RDE) Hospital ((Berry et al 2011)). The 
author noted, inter alia, the impact of pre-operative assessments on allogeneic blood 
usage. The researcher contacted the anaesthetist with a copy of his HFMA article. 
This facilitated an introduction to the clinical blood conservation coordinator at the 
RDE. In turn it was suggested a meeting with the transfusion coordinator at the 
Royal Cornwall Hospitals NHS Trust would be useful to assess their level of 
information availability. This was the breakthrough the researcher was hoping for, as 
Royal Cornwall Hospitals’ team had been collecting most of the information the 
researcher required. In early 2012 the transfusion coordinator at the Royal Cornwall 
Hospitals introduced the researcher to his counterpart at South Manchester 
University Hospital Trust who was a co-author of the HTA study (Davies et al 
(2006)). South Manchester were happy to release similar data recently collected to be 
incorporated into a comparative study. 
By mid-2012 the researcher now had two sets of comparative information. There 
were, however, still gaps in the information for both organisations: 
• The operation date. Both hospitals used the patient admission date which 
could be the day prior to the operation if, for whatever reason, the patient 
was admitted early. 
• Neither hospital extracted the HRG coding system to classify the operation 
as to its resource requirements. 
The researcher met again with the transfusion coordinators at the Royal Cornwall 
Hospitals and South Manchester to discuss the potential collection of the additional 
information. The researcher again suggested being employed on an honorary contract 
and extracting the information himself under supervision. Again, the issue of patient 
confidentiality was raised. The researcher agreed with the two transfusion 
coordinators that they (or their staff) would extract the relevant information. This 
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proved to be very slow, but the final elements of the information were made 
available to the researcher in late 2014. 
The researcher had previously discussed pre-operative assessments with clinicians at 
NHSBT. One of the clinicians held a joint post as a consultant haematologist with an 
NHS Trust. The operations of this Trust included a Specialist Elective Orthopaedic 
Centre (SOC). The consultant had previously undertaken studies in pre-operative Hb 
levels. She was a strong advocate of deferring a patient’s surgery if their Hb levels 
were low (para 1.19). She therefore had first-hand experience of how difficult it was 
to collect the information and could empathise with the researcher’s problem in 
acquiring the relevant information. 
The consultant offered to support the researcher in extracting information from the 
Trust relating to patients at the SOC.  
The SOC did not utilise cell salvage for primary hip replacement operations so, along 
with South Manchester University Hospital, would provide a benchmark to assess 
against the data from the Royal Cornwall Hospitals who salvage all elective primary 
total hip replacement patients. 
A list of consecutive elective primary total hip replacement patient identifiers was 
obtained from the Information Department for the SOC. Also generated was the 
operation date, the date of discharge and the HRG code. The rest of the information 
from table 18 needed to be extracted from the individual patient record, using the 
patient identifier. The consultant offered to sit with the researcher and extract the 
information by accessing the patient records system and calling out the specific 
details to the researcher who would enter the information in a spreadsheet. The 
requisite documentation was sent to the Trust’s Ethics’ Committee who approved the 
process subject to the SOC being anonymised in the published study. The researcher 
agreed to call the organisation the Specialist Orthopaedic Centre or ‘SOC’ in any 
narrative and the consultant agreed to be directly involved in the data collection. 
The consultant suggested the data extraction work be undertaken in mid-late 
evenings when there were fewer users accessing the information system and 
response times were faster. Monday evenings were traditionally quieter, and this 
work commenced in autumn 2012; being completed prior to Christmas 2012. 
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Perversely, though the information collection commenced last, it was completed first. 
In early 2013 the researcher was able to analyse the SOC information over HRGs 
and share this anonymised information with the Royal Cornwall Hospitals and South 
Manchester. The aim of sharing the information was to show the higher level of 
certainty and reassurance on homogeneity the HRG information would provide. It 
slowly helped encourage the other two organisations to eventually deliver the HRG 
information. 
The researcher was invited to present his provisional findings to the Hospital 
Transfusion Special Interest Group (HOTSig) conference in Birmingham in May 
2013. The researcher took part and presented on variations in transfusion rates and 
length of stay. Though the presentation was well received and there was useful 
feedback he came away feeling he had not added a great deal to the overall 
discussions. He felt the comparison on HRGs would add more analysis to the 
discussion and adopt a new angle to the discussion. 
The researcher had been employed at NHSBT, and its forerunner, the National Blood 
Service (NBS) since 1998. He had a wide exposure to the discussions on blood 
conservation. He had been an active blood donor since his undergraduate days and 
conceived and developed the project at work both in discussions with colleagues and 
being involved with the setting up of the UK Cell Salvage Action Group (para 1.15. 
The researcher supported the Group on developing spreadsheet models of activity 
and provided financial input into various papers. This was mainly on an informal 
basis and undertaken in the researcher’s spare time. 
Running concurrently with the research work in gathering information for the thesis 
was the evolving strategic plans for NHSBT. In 2011 the researcher’s post and the 
rest of the NHSBT Finance Department posts based in Bristol were placed ‘at risk’. 
There was a long period of uncertainty and a high number of redundancies to 
facilitate the centralisation of support services in Leeds. The justification of the 
centralisation was to cut costs in the light of lower activity. The researcher secured a 
new post, based at Bristol, in the organisation however the disruption impacted on 
the ability to devote much time to the thesis in 2011. 2013 was also a challenging 
year as the researcher’s new post was then declared ‘at risk’ in March 2013. There 
then followed an arduous consultation period culminating in the researcher finally 
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being made redundant in October 2013. Again, the thesis had to be put to one side 
while the researcher looked for another job. He commenced a new role in the NHS in 
Torquay in January 2014. It took a couple of months to settle down before he could 
resume serious work on the thesis and build up lost momentum. Family life also 
suffered, and the researcher felt that home life and securing paid employment had to 
be the priority in this uncertain period. 
In December 2014, the researcher moved to a permanent position as Corporate 
Development Manager at the West of England Academic Health Science Network in 
Bristol. A family bereavement in March 2015 again took time to come to terms with 
and it was not until late-2015 that the researcher felt that his studies were again 
picking up momentum. 
5.5 Preparation-Isolation of Impacts of Cell Salvage 
As noted previously, a key challenge is to isolate the impact of cell salvage as a 
technique to avoid an allogeneic blood transfusion. Many allogeneic blood avoidance 
techniques are adopted simultaneously in surgery and a plan to isolate the impact of 
cell salvage required a wide-ranging discussion with key proponents of cell salvage. 
Some slightly less enthusiastic clinicians’ views were also sought to ensure, as far as 
possible, an objective approach to a comparative study was maintained. The 
recurring point raised was that a packet of iron tablets cost only a few pennies. Cell 
salvage utilisation in an operation would cost at least £100. Both strategies would 
potentially reduce allogeneic transfusion rates. The main advice from these 
discussions was that cell salvage should be adopted after cheaper blood conservation 
methods had all been utilised. One of the main challenges for staff would therefore 
be when to set up and run the cell salvage equipment, thereby incurring costs. Given 
the timings it may have been uncertain whether the equipment would be required 
since the cheaper strategies had actually proved to be effective. 
From the literature review Thurer et al (2011) highlighted the issue of a number of 
blood avoidance techniques running concurrently, concluding “Further study is 
needed to better understand the relative contribution of each of these modalities”. 
Similarly, Phillips S et al (2006) undertook a combined study of utilising cell salvage 
and tranexamic acid, concluding the joint contribution was significant. They noted, 
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however, that they did not study the two techniques in isolation. Without further 
study, there was no way for Phillips S et al (2006) to conclude which of the two 
techniques had been the more effective. Carless et al (2010) also concluded “To 
delineate the efficacy of the various techniques used in non-cardiac settings is rather 
difficult as the current available evidence is equivocal”. Most other studies did not 
highlight this issue of the impact of utilising different blood avoiding strategies. 
Initial discussions had been held in 2008/2009 with clinicians from Liverpool, 
Swansea, Oxford, London and Bristol. Additionally, the author discussed issues on 
cell salvage with colleagues in NHS Blood & Transplant (NHSBT) while employed 
there up to October 2013. Wider ranging discussions were also held with a consultant 
haematologist at Basildon. The haematologist had forthright views on the logistics 
required to support electronic cross matching to speed up the checking of any 
incompatibilities in the patient’s own blood (para 4.2). He suggested the researcher 
liaise with the South West London Elective Orthopaedic Centre (Swleoc), who were 
extensive users of cell salvage. The researcher tried on several occasions but failed to 
elicit any response from the Swleoc. 
Opinions on the use of cell salvage from those contacted were generally in favour of 
its introduction and development. All the clinicians stressed that the researcher would 
have a challenging task in answering the research question. As noted above the 
challenge was to isolate the benefits cell salvage offered if an array of other 
allogeneic blood avoidance techniques were also being adopted at the same time. 
Chapter 1 makes references to the development of blood clotting drugs (para 1.9) and 
the Better Blood Transfusion Initiatives along with the more recent Patient Blood 
Management Initiative (paras 1.11 and 1.12). These elements are discrete and 
tangible. There are other factors that are considered best practice e.g. keeping the 
patient warm or positioning the patient correctly during surgery to allow the surgeon 
access which would minimise blood loss. These factors are less tangible and would 
not be directly associated with an allogeneic blood avoidance initiative however the 
operating staff would be expected to follow these procedures. Shander et al (2012) 
summarise the differing issues in their “three pillar approach”. The pillars involve 
adopting: 
118 
• approaches to ensure the patient’s blood cells are maximised when 
presenting for surgery. 
• during surgery ensuring the patient’s blood loss is minimised 
• post-surgery effectively managing the patient recovery to minimise the 
chances of anaemia progressing. Minimising the progression of anaemia 
would thereby support the recovery process and contribute to minimising 
blood loss. 
Shander et al’s (2012) schematic is reproduced below: 
Figure 13. Shander et al (2012) Summary of Patient Blood Management 
 
Key: 
 Pre-Operative Stage 
 Intra-Operative Stage 
 Post-Operative Stage 
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Shander et al’s (2012) schematic attempts to capture the main potential surgical 
processes and covers both elective and non-elective surgery. As would be expected, 
managing anaemia crosses all the pillars and operation stages. Cell salvage features 
in the ‘autologous blood options’ in the second pillar’s intra-operative stage and the 
‘autologous blood salvage’ in the post-operative stage (e.g. utilising the OrthoPat 
post-operative cell salvage machine). What is significant is the number of potential 
areas that could influence the process. Though Shander et al’s (2012) article had not 
been published when the researcher commenced discussions with the various 
clinicians the message from the clinicians was consistent and repetitive; the 
researcher would be faced with a major challenge to isolate the impact of cell 
salvage. In all studies, there would be a level of subjectivity and the researcher 
needed to develop a plan to satisfy Carless et al’s (2010) conclusion that “large, 
methodologically rigorous comparative trials” were required to “assess the cost 
effectiveness of cell salvage..”. 
The conclusion from the discussions with the clinicians was to undertake a 
comparison of patient information over the three areas of: 
• Pre-operative assessments. The key indicator as to their impact would be 
the patients’ Hb levels. 
• Intra-operative. The level of resource required in the operation. This 
approach was novel. The more severe the HRG category the more likely a 
requirement for an allogeneic blood transfusion or a potential longer 
associated length of stay. A more detailed explanation of HRGs is outlined 
in para 5.7 below. 
• Post-operative. Factors such as discharge day that may point to differing 
trends in post-operative therapy support for primary total hip replacement 
patients. These are highlighted in para 1.19 on enhanced recovery 
pathways. 
This approach followed the emphasis of Shander et al (2012). All the clinicians 
stressed the need to ensure the researcher could, as far as possible, verify patient 
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group homogeneity and suggested a number of datasets to form the basis of an 
analysis to verify this was the case. 
The discussions with the clinicians were invaluable in framing the researcher’s 
thoughts on how to approach the collection of information to develop an answer to 
the research question. The choice of operation to consider was developed in chapter 
1. The researcher believed that a multi-site study was required to compare primary 
total hip replacement at two or more hospitals to minimise any of the Carless et al 
(2010) criticisms (para 4.5). The hospitals needed to have, as far as possible, a 
homogeneous cohort of patients. At least one of the hospitals needed to utilise cell 
salvage. All the hospitals needed to be assiduous in minimising the exposure to 
allogeneic blood. The hospital or hospitals not utilising cell salvage in primary total 
hip replacement surgery would therefore provide a baseline for cell salvage to 
measure against. ‘Ceteris paribus’ lower allogeneic blood usage in the hospital 
utilising cell salvage would therefore be assumed to be due to the impact of cell 
salvage decreasing the allogeneic blood requirements. Hospital based costs could 
then be segregated to allow a comparison between patients undergoing cell salvage 
and those that did not. In addition, ensuring the usage of allogeneic blood is kept to a 
minimum allows a comparison between different cell salvage machine costs in the 
same organisation. 
This approach, though challenging, was viewed as the optimal way of isolating the 
impact of cell salvage. By assuming homogeneity of patients, procedures and 
assessments the only difference in the allogeneic blood requirements of the patients 
would therefore be due to the contribution of cell salvage. 
5.6 Preparation-Recruiting Study Sites 
As noted above the researcher had discussed issues around cell salvage with 
clinicians around England and Wales. His initial discussions were at Abertawe Bro 
Morgannwg (ABM) University Health Board, Swansea and at the Royal Liverpool 
and Broadgreen University Hospitals NHS Trust in 2008. This led to further 
discussions/development of plans. A brief chronology of the progression is shown in 
table 21 below:  
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Table 21. Progression of Information Gathering Discussions 
 
Year Main Events 
2008 Discussions with ABM. Met with Royal Liverpool to discuss cell salvage 
applications in cardiac. Discussions with staff at NHSBT noted 
expectancy of increased orthopaedics activity and consequent increased 
use of allogeneic blood. Decided to focus on orthopaedics following 
discussions with NHSBT medical staff (para 1.20). 
2009 Preliminary discussions at Oxford and Basildon. Both noted the high use 
of cell salvage at the Nuffield Orthopaedic Centre (NOC) in Oxford and 
the South West London Elective Orthopaedic Centre (SWLEOC).  
2010 Guy’s agreed to take part and collect data. ABM and Oxford also agreed 
to commence collecting data. The researcher was planning for a three-
way comparison. 
Guy’s then stated the resources required to extract the information were 
too costly and pulled out. ABM finally highlighted the difficulty in 
getting foundation level doctors to support the data collection and stated 
they felt they could not support the researcher. 
2011 Oxford and ABM formally pulled out, citing difficulties in collecting the 
information. Introduced to the Royal Cornwall Hospitals NHS Trust; a 
keen user of cell salvage in orthopaedics. They were confident of being 
able to extract most of the data. Introduced to South Manchester who 
utilised cell salvage in cardiac but not in orthopaedics. South Manchester 
had been collecting anonymised total hip replacement data that they were 
willing to share with the researcher. 
2012 Discussions within NHSBT identified a specialist elective orthopaedic 
centre (SOC). The SOC stated the information would be made available if 
the researcher undertook the information gathering under the supervision 
of the consultant haematologist. The SOC information gathering was 
completed immediately prior to Christmas 2012. 
 
The final choice of sites on which to base the study was therefore: 
• Royal Cornwall Hospitals NHS Trust. Orthopaedic services are delivered in 
the main Royal Cornwall Hospital in the Treliske area of Truro and St 
Michael’s Hospital in Hayle, Cornwall. St Michael’s is approximately 17 
miles south west of Truro. 
• University Hospital of South Manchester NHS Foundation Trust (‘South 
Manchester’), based in Wythenshawe, approximately nine miles south of 
the centre of Manchester. 
• The specialist orthopaedic centre (SOC). The SOC undertakes extensive 
elective and non-elective orthopaedic work on behalf of five clinical 
122 
commissioning groups (CCGs). This organisation currently wishes to 
remain anonymous. 
All three sites undertake orthopaedic work in both elective and non-elective settings. 
The published HRG statistics for the three sites for total 2010/11 orthopaedic 
operations was: 
Table 22. Summary of Orthopaedic Operations 2010/11 
 
Site\ 
Classification 
South 
Manchester 
Royal 
Cornwall 
Spec Orth 
Centre Total 
Day Case 345 310 135 790 
Elective 252 759 959 1,970 
Non-Elective 36 134 106 276 
Total 633 1,203 1,200 3,036 
Extracted from Department of Health National Schedule of Reference Costs 2010/11 
 
The main emphasis of the study would be on the analysis of elective primary total 
hip replacement surgery. On overall totals the orthopaedic activity at South 
Manchester is significantly lower than the other two sites. Part of this may be 
explained by the geographical nature of the location of South Manchester where 
there are a number of specialist and other large teaching hospitals in close proximity. 
The Royal Cornwall Hospitals is the only orthopaedic service in a wide catchment 
area. Similarly, the SOC specialises in orthopaedic cases with CCGs encouraging 
their patients to travel to the SOC for elective orthopaedic surgery. 
5.7 Approach to Designing Study to Measure Patient Group Homogeneity 
The researcher discussed with the various clinicians how to measure the key 
elements influencing a requirement for an allogeneic blood transfusion before, 
during and after the operation. These elements were key to establishing a number of 
currencies to support the objectives in para 3.3. These key factors were: 
Patient Preparation. As noted in para 1.9 the pre-operative Hb levels are crucial in 
determining the patients’ readiness to undergo an operation. The English NHS 
Enhanced Recovery Programme highlights the need for the pre-operative assessment 
to gauge whether the patient is ‘match fit’ to present for surgery. If the patient is 
anaemic then the pre-operative assessment, held generally two to three weeks prior 
to the operation, will recommend the patient be referred to their GP for investigation 
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prior to surgery. Discussions with the clinicians noted that patients with a lower pre-
operative Hb level would be more likely to require an allogeneic transfusion. It was 
highlighted by clinicians at the Morriston Hospital, Swansea and others, however, 
that cell salvage effectively slows down the fall in Hb levels during and after surgery. 
This would therefore give the impression that its contribution was effective in 
lowering the requirement for an allogeneic blood transfusion. The patient’s initial Hb 
level, however, may have been too low at the outset and the elective operation should 
not have taken place. Clinicians stressed that the researcher should therefore address 
the key issue of cell salvage masking inefficiencies in the patients’ pre-operative 
assessments in elective surgery. 
Post-operative Hb Levels. These are a strong indicator of the progression in recovery. 
A higher level of oxygen will stimulate organs to support the recovery process. 
Clinicians unanimously advised that the post-operative reading must be available. 
Post-operative Hb levels are typically taken using a portable or a hand-held point of 
care device. This involves taking a pin prick sample of blood onto a slide and placing 
this slide onto a portable analyser which is not much bigger than a large mobile 
phone. 
The lowest available post-operative Hb reading would therefore give a strong 
indication of the recovery rate and indicate the ‘worst state’ the patient was in after 
the operation. The reading may not be the actual lowest Hb point the patient reached. 
It is reasonably safe, however, to assume that if the Hb level continued to fall the 
patient would start to show signs of distress and interventions would be required. If 
this was the case, then the additional procedures would categorise the patient into a 
higher graded HRG code. The post-operative Hb reading is therefore a reasonable 
indicator of recovery. 
Invasive Level of Primary Total Hip Replacement Operation. Para 1.24 introduced 
the concept of the HRG (healthcare resource group) with software that groups 
together similar surgical procedures and assigns an HRG code to the operation. This 
code effectively separates operations that require different levels of intervention. 
HRG classifications are used as a funding currency in the English NHS internal 
market. The suggestion to sub-analyse the total hip information in this level of detail 
was put to the clinicians; none of whom had previously undertaken any analysis of 
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operations in this level of detail. The researcher had attempted to find a cell salvage 
study including this level of detail however he failed to uncover any. The researcher 
also noted how unfamiliar the clinicians were with the term ‘HRG’. None of the 
clinicians used this currency to record and quantify their own, and their teams’, 
activity. This seemed surprising and some of the clinicians also expressed surprise 
that there was no HRG code for total hip replacements. There was only, as described 
in table 23 below, a coding system to reflect the severity of the operation/associated 
comorbidities, grouping together procedures. The individual procedures may be e.g. 
a primary (first) hip replacement, a secondary (subsequent) hip replacement or a 
revision of an existing hip replacement operation undertaken previously. These three, 
significantly different, operations could be identified to the same HRG category 
depending on the relative severity/comorbidity. 
The level of detail that can be generated by the HRG coding is extracted from the 
English NHS national schedule of reference costs and shown in table 23 below. The 
aim was to gather the detailed HRG information for primary total hip replacement 
operations by each site. This would be statistically tested to check any significant 
difference in the composition of procedures between the comparative sites. Again, 
the aim would be to avoid any potential bias in the selected patient details and seek 
reassurance that the patients considered were from homogeneous groups. 
Table 23. Non-Trauma Hip Interventions by HRG Code 
HRG 
Ref 
Description 
HB11A Major Hip Procedures for Non-Trauma Category 2 with Major CC 
HB11B Major Hip Procedures for Non-Trauma Category 2 with CC 
HB11C Major Hip Procedures for Non-Trauma Category 2 without CC 
HB12A Major Hip Procedures for Non-Trauma Category 1 with Major CC 
HB12B Major Hip Procedures for Non-Trauma Category 1 with CC 
HB12C Major Hip Procedures for Non-Trauma Category 1 without CC 
HB13Z Intermediate Hip Procedures for Non-Trauma Category 2 
HB14B Intermediate Hip Procedures for Non-Trauma Category 1 with CC 
HB14C Intermediate Hip Procedures for Non-Trauma Category 1 without CC 
HB15D Minor Hip Procedures for Non-Trauma Category 2 19 years and over 
with CC 
HB15E Minor Hip Procedures for Non-Trauma Category 2 19 years and over 
without CC 
HB15F Minor Hip Procedures for Non-Trauma Category 2 18 years and under 
with CC 
HB15G Minor Hip Procedures for Non-Trauma Category 2 18 years and under 
without CC 
HB16B Minor Hip Procedures for Non-Trauma Category 1 with CC 
HB16C Minor Hip Procedures for Non-Trauma Category 1 without CC 
Note CC = comorbidities and complications 
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Day of week/Length of Stay (LOS) Relationship. As noted in para 4.7 the discussion 
on length of stay has tailed off in later articles. Earlier articles noted a correlation 
between allogeneic blood transfusions and longer length of stay. Correlation, 
however, does not imply causation and the patients may have been older, the patients 
may have presented as anaemic, the surgery being more invasive or patients having 
experienced reactions to the surgery with these issues ameliorated by the allogeneic 
blood transfusion rather than the transfusion actually causing the longer length of 
stay. When in Pittsburgh the researcher examined the activity statistics for primary 
hip replacement operations and noted that the majority of the primary hip 
replacement operations were undertaken on a Tuesday morning. This was raised with 
the Pittsburgh team who stated that this was deliberate, the patient would have had 
their pre-operative assessment up to three weeks’ prior and be given a date/time to 
attend for surgery. This would generally be a Tuesday and the time to attend would 
be between 0400 and 0600. Operations were generally all finished by 1400 on the 
day. With an average length of stay of 3-4 days the majority of patients would 
commence their rehabilitation as early as possible and usually be back home by the 
Friday afternoon/evening. Therapy support would continue to be available but, 
crucially, UPMC would not bear the costs of caring for the majority of patients over 
the weekend as they would have already been discharged. In a Danish study on 
elective primary hip replacement surgery, Husted et al (2007) also concluded the 
length of stay increased when surgery was undertaken later in the week. 
It soon became apparent that the length of stay was both a challenging issue to 
interpret and highly subjective as to whether there is any causal relationship between 
allogeneic blood transfusions and length of stay. In order to scrutinise further, the 
researcher decided that the date of operation and the date of discharge would need to 
be extracted in his analysis. The difference between the two dates would 
automatically generate the length of stay and, by using Microsoft Excel formula, the 
day of the week of the operation and subsequent discharge day. 
Other Comparative Factors to Gauge Homogeneity. There were other factors that 
may have distorted the comparison between groups of patients. It was highlighted to 
the researcher in his discussions with clinicians that he would need to establish the 
age and gender of each of the patients selected. Additionally, it would be of interest 
to the selected hospitals to identify internally the data by consultant/firm to get an 
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indication in emerging trends in decisions on blood usage. This information, though 
gathered, was felt to be of more use after the thesis had been completed in order to 
continue the dialogue. 
As noted above the relevant information was not available at the press of a button 
from a computerised system though some steps have been taken at the Royal 
Cornwall Hospitals to automate the process. UPMC utilised a blood ordering system 
that generated management information to e.g. automatically match up Hb levels to 
allogeneic blood requests. The availability of data at UPMC was far superior to that 
available in the three sites studied reflecting significant levels of investment in 
information technology. 
An emerging issue, discussed with the Transfusion Coordinators, was could hospitals 
effectively manage their allogeneic blood usage monitoring on a day to day basis as 
the UPMC information was from such disparate sources? Hospital Transfusion 
Committees meet monthly or quarterly with the information analysis being manually 
extracted. The level of resource to extract the information would need to be 
considered. 
5.8 Study to Determine Activity and Actual Costs 
The viewpoint from the clinicians was primarily associated with allogeneic blood 
costs in the hospital setting. As noted in para 4.2 there are also costs incurred at 
NHSBT and the costs incurred by the donor who is unpaid for donating. Donors are 
also not recompensed for the costs of getting to/from the donation centre. Other 
costs, not considered, are the costs incurred by the various companies who supply the 
cell salvage equipment and the consumables. Given these costs will be passed on 
(plus a profit margin) to the hospitals these are effectively a transfer price. 
As this study investigates the differences in blood usage the common costs across the 
three sites can be excluded from the analysis so, e.g. the costs of cross matching 
(para 4.2), the operation of the blood bank (para 1.10), operating theatre staff (para 
1.18) and the administration of tranexamic acid (para 1.9) do not need to be 
considered. These costs will be incurred in all three sites and will not be affected by 
the volume of cell salvage at the Royal Cornwall Hospitals. 
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The costs associated with the utilisation of cell salvage and avoiding allogeneic 
blood transfusions are summarised in figure 14 below: 
Figure 14. Cell Salvage Cost Groupings 
 
 
 
 
 
Activity information relating to patients, allogeneic blood usage and cell salvage (at 
the Royal Cornwall Hospital only) from the three sites was compared and analysed. 
This analysis followed the pattern: 
• Baseline. For each of the three centres the activity data would be analysed 
to gain assurance that the patients are homogenously grouped, and they are 
adequately prepared for the operation. The HRG information (para 5.7) 
would also be tested to ensure the operations required a similar level of 
intervention as defined by the HRG Grouper software. Activity data on 
‘before’ and ‘after’ the operations would be compared and analysed. 
• Segregate the Royal Cornwall Hospital activity into those patients who had 
their shed blood salvaged and those that did not. For the salvaged group 
this is sub-divided into those patients that had the salvaged blood reinfused 
and those patients whose own blood was not reinfused. This therefore 
segregates the impact of the reinfusion and allows a direct comparison of 
statistics relating to reinfused patients against patients who have not had 
cell salvage at Royal Cornwall Hospitals or the other two centres. A 
diagram of the flow of information leading to the relevant comparisons is 
shown below. The main comparator route is in the green pathway: 
Hospital Based 
Costs 
Cost associated 
with providing 
allogeneic blood 
or cell salvage (or 
both). 
 
Donor/Societal 
Costs 
Costs of donors 
taking time off work 
to donate, travel to 
the session. 
Opportunity cost of 
time not spent 
elsewhere. 
 
 
 
 
Costs at NHSBT 
Costs associated 
with collecting, 
processing, testing, 
storage and issue 
of allogeneic 
blood. 
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Figure 15. Main Approach to Comparisons 
 
Hospital Based Costs and Activity  
 
The analysis of the required hospital information to undertake the study can be 
summarised in table 24 below:  
 
Table 24. Summary of Information Required to Analyse Across the Three Hospitals 
Objective Comparative Data Statistical or Other Method 
of Calculation where 
Relevant 
1. Develop costs of operating 
cell salvage. 
Derive costs for cell 
salvage. 
Actual costs of consumables 
at Royal Cornwall Hospitals. 
NICE Costing Statement 
(November 2015). 
2. Reconciliation of price of 
allogeneic unit to income in 
published accounts for 
2010/11. 
Use £122 unit price with 
activity from NHSBT 
annual report. 
Calculate allogeneic blood 
cost as a percentage of total 
NHSBT costs. 
3. Extract transfer price from the 
£122 unit price. Challenge the 
efficacy of using the ‘gross’ 
price in all the studies.  
Derive from published 
accounts VAT, income tax 
and national insurance 
elements. 
Apportionments based on 
headcounts and HMRC/NHS 
data on tax/national 
insurance. 
4. ‘Sell’ HRG concepts to staff 
in three sites. 
Compare the splits of 
HRG data at each site. 
Rely on the relevant hospital 
information department to 
extract using patient 
identification number. 
5. Estimate wider costs of 
donating by generating a 
societal cost and costs to 
donors. 
Generate data from donor 
questionnaire issued in 
2013. 
Analysis of responses. 
NHSBT’s electronic survey 
system automatically 
stratifies donors. 
Royal 
Cornwall
Hospitals
Allogeneic
Transfusion?
Yes No
Salvaged/
Reinfused?
No Yes
Direct 
Comparison
with South 
Manchester
and SOC
Direct 
Comparison
with South 
Manchester
and SOC
Direct 
Comparison
with South 
Manchester
and SOC
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Objective Comparative Data Statistical or Other Method 
of Calculation where 
Relevant 
6. Compare patients at the three 
sites to isolate any significant 
difference in their profile. 
HRG breakdown 
Gender split 
Age profile 
Chi Square 
Chi Square 
ANOVA 
7. Achieve a level of confidence 
that the patients are 
adequately prepared for 
surgery. 
Compare pre-operative Hb 
levels statistically and in 
relation to WHO 
thresholds. 
ANOVA 
Segregate patients over/under 
WHO thresholds (para 1.9). 
8. Highlight potential slower 
recovery and potential impact 
on length of stay 
Compare post-operative 
Hb levels 
Compare length of stay 
ANOVA 
 
ANOVA 
9. Compare other potential 
influences on length of stay 
Develop a linear 
regression to investigate 
potential causation 
between factors and length 
of stay. 
Linear regression using the 
‘stepwise’ approach. 
 
 
10. For each hospital compare the 
number of allogeneic 
transfusions. 
Compare percentage of 
allogeneic blood 
transfusions 
Compare number of units 
used 
Chi Square 
 
ANOVA 
11. Royal Cornwall Hospitals 
only 
Compare pre-and post-
operation data for 
reinfused/ non-reinfused 
patients 
Compare cell salvage rates 
Compare machine 
utilisation rates 
ANOVA and extraction of 
percentage splits combined 
with costs. 
 
Once the data was collected it required adjustment and manipulation. For example, 
the mean length of stay for each patient was generated by calculating “the difference 
in days between the date the patient was discharged from hospital and the date they 
were admitted”. This is the NHS Choices definition. In this thesis, the researcher 
requested the operation date be accessed to replace the admission date. This would 
more accurately generate the time the patient spent recovering from their operation. 
In turn these two dates could be used to generate the day of the week of the operation 
and the day of week of discharge. 
The data was checked for obvious input errors e.g. a date of birth after 2000 or 
before 1910 would not be expected. Outliers were excluded as these would distort 
the results and may be a result of other health issues having arisen while in hospital. 
The cut off for an outlier was identified as a patient length of stay being greater than 
14 days. This removed 20 patients’ records from the analysis (table 20), leaving 498 
remaining to analyse. 
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The majority of the patient data relates to operations undertaken in 2010. There were 
no financial problems noted in any of the three organisations at the time. 
Additionally, there were no directives from the then English Department of Health to 
require any changes to procedures in operations for primary hip replacement surgery. 
As noted previously, extraction of the relevant data was challenging and time-
consuming. This was due to the hospital information systems not being set up in a 
way to readily output the datasets. The Royal Cornwall Hospital have subsequently 
requested their patient record system extract the data monthly to facilitate additional 
analysis by HRG. This project is currently being developed in liaison with the Royal 
Cornwall Hospital IT Department. There are various separate systems that capture 
elements of information and this amalgamation of information is a relatively large 
project. 
The information was collated into an overall Microsoft Excel spreadsheet and 
subsequently imported into SPSS v 20 which was then upgraded to v 22 at Swansea 
University. The statistical analysis was undertaken using SPSS supported by Excel 
pivot tables. Excel pivot tables allow the information to be analysed and presented in 
many ways with the advantage over SPSS that all users in the NHS have access to 
Microsoft Excel. This made the sharing of the information and analysis with users 
easier, facilitating wider discussions. 
The information extracted in table 24 would be statistically tested to ensure the 
cohorts of patients were homogeneous. This would allow a comparison on the pre-
operative and post-operative data when no allogeneic transfusion or cell salvage is 
utilised (cell salvage data at the Royal Cornwall Hospitals only). Further analysis 
would be undertaken to test any differences in results using appropriate statistical 
analysis. The length of stay differences were therefore investigated further by 
utilising linear regression with a stepwise approach to derive a potential number of 
factors that could explain the actual variations in length of stay. This would then 
allow discussions with the relevant site on potential contributory factors. 
This statistical work would be instrumental in establishing a rigorous comparison to 
minimise any potential accusation of bias raised in Carless et al (2004 and 2010). 
A summary of the data for analysis is shown in table 25 below: 
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Table 25. Summary of Key Statistics to be Extracted 
Factor Comparative Data 
Technique 
Adopted  
Patient and Operation 
Comparison 
HRG breakdown 
3 x 3 Chi 
Square 
  Gender split 
2 x 3 Chi 
Square 
  Age profile ANOVA 
Patient Preparation 
Pre-operative Hb levels 
All patients 
ANOVA 
  
Pre-operative Hb levels: 
Patients not undergoing 
allogeneic transfusion or 
reinfusion 
ANOVA 
  
Separate pre-operative 
patients below WHO 
anaemia levels 
2 x 3 Chi 
Square 
Patient Recovery 
Compare post-operative Hb 
levels excluding allogeneic 
transfusions and reinfusions 
ANOVA 
  Compare length of stay ANOVA 
Allogeneic Blood 
Usage 
Compare percentage of 
allogeneic blood transfusions 
ANOVA  
  
Compare number of 
allogeneic units used 
ANOVA 
Comparison of RCH 
patients not salvaged 
(33) with those patients 
salvaged (180) 
HRG breakdown 
3 x 2 Chi 
Square 
Gender split 
2 x 2 Chi 
Square 
Age profile t test 
Compare Pre-operative Hb 
levels 
t test 
Compare post-operative Hb 
levels 
t test 
Factors potentially 
influencing length of 
stay across sites 
Patient age 
Linear 
regression 
  Operation day 
Linear 
regression 
  Discharge day 
Linear 
regression 
 Other factors 
Linear 
regression 
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All the data was in a form that was readily comparable over the three sites, this 
would allay one of the Carless et al (2004 and 2010) criticisms of the low quality of 
comparative studies. Two other criticisms from Carless et al (2004 and 2010) were 
that the “methodological quality of the trials was poor” and un-blinded trials “lacked 
adequate concealment of treatment allocation”. The data extracted was retrospective 
and there was no decision on whether or not to salvage at South Manchester or the 
SOC as the two organisations did not utilise cell salvage anyway. At the Royal 
Cornwall Hospitals, the decision not to salvage the 33 patients identified was due to 
non-availability of trained staff or the actual cell salvage machines not being 
available at the time. None of this was pre-planned and would therefore not introduce 
any level of bias into the analysis. The pre-and post-operative data can be used as an 
additional comparator in the Royal Cornwall Hospitals to check whether there is any 
significant difference between the 33 non-salvaged and 180 salvaged patients at the 
Royal Cornwall Hospitals as this could, arguably, point to potential bias. 
NHS Blood & Transplant Costs 
The total cost of the NHSBT operation in 2010/11 was approximately £420m 
(NHSBT 2010/11 audited accounts). NHSBT’s role is to supply allogeneic blood and 
related products for use in hospitals. These include blood and specialist 
haematological products along with operating the UK-wide organ donation and 
transplant service. NHSBT uses an activity-based costing (ABC) system to map its 
costs and support the forecasting of the impact of activity changes on its future costs. 
ABC, according to Wood and Sangster (2005), is “the process of using cost drivers 
as the basis for the apportionment of indirect manufacturing costs to individual 
products”. Within NHSBT there are discrete cost drivers and a suitably aligned 
general ledger coding structure to capture the costs to categories. The costs 
associated with the collection, processing, testing and issue of allogeneic blood are 
highly relevant. Any changes in allogeneic blood requirements e.g. through an 
expansion in cell salvage usage will have an impact on the costs associated in the 
NHSBT supply chain. Most of the NHSBT costs have been collected and reported by 
the researcher’s former colleagues in NHSBT. Additional information was provided 
on numbers of donors in 2018. 
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The above costs would need to be adjusted to reflect e.g. transfer payments that are 
included from a financial perspective but need to be excluded from an economic 
costing perspective (chapter 2). Depreciation is charged to cost centres for capital 
assets utilised. These are a mix of building and infrastructure costs, where the 
property is owned by NHSBT, and equipment/vehicle costs where owned. 
Table 26 below summarises the identification and treatment of the costs incurred by 
NHSBT using its ABC system. 
Table 26. NHSBT Cost Classification 
 
Donor/Societal and Wider Economic Costs 
As noted in para 4.9 very little consideration was given to the wider costs of 
allogeneic blood transfusions in academic studies. This thesis revisits the main UK 
ABC Cost 
Element 
 
Fixed/Variable? Justification of Treatment 
Source Donors Fixed The majority of costs are fixed in the medium term. TV and radio 
campaigns are booked at least 18 months in advance. There is a 
long-term contract with the US communications company, 
Teleperformance, for donor recruitment/retention via call centre 
and on-line support. 
Blood 
Collection-
fixed elements 
Fixed Staffing costs are regarded as fixed for two years. A high 
proportion of staff have a long NHS service record with high 
associated redundancy costs. Blood collection teams are based in 
leased premises with the typical lease contracts involving a five-
year lease with a break clause at three years. Refrigerated 
deliveries transport the collected blood overnight to the three 
main blood centres for processing. 
Blood 
Collection-
blood bags and 
test kits 
Variable The blood collection bags and test kits are supplied by at least 
three suppliers to maintain certainty and continuity of supply. 
Contracts are for a minimum guaranteed amount (typically 80% 
of requirements) with a variable element charged on use. Over a 
range of activity, they are therefore regarded as variable. 
Processing Fixed All the blood processing is undertaken in three NHSBT centres 
with the majority of the work automated. See para 1.6 relating to 
the donated blood ‘journey’. 
Testing Fixed Automated analysers will undertake the first level of testing. It is 
only if issues are raised e.g. if there is a contaminated donation 
that a specialised member of staff will intervene. 
Order 
Processing, 
Storage and 
Dispatch 
Fixed The majority of staff perform a warehousing function that is 
required. Changing volumes over the short term will not free up 
staff. 
Distribution Fixed Delivery to customers is provided by NHSBT’s in-house transport 
service. The majority of hospitals will require at least one 
delivery per day and the routes are planned by NHSBT’s transport 
management system. In the short term the vehicles (leased for a 
minimum of three years) and driver costs are fixed. 
Contribution to 
Overheads 
Fixed These are the traditional overheads (estates costs, support 
departments) that are generally fixed in the short to medium term.  
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study (Varney & Guest (2003)) and estimates the wider costs associated with a fall in 
demand for blood due to the expansion in cell salvage. 
Varney and Guest (2003)’s study derived the costs associated with blood transfusions 
in the UK. The basis of the donors’ costs was undertaken by a telephone survey that 
involved interviewing respondents to advertisements placed in selected newspapers. 
In early 2013 the researcher met with NHSBT’s Head of Market Research and 
Analysis and the Assistant Head to discuss costs associated with donors attending 
sessions to donate blood. The original aim was to extract information similar to that 
analysed by Varney & Guest (2003). The Market Research and Analysis team felt, 
however, that the wider views of the donors should also be sought for the team’s 
separate analysis and both sets of requirements be combined in one questionnaire. 
This, in part, was initiated by a discussion on the views expressed in the 16 February 
2011 Economist article on the level of altruism felt by blood donors (para 1.8). 
Technology has obviously developed to support marketing/customer services since 
2003 and discussions with the Market Research Team led to their support for the 
development and issue of a questionnaire to re-visit the conclusions of the 2003 
survey. To the best of the author’s knowledge there has been no subsequent 
published study or follow up of the information in the 2003 study in the UK. The 
researcher contacted Catalyst Health Economics (Prof Julian Guest is Managing 
Director) in early 2013. There was no interest on the company’s part to become 
involved in a re-visit of the 2003 findings. 
NHSBT’s donor management system (part of the overall PULSE information 
management system) can extract stratified random samples of donors. A series of 
questions was developed (table 27) with the Assistant Head. The questions were 
aimed at estimating: 
• The level of altruistic feelings and ‘feel good’ expressed by blood donors. 
• The costs associated with donating that were incurred by the donor that 
were not recompensed. 
• Costs of lost productivity by the donor who was donating rather than being 
in paid employment. 
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• Any additional costs e.g. environmental costs associated with vehicle 
emissions. 
NHSBT’s Marketing Department holds blood donor information on a centralised 
database. There were c. 1.28m active donors at March 2013 when the survey was 
being discussed. The database can extract a stratified sample of donors and e-mail 
questionnaires to them using Survey Monkey. In 2013 an ‘active donor’ was one who 
had made one donation in the previous year. This was subsequently redefined as a 
donor who had made at least two donations in the past year. The corresponding 
figure for 2017 was c. 0.5m. 
For the questionnaire, a randomised stratified sample of 5,000 active blood donors 
was extracted from the database and the questionnaire was issued via e-mail by the 
NHSBT Marketing Department under the guise of a customer relations survey. The 
number of responses to the questionnaire was 1,161 indicating a ‘hit rate’ of 23.2%; 
this was viewed as a typical response rate for NHSBT e-mail surveys. 
The final set of 13 questions agreed is shown in table 27 below: 
Table 27. Blood Donor Questionnaire 
 
The main aim of the data collection was to compare the cost of allogeneic blood 
usage at South Manchester and the SOC against the aggregated cost of the allogeneic 
blood and operation of cell salvage at the Royal Cornwall Hospitals. The estimated 
No Question 
1 Have you attended a blood donation session or clinic in the last four months? Y/N? 
2 
Which of the reasons explains why you haven't attended a blood donation session in the last four 
months? Tick box. 
3 
Which of the statements below apply to you and your reasons for attending your last donation 
session?  Tick box. 
4 How likely are you to give blood in the future? Y/N 
5 
On a scale of one to ten, where one is “strongly disagree” and ten is “strongly agree”, please say how 
strongly you agree with the following statements. 
-Giving blood is important to me. 
-I have so many commitments it is sometimes hard to give blood. 
-I really enjoy giving blood. 
6 How many minutes did you spend travelling to your last donation session from your starting point? 
7 How many minutes did you spend travelling from your last donation session to your destination?  
8 What was your main mode of transport to your last donation session? 
9 Which of the following best describes you (tick as many as relevant)? 
10 Which of the following best describes your employment (Tick as many as relevant)? 
11 Does your employer deduct pay because you attend a blood donation session? 
12 Are you expected to make up the time in your work for attending a blood donation session? 
13 
What actual costs did you incur in order to allow you to donate at your last donation session (Tick as 
many as relevant)? 
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societal costs associated with the allogeneic blood usage could then be included to 
generate overall comparative costs. A comparison of the aggregation of these costs 
would therefore answer the research question. 
5.9 Summary of Chapter 5 
A robust set of comparative data for the three sites was finally collected and available 
for analysis in late 2014. The consecutive data for the Royal Cornwall Hospitals was 
also detailed enough to identify patients who were/were not salvaged and 
subsequently were/were not reinfused. This amount of comparative data, though 
taking a long time to extract, would be sufficient to support the analysis and combine 
with the cost information. 
The data had the unique trait of being identifiable by HRG. This allowed an 
additional check on the homogeneity of the severity of the operation and associated 
comorbidities and would allow additional analysis of the allogeneic blood 
requirements across the sites. 
Para 5.7 noted the discussions with clinicians regarding the assertion that cell salvage 
could mask inefficiencies in the pre-operative assessments of the patients. The 
patients would present while being anaemic. This issue was also highlighted in 
Enhanced Recovery Pathways in para 1.19. The comparative information on Hb 
levels would address this issue. 
As noted in para 5.8 the costs fall into three categories (hospital, NHSBT and 
societal). Combining the three sets of costs would give a total estimated cost of 
supplying one unit of allogeneic blood. The rationale was to calculate the allogeneic 
blood costs at each site and add in the cell salvage costs at the Royal Cornwall 
Hospitals. Utilising an average cost incurred by the donor and the derived societal 
cost would then give a total associated blood cost. This would then be a direct 
comparator between the costs associated with the higher allogeneic units against 
utilising cell salvage. The basic calculation is shown in table 28 below. This will 
comprise two tables; one to reflect the costs from a financial perspective (the 
accountants’ view at the Hospitals and NHSBT) and an overarching schedule from 
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an economic analysis perspective excluding e.g. transfer payments and the charges 
via the NHS internal market for allogeneic blood. 
Table 28. Derived Cost of Blood per Patient for Primary Total Hip Replacement Patients-Financial 
and Economic Perspective 
Hospital 
\Category 
South 
Manchester 
Royal 
Cornwall 
Specialist 
Orthopaedic 
Centre 
Allogeneic Blood Costs √ √ √ 
Cell Salvage Cost X √ X 
Donor Cost √ √ √ 
Societal Cost √ √ √ 
Total Derived Cost √ √ √ 
Total Patients 148 213 137 
Unit Cost of Blood per Patient £x £x £x 
 
Table 28 is designed to generate an overall average cost. This can be used for 
indicative purposes. Most of the non-allogeneic blood costs are relatively fixed in the 
short to medium term and it is unlikely there will be immediate savings if the 
allogeneic blood requirements fell nationally. Chapter 6 extracts and derives the costs 
in order to populate table 28 above. Discussions of these costs can subsequently be 
undertaken in chapter 7. 
Table 28 is unique as it derives an overall cost of blood. This adopts a similar 
approach to the Varney and Guest (2003) analysis but the key difference is that this 
thesis includes cell salvage in the calculations. As highlighted in the literature review 
the wider adjusted economic costs were ignored in virtually all studies. To the best of 
the researcher’s knowledge the researcher’s approach is unique and will therefore 
support the answer to the research question: 
Is cell salvage an appropriate method of blood conservation to support the reduction 
in costs associated with the collection and utilisation of allogeneic blood? 
The time and effort invested in finding the sites and collecting the information finally 
paid off and a firm foundation for a detailed analysis of the activity and costs was 
now possible. In hindsight, the researcher was too optimistic in relying on hospitals 
to extract the information. It was a salutary lesson to learn that, though the NHS has 
extensive IT systems, the ability to drill down and collect a series of common 
datasets in table 25 required many days of manual information gathering.  
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Chapter 6. Main Findings 
6.1 Introduction 
Chapter 5 noted the planned approach to collecting and utilising the relevant data to 
generate a comparison of costs associated with operating cell salvage as an 
alternative to utilising allogeneic blood. A key aim was to minimise the subjectivity 
noted in the literature review where authors undertook comparative studies on 
patients using cell salvage with corresponding cohorts of patients who were not 
salvaged. The differences in allogeneic transfusion rates were often assumed to be 
due to cell salvage. 
Chapter 5 additionally noted the approach adopted to identify any differences in the 
patients’ profiles, variations in the severity of accompanying comorbidities and level 
of invasiveness of the operation by utilising the HRG coding. Any differences may 
contribute to a differing level of allogeneic blood required irrespective of whether 
any allogeneic blood avoiding techniques were adopted. The data also utilises 
patients’ pre-operative Hb levels as an indication of general preparedness of the 
patient for surgery. 
The approach in this thesis differs from the above ‘traditional’ approach. The focus is 
on a multi-site comparison that initially compares a common set of data for patients 
who have not had an allogeneic transfusion or, in the case of the Royal Cornwall 
Hospitals, had their own blood reinfused. This comparison (figure 15 on page 128) 
would establish a ‘background count’, allowing a direct comparison between patient 
statistics. Any differences would be highlighted, and it could therefore be stated with 
100% confidence that the differences were not due to allogeneic blood transfusions 
since any patient who had received an allogeneic blood transfusion would be 
excluded from the initial analysis. 
The analysis would then be extended to incorporate allogeneic blood transfusions 
and cell salvage/blood reinfusions at the Royal Cornwall Hospitals. Any further 
differences would more likely be due to the impacts of the allogeneic blood 
transfusion; being potentially ameliorated by cell salvage at the Royal Cornwall 
Hospitals.  
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Following this, the financial and economic costs would be calculated. These costs 
will be an amalgam of actual running costs and supplier charges at the Royal 
Cornwall Hospitals. The costs supplied by NHSBT would then be incorporated into 
the comparison, with adjustments where appropriate. 
6.2  Main Patient Characteristics 
The profile of the patient information is summarised in table 29 below: 
Table 29. Summary of Patient Statistics Over the Three Organisation (2010/11 Base Data) 
Hospital/ 
Category 
South 
Manchester 
Royal 
Cornwall 
Specialist 
Orthopaedic 
Centre 
Totals 
Number of patients 148 213 137 498 
Mean (SD) Age (years) 67.5 (10.9) 67.7 (11.3) 67.4 (11.9) 67.5 (11.3) 
Mean (SD) Length of Stay 
(days) 
6.3 (2.5) 5.2 (2.0) 5.1 (2.0) 5.5 (2.2) 
Mean (SD) Pre-Op Hb level 
(g/l) 
135 (14.6) 137 (11.5) 135 (12.4) 136 (12.7) 
Mean (SD) Lowest Post Op 
Hb Level (g/l) 
104 (14.9) 102 (15.9) 100 (15.3) 102 (15.5) 
Fall in Mean Hb Level (g/l) 31 35 35 34 
Number of Patients 
Transfused 
14 13 23 50 
Number of Allogeneic Units 
Transfused 
27 26 47 100 
Allogeneic Transfusion Rate 9.5% 6.1% 16.8% 10.0% 
Percent Male 43.9% 38.5% 39.4% 40.4% 
 
The activity at the Royal Cornwall Hospitals is further analysed into the categories of 
the utilisation of cell salvage in table 30 below: 
Table 30. Breakdown of Cell Salvage Activity at Royal Cornwall Hospitals 
Gender / 
Category Males Females Total 
 n 
Number 
Transfused n 
Number 
Transfused n 
Number 
Transfused 
Not Salvaged 16 - 17 3 33 3 
Salvage-No 
Reinfusion 21 - 55 5 76 5 
Salvage-With 
Reinfusion 45 1 59 4 104 5 
Total 82 1 131 12 213 13 
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6.3 Healthcare Resource Group (HRG) Analysis 
As noted in para 5.1, the primary total hip replacement operations will be sub-
divided into HRGs. The tariff price and therefore the resource requirement of 
undertaking the specific HRG can vary markedly. The start point in the analysis was 
to assess whether the split of HRGs was similar between the three sites. If this was 
the case, then the assumption could be made that both the resources required, and the 
level of comorbidities would be similar. This would therefore allay fears that the 
comparison between blood requirements would differ significantly due to e.g. the 
number of operations being more complicated or invasive in one of the centres, 
thereby causing a distortion. 
The breakdown of operations by HRG at the three sites is shown in table 31 below: 
Table 31. Analysis of Operations by HRG Category 
Hospital: 
\HRG 
South 
Manchester 
Royal 
Cornwall 
Spec Orth 
Centre Total 
HB11A 1 1  - 2 
HB11B 2 6 4 12 
HB11C  - 3 1 4 
HB12A 8 12 8 28 
HB12B 108 137 95 340 
HB12C 27 54 29 110 
HB13Z 2  -  - 2 
Total 148 213 137 498 
 
The resource requirements are the highest for HB11A with requirements decreasing 
down to HB13Z. On first assessment, most of the activity is clustered around the two 
HRGs HB12B and HB12C (non-trauma category 1 with and without comorbidities 
and complications-CCs). This is not surprising since, generally, elective hip 
replacement surgery would not be expected to have any major CCs. A very high level 
of CCs would be likely to categorise the operations as non-elective (emergency) 
operations, without the associated pre-operative planning and assessments. 
Figure 16 below analyses the percentage split of primary hip replacement operations 
by HRG by hospital. The pattern follows a similar distribution with HB12B 
dominating the activity figures and HB12C taking most of the remaining cases. 
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Figure 16. Analysis of Percentage of Total Hip Replacement Operations by HRG by Organisation 
 
The proportions of HRGs appear consistent across the hospitals. The HRGs were 
then grouped into three groups; one group each for the HRGs commencing HB12B 
and HB12C and the remainder into a separate group. 
The Pearson Chi-square value was calculated at 3.281 with a p value of 0.512; this is 
not significant i.e. there appears to be no association between HRG grouping and 
hospital. It can therefore be assumed that there is no significant difference in the 
morbidity of patients presenting at each hospital. 
6.3.1 Age and Gender Profile 
These splits are shown in the tables 32 and 33 below. ANOVA and post hoc tests 
indicate that the mean age is similar across the three hospitals (p=0.974) but with a 
significant difference between the two main HRG (HB12B and HB12C) categories 
(p<0.0005). 
Table 32. Mean Age by Patient by HRG 
Hospital: 
\HRG 
South 
Manchester 
Royal 
Cornwall 
Spec Orth 
Centre 
Mean  
Age 
HB12B 67.9 69.0 69.1 68.7 
HB12C 64.5 64.3 60.6 63.4 
Other 71.0 67.2 69.6 68.9 
Total 67.5 67.7 67.4 67.5 
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HB12B requires more supporting procedures and hence being more likely to be 
associated with older patients. 
With gender, there are a slightly higher proportion of males at South Manchester than 
the other two hospitals. The national average across all types of hip surgery is 40% 
male patients. 
Table 33. Gender Mix of Patient by HRG-Percentage Male Patients 
 Hospital: 
\HRG 
South 
Manchester 
Royal 
Cornwall 
Spec Orth 
Centre Total 
HB12B 45.4% 40.9% 34.7% 40.6% 
HB12C 44.4% 40.7% 44.8% 42.7% 
Other 30.8% 18.2% 61.5% 33.3% 
 Mean 43.9% 38.5% 39.4% 40.4% 
 
The Pearson chi-square result on the numbers within the overall gender mix is not 
significant (p=0.567) indicating that there is no significant difference in the gender 
split across the three sites.  
Of potentially more interest is the mean age of the patients by HRG. As noted in para 
1.9 older patients are more likely to require an allogeneic blood transfusion. Only 
two patients (one male HB12C HRG, one female, HB12B HRG) below 65 years’ old 
received allogeneic blood transfusions at the Royal Cornwall Hospitals. Both 
patients were salvaged on Electa machines and both had shed blood reinfused. There 
was a total of 66 patients under 65 years’ old who were salvaged (11 patients under 
65 were not salvaged). Statistically the two transfused patients (utilising a total of 
three allogeneic units) were too small to undertake any comparison but the question 
could be asked whether, given the low transfusion rates, was it necessary to salvage 
as many as the 66 patients below age 65? The table below shows the gender and 
transfusion comparison over the three sites: 
Table 34. Analysis by Gender of Patients <65 Years Old Having an Allogeneic Transfusion 
Gender/Hospital Male Female Total 
Patients 
<65 
years 
Transfusion 
Rate for 
<65 years 
South Manchester - 2 60 3.3% 
Royal Cornwall  1 1 77 2.6% 
SOC - 4 46 8.7% 
Total 1 7 183 4.4% 
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South Manchester also exhibits a low transfusion rate for patients aged under 65 
years’ old. The SOC transfusion rate, though higher is significantly lower than its 
overall transfusion rate of 16.8% (table 29). For the Royal Cornwall Hospitals, the 
variable costs of the cell salvage operation can be calculated by identifying the 
machine types utilised. These are: 
 
Table 35. Analysis of Cell Salvage on Patients <65 Years’ Old 
Machine Type/ 
Reinfusion 
Electa OrthoPat Total 
Not Reinfused 18 7 25 
Reinfused 15 26 41 
Total 33 33 66 
 
6.3.2  Pre-Operative Hb Level 
As highlighted in para 5.7 a key indicator of patient preparedness is the Hb level, this 
indicates a patient’s iron levels and, in turn, the level of oxygen circulating in the 
bloodstream. The higher the Hb level the more oxygen rich the patient’s blood (para 
1.4). The boxplot in figure 17 below groups the mean Hb levels; these are clustered 
around the 135 g/l mark. 135 g/l is comfortably above the WHO recommended Hb 
level for preparedness for surgery (130g/l for men and 120 g/l for women, para 1.9). 
An analysis of mean Hb levels by HRG is shown in table 36 below. 
 
Table 36. Analysis of Mean Pre-Operative Hb Levels by HRG (n=498) 
Hospital: 
\HRG South Manchester Royal Cornwall Spec Orth Centre Total 
HB12B 134.6 136.6 133.8 135.2 
HB12C 135.8 139.1 138.4 138.1 
Other 132.2 133.5 134.6 133.5 
Total 134.6 136.9 134.8 135.6 
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Figure 17. Mean Pre-Operative Hb Levels Across Three Sites 
 
The initial indications are therefore that the patients are optimised and ready for 
surgery. Procedurally, the patients will have undergone a pre-operative assessment 
(para 1.19) where, inter alia, blood tests will have been undertaken and results would 
be available for the clinician to assess.  
The box plot in fig 17 above and the mean pre-operative Hb levels indicate a strong 
level of similarity between the patients at the three sites. Mean Hb levels are all 
above the WHO anaemia thresholds for males and females however, the standard 
deviation is higher at South Manchester (14.6 g/l) than the Royal Cornwall Hospitals 
(11.5 g/l) or the Specialist Orthopaedic Centre (12.4 g/l). It should be noted, 
however, that the WHO definition is wide ranging. An Hb level of 125 in a 50-year-
old man would, on its own, be of less concern than the same level in a 75-year-old 
man. The numbers of patients falling below the thresholds at the three organisations 
is shown in table 37 below. 
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Table 37. Analysis of Patients with Pre-operative Hb Levels Below WHO Criteria 
Indicator 
/Hospital 
Mean 
Age 
Male 
Mean 
Pre-op 
Hb 
Male 
No of 
Males 
Hb 
Below 
130 g/l 
Mean 
Age 
Fem 
Mean 
Pre-op 
Hb 
Fem 
No of 
Fems Hb 
Below 
120 g/l 
Total 
Below 
WHO 
Criteria 
Total 
Patients 
% 
Anaemi
c 
(WHO 
Criteria) 
South 
Manchester 
72.6 122 15 71.2 111 18 33 148 22.2% 
Royal 
Cornwall 
Hospitals 
70.7 123 10 80.1 117 10 20 213 9.3% 
Spec Orth 
Centre 
72.0 116 7 77.8 114 8 15 137 10.9% 
Total 71.9 121 32 75.1 113 36 68 498 14.5% 
 
Patients, falling within the WHO definition as anaemic, present at over twice the rate 
at South Manchester compared to the other two hospitals. This indicates that the 
South Manchester patients may not be as adequately ‘prepped’ as the other two 
hospitals and the preparation may be a contributor to the increased length of stay at 
South Manchester due to a slower recovery or an indicator of a separate comorbidity. 
This relatively high level of patients not meeting the WHO criteria will by now 
(spring 2018) have been addressed by South Manchester who have developed a more 
assiduous patient blood management programme. 
A Chi square analysis indicated that there was a significant association between 
hospital and proportion of patients not meeting the WHO criteria (p = .001). The 
implication is therefore that the issue of anaemia can be controlled locally. The data 
can be analysed further in table 38 by extracting the patients who received an 
allogeneic transfusion and were below the WHO pre-operative criteria by gender. 
Table 38. Analysis of Allogeneic Transfused Patients (Pre-Operative Hb Levels below WHO Criteria) 
Indicator 
/Hospital 
Mean 
Pre-
op 
Hb 
Male 
Male Mean 
Pre-op 
Hb 
Female 
Female Total 
Patients 
 
Overall 
Transfused 
Percent 
below 
WHO 
Threshold 
South Manchester 106 1 105 7 8 14 57.1% 
Royal Cornwall 
Hospitals 
 - 113 1 1 13 7.7% 
Spec Orth Centre 112 4 112 5 9 23 39.1% 
Total 111 5 108 13 18 50 36.0% 
 
It is immediately apparent from tables 37 and 38 that the Royal Cornwall Hospitals 
have a significantly lower proportion of patients presenting with WHO defined 
anaemia. The mean pre-operative Hb level for the Royal Cornwall Hospitals patients 
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is also higher than the other two sites. This therefore suggests that the Royal 
Cornwall Hospitals’ pre-operative programme is more effective in managing anaemia 
with the impact of only one patient requiring an allogeneic transfusion. 13 of the 23 
patients at the Royal Cornwall Hospitals who were below the WHO criteria had 
salvaged blood reinfused (average pre-operative Hb level of 119 g/l); only three 
(mean of 121 g/l) out of the 23 were not salvaged leaving seven (120 g/l) patients 
who were salvaged but their salvaged blood was not reinfused. The mean pre-
operative Hb levels for the Royal Cornwall Hospitals over salvaged/reinfused 
patients are very similar implying the pre-operative Hb level was not a factor in 
dictating whether or not the patient should be reinfused with their own salvaged 
blood. It is likely the ‘Ribena’ v ‘Smoothie’ criteria used in para 1.13 took precedent 
over reference to pre-operative the Hb level. 
A further ANOVA comparison of the pre-operative Hb levels of all the patients from 
South Manchester and the Specialist Orthopaedic Centre along with the 
corresponding data from Royal Cornwall Hospitals patients who did not have their 
blood reinfused (tables 29 and 30) was undertaken. This excluded 104 (5 + 99) 
patients from the Royal Cornwall Hospitals activity. The rationale being that this 
comparison would be the ‘background count’ and a comparison of the Hb position 
before and after the operation would facilitate a direct comparison without any 
influence or impact of cell salvage. The resultant ‘p’ value of 0.64 implies, again, 
that there is no significant difference between the mean pre-operative Hb levels after 
excluding the Royal Cornwall Hospitals patients who had their shed blood reinfused. 
6.3.3 Overall Pre-Operative Position 
 
The conclusion from the analysis of the above factors is that the overall profile of 
patients is very similar, and, except for the WHO anaemia definitions, there are no 
obvious factors that appear to contribute to one set of patients being more likely to 
require an allogeneic transfusion than another. Elective primary total hip surgery is 
classed as ‘high volume/low risk’ (Aylin et al (2013)). This low risk implies less 
volatility and variation. This therefore supports a comparison between the 
effectiveness of cell salvage as a means of minimising allogeneic blood transfusions. 
Three very similar sets of patients underwent the same routine operation. The outputs 
were effectively the same (a successful hip replacement) therefore the only 
147 
significant difference in the whole process would be the use of cell salvage at the 
Royal Cornwall Hospital contributing to a planned lower utilisation of allogeneic 
blood compared to the other two organisations. 
The higher rate of WHO defined anaemia at South Manchester may potentially 
explain the longer length of stay compared to the Royal Cornwall Hospitals and the 
SOC. 
6.4 Analysis of Post-Operative Hospital Based Activity 
6.4.1 Post-Operative Hb Analysis 
As noted in para 1.4, the main reason for a clinician prescribing an allogeneic blood 
transfusion is to improve the patient’s Hb level. The Hb level will fall due to the 
blood loss during the operation but the techniques highlighted in Patient Blood 
Management practices and earlier Better Blood Transfusion initiatives (paras 1.11 
and 1.12) should mitigate the fall between the pre-and post-operative levels. This 
section will exclude all patients who have had an allogeneic blood transfusion in the 
three centres (50 patients) and the Royal Cornwall Hospitals patients who had their 
blood reinfused (104, 5 of whom also had an allogeneic transfusion).  
Table 39. Analysis of Mean Post-Operative Hb Levels by Grouped HRG Excluding Allogeneic 
Transfusions and Excluding Reinfused Patients at Royal Cornwall Hospitals 
Hospital: 
      \HRG 
South 
Manchester 
Royal 
Cornwall 
Spec Orth 
Centre Mean 
 
No 
HB12B 106.1 104.8 103.7 105.0 240 
HB12C 107.8 103.1 107.2 106.0 83 
Other 98.8 104.1 99.5 100.5 26 
Overall Mean 105.9 104.3 104.3 104.9 349 
 
Using an ANOVA comparison, the overall differences are not significant (p= 0.56) 
for non-transfused patients i.e. post-operative Hb levels are relatively uniform so the 
non-transfused (and non-reinfused) patients have very similar outcomes after surgery 
to support their recovery. 
The box plot in figure 18 below represents post-operative Hb readings for all 498 
patients. 
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Figure 18. Mean Post-Operative Hb Levels Across Three Sites 
 
The corresponding output for an ANOVA comparing post-operative Hb levels as the 
independent variable against the three HRG groupings shows: 
Table 40. One Way ANOVA-Comparison of Post-Operative Hb Levels with HRG Groups 
Hospital: 
      \’p’ value 
South 
Manchester 
Royal Cornwall 
Hospitals Spec Orth Centre 
‘p’ Value for all 498 
patients .049 .232 .023 
‘p’ Value for 349 patients 
no allogeneic transfusion or 
re-infusion .162 .854 .226 
‘p’ Value for 99 Royal 
Cornwall Hospitals patients 
reinfused, no allogeneic 
transfusion - .040 - 
 
For all patients, at the p<.05 level, there was a significant difference in the mean 
post-operative Hb level at both South Manchester and the SOC within the HRG 
groupings, irrespective of whether allogeneic blood transfusions or reinfusions were 
utilised. The test was run again to eliminate the Royal Cornwall Hospitals patients 
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reinfused and any patient at the three sites that had an allogeneic transfusion. On this 
occasion, there were no significant differences within or between the three sites. This 
would be expected given the lower likelihood in variations in post-operative Hb 
levels triggering a decision to undertake an allogeneic blood transfusion or, in the 
case of the Royal Cornwall Hospitals, a reinfusion.  
The test was run for a third time on the 99 patients who had a reinfusion (excluding 
the five patients who had both a reinfusion and an allogeneic transfusion) at the 
Royal Cornwall Hospitals (p = .040). In this case, there was a significant difference 
between the HRG category HB12C (25 patients, mean Hb of 109) and the ‘other’ 
group (14 patients, mean Hb of 97). The corresponding Hb levels without a 
reinfusion were HB12C (28 patients, mean Hb of 103) against the ‘other’ group (7 
patients, mean Hb of 104). This implied the reinfusions helped to offset the fall in Hb 
level by a mean of 5.5 g/l in the more minor cases (HB12C) but had a negligible 
impact on the patients with greater comorbidities and complications. The full 
comparison is shown in table 41 below. 
Table 41. Split of RCH Patients Without Allogeneic Transfusion 
     Category\ 
HRG Without Reinfusion 
 
With Reinfusion 
 
Totals 
 
Mean 
Post Op 
Hb 
Number 
of 
Patients 
Mean Post 
Op Hb 
Number 
of 
Patients 
Mean Post 
Op Hb 
Number 
of Patients 
HB12B 104.8 66 104.5 60 104.7 126 
HB12C 103.1 28 108.6 25 105.7 53 
Other 104.1 7 96.9 14 99.3 21 
Mean/Total 104.3 101 104.3 99 104.3 200 
 
Across all three sites the post-operative Hb level is relatively uniform with a slightly 
wider variation at the Royal Cornwall Hospitals. The mean post-operative Hb level 
for patients who have had an allogeneic blood transfusion is lower at the Royal 
Cornwall Hospitals than the other two sites (table 42 below). This is consistent with 
a more restrictive transfusion regime. Note that, at the Royal Cornwall Hospitals, the 
mean post-operative Hb level is lower for allogenic transfused patients who were 
reinfused (mean Hb 64.4, SD 5.6) than those who were not reinfused (72.8, 7.5). The 
numbers of patients are low (5 + 8=13) but suggest that the reinfusions may have 
taken place in order to further decrease the chances of requiring additional allogeneic 
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units being transfused. This may not have been successful as the four females who 
had allogeneic transfusions and reinfusions all received two allogeneic units each. 
The NHS Patient Blood Management directive (June 2014) is not prescriptive on a 
specific Hb level to initiate an allogeneic blood transfusion highlighting instead “the 
use of appropriate dose and thresholds for transfusion”. The American Association of 
Blood Banks (AABB) guidelines (appendix 4) notes “a restrictive threshold (7.0g/dl-
8.0 g/dl i.e. 70-80 g/l) should be used for stable patients”. Table 42 below extracts 
the mean post-operative Hb level by gender for transfused patients. The smaller table 
43 highlights the Royal Cornwall Hospitals patients who were also reinfused. 
 Table 42. Mean Post-Operative Hb Levels for Allogeneic Transfused Patients (no reinfusions) 
Hospital\ 
Gender South Manchester Royal Cornwall Spec Orth Centre Total 
 Hb n Hb n Hb n Hb n 
Male 79.0 2 - - 84.4 5 82.9 7 
Female 82.1 12 72.8 8 80.4 18 79.3 38 
Mean/Total 81.6 14 72.8 8 81.3 23 79.9 45 
 
Table 43. Mean Post-Operative Information for Allogeneic Transfused Patients with Reinfusions 
 
By Gender 
 
By Machine Type 
 Hb n Machine 
Type 
Hb n Mean LOS 
Male 67.0 1 Electa 61.5 2 8.5 
Female 63.8 4 OrthoPat 66.3 3 8.7 
Totals 64.4 5 Totals 64.4 5 8.6 
 
Patients numbers are relatively small in table 42 however the indications are that the 
Royal Cornwall Hospitals are comfortably within the 70-80 g/l AABB restrictive 
threshold. The other two sites fall slightly outside of this range implying the Royal 
Cornwall Hospitals clinicians will wait longer to administer an allogeneic 
transfusion. This is further reinforced by table 43 where, when reinfusions are 
undertaken, the Hb level is allowed to fall even further. The post-operative Hb level 
is lower for the five patients who were also reinfused. The sample size is small but 
suggests that the recovery for these patients was taking longer, necessitating the 
allogeneic transfusion. Average LOS was also higher than the average of 7.9 days for 
Royal Cornwall Hospitals patients who had an allogeneic transfusion. 
151 
A comparison of the pre and post-operative Hb levels across the three hospitals is 
shown in table 44 below. 
Table 44. Mean Pre- and Post-Operative Hb Levels Excluding Allogeneic Transfusions and Excluding 
Reinfused Patients at Royal Cornwall Hospitals (n=349) 
Hospital/ 
Hb      
South 
Manchester 
Royal 
Cornwall 
Spec Orth 
Centre Total 
Mean Pre-Op 
Hb 136.5 136.5 137.2 136.7 
Mean Post-Op 
Hb 105.9 104.3 104.3 104.9 
Decrease 30.6 32.2 32.9 31.8 
 
The difference in the mean fall in the Hb level across the three sites is minimal. This 
implies the majority of the patients who have not had an allogeneic transfusion (or 
additionally, no reinfusion at the Royal Cornwall Hospitals) have had a successful 
outcome to their operation. The difficulty arises in attempting to explain the 
differences in LOS where, even without an allogeneic transfusion, South 
Manchester’s LOS is significantly longer. 
6.5  Length of Stay (LOS) 
The LOS information collected is now standardised. The initial information received 
from South Manchester used the standard NHS Choices definition. Following 
discussions with the lead transfusion coordinator in South Manchester it was agreed 
that the operation date would be provided (table 18 on page 104). There were a 
number of cases where the patient was admitted the day before surgery; this gave the 
appearance that the recovery period was longer when comparing the two dates. The 
adjusted information was subsequently provided to the researcher. 
The box plot below notes the difference in LOS between the three centres: 
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Figure 19. Mean Length of Stay (all patients) 
 
The mean length of stay can be extracted for patients with or without an allogeneic 
blood transfusion having been undertaken. This was outlined in para 5.8. The overall 
difference noted the mean length of stay was 1.1 days longer at South Manchester 
than the Royal Cornwall Hospitals and 1.2 days longer at the SOC. 
ANOVA and Dunnett T3 post hoc analysis was undertaken, implying the mean LOS 
at South Manchester was significantly longer at the 5% significance level (p<.001) 
from the two other hospitals. There was no significant difference between the Royal 
Cornwall Hospitals and the Specialist Orthopaedic Centre. 
Continuing to segregate the patients who did not have an allogeneic transfusion, or, 
in the case of the Royal Cornwall Hospitals, allogeneic blood reinfused the LOS is 
6.2 days for South Manchester and 4.9 days each for the Royal Cornwall/SOC. 
Looking at the day of the week of the operation then Wednesday (day 3) is by far the 
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busiest with over 60% of patients undergoing their operations at South Manchester 
on this day. 
The graphs in figure 20 below compare the percentage of patients’ operation days by 
hospital. 
Figure 20. Mean Length of Stay (all patients) 
 
 
It is clear that South Manchester admits a higher percentage of patients in mid-week 
and discharge a lower proportion of their patients on the weekend than the other two 
hospitals. 
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It is likely the main rehabilitation work under the Enhanced Recovery Programme 
(para 1.19) would commence on a Friday following Wednesday surgery; if therapy 
support is unavailable on the weekend this would almost certainly impact on the 
progress of recovery. Table 45 below extracts the patients at the three sites who have 
had surgery on Wednesdays. It excludes the patients who have had allogeneic 
transfusions or, in the case of the Royal Cornwall Hospitals, reinfusions. 
Table 45. Comparison of Mean Length of Stay for Wednesday Surgery (no allogenic transfusions or 
reinfusions) 
Category 
/Hospital 
South 
Manchester 
Royal 
Cornwall 
SOC 
Number of patients on Wednesday 82 35 22 
Total patients (no transfusion or reinfusion) 134 101 114 
Percentage of total 61.1% 34.7% 19.2% 
Mean length of stay for patients 6.3 4.6 4.5 
Males on Wed (Total males not transfused or 
reinfused) 
39 (63) 11 (37) 12 (46) 
% males on Wed 47.5% 31.4% 54.5% 
 
Patients’ recovery and their consequent LOS will therefore be impacted by the lower 
level of therapy support to aid recovery on a weekend. Reinfusions at the Royal 
Cornwall Hospitals and allogeneic blood transfusions have been excluded from table 
45 above. 
Table 45 implies there is a wide variation in the numbers of male patients. Para 6.3.1. 
above asserted that there was no significant difference in the gender split of patients 
in the three hospital groups. A breakdown of mean length of stay by gender for the 
349 patients with no allogeneic transfusions or reinfusions is shown in table 46 
below: 
Table 46. Comparison of Mean Length of Stay by Gender for Surgery (no allogenic transfusions or 
reinfusions, n = 349) 
Hospital/ 
Gender 
South 
Manchester 
Royal 
Cornwall SOC Total 
Male 6.0 4.5 4.6 5.1 
Female 6.4 5.1 5.2 5.6 
Total 6.2 4.9 4.9 5.4 
 
A one-way ANOVA test was undertaken to explore the difference between hospital 
on LOS for Wednesday operations. The differences between the mean LOS were 
significant (p<.001). A Tukey HSD analysis found significant differences in LOS 
between South Manchester and both the Royal Cornwall and the SOC (p<.001). 
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There were no significant differences in LOS between the Royal Cornwall and the 
SOC for Wednesday operations. 
The graphical output is shown in figure 21 below: 
Figure 21. Mean Length of Stay for Patients- ‘Baseline’ Position (no allogenic transfusions or 
reinfusions, n = 349) 
 
Figure 21 and table 46 above therefore reflect a ‘baseline’ position with the LOS for 
patients having surgery on any particular day of the week not being affected by a 
patient having an allogeneic blood transfusion. The difference in LOS is therefore 
likely to be a factor not related to the surgical process. 
This analysis was expanded to incorporate a regression analysis, using the logarithm 
of LOS as the dependent variable to mitigate against heteroscedasticity. A dummy 
control of South Manchester was set up to facilitate interpretation of the impact of 
selected variables on LOS. The R square value was calculated at 0.363. This implies 
approximately 36% of the variation is explained by the variables included. Other 
factors must therefore contribute to the remainder of the variation; these will be 
considered in chapter 7. The output from the analysis is shown in table 47 below: 
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Table 47. Regression on Logarithm of Length of Stay 
Variable B 
Coeff 
‘p’ 
(Constant) 1.783 <.0005 
Discharge Day=Saturday -.240 <.0005 
HRG No=HB12C -.199 <.0005 
Age .006 <.0005 
Lowest Post Op Hb Level -.005 <.0005 
Hosp No=Specialist Orth Centre -.178 <.0005 
Hosp No=Royal Cornwall -.180 <.0005 
Op Day=Sunday .782 <.0005 
Op Day=Tuesday .204 <.0005 
Discharge Day=Tuesday .142 .001 
Discharge Day=Thursday .164 .009 
Op Day=Wednesday .095 .020 
Note-Excludes patients who received allogeneic blood transfusions or reinfused blood 
Negative coefficients on the ‘Hosp no’ for the SOC and Royal Cornwall in table 47 
imply LOS at South Manchester is longer. One would expect LOS to generally 
increase as a patient gets older however this is at a slightly faster rate than the other 
two sites. There are no operations undertaken on a Sunday at South Manchester or 
the Royal Cornwall Hospitals therefore the Sunday entry can be ignored. 
A Tuesday operation day giving a longer LOS is not consistent with the view held in 
Pittsburgh (para 3.2). This was investigated further and table 48 below profiles out 
the discharge day for patients having their operation on a Tuesday. 
Table 48. Discharge Day and Mean Length of Stay for Patients Having Tuesday Operations 
Discharge Day 
/Hospital 
Mean 
LOS Wed Thu Fri Sat Sun Mon Tue Total 
South Manchester 6.4 - - 6 2 3 3 4 18 
Royal Cornwall Hospitals 5.3 2 1 2 4 3 5 4 21 
Spec Orth Centre 6.0 3 1 2 5 4 4 4 23 
Note-Excludes patients who received allogeneic blood transfusions or reinfused blood. Wednesday 
will be day 8 i.e. the week later. 
The analysis was further extended to identify days per patient in table 49 below. 
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Table 49. Patients Length of Stay for Tuesday Operations 
Length of Stay 
(Days) South Manchester 
Royal 
Cornwall 
Hospitals 
SOC Total 
2 - 1 - 1 
3 5 2 2 9 
4 2 4 5 11 
5 3 3 4 10 
6 2 5 4 11 
7 2 4 3 9 
8 - 2 3 5 
9 - - 1 1 
10 1 - - 1 
13 1 - - 1 
14 2 - 1 3 
 Total 18 21 23 62 
% Discharge 
Within 1 Week 78% 90% 78% 82% 
Note-Excludes patients who received allogeneic blood transfusions or reinfused blood 
 
There is a noticeably wider range that impacts on the average LOS. In particular, four 
patients at South Manchester had a LOS of over nine days against two for the Royal 
Cornwall Hospitals and one for the SOC. It is interesting to note that six patients at 
South Manchester were outside the WHO anaemic thresholds in the pre-operative Hb 
readings against two at the Royal Cornwall Hospitals and one at the SOC. This 
variable, however, did not show as significant in the stepwise analysis. 
Analysis of the three hospitals’ discharges on a Saturday/Sunday verified all the 
patients had undergone their operations on the previous Tuesday. One cannot 
therefore extract any definitive conclusions from this analysis. The R squared value 
implies there are other factors that influence the LOS. 
The Wednesday surgery at South Manchester was subsequently analysed. An 
operation undertaken on a Wednesday accounted for over 61% of all the week’s 
primary hip replacement operations at South Manchester. Table 50 below profiles the 
position for the three hospitals, noting the average length of stay. Again, this 
excludes those patients having received an allogeneic transfusion. 
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Table 50. Discharge Day and Mean Length of Stay for Wednesday Operations 
(excludes patients who have had allogeneic transfusions or reinfusions) 
 
 Discharge Day  
Site Indicator Thu Fri Sat Sun Mon Tue Wed Total 
South 
Manchester Number of patients 5 9 3 6 29 17 13 82 
 Mean LOS 8.0 7.4 5.3 4.0 5.5 6.4 7.5 6.3 
 Patients with LOS + 1 week 5 7 1 - 2 1 1 17 
Royal 
Cornwall 
Hospitals Number of patients 2 1 15 2 6 9  - 35 
 Mean LOS 8.0 9.0 3.0 4.0 5.0 6.2  - 4.7 
 Patients with LOS + 1 week - 1 - - - - - 1 
SOC Number of patients 1 1 3 6 10 1  - 22 
 Mean LOS 8.0 2.0 3.0 4.0 5.0 6.0  - 4.5 
 Patients with LOS + 1 week 1 - - - - - - 1 
 
The implication is that the factors noted previously on the therapy support and staff 
availability to discharge patients at weekends have an impact on LOS. These factors, 
combined with more patients falling within the WHO definition of anaemia, are 
likely to increase the upward pressure on LOS at South Manchester. Only four out of 
59 patients discharged between a Monday and Wednesday (29+ 17+ 13) had stayed 
for longer than a week at South Manchester implying recovery, as indicated by post-
operative Hb levels, is not dissimilar to the other two hospitals. The implication is 
that a number of the 29 patients discharged on a Monday could possibly have been 
discharged on the weekend thereby lowering the average LOS. This is, however, only 
speculation but there is a relatively high proportion of patients remaining over the 
weekend until Tuesday (46/82, 56%). Comparing this to the other two sites implies 
there is likely to be a backlog in discharging patterns at South Manchester or a delay 
in therapy support to facilitate the patient’s return home as early as possible. 
Within the stepwise analysis above the discharge day is likely to be a proxy for some 
other factor. An analysis of the Tuesday discharges (the highest day for discharges) 
for the three sites was undertaken and the output is summarised in table 51 below. 
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Table 51. Analysis of Length of Stay for Tuesday Discharges 
(excludes patients who have had allogeneic transfusions or reinfusions) 
Site 
Operation Day 
/Indicator Mon Tue Wed Thu Fri Total 
South Manchester Number of patients 1 4 17 2 8 32 
 Mean LOS 8.1 10.5 6.4 5.0 5.8 6.7 
Royal Cornwall 
Hospitals Number of patients 3 4 9 3 10 29 
 Mean LOS 8.7 6.8 6.2 4.7 3.9 5.6 
SOC Number of patients - 4 1 9 13 27 
 Mean LOS - 8.8 6.0 5.0 4.0 5.1 
All Sites Total Patients 4 12 27 14 31 88 
 Overall Mean LOS 8.5 8.7 6.3 4.9 4.4 5.9 
 
A one-way ANOVA was undertaken to explore the impact of Tuesday discharges by 
site on LOS. There was a statistically significant difference (p=.02) in the mean LOS 
between the three sites. The effect size, calculated using eta squared, was .09, 
implying a relatively large proportion of the variance in LOS for Tuesday discharges 
is explained by differences in the three sites. 
The above analysis was all undertaken on the data relating to patients who did not 
have an allogeneic transfusion or, in the case of the Royal Cornwall Hospitals, an 
allogeneic transfusion or shed blood being reinfused. The implication is that there are 
significant underlying reasons why there is a longer LOS at South Manchester. It can 
be safely said that these reasons are not connected with patients having allogeneic 
blood transfusions or reinfusing blood as the above comparisons have been made on 
patients that did not fall into these categories. Chapter 2 noted that a cost benefit 
analysis approach may support the comparison. It therefore seems highly likely that 
an allogeneic blood transfusion is not a factor in impacting on LOS. The most 
appropriate method of economic appraisal is therefore a cost minimisation study 
focusing on the blood (both allogeneic and salvaged) related costs. 
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6.6 Comparison with Royal Cornwall Hospitals Patients Not Salvaged 
As highlighted in table 30 there were 33 Royal Cornwall Hospitals patients who 
were not salvaged. This group of patients provides an additional comparison. The 
SPSS analysis is summarised in table 52 below: 
Table 52. Comparison of 33 Patients not Salvaged 
Factor Tested Test 
‘p’ 
Value 
Not 
Salvaged Salvaged 
Total 
Patients 
Pre-Op Hb Level t-test .41 33 180 213 
Post-Op Hb Level t-test .58 33 180 213 
Age t-test .58 33 180 213 
Gender Chi-square .28 33 180 213 
HRG Chi-square .27 32 159 191 
Note-Initial HRG test violated minimum cell frequency test. The test was therefore restricted to HRGs 
HB12B and HB12C. 
The independent samples t-tests established that there was no significant difference 
between the two groups of salvaged and non-salvaged patients. The Chi-square test 
for independence (with Yates Continuity Correction in both cases) indicated no 
significant association between gender in the salvaged/non-salvaged category and 
also no significant association between the HRG group and the salvaged and non-
salvaged patients. The allogeneic transfusion rate is consistent between the two 
groups though the number of allogeneic transfusions in the non-salvaged patients 
was 3/33, thereby violating the ‘minimum expected cell frequency’ of the Chi-square 
test. 
6.7 Analysis Where Allogeneic Blood Transfusion Administered 
Toleration of a lower Hb level (Goodnough and Murphy (2014)) can be an effective 
method for a patient to avoid an allogeneic blood transfusion. Table 40 (page 149) 
indicates a fairly uniform post-operative Hb level. The graph in figure 22 below 
breaks down the post-operative Hb levels over whether or not the patient had an 
allogeneic transfusion. What is noticeable in table 42 (allogeneic transfusions 
without reinfusions, page 150) is the much lower post-operative Hb level for a 
patient undergoing an allogeneic transfusion at the Royal Cornwall Hospital (mean 
of 72.8) than South Manchester or the Specialist Orthopaedic Centre (81.6 and 81.3 
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respectively). The indications are that the decision to transfuse is therefore made on a 
lower rate at the Royal Cornwall Hospital.  
Figure  22. Mean Post-Operative Hb Level With and Without an Allogeneic Transfusion 
 
The table below extracts the number of patients who have received an allogeneic 
blood transfusion. Given the differing sample sizes table 53 below converts the 
numbers to percentages, although caution should be exercised due to the small 
numbers. The most striking feature is the low proportion of HB12C patients who 
receive an allogeneic transfusion. 
Table 53. Number/(Percentage) of Patients Receiving Allogeneic Blood Transfusions 
Hospital: 
\HRG 
South 
Manchester 
Royal 
Cornwall 
Spec Orth 
Centre Total 
HB12B 11 (10.2%) 11 (8.0%) 18 (18.9%) 40 (11.8%) 
HB12C 1   (3.7%) 1 (1.9%) 0   (0.0%) 2   (1.8%) 
Other 2 (15.4%) 1 (4.5%) 5 (38.5%) 8 (16.7%) 
Total 14   (9.5%) 13 (6.1%) 23 (16.8%) 50 (10.0%) 
 
As expected the mean post-operative Hb level is noticeably lower where an 
allogeneic transfusion is administered. Given the main reason for an allogeneic 
transfusion is to increase the patient’s Hb level it is reasonable to assume that the 
transfusions were given after the readings were taken. 
Excluding the two HB12C patients and the patients reinfused at the Royal Cornwall 
Hospitals the LOS for the three sites is: 
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Table 54. Number and Mean Length of Stay with Allogeneic Transfusion/No Reinfusion; Excluding 
HRG HB12C 
Hospital: 
\HRG 
South 
Manchester Royal Cornwall 
Spec Orth 
Centre Total 
 n 
Mean 
LOS n 
Mean 
LOS n 
Mean 
LOS n 
Mean 
LOS 
HB12B 11 7.6 7 7.7 18 6.0 36 6.8 
Other 2 10.0 1 9.0 5 6.4 8 7.6 
Total 13 8.0 8 7.9 23 6.1 44 7.0 
 
There is therefore negligible difference between the mean LOS for those patients 
who received an allogeneic transfusion at South Manchester and those at the Royal 
Cornwall Hospitals. The numbers of patients are relatively small, but these patients 
required additional procedures (as indicated by the HRG category) that therefore 
contributed to LOS.  
Figure 23 below shows that, where an allogeneic transfusion is administered at the 
Royal Cornwall Hospital, over 90% of the patients who have received an allogeneic 
blood transfusion were permitted to have their Hb level fall to below 80 g/l. The 
corresponding figure for the other two hospitals was less than 50%. The implication 
is therefore that the Royal Cornwall Hospital operates a more restricted allogeneic 
transfusion regime with the decision to undertake an allogeneic transfusion based on 
a lower ‘transfusion trigger’ Hb level. This is consistent with the higher standard 
deviation in the differences between the mean pre-and post-operative Hb levels in 
para 6.2. As an indication, the highest post-operative Hb readings were 105 g/l for 
South Manchester, 104 g/l for the SOC and 82 g/l for the Royal Cornwall Hospitals 
when an allogeneic transfusion was undertaken. 
163 
Figure 23. Post-Operative Hb Levels with an Allogeneic Transfusion 
 
An independent samples t-test was undertaken to compare the post-operative Hb 
levels for patients who did or did not have an allogeneic blood transfusion at each 
site. There was no significant difference in mean post-operative Hb levels for South 
Manchester (p = .27) or the SOC (p =.60) however the difference in the Royal 
Cornwall Hospitals was significant (p = .02). This is consistent with a potentially 
more subjective approach and a greater tolerance to allowing the post-operative Hb 
level to fall lower at the Royal Cornwall Hospitals. 
The analysis was extended to quantify the numbers of patients transfused with Hb 
levels below 90g/l. This is shown in table 55 below. This extracts the data relating to 
patients with a post-operative Hb reading of <90 g/l, which is approximately the 
highest Hb rate at the Royal Cornwall Hospitals where a patient receives an 
allogeneic transfusion. 
Table 55. Allogeneic Transfusions Undertaken on Patients with Post-Operative Level <90 g/l 
Indicator 
/Hospital 
Number 
of 
Patients 
Proportion 
of Total 
Patients 
Number 
Transfused 
% 
Transfusion 
Rate on < 90 
g/l patients 
South Manchester 25 16.9% 12 48.0% 
Royal Cornwall Hospitals 40 18.8% 13 32.5% 
With reinfusion 20 9.3% 5 25.0% 
Without reinfusion 20 9.3% 8 40.0% 
Spec Orth Centre 33 24.0% 17 51.5% 
Total 98 19.7% 42 42.9% 
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The Royal Cornwall Hospitals ‘without reinfusion’ transfusion rate is still lower than 
South Manchester or the SOC. This implies that the restrictive transfusion practice in 
place at the Royal Cornwall Hospitals is more effective at avoiding allogeneic 
transfusions than the other two sites even without the benefits of cell salvage. The 
numbers are low, but cell salvage appears to therefore have only a small impact on 
avoiding allogeneic blood transfusions and other blood avoidance strategies are 
having a more beneficial impact at the Royal Cornwall Hospitals than the other two 
sites. 
As noted previously the LOS varies markedly between the three hospitals. The two 
graphs below summarise the LOS over the HRG noting the significant difference at 
South Manchester highlighted previously. 
Figure 24. Mean Length of Stay Without Allogeneic Transfusion 
 
 
Figure 25. Mean Length of Stay with Allogeneic Transfusion 
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Figures 24 and 25, with table 56 below, highlight the implied relationship between 
the LOS and whether an allogeneic blood transfusion was administered. The position 
is however distorted by the number of transfusions being so low in the HB12C HRG 
category. Approximately 68% of all the operations relate to the HB12B category 
(table 31, page 140). Analysing the transfusion rates by HRG will therefore minimise 
the averaging effect of the low transfusion rate in the 110 operations in the HB12C 
category.  
Table 56. Transfusion Rates Excluding HRG HB12C 
Hospital: 
      \ Transfusion 
Rate 
South 
Manchester 
Royal 
Cornwall 
Spec Orth 
Centre Total 
 
 
N 
HB12B 10.2% 8.0% 18.9% 11.8% 340 
Other 15.4% 4.5% 38.5% 16.7% 48 
Total 10.7% 7.5% 21.3% 12.4% 388 
 
The most frequently occurring HRG in the ‘other’ category is the HB12A that 
includes major comorbidities and complications. The transfusion rate is markedly 
lower for this group at the Royal Cornwall Hospitals compared to the SOC. The 
‘other’ category can comprise higher or lower levels of invasive surgery. The 
proportions of patients within each HRG category is consistent across the three sites. 
This was undertaken by grouping the relatively few patients who were not classed in 
the HB12B and HB12C. 18 patients fell within the HB11A to HB11C category; these 
patients have more complications and hence attract a higher tariff funding. The Royal 
Cornwall Hospitals treated 10 of these patients against three in South Manchester 
and five at the SOC. This level of activity is too small to analyse separately but 
implies that, using the HRG evidence available, the SOC is not treating a higher 
proportion of patients who have additional complications and comorbidities than the 
other two sites. This again points to dispelling one of the possible reasons behind the 
SOC’s higher allogeneic transfusion rate. 
The HB12C HRG was then reanalysed, excluding patients who were transfused and 
re-infused at the Royal Cornwall Hospitals. The mean length of stay (table 57 below) 
is still markedly higher at South Manchester. It can be said, with certainty, that there 
are additional factors affecting the longer length of stay at South Manchester. These 
factors obviously do not include the impact of allogeneic blood transfusions or cell 
salvage at the Royal Cornwall Hospitals. 
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Table 57. HRG HB12C Length of Stay Excluding Allogeneic Transfusions and Excluding Reinfused 
Patients at Royal Cornwall Hospitals 
Hospital: 
      \ LOS 
South 
Manchester 
Royal 
Cornwall 
Spec Orth 
Centre Total 
Number 26 28 29 83 
Length of Stay 
(days) 5.1 4.3 4.0 4.4 
 
Though the overall age and gender distributions of the patients at the three sites are 
not significantly different, the transfusion rates by gender reveal a consistently 
marked difference. 
Table 58. Transfusion Rates by Age and Gender 
Indicator 
/Hospital 
Mean 
Age 
Male 
Males 
n 
Txn 
Rate 
Male 
Mean 
Age 
Female 
Females 
n 
Txn 
Rate 
Female 
Av 
Age 
Overall 
Total 
n 
Txn 
Rate 
Overall 
South 
Manchester 78.5 2 3.1% 74.4 12 14.5% 75.0 14 9.5% 
Royal 
Cornwall 
Hospitals 44.0 1 1.2% 75.1 12 9.2% 72.7 13 6.1% 
Spec Orth 
Centre 75.8 5 9.3% 73.0 18 21.7% 73.6 23 16.8% 
Total 72.5 8 4.0% 74.0 42 14.1% 73.8 50 10.0% 
 
The proportion of males who have had an allogeneic blood transfusion is very low. 
Little or no conclusions could be drawn on whether cell salvage and a reinfusion had 
an impact on the sole male patient at the Royal Cornwall Hospitals (patient R148 
who was in hospital for 11 days and was identified to the lower HRG classification 
of HB12C). The other two centres’ allogeneic transfusion rates were also 
significantly lower in the male category. The question could therefore be asked that, 
given there is low likelihood of an allogeneic transfusion, should the Royal Cornwall 
Hospitals salvage male total hip replacement patients? 
The reinfusion rate by gender was extracted. Out of the 180 patients salvaged 68% of 
males were reinfused against 52% of females being reinfused. Given males have a 
lower likelihood of requiring an allogeneic transfusion it logically follows that their 
blood is more suitable for reinfusing (see para 1.13 for the ‘smoothie’ interpretation). 
A Chi-square test for independence (with Yates’ continuity correction) indicated that 
there was a significant association between gender and reinfusion (p = .046). 
Patient Blood Management, PBM, initiatives recommend the administration of 
allogeneic blood in separate single units with an assessment of the patient’s condition 
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and Hb levels before a second or subsequent allogeneic unit is administered. This has 
not been recorded in the data gathered. This omission may have had an impact on the 
overall allogeneic blood usage if this more restrictive procedure was adopted. The 
breakdown of the 50 patients who had an allogeneic transfusion is shown in table 59 
below: 
Table 59. Analysis of Number of Units Transfused 
Indicator 
\Hospital 
Patients 
Having 1 Unit 
Transfused 
Patients 
Having 2 
Units 
Transfused 
Patients 
Having >2 
Units 
Transfused 
Total Units 
Transfused 
Total 
Patients 
South Manchester 1 13 0 27 14 
Royal Cornwall 
Hospitals 1 11 1 26 13 
Spec Orth Centre 3 18 2 47 23 
Total 5 42 3 100 50 
 
The indication from table 59 is that the PBM assertion of a ‘habitual’ level of two 
units being transfused happens regularly. The 2014 National PBM Report 
recommended to only transfuse one allogeneic unit at a time to non-bleeding 
patients. Following this transfusion, the patient would be clinically reassessed to 
determine whether an additional unit would be required. It is likely that a number of 
the units were administered together but this cannot be verified. 
The split of intra-operative and post-operative allogeneic blood transfusions is not 
available. As highlighted in para 1.9 60% of allogeneic blood transfusions are 
administered post-operatively (Thomas et al (2005)). Intra-operative allogeneic 
blood transfusions are mainly administered where there is significant blood loss. For 
table 59 above it is therefore reasonable to expect that significant blood loss has 
happened to only three patients (one patient at the Royal Cornwall Hospitals and two 
patients at the SOC each received three allogeneic units). The vast majority of 
patients were therefore highly unlikely to have required emergency allogeneic blood 
transfusions. The decision to administer an allogeneic transfusion was therefore one 
of judgement by the clinician on the ward and not in an emergency setting. 
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6.8 Financial Impact of Cell Salvage at Royal Cornwall Hospitals NHS Trust 
Cell salvage has been utilised since the late 1990’s at the Royal Cornwall Hospitals 
Trust and currently the majority of primary hip operations have shed blood salvaged. 
During the analysis period (late 2010) this was not the case with 33 patients out of 
the 213 patients (15.4%) not salvaged, primarily due to lack of suitably trained staff 
being available. These patients were identified separately, and the analysis of cell 
salvage results can be undertaken on the patients that were actually salvaged. Two 
types of cell salvage machine were utilised at the Trust for intraoperative cell salvage 
and post-operative cell salvage. The machines can only be used for one patient at a 
time and either type is suitable for salvaging a primary hip operation. The available 
machines at the time were: 
• Sorin Electa-Intraoperative cell salvage. 
• Haemonetics OrthoPat-Post-operative cell salvage. 
 
The Trust’s orthopaedic service is delivered from two centres, the Royal Cornwall 
Hospital in Truro and St Michael’s Hospital, near St Erth 18 miles further to the 
south west of Truro. The breakdown of the activity is shown in table 60 below. 
Table 60. Operations by Site and Salvage Machine 
Hospital: 
\Machine Type 
Royal Cornwall 
Hospital 
St Michael’s 
Hospital Total 
Electa 23 53 76 
OrthoPat 29 75 104 
None 16 17 33 
Total 68 145 213 
 
Tables 61 and 62 further analyse the cell salvage activity by HRG/salvage machine 
utilisation and gender 
Table 61. Number of Royal Cornwall Patients’ Data Collected 
 
 
 
 
 
Machine Type: 
\HRG Electa OrthoPat 
Not 
Salvaged Total 
HB12B 41 70 26 137 
HB12C 25 23 6 54 
Other 10 11 1 22 
Total 76 104 33 213 
Male 25 41 16 82 
Female 51 63 17 131 
Total 76 104 33 213 
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To calculate the direct costs of the salvage operations the 33 patients who were not 
salvaged noted in table 61 above can be excluded and the comparison made between 
the patients who were salvaged, reinfused (where sufficient blood was recovered) 
and, where occurring, an allogeneic transfusion was administered, and the number of 
units given.  
The Electa and OrthoPat activity can be sub-divided into those patients salvaged and 
those where the salvaged blood was subsequently reinfused. This is shown in table 
62 below. 
Table 62. Number of Royal Cornwall Patients Reinfused after Being Salvaged 
Machine Type: 
\HRG Electa OrthoPat Total 
HB12B 17 47 64 
HB12C 8 18 26 
Other 4 10 14 
Total 29 75 104 
Proportion Reinfused 38.2% 72.1% 57.8% 
 
The rate of Electa salvaging is lower. This is due to the Electa having a ‘collect first’ 
reinfusion option where, if the salvaged blood is deemed not suitable for reinfusion 
(see para 4.7), then the salvaging can be discontinued and the costs of some of the 
consumables avoided. This option is not available with the OrthoPat machine and 
there is therefore a tendency to continue salvaging as all the costs have already been 
incurred. 
With both types of machine, the key priority for their use is to, as far as possible, 
avoid the need to utilise allogeneic blood. Table 64 below works up the direct costs 
associated with utilising the two types of cell salvage machines. The costs are based 
on actual supplier charges with estimates for the electricity usage. Maintenance 
expenditure, approximately £1,000 per machine, are estimated based on the 
proportion of primary total hip replacement operations as a ratio of the total 
orthopaedic operations. The calculation deriving a maintenance cost of £1,260 (£126 
x 10 machines) is shown in Table 63 below: 
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Table 63. Extraction of Primary Hip Element of Cell Salvage Costs 
 
The data can identify the number of allogeneic blood transfusions by machine type. 
Utilising the £122 charge from NHSBT will generate a total blood (allogeneic and 
salvaged) cost for each machine type. 
 
Table 64.Total Allogeneic and Salvaged Blood Costs Including VAT and Transfer Prices 
  Electa OrthoPat 
No 
Salvage Total 
Basis of Cost 
No of Patients: 76 104 33 213 Table 60 
 Element: £ £ £ £  
Collection 1,730 - - 1,730 Supplier charge inc discounts 
Processing 1,297 - - 1,297 
Supplier charge inc discounts-
note reinfusion elements only 
Combined Kit - 16,120 - 16,120 Supplier charge inc discounts 
OrthoPAT Lines - 1,546 - 1,546 Supplier charge inc discounts 
Heparin and Saline 1,930 2,642 - 4,572 NHS framework charges 
Electricity 11 24 - 35 
0.8KwH. 2.5 hrs Electa, 4 hrs 
OrthoPat 7.03p per KwH inc 
climate change levy 
Maintenance 532 728 - 1,260 
From table 63, apportioned in 
ratio of table 60 (ex vat) 
Depreciation 798 1,092  1,890 Table 69 @ six months 
 Operating Cost 6,298 22,152  28,450  
Allogeneic Units 
Utilised 11 9 6 26 Table 67 
Allogeneic Blood Cost  
£122 per unit 1,342 1,098 732 3,172 
Table 67NHSBT charge 
including transfer prices 
Step 1 Extract the number of hip HRGs from total orthopaedic non emergency HRGs at Royal Cornwall
No %
Hips 1,695 28.2%
Total Orthopaedic 6,019
Step 2 Apportion hip HRGs between primary hip replacement and total hip HRGs
Using National Joint Registry 9th report apportionment based on national data
No %
Primary Hip 71,672 89.2%
Revision Hip 8,641 10.8%
80,313 100.0%
Step 3 Combine steps 1 and 2
Hip HRGs 28.2%
x proportion primary 89.2%
Derived percentage to apportion costs 25.1%
Estimated Maintenance Costs per Machine £1,000
(ex VAT, reclaimable)
Element of Machine Attributable to Primary Hip Surgery £251 p.a.
For six months (1/9/2010 to 28/2/2011) £126
10 Salvage Machines in Orthopaedics £1,260
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  Electa OrthoPat 
No 
Salvage Total 
Basis of Cost 
 Total Allogeneic 
Blood/Cell Salvage 
Costs 7,640 23,250 732 31,622  
Mean Blood Cost Per 
Patient £101 £224 £22 £148 
Total cost divided by number 
of operations 
Mean Cell Salvage 
Cost Per Operation £83 £213 - £134 
Operating cost divided by 
number of operations 
 
The unit costs were derived from a combination of supplier charges and estimates for 
the electricity and the maintenance costs. These are shown in table 65 below: 
 
Table 65.Running Cost Estimates for Cell Salvage Machines Utilised for Primary Total Hip 
Replacement Surgery 
 
 Unit Costs Basis of Calculation 
 Electa OrthoPat  
 £ £  
Collection Reservoir 22.76  Supplier charges including discounts over total 
Processing Kit 44.72 155.00 range of activity for other procedures and 
Suction Line  8.50 specialties 
Post-Op Line  6.37  
Heparin 21.20 21.20 NHS framework charge 
Saline 4.20 4.20 NHS framework charge 
Electricity 0.17 0.28 0.8 KwH x 7.03p per KwH @ 2.5 hours (Electa) and 
4 hours (OrthoPat)  
Maintenance £7 £7 Used HRGs to apportion c. £1,000 per machine per 
annum over usage on primary total hip 
replacements. 
Note: No totalling due to Electa processing kits being dependent on adequate level of shed blood collected. VAT 
included, where not reclaimable 
Though average costs have been criticised (paras 1.18 and 2.3) they can provide an 
indicator of where the calculated blood/cell salvage costs are distributed. Table 66 
below apportions the £31,622 (£28,450 cell salvage cost plus £3,172 allogeneic 
blood cost) over the age/gender groups and generates an average blood cost for each 
group. 
Table 66. Average Blood Cost by Patient/Gender Group 
  Electa OrthoPat No Salvage Total 
Numbers of Patients:        
Male under 65 10 15 7 32 
Male over 65 15 26 9 50 
Female under 65 23 18 4 45 
Female over 65 28 45 13 86 
  76 104 33 213 
Average Cost Salvage 
only        
Male under 65 £829 £3,195 - £4,024 
Male over 65 £1,243 £5,538 - £6,781 
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  Electa OrthoPat No Salvage Total 
Female under 65 £1,906 £3,834 - £5,740 
Female over 65 £2,320 £9,585 - £11,905 
Sub total £6,298 £22,152 - £28,450 
Average Salvage Cost £83 £213 - £158 
Average Cost Salvage 
plus Allogeneic Blood     
Male under 65 £951 £3,195 - £4,146 
Male over 65 £1,243 £5,538 - £6,781 
Female under 65 £2,150 £3,834 - £5,984 
Female over 65 £3,296 £10,683 £732 £14,711 
Total Blood Costs £7,640 £23,250 £732 £31,622 
 
Crudely the average cost of salvaging a patient is £28,450/180 which is c. £158 per 
patient (broken down over £83 for a patient being salvaged via an Electa machine 
against £213 per patient utilising the OrthoPat). The unit cell salvage operating cost 
(£158) divided by the £122 charge for an allogeneic unit implies, on average, 1.3 
units of allogeneic blood need to be avoided in each operation. Given the transfusion 
rate is only 6.1% the implication is that cell salvage is a very costly way of avoiding 
a small number of allogeneic transfusions.  
Table 67 below derives the simple average costs of blood (both salvaged and 
allogeneic) per operation for the three Trusts being considered. It subdivides the 
Royal Cornwall Hospital patients into those that were salvaged and those that were 
not.  
Table 67. Comparison of Average Blood Costs per Operation (n = 498) 
 
South 
Manchester 
Royal 
Cornwall 
without Cell 
Salvage 
Spec 
Orthopaedic 
Centre 
Royal 
Cornwall 
with Cell 
Salvage 
Number of Allogeneic 
Units 27 6 47 20 
Allogeneic Blood Cost 
(£122 per unit) £3,294 £732 £5,734 £2,440 
Cell Salvage Cost (table 
64) - - - £28,450 
Sub Total £3,294 £732 £5,734 £30,890 
Number of Operations 148 33 137 180 
Cost of allogeneic /salvaged 
blood per patient £22.25 £22.18 £41.85 £171.61 
Allogeneic Transfusion 
Rate 9.5% 9.1% 16.8% 5.6% 
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From a financial perspective, the Royal Cornwall Hospital cell salvage programme 
results in a c. £149 higher average blood cost (allogeneic blood plus salvaged blood 
costs) than South Manchester (£171.61 - £22.25). There are some differences in the 
pre-operative Hb levels of patients presenting for operation (para 6.3); the outputs 
are similar, so the focus should be on the benefits of cell salvage. This will be 
discussed in chapter 7. Additionally, the higher transfusion rate at the Specialist 
Orthopaedic Centre almost doubles the allogeneic blood costs but again this cost is 
very small compared to the overall Royal Cornwall Hospital combined blood costs. 
Arguably the costs of the operation of cell salvage are understated given factors such 
as training costs and the capital costs of the cell salvage machines are not included in 
the comparison. These would all contribute to a higher overhead cost; however, these 
costs are mainly sunk costs i.e. the costs have already been incurred and therefore not 
part of ongoing decision making. 
The key challenge is attempting to isolate the contribution made by cell salvage. This 
was highlighted in para 1.13. Based on the costs in table 67 the isolated cell salvage 
costs seem prohibitive in the pursuit of trying to avoid a potentially small volume of 
allogeneic blood. 
Further analysis was undertaken following the publication of the article by Dusik et 
al (2014) (para 3.3) to generate a comparison between the two types of machines 
used. An extract is shown in table 68 below where the data relating to five patients 
who received an allogeneic transfusion was extracted. 
Table 68. Summary of Allogeneic Transfused Patients with Cell Salvage/Without Reinfusions 
 
Electa 
 
OrthoPat 
 
  
  
Number 
of 
Patients 
Mean 
Age 
Average of 
Pre_Op_Hb 
Mean 
Lowest 
Post 
Op Hb 
Number 
of 
Patients 
Mean 
Age 
Average of 
Pre_Op_Hb 
Mean 
Lowest 
Post 
Op Hb 
HB12B 4 77.5 132.8 75.0 1 78.0 123.0 60.0 
 
The patients, all five of whom were female, were sufficiently prepared for surgery; 
all having pre-operative Hb levels over the WHO guidelines of 120 g/l. The 
allogeneic transfusion would have been administered in response to the post-
operative Hb reading being low. The decision not to reinfuse would have been taken 
by reference to clinical judgement for the Electa patients and it would be likely that 
174 
the blood volume collected was too small for the OrthoPat patient to bother 
reinfusing. This approach will be discussed further in the next chapter but, 
statistically, the sample sizes are too small to facilitate a comparison between the two 
types of cell salvage machine without reinfusions.  
6.9 Comparison of Costs of Salvaging Male Patients 
As highlighted in table 68 only 1 male patient received an allogeneic transfusion. 
Approximately £10,900 (£4,146+ £6,781) was incurred in salvaging male patients. A 
simple breakeven analysis indicates that c. 89 allogeneic units (£10,900/£122 per 
allogeneic unit) would need to be avoided to cover the costs of operating cell salvage 
on male patients. Given there are 82 male patients this logic would assume that, on 
average, salvaging a male patient would always avoid an allogeneic blood 
transfusion. The relatively low rates of male allogeneic blood transfusions at both 
South Manchester and the Specialist Orthopaedic Centre, obviously without utilising 
cell salvage, would imply that 89 allogeneic units being avoided is not realistic. 
6.10  Treatment of Depreciation and Opportunity Cost 
Para 2.7 highlighted that the treatment of capital expenditure is similar from both a 
financial and economic perspective. The main conceptual differences in this analysis 
are that VAT will be included in the calculations in a financial analysis with this 
being excluded in the economic approach. Additionally, an economic approach 
would require the calculations to be discounted to reflect the opportunity cost of 
investing in the resource. The Treasury discount rate of 3.5% was used in the 
calculations in table 69 below. 
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Table 69. Comparison of Discounted Capital Costs 
 
There appears to be little difference between the derived costs from both approaches 
however this is mainly a product of the differing treatment of VAT. It is assumed 
there will be no residual value following the disposal of the machines after a ten-year 
period. From both perspectives, however, the analysis has extracted a 25.1% 
apportionment of the machine costs for primary total hip replacement calculations. 
This is not realistic as the individual machines are utilised across all the specialties 
and these fixed costs will still be borne by the hospital over the lifetime of the 
equipment. These costs are not therefore divisible in order to apportion to a particular 
operation or specialty. The corresponding differences utilising a discount factor of 
3% and 4% give differences ranging from -£87 to +£103 respectively. These 
differences are not material and the capital costs of the cell salvage equipment would 
not therefore influence the overall comparison between the financial and economic 
costs in order to answer the research question. 
6.11 Costs and Income at NHS Blood and Transplant 
The overall operation of NHSBT in 2010/11 cost approximately £420m. NHSBT’s 
role includes the provision of blood and specialist haematological products along 
with operating the UK wide organ donation and transplant service. Table 70 below 
summarises the position extracted from the 2010/11 published audited accounts: 
Economic Approach
Acquisition cost (10 machines) £125,000 ex VAT
zero residual value
Year: 1 2 3 4 5 6 7 8 9 10
Depreciation 12,500 12,500 12,500 12,500 12,500 12,500 12,500 12,500 12,500 12,500
Undepreciated balance 125,000 112,500 100,000 87,500 75,000 62,500 50,000 37,500 25,000 12,500
Opportunity cost (3.5%) 4,375 3,938 3,500 3,063 2,625 2,188 1,750 1,313 875 438
Dep + opp cost 16,875 16,438 16,000 15,563 15,125 14,688 14,250 13,813 13,375 12,938
Discount factor 0.966 0.934 0.902 0.871 0.842 0.814 0.786 0.759 0.734 0.709
Present Value 16,304 15,345 14,431 13,562 12,735 11,948 11,200 10,489 9,814 9,172
Total NPV 125,000
Equivalent Annual Cost (EAC) factor 3.5% over 10 years = 8.3166
EAC per year £15,030
At 25.1% for primary total hip replacement operations = £3,777
Financial Approach
Acquisition cost (10 machines) £150,000 inc VAT
Year: 1 2 3 4 5 6 7 8 9 10
Depreciation 15,000 15,000 15,000 15,000 15,000 15,000 15,000 15,000 15,000 15,000
Undepreciated balance 135,000 120,000 105,000 90,000 75,000 60,000 45,000 30,000 15,000 0
At 25.1% for primary total hip replacement operations = £3,770
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Table 70. NHSBT Income & Expenditure from Published 2010/11 Audited Accounts 
 Sales 
Income 
£m 
Revenue 
Grant in 
Aid £m 
Total 
£m 
Income:    
Blood Components 304 4 308 
Specialist Services 45 4 49 
Organ Donation & Transplant 7 55 62 
Group Services 12 3 15 
Total Income 368 66 434 
    
Total Expenditure   420 
    
2010/11 Operating Surplus   14 
Source: Analysis of 2010/11 NHSBT Annual Report and Accounts 
Red cell issues are responsible for £224m of the £304m of income from the sale of 
blood components (1,838,000 units issued at £122 per unit). Platelet issues account 
for c. £55m with the remainder being specialist component products and other 
services provided. Red cell issues therefore account for c. 74% of all blood 
component income. 
NHSBT utilises an activity-based costing (ABC) system to report on its costs (para 
5.8). There are discrete cost drivers and a suitably aligned general ledger coding 
structure to capture NHSBT costs to categories. Table 71 below summarises the 
breakdown of the costs incurred by NHSBT. 
Table 71. Analysis of the Cost Breakdown of an Allogeneic Unit of Blood 
Source: Information provided by NHSBT Finance Nov 2012; extract from Board paper 
ABC Cost Element 
Unit 
Price £ Examples 
Source Donors 11 
Marketing/Advertising; recruitment & retention costs, 
database management 
Blood Collection-fixed 
elements 30 
Costs include staff, equipment, location hire, team base 
costs, medical, transport 
Blood Collection-variable 
elements 18 Blood collection bags, test kits and other consumable costs 
Processing 12 Costs of separating whole blood into constituent elements 
Testing 14 Testing for specific disease types 
Order Processing, Storage and 
Dispatch 6 Receipt of orders from hospitals, picking and packing 
Distribution 4 Delivery to customers 
Sub Total-Allocated Costs 95   
Current Cost/Transfer Price 122   
Contribution to Overheads 27 
Finance, Payroll, HR, Public Affairs, Chief Executive, IT, 
Customer Services, Estates (including building depreciation)  
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A key feature of the table is the relatively low level of variable costs (£18). The 
balance, £104, in the short to medium term is relatively fixed. For example, the 
NHSBT estate is either owned or is utilised under a long-term lease. To remove these 
costs from the NHSBT cost base requires complex long-term negotiations to dispose 
of the estate. Both the Southampton and Oxford buildings were re-profiled when the 
majority of services were transferred out with the respective local hospital taking 
over the estate. Over the past 10 years NHSBT has steadily consolidated its 
operations on fewer sites and centralised its blood processing and testing services in 
Bristol, Manchester and Colindale in North London. 
The above cost profile can be contrasted with the cost profile of cell salvage at the 
hospital level where costs of consumables and allogeneic blood are viewed as 
variable costs. This can be viewed as a variation on the theme of ‘goal congruence’ 
that Horngren et al (2015) describe as where “individuals and groups work towards 
achieving the organisation’s goals”. There are different views on what the 
‘organisation’ is comprised of. This could be interpreted as the overall NHS 
allogeneic blood usage down to the individual hospital department that receives an 
internal charge for allogeneic blood use. In the short term these goals will vary from 
a financial perspective (table 8 para 2.2) however, over time and, with an annual 
review of the blood charge (effectively the transfer price, para 1.23), the aim of 
achieving an optimal volume of allogeneic blood to be collected by NHSBT can be 
developed. 
6.12 Summary of Financial Analysis 
The above analysis is based on a financial analysis of the costs and income 
associated within the relevant ‘business units’ in the NHS. It follows the similar 
pattern of most previous studies. The costs include: 
• Transfer payments, such as VAT and employers’ national insurance 
contributions. 
• The internal transfer payment of £122 per unit of allogeneic blood, which 
also includes elements of VAT and employers’ national insurance. 
• Elements such as depreciation of the NHSBT properties and equipment are 
also included in the £122 charge. 
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The analysis uses basic average (unit) costs to make a comparison. Horngren et al 
(2015) advise to use average costs “cautiously”. Given a unit of allogeneic blood is a 
homogenous product it is accepted through the NHS that the one national charge of 
£122 (reviewed annually) is a fair reflection of the aggregated costs across NHSBT. 
For the cell salvage costs the majority of these are based on actual prices (including 
VAT). These prices were unchanged through the base period in financial year 
2010/11. Costs of cell salvage consumables and allogeneic blood costs are viewed as 
variable costs at hospital level whereas, at NHSBT, most costs are viewed as fixed in 
the short term. 
 
The next section will review the associated societal (also referred to as ‘social cost’) 
costs from an economic, rather than financial, angle. 
6.13 Development of Donor/Societal Costs Associated with Blood Donation 
The questionnaire (para 5.8 on page 135) was, in part, designed to estimate the costs 
incurred by the donor attending a donation session, in order to obtain a holistic view 
of the costs associated with a transfusion. The assertion was that, all other things 
being equal, an expansion in cell salvage would therefore reduce the demand for 
allogeneic blood and therefore make more time available for a donor to do something 
other than give blood. The questions/responses are shown in appendix 8 with a 
summary of the main conclusions grouped below; where relevant a comparison is 
made against the Varney & Guest (2003) findings: 
Donors’ altruistic views (questions 1-5). The answers to these series of questions was 
very positive and attracted the highest response rates. The number of respondents 
was high, and the level of altruistic views was apparent through the responses. 
Question 4 highlighted that over 88% of donors would “definitely” give blood in the 
future and question 5 elicited that over 90% of respondents felt “giving blood is very 
important to me”. Comments from NHSBT staff noted that many donors made the 
point at donation sessions that giving blood was part of their civic duty. This was 
consistent with the claim in the Economist (para 1.8) that “Blood donors are 
stalwarts of the voluntary sector”. 
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Donors’ travel (questions 6-8). Travel time was virtually unchanged from the 2003 
findings for donors with a high (53%) rate of single car occupancy journeys to/from 
the donation session. 
Employment/Earnings/Leisure (questions 9-12). 63% of donors were in paid 
employment with only a low proportion of donors having pay deducted from their 
employer for taking time off to give blood. Given the increased opening times and 
pre-booking availability of donation at sessions it is also more likely that donors will 
give blood in their leisure time than requiring time off work. 
Actual Donor Costs Incurred (question 13). Donors highlighted the costs of parking 
and travel to/from the donation session. The cost of fuel, especially, was flagged by a 
high proportion (36%) of the respondents.  
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Table 72. Comparison of 2003 and 2013 Questionnaire Results 
Issue 2003 Varney & Guest 
Study 
2013 Questionnaire 
Length of time to donate 
(excludes travel time) 
55 mins (derived from 
study) 
60 mins 
Lost Leisure time (000’s hours) 3,001 1,274 
Altruistic Questions:   
Attendance and views on blood 
donation 
n/a Highly satisfied ‘customers’ 
and a feeling of making an 
active contribution to 
society 
Travel Questions:   
Journey length by car (return) 5.6 miles Calculation based on 20 
mph for 10 mins = 6.7 miles 
Mode of travel-Driving single 
occupancy or car share 
52% 53% 
CO2 emissions from cars? Not calculated c. 2,500 tonnes CO2 
Other travel costs estimated? Yes Yes 
Employment/Earnings and 
Leisure Questions 
  
Loss of Earnings? 1% lost 3.2% lost (Q13) 
Salary Donors asked which 
salary bracket they fell 
within. 
Used ONS final 2013 
median earnings £11.59 per 
hour. 
Child care costs? 0 Negligible 
Percent in paid employment 75% 63% 
Percent lost productive time 14% (100%-49.5% Q11 working) 
x 69% (Q12) = 34.8% in 
work and work time not 
made time up 
Donors’ costs n/a Average of £0.62 per 
donation 
 
Table 72 above notes more similarities than differences. Varney and Guest’s (2003) 
study was UK based for all blood components rather than the England and North 
Wales survey base of allogeneic blood donors for the 2013 questionnaire. Against a 
significantly higher level of donor collections the leisure time calculation is therefore 
not a valid comparison. 
The only other noticeable difference is in the lost productive time estimate. This 
recalculation was based on an assessment of the responses to questions 11 and 12. 
This difference may be reflective of an increased awareness of blood donations. High 
profile TV advertisements and more marketing compared to 2003 may influence the 
discussions on altruism and corporate social responsibility within employer groups, 
therefore allowing a more flexible employment policy. An article in the Health 
Service Journal (4 December 2006) quoted an NHS Networks poll that indicated 
45% of NHS staff donated blood regularly. NHSBT do not keep records on donors’ 
occupations or employers. This poll may point to the NHS being a large supplier of 
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blood donors given the enthusiasm of NHS staff to give blood. A substantial 
proportion of the lost productivity costs may therefore be NHS staff related. 
The detailed workings are shown in table 73 below. They are utilised primarily to 
generate estimates of donor transport costs and estimates of lost production and 
earnings and are based on the median hourly earnings paid in 2011. 
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Table 73. Derivation of Donor Costs and Estimates of Lost Earnings and Production 
 
  
Median Earnings ONS 2011 final  results 2011 £12.62 per hour
Website accessed on 4 April 2018
Percent of donors in paid employment 63.3% Q 9
Pay deducted by employer Y? 2.6% Q 11 Adjusted proportions
Pay deducted by employer N? 49.5% Q 11 See working
N/A because in own time 47.9% Q 11
Percent working having to make up time Y? 31.0% Q 12
Percent working having to make up time N? 69.0% Q 12
81 /1161 noted parking costs 7.0% Q 13
172/1161 noted fuel costs 14.8% Q 13
Lost pay-use actual noted 3.20% Q 13
Median journey duration  (mins) 10 Each way so 20 mins or 0.33 of hour
Driving 52.9% Q8
Car shared with other donor 9.6% Q8
Walk/Bike 31.3% Q8
Other 6.2% Q8
Driving MPH 20
Average emissions per km/Kg 0.2
No of Donations Collected 1,933,854
No of Units issued 1,838,000 2010/11 issues
Leisure time-1.33 hour per donation 1,231,979 hours Donations x own time % x 1.33 hours
How many drove? 1,023,009 Drivers x donations
Cost of fuel:
20 mph at 10 minutes each way 6.67 miles
At 10 miles to litre of fuel (45 mpg) 0.67 litres
@£1.30 per litre £0.87 per donor
Total fuel cost to donors £886,608 NB excise duty and VAT revenue flows back to government
Less 60% tax, excise duty and VAT -£531,965 £531,965
Cost of parking: £71,373 No of drivers x 7% @ £1/hour parking cost, ex VAT, Q13
Less VAT on parking -£11,895 £11,895
Other public transport @ £2 for return £239,798
Total Donor Transport Cost £653,918 £1,197,778 total of fuel parking and other pub trans (gross)
Divide by no of donations = £0.62
Emissions convert miles to km 11,366,787 Used 1.67
Emissions tonnes CO2 2,273
Lost earnings @ 1.33 hours £657,316 £657,316 Percent in paid empl x 3.2%
Lost production @ 1.33 hours £14,173,366 £14,173,366 Percent in paid empl x not having to make up lost time (69%)
Total opportunity cost of lost prodn/earnings £14,830,682 £14,830,682
Total Cost £15,484,600 £16,028,460
Donor 
Transport
lost 
earnings Total Bal (check)
Per unit of allogeneic blood issued £8.42 ex tax £8.72 inc tax Donor cost element inc tax £0.65 £0.36 £1.01 £7.71
Ties to table 74 Both with and ex tax are relevant Donor cost element ex tax £0.36 £0.36 £0.71 £7.71
Tax: £0.296
Varney & Guest (2003), pg 212. Total Donor Costs £ Cost prop 2003 study
Direct 8,121,947 Red cells 69 83.1%
Indirect 7,196,597 Other 14 16.9%
15,318,544 83
Red Cell element 12,734,693
"NBS" element 84% 10,697,142 pg 208 of V&G
infl 2.5% p.a. from 2001 base period 1.280
£13,693,247
Donation ratio
2001/02 2010/11
Donations Collected 2,357,568 1,838,000
Unit cost £5.81 £8.42
Percentage increase 45.0%
Tax on Fuel 60% (VAT and excise duty) £531,965
Tax on parking (VAT) £11,895
£543,860 /no of donations 2m= £0.28
Potential understatement since NHSBT do not pay donors' travel expenses
Assume paid for own fuel, potential wear and tear on car not included
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The total costs incurred by the donor and the derived societal costs are summarised 
in table 74 below: 
Table 74. Estimated Total Donor/Societal Cost of a Unit of Allogeneic Blood Including Transfer 
Prices 
Category £’000 Unit £ 
Donor transport (inc taxes) 1,198 0.65 
Societal Costs:   
Lost earnings (1.33 hours) 657 0.36 
Lost production (1.33 hours) 14,173 7.71 
Total 16,028 8.72 
Number of units issued (2010/11) 1.838m  
Total Donor/Societal Cost per Unit Issued (inc VAT) £8.72  
Note costs based on allogeneic units collected, total cost based on issues 
The main aim of this analysis was to estimate avoidable costs relating to the donor in 
the event of a downturn in demand for allogeneic blood due to an expansion in cell 
salvage. It is beyond the scope of the thesis to assess whether the donor derives more 
benefit from his/her perceived altruistic action or freeing up a few pounds and an 
hour’s leisure time every four to six months. The c. £8.72 unit cost figure is 
obviously an estimate, based on averages, but implies that a proportion of donor 
costs would be avoided if the demand for allogeneic blood were to decrease through 
an expansion in cell salvage. 
A pertinent discussion point was that the calculations estimated the revenue to 
HMRC from the combined VAT and vehicle excise duty (VED) was approximately 
£544k. Though this is only a miniscule amount of tax revenue the principle that 
altruistic donors must pay additional tax to complete their donation seems hard to 
justify. The indicative VAT revenue on fuel/car parking for each blood donation is 
therefore estimated to be in the region of 28p. 
On a related note, the estimated vehicle emissions for donors driving to/from 
sessions were calculated at approximately 2,350 tonnes of CO2. These 
environmental costs may be unavoidable but again, would fall if there were an 
expansion in cell salvage use and a fall in the demand for allogeneic blood deeming 
fewer donor related journeys. 
The calculated loss of leisure time has been assumed to be freely donated so the 
individual will derive benefit from their altruistic ‘gift’ and this is consistent with the 
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high positive responses to question 3. This issue is beyond the scope of the thesis, 
but it can be argued that the donors are more than willing to incur costs as they 
derive more benefit from their altruism than the income lost. 
Table 67 can therefore be restated to incorporate the donor costs in table 75 below: 
Table 75. Derived Cost of Blood per Patient (Including Donor Costs and Transfer Prices) 
Hospital 
\Category 
South 
Manchester 
Royal 
Cornwall 
without Cell 
Salvage 
Spec 
Orthopaedic 
Centre 
Royal 
Cornwall 
with Cell 
Salvage 
No of Allogeneic Units 27 6 47 20 
Allogeneic Blood Costs (£122/unit) 3,294 732 5,734 2,440 
Cell Salvage Cost - - - 28,450 
Donor Costs (£0.65 +£0.36 per unit) x 
allogeneic units 27 6 47 20 
Lost Production Costs (£7.71) x 
allogeneic units 208 46 362 154 
Total Derived Cost £3,529 £784 £6,143 £31,064 
Total Patients 148 33 137 180 
Unit Blood Cost per Operation £23.84 £23.76 £44.84 £172.57 
 
The Royal Cornwall Hospitals therefore generates the lowest allogeneic blood cost 
when not using cell salvage. This is no surprise, given the lowest allogeneic 
transfusion rate. There is, however, a significant increase in the unit costs when cell 
salvage is utilised. The above costs all include the transfer prices. A financial analysis 
of blood costs would primarily be the cost of allogeneic blood utilised (plus cell 
salvage costs at the Royal Cornwall) divided by the number of patients treated. 
Given the donor/societal costs are also unit costs the same relative difference is 
maintained. South Manchester and the Royal Cornwall non-salvaged patients have 
the lowest unit cost given their low allogeneic transfusion rate. The 180 Royal 
Cornwall patients who are salvaged have the highest unit costs. The argument would 
be that this additional cost would offset the cost of allogeneic blood usage however 
the unit costs do not support this argument given the relatively low allogeneic blood 
transfusion rates at the other two sites. 
6.14 Extraction of Transfer Prices 
Table 75 above includes the transfer prices; most notably the £122 charge for an 
allogeneic unit. An economic analysis approach would calculate the cost of the 
allogeneic blood/cell salvage from an NHS wide perspective. The key element would 
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be to extract the transfer price elements from the overall £122 transfer price. This 
was undertaken by reference to the 2010/11 NHSBT published audited accounts. 
Table 76. Adjusted costs for the Provision of Blood Components-NHSBT Annual Accounts 2010/11 
 
£'000 £'000
Transfer 
Payment?
Direct 
Alloc
NI/Pension/
VAT Adjust
Note 3.1 Salaries & Wages:
Permanent 171,275 N
NI 11,415 Y -11,415
Pension 19,531 Y -19,531
202,221
Note 3.2 Other Administrative Expenses With VAT?
Other staff related costs 14,747 N 0
Consumable supplies 68,776 Y -11,463
Maint of buildings plant & equipment 16,705 N 0
Rent & rates 11,506 N 0
Transport Costs 10,061 N 0
External contractors 14,916 N 0
Purchase and lease of equipment & furniture 3,914 Y -652
Utilities & telecommunications 7,842 Y -1,307
Media advertising 2,597 N 0
ODT scheme payments 29,241 to ODT 0
Professional fees 7,821 N 0
Capital charges 18,765 Separate 0
Capital non cash 3,085 0
Auditors' remuneration 120 N 0
Miscellaneous 8,510 Y -1,418
218,606
Total 420,827
Less Capital Charges -18,765
Ties to Staff Costs and Other Admin Exps note 2 page 49 402,062
Total
Blood 
Compone
nts
Spec 
Servs ODT Group
Total from above, already split out in a/cs (para 2 of a/cs) 402,062 198,672 37,775 52,966 112,649
Less direct to ODT -29,241 -29,241
Apportion Group costs 0 77,330 14,703 20,616 -112,649
Sub total 372,821 276,002 52,478 44,341 0
Cap Charges 0
NI -11,415 -8,451 -1,607 -1,358 0
Pension -19,531 -14,459 -2,749 -2,323 0
Consumable supplies -11,463 -8,486 -1,613 -1,363 0
Purchase and lease of equipment & furniture -652 -483 -92 -78 0
Utilities & telecommunications -1,307 -968 -184 -155 0
Miscellaneous -1,418 -1,050 -200 -169 0
Costs less transfer payments 327,035 242,106 46,033 38,896 0
Blood Components Costs less transfer payments 242,106
Red cells a/c for £224m/£304m sales = 73.7% £224m is £122 x 1,838,000 units
£'000
Net costs of providing red cells 178,394
2010/11 Unit Cost-Divide by number of red cells issued (1,838k) £97.06
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Para 2.8 noted that VAT and other transfer payments would be included in the main 
calculations in a financial analysis. This decision was primarily based on discussions 
with hospitals who readily recognised the £122 figure for the charge for a unit of 
allogeneic blood from NHSBT and virtually all published studies ignored the issue of 
transfer payments. The majority of non-pay expenditure incurred by NHS 
organisations includes VAT. The provision of healthcare is an exempt supply in VAT 
accounting and the NHS can only report transactions exclusive of VAT in specific 
circumstances. These transactions mainly fall into the ‘contracted out services’ 
category and include the provision of external services e.g. professional advice and 
training.  Table 76 recalculates the costs associated with allogeneic blood at NHSBT 
in 2010/11 by extracting the transfer payments. The notes accompanying the audited 
accounts were used as the start point and adjustments made. The revised cost of a 
unit of allogeneic blood was thus estimated at c. £97. Approximately 20% of the 
£122 charge therefore related to calculated transfer payments. This is not surprising 
given the high proportion of staffing costs and the associated national insurance and 
pension payments made to HM Revenue and Customs (HMRC) and the Department 
for Work and Pensions (DWP).  
An adjustment to extract the VAT element in the cell salvage costs is required. This is 
shown in table 77 below. 
Table 77. Extraction of VAT from Cell Salvage Costs 
  Electa OrthoPat Total 
 £ £ £ 
Operating Costs (table 64 above) 6,298 22,152 28,450 
Less Maintenance (ex VAT as reclaimable) 532 728 1,260 
Sub Total 5,766 21,424 27,190 
Less VAT 961 3,571 4,532 
Net Position ex VAT 4,805 17,853 22,658 
Add back Maintenance 532 728 1,260 
Total Cell Salvage Costs ex VAT 5,337 18,581 23,918 
 
The derived unit cost of blood per patient, excluding transfer prices, can now 
therefore be restated in table 78 below: 
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Table 78. Derived Unit Cost of Blood per Patient (Excluding Transfer Prices) 
Hospital 
\Category 
South 
Manchester 
Royal 
Cornwall 
without Cell 
Salvage 
Spec 
Orthopaedic 
Centre 
Royal 
Cornwall 
with Cell 
Salvage 
No of Allogeneic Units 27 6 47 20 
Allogeneic Blood Costs (£97/unit) 2,619 582 4,559 1,940 
Cell Salvage Cost (table 77) - - - 23,918 
Donor Cost (transport and earnings 
£0.36 + £0.33 =£0.69) x allogeneic 
units 19 4 32 14 
Social Cost (£7.08) x allogeneic units 191 42 333 141 
Total Derived Cost £2,829 £628 £4,924 £26,013 
Total Patients 148 33 137 180 
Unit Blood Cost per Operation £19.11 £19.03 £35.94 £144.52 
 
The same trend is exhibited as in table 75 above where there is a miniscule difference 
in the unit allogeneic blood costs between the non-salvaged Royal Cornwall patients 
and South Manchester. The other two categories are both consistently higher as with 
the financial analysis in table 75. 
6.15 Summary of Chapter 6 
This chapter has analysed the detailed HRG patient statistics and concluded that 
there is little evidence to indicate that the three sample groups of patients are 
significantly different in their composition. The only significant difference is the 
higher rate of anaemic patients presenting for surgery at South Manchester. This will 
impact on the LOS. The evidence therefore facilitates a direct comparison between 
approaches to allogeneic blood management. 
Approaching the costs from both a financial and economic analysis therefore 
concludes that the utilisation of cell salvage significantly adds to the total blood costs 
and hence the unit costs per patient undergoing primary total hip replacement 
surgery. 
The initial findings are shown in table 79 below: 
Table 79. Initial Findings from Analysis 
Ref Finding Evidence 
1 Patients are equally ‘prepped’. 
No significant difference in pre-operative Hb levels 
(ANOVA) though South Manchester has a 
significantly higher rate of WHO defined anaemic 
patients (Chi square). 
2 Homogeneous set of patients. 
Age and gender distributions are not significantly 
different (Chi square and ANOVA). 
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Ref Finding Evidence 
3 
Patients present and are treated with 
similar levels of intervention. 
HRG distribution is similar (Chi square). 
4 
Immediate post-operative recoveries 
are similar. 
No significant difference in post-operative Hb levels 
(ANOVA). 
5 
Mean LOS significantly higher at 
South Manchester with or without 
allogeneic transfusion. 
ANOVA analysis and regression. 
6 
LOS is unlikely to be influenced by 
an allogeneic blood transfusion. 
Hence a cost benefit analysis can be 
excluded from the discussion (para 
6.5) and a cost minimisation approach 
adopted. 
ANOVA analysis and regression. Cross reference to 
paras 2.3 and 2.4. 
7 
Royal Cornwall Hospitals adopt a 
more restrictive allogeneic 
transfusion regime. 
Comparison of ‘Transfusion trigger’ points and t test 
on post-operative Hb levels to compare with other 
two sites. 
8 
Royal Cornwall Hospitals salvaged c. 
85% of patients-reinfusion rates vary 
significantly depending on machine. 
Can access the relevant data by patient by machine 
utilised. 
9 
Significant differences in costs 
associated with consumables for 
OrthoPat and Electa. 
Received prices from Royal Cornwall Hospitals 
Transfusion Coordinator. Utilising with activity will 
generate the costs. 
10 
No significant difference between 
patients at RCH that were or were not 
salvaged. 
t test on pre-and post-operative Hb levels, age, 
gender and HRG comparisons.  
11 
Overall blood costs are significantly 
higher when utilising cell salvage. 
Aggregating actual costs and derived donor /societal 
costs. Consistent difference from both a financial 
and economic methodology. 
12 
Virtually all NHSBT costs are fixed 
in the short term. 
Received and discussed information with Planning 
& Management Accountant at NHSBT. 
13 
Societal costs are relatively small 
compared to the costs of operating 
cell salvage. 
Derived an average indicative cost. 
 
When comparing overall allogeneic and salvaged blood use the indications are that 
the hospital-based costs are higher when cell salvage is utilised than when allogeneic 
blood is used to maintain or increase Hb levels. This is evidenced by the relatively 
small difference in the allogeneic transfusion rate between the Royal Cornwall 
Hospitals and South Manchester. Length of stay does not appear to be affected by 
allogeneic transfusions as the length of stay is significantly longer at South 
Manchester even when comparing operations where no allogeneic transfusion was 
administered and there were no discernible differences between the cohorts of 
patients. 
The summary statistics for the pre-operative Hb levels indicate that there is a wider 
variation of Hb levels at South Manchester than at the other two sites. This is 
highlighted by the significantly higher proportion of patients who present with Hb 
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levels below the WHO threshold. It is likely that this has contributed to the longer 
length of stay and the higher allogeneic transfusion rate. 
It was confirmed that costs at NHS Blood and Transplant were stable over the period; 
the transfer price of £122 was static and was subsequently being lowered to £120 for 
2015/16. It is currently (2018/19) back to c. £122. Red cell sales income accounted 
for c. 70% of all blood related income for NHS Blood and Transplant in 2010/11. A 
fall in allogeneic blood usage would have a significant impact on NHS Blood and 
Transplant’s financial position given the high level of fixed costs. 
The donor cost methodology/calculation is subjective. Most of the results are 
consistent with Varney and Guest’s (2003) study and are indicative of the costs a 
blood donor would incur. An overall headline summary of the cost comparison is 
shown in table 80 below. 
Table 80. Mean Blood Costs by Site 
Hospital 
\Category 
South 
Manchester 
Royal 
Cornwall 
without Cell 
Salvage 
Spec 
Orthopaedic 
Centre 
Royal 
Cornwall 
with Cell 
Salvage 
Unit Blood Cost per Operation (table 
67) Including Transfer Payments £22.25 £22.18 £41.85 £171.61 
Unit Blood Cost per Operation (table 
78) Excluding Transfer Payments £19.11 £19.03 £35.94 £144.52 
 
The overall conclusion from the results is that adopting cell salvage is significantly 
more expensive than relying on allogeneic blood transfusions. South Manchester, 
however, exhibits a significantly longer patient length of stay for the selected data in 
primary total hip replacement surgery than the other two sites. On the results in this 
chapter the indications are that there are other, non-blood related, factors that impact 
on length of stay given the length of stay is higher when there are no allogeneic 
transfusions utilised. Additionally, the Specialist Orthopaedic Centre’s allogeneic 
blood usage is higher with the length of stay being approximately the same for the 
Royal Cornwall Hospitals.  Adopting the dual approach of calculating both the 
financial costs and the economic costs allows the discussions to develop in both 
arenas. The accountants at NHSBT and the hospitals can compare blood/salvage 
usage against activity whereas the economic appraisal can focus on the opportunity 
costs of utilising both allogeneic blood and cell salvage; adopting a cost 
190 
minimisation approach. Table 80 above, though using unit costs, is indicative of the 
same trends exhibited by either approach. 
These interrelationships will be discussed in chapter 7. 
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Chapter 7. Discussion 
7.1 Introduction 
This chapter will revisit the objectives of the thesis set out in chapter 3 and determine 
whether the results presented in chapter 6 can provide sufficient reassurance that the 
research question can be answered. The three elements of the objectives noted in 
para 3.3 were: 
• Establish the homogeneity of the patient cohorts selected in order to minimise 
allegations of bias and compare patient data between sites that use and do not 
use cell salvage. This will support a valid comparison between the three sites. 
• Evaluate the cost impacts of cell salvage against using allogeneic blood from 
both a financial and an economic perspective; 
• Investigate other possible factors that may impact on comparison across sites 
such as preparation for surgery and length of stay. 
 
As noted previously the discussions on whether cell salvage can reduce overall 
healthcare costs in primary total hip replacement surgery have been inconclusive. 
The researcher has been aware that the focus on blood conservation has evolved into 
international Patient Blood Management (PBM) initiatives with cell salvage being an 
element within the initiatives. The schematic in para 5.5 (figure 13) highlights that 
cell salvage is one of the few initiatives being utilised both intra-operatively and 
post-operatively within the PBM framework. PBM is currently being rolled out 
across the four home nations and extensively publicised worldwide so any 
conclusions from this study can be incorporated into the wider debate. 
The elements above will be dealt with in turn and a number of limitations in the 
study will be noted that will require further investigation. 
7.2 Objective One: Establish Patient Homogeneity and Compare Data 
This section will cover a number of elements: 
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Pre-Operative Haemoglobin Levels 
It should be stressed that the researcher has focused on elective, rather than 
emergency, primary hip replacement surgery. This was deliberate in order to ensure 
the hospitals were able to prepare the patient for surgery. By its very nature 
emergency surgery requires a different set of treatments and invariably the patient is 
not optimised prior to surgery. This would make comparisons and interpretations on 
e.g. requirements for allogeneic blood usage, highly subjective. 
The mean Hb level across the three sites was virtually the same. The standard 
deviation was higher at South Manchester and figure 17 (boxplot on page 145) 
indicated a wider range of Hb readings. There was a much higher proportion of 
patients presenting at South Manchester below the WHO Hb criteria (males < 130g/l, 
females <120 g/l). This trend was not immediately apparent. Para 5.7 noted 
clinicians asserting that cell salvage can mask inefficiencies in patient preparation 
however this was not the case with the Royal Cornwall Hospitals having the lowest 
proportion of patients (9.3%) presenting with Hb readings below the WHO threshold. 
The corresponding readings at the SOC and South Manchester were 10.9% and 
22.2% (table 37) respectively. The significantly higher rate at South Manchester may 
be a contributor to the higher transfusion rate compared to the Royal Cornwall 
Hospitals. This rate difference was not identified as a significant contributor to the 
longer length of stay at South Manchester in the regression analysis (para 6.5).  
The sample size was too small to determine the contribution of cell salvage in 
minimising the allogeneic transfusion rate for the 9.3% (23) of the Royal Cornwall 
Hospitals patients presenting who were below the WHO threshold. The likelihood is, 
however, that the comparatively lower anaemia rate at the Royal Cornwall Hospitals 
would contribute towards achieving a lower allogeneic transfusion rate. Cell salvage 
at the Royal Cornwall Hospitals may therefore appear to be more effective compared 
to South Manchester by the proxy of a more effective pre-operative assessment 
programme. It could be asserted that cell salvage is contributing less to the avoidance 
of an allogeneic transfusion at the Royal Cornwall Hospitals than thought since c. 
90% of the patients have pre-operative iron levels capable of adequately supporting 
the surgery. This is compared to c. 78% of South Manchester patients (figure 23). 
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Various articles e.g. Phillips S et al (2006) and Spahn (2010) in the literature review 
stressed the causational link between lower pre-operative readings and a higher 
likelihood of a requirement for an allogeneic transfusion. The researcher drew 
similar conclusions; Spahn (2010) recommended “high impact prospective studies” 
to be undertaken however the similar issue in para 1.4 is pertinent in that it is 
difficult from an ethical perspective to withdraw other allogeneic blood avoidance 
techniques to just focus on testing one. A recent study, Guzel et al (2017), segregated 
a cohort of patients to receive tranexamic acid or post-operative cell salvage on knee 
replacement surgery. The authors concluded that tranexamic acid was more cost 
effective than post-operative cell salvage. The study was relatively small scale (50 
patients in each cohort) and the lesser used post-operative cell salvage is significantly 
more expensive than intra-operative cell salvage anyway. The study does, however, 
point to the ethical perspectives now being stretched to enhance the discussions. 
An overall comparison of WHO pre-operative anaemia rates against overall 
transfusion rates is shown in table 81 below. 
Table 81. Comparison of Transfusion Rate to WHO Defined Anaemia Rate 
Hospital: 
\Rate 
South 
Manchester 
Royal 
Cornwall 
Spec Orth 
Centre 
Mean 
Overall 
% Patients Defined as Anaemic (WHO) 22.2% 9.3% 10.9% 14.5% 
Allogeneic Blood Transfusion Rate 9.5% 6.1% 16.8% 10.0% 
A simple assertion would be that, if South Manchester could decrease the rate of 
anaemic patients presenting for surgery, then, all other things being equal, less 
allogeneic blood would be required. Whether or not this rate would decrease to the 
Royal Cornwall’s allogeneic blood transfusion rate is a moot point. The researcher 
has shared this information with the three sites and has been reassured that the pre-
operative anaemia rate has improved at South Manchester with a corresponding fall 
in the allogeneic blood transfusion rate.  
It is interesting to note that the regression analysis on length of stay (LOS) does not 
highlight the South Manchester’s higher WHO classed anaemia rate as being a 
contributor to the increased LOS at South Manchester (para 6.5). 
Each of the sites’ subsequent approach to the challenges of minimising pre-operative 
anaemia were encouraging. The data analysed was from 2010/11 and could be 
194 
perceived as being out of date (e.g. the researcher criticised Tawfick et al (2008) 
where the data collection period spanned nine years) however the principle remains 
that there is a higher probability of an allogeneic blood transfusion being required 
when pre-operative Hb levels are lower. Additionally, the data from the three sites 
was extracted over a relatively short time period thereby minimising any likelihood 
of staff changes or developments in health technologies being utilised. The detailed 
results were shared and discussed with the leads in the three hospitals in 2014/15; the 
leads confirmed that the information had been shared with their respective anaemia 
leads to support further initiatives to managing pre-operative anaemia. 
A number of authors assert that the pre-operative Hb level is a reliable indicator of 
how well the patient is prepared for the operation (Spahn (2010) above, Waters 
(2010b)). A more recent conference poster (Rajkumar et al (2015)) highlighted the 
proportion of patients presenting for primary hip replacement surgery at Guy’s 
Hospital with a Hb level of <120 g/l falling from 19% in 2007 to 5% in 2014 with a 
concomitant fall in the allogeneic transfusion rate from 13% in 2007 to 0% in 2014. 
As noted previously, the pre-operative Hb level significantly influences whether an 
allogeneic transfusion is administered during or after elective surgery. It is likely that 
the pre-operative Hb level is therefore an indicator of the assiduous application of 
other best practice pre-operative techniques e.g. the supply of pre-operative nutrients 
or ‘pre-habilitation’ advice at the patient’s assessment appointment (para 1.19). A 
wider study would clarify this point. 
Preparedness for surgery can vary with factors such as a patient’s age, personal 
circumstances or comorbidities. Any significant comorbidity would, however, impact 
on the patient’s HRG coding. The Hb analysis therefore points to the Royal Cornwall 
Hospitals and the SOC’s patient preparation being potentially more comprehensive 
than South Manchester after other factors potentially contributing to the variation 
being ruled out. 
Patient and Condition Homogeneity 
As highlighted in para 6.15 (table 79, ref 2) the age and gender of the patients at the 
three sites are consistent. This gives a significant level of reassurance over the 
homogeneity of the patients presenting. Most studies identify these two categories in 
their analysis. There is the assertion that some studies may differ as they may have, 
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on average, younger patients or a higher proportion of male patients. A single site 
study may therefore have an unintended level of bias if the data selected in these 
categories is significantly different from the population’s overall characteristics. 
Homogeneity in this three-site study would therefore minimise the possibility of 
patient age and condition bias. 
This study was novel in that it utilised Healthcare Resource Groups (HRGs) to 
compare the severity of the total hip replacement operations. The widely-held view 
would be that the more severe the operation, requiring additional procedures, the 
more likely an allogeneic blood transfusion would be required. The uniformity of the 
HRG breakdown gave a level of confidence that the operations were of a similar 
intensity and level of invasiveness. An initial assertion from a member of the SOC 
staff was that, as a specialised centre, the higher allogeneic transfusion rate may have 
reflected surgery undertaken on more severe cases. The HRG coding results refuted 
this assertion, highlighting the similarity in the profiles of operations at the SOC to 
the other two sites. Adoption of the HRG coding therefore added a level of 
reassurance that is not included in any other study regarding allogeneic transfusion 
rates and cell salvage. It also provides an additional level of objectivity. Following 
discharge, the hospital clinical coders summarise the care provided to the patient by 
reference to the ICD-10 and OPCS-4 procedural classification codes. The NHS 
‘grouper’ software (para 1.24) generates the HRG code from this information. This 
retrospective coding and assignment of the HRG classification is therefore 
undertaken independently of the staff associated with the allogeneic blood 
transfusions; thereby minimising the potential allegations of DRG/HRG ‘creep’. The 
researcher received the HRG codes directly from the relevant Trust information 
department thereby adding an additional level of independence. 
The HRG coding prompted further discussions with clinicians, few of whom had 
even heard of the term ‘HRG’ but appreciated the additional level of granularity. The 
researcher noted the conclusion of Jaben et al (2010) who studied long term survival 
rates following surgery when an allogeneic transfusion was required. The study 
utilised the Charlson comorbidity index to measure and classify the severity of the 
comorbidities. More recent US studies e.g. Frank et al (2014) have commenced the 
introduction of Diagnosis Related Groups (DRGs) into comparisons of allogeneic 
blood usage. These are the US equivalent of HRGs. Being able to incorporate this 
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additional level of information would help to minimise the potential allegations of 
bias and allow more objective comparisons. There are currently no published 
comparative studies on allogeneic blood usage utilising HRGs in the UK. By not 
adopting this additional check on the severity of the operation other studies run the 
risk of potential allegations of bias in their results. 
The pre-operative results showed the patients’ age, gender and pre-operative 
conditions (HRG profile) were homogeneous. Prior to delving deeper, a general 
overall reassurance is implied that these three factors would not influence any 
differences in the post-operative comparisons. Table 37 (page 146) highlights the 
higher proportion of South Manchester patients who are presenting as anaemic as 
defined by the WHO limits. This issue is likely to be significant and may influence 
the LOS, impacting on patients who were not adequately ‘prepped’ for surgery. 
Post-Operative Results 
Para 6.4.1. (Page 148) noted that the mean post-operative Hb levels are relatively 
uniform across the three sites and table 44 (page 151) compared the mean post-
operative falls. With there being so little difference in the post-operative Hb levels it 
can be safely assumed that most operations have been successfully completed. 
Figure 23 (page 163) highlighted the significant disparity in the post-operative 
transfusion rates. The challenge has been to isolate the impact of cell salvage at the 
Royal Cornwall Hospitals rather than the impact of other blood avoidance 
techniques. The first key aspect is the allogeneic transfusion rates. The percentages 
are ‘diluted’ by a negligible number of allogeneic transfusions in the HB12C 
category across all three sites. This adds reassurance to the assertion in chapters 1 
and 4 that previous studies were not deriving the effective allogeneic transfusion rate 
since they were using the generic category ‘total hip replacement’. By excluding the 
HRG HB12C the Royal Cornwall Hospitals’ adjusted allogeneic transfusion rate is 
7.5% against 10.7% for South Manchester and 21.3% for the SOC (table 56 page 
165). Overall one could assert that, given the overall length of stay was 4.9 days for 
both the Royal Cornwall Hospitals and the SOC against 6.2 days for South 
Manchester, the Royal Cornwall Hospitals were therefore deriving a successful 
outcome from their cell salvage programme (table 46 page 154). This assertion is 
however, simplistic. 
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A key contributor is the restrictive allogeneic transfusion practice that the Royal 
Cornwall Hospitals adopts. This may not be as formal as an assessment of 
“computerized physician order entry” as described by Goodnough et al (2014) but 
figure 23 shows that Royal Cornwall Hospitals staff are prepared to let the patients’ 
Hb levels drop significantly lower before administering an allogeneic transfusion. 
Goodnough et al (2014) set their hospital transfusion trigger at 70 g/l (at the lower 
end of the AABB recommended scale). This did not differentiate between genders 
and there was a slight decrease (52.7% to 49.9% over the five-year study) in the 
proportion of females who generally tolerate a lower Hb level before being 
considered anaemic under the WHO categories. Figure 23 indicates that only the 
Royal Cornwall Hospitals come near the AABB transfusion trigger (para 4.7 and 
appendix 4). 
There is little difference in the post-operative Hb levels for patients at South 
Manchester and the non-reinfused patients at the Royal Cornwall Hospitals (table 
34). This reinforces the assertion that there is very little difference in the procedures 
required within the operation and that it is the extraneous factors of the weekend 
impacts that are contributing to the longer LOS for the South Manchester patients 
who did not receive an allogeneic transfusion. It is possible (though not verifiable) 
that the condition of the South Manchester patients who had allogeneic transfusions 
were regarded as more serious within the parameters of each of the HRG code and 
required more post-operative input. 
Overall the post-operative analysis indicates: 
• The Royal Cornwall Hospitals practice a significantly more restrictive 
transfusion regime. Four of the five patients who were salvaged and also 
received an allogeneic transfusion, had post-operative Hb readings below 67 
g/l. The remaining patient had a reading of 71. The implication is that the 
allogeneic transfusions were a ‘last resort’ after all other procedures had been 
utilised. This factor therefore contributes towards the lower allogeneic 
transfusion rate. 
• The differences in length of stay are likely to be the product of factors not 
associated with a patient having an allogeneic blood transfusion. Given the 
number of allogeneic transfused patients is relatively small it would be 
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necessary to obtain activity relating to a longer period to fully investigate and 
substantiate this assertion. The SOC length of stay is significantly lower for 
the patients who have an allogeneic transfusion than the other two sites. This 
may be that there are more experienced orthopaedic staff who can rehabilitate 
older, less responsive patients than the other two sites. This assertion, again, 
would benefit from a fresh study. 
7.3 Objective Two: Evaluation of Cost Impacts and Assessment of the Cost 
Effectiveness of Cell Salvage 
As highlighted in para 6.13 the majority of costs associated with allogeneic blood 
transfusions comprise the charge from NHSBT for the allogeneic blood and the cell 
salvage related costs. All other costs are viewed as being constant (e.g. cross 
matching, utilisation of tranexamic acid) and would be incurred regardless of 
whether a patient had an allogeneic transaction, cell salvage or no blood 
requirements at all. This would include the cost of the operation of the blood bank 
(para 2.2). 
This study has benefited from the Royal Cornwall Hospitals holding patient 
information on two types of cell salvage machine, separate information on patients 
who were not salvaged and also information relating to patients being salvaged but 
not being reinfused. This has allowed multiple comparisons, not usually adopted in 
studies. The main aspects are: 
7.3.1 This study is not as detailed as some other published studies (e.g. Waters et al 
(2007), NICE NG24 Guideline (2015)). This thesis has a wider focus; utilising cell 
salvage against an allogeneic blood transfusion without cell salvage. A further 
difference is that both quoted studies include an allowance for additional staff time to 
operate the machine. At the Royal Cornwall Hospitals, additional staff time in theatre 
is not required when utilising cell salvage. Staff are trained to operate the machines 
within their existing duties. The NICE guidance includes an additional 3.5 hours of 
nursing time when cell salvage is utilised. The researcher has additionally seen hip 
replacement surgery undertaken in Swansea and Pittsburgh where only a surgeon and 
one nurse or ODP were involved in the surgery. This requirement will be different for 
e.g. a complex cardiac operation, but it is likely the NICE (2015) staffing costs of 
cell salvage are overstated. 
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7.3.2 The cell salvage costs derived in chapter 6 utilise a significantly different 
comparison methodology from those utilised in previous studies. Other studies (e.g. 
Rao et al (2012)) include a notional element from the allogeneic blood not required 
but South Manchester has shown that the low allogeneic blood transfusion rate can 
be achieved without the need for cell salvage. Hence the notional cost savings of cell 
salvage are irrelevant. The factors that influence South Manchester’s longer LOS 
appear to be independent of allogeneic blood transfusions. The cost of the additional 
LOS compared to the Royal Cornwall Hospitals or the SOC is not therefore likely to 
be an impact of the higher allogeneic blood transfusion rate. 
7.3.3 Patients at the Royal Cornwall Hospitals tolerate greater falls in post-operative 
Hb levels than the other two sites. This would have the effect of reducing the 
requests for allogeneic blood and would contribute towards the lower allogeneic 
transfusion rate. Given this policy runs concurrently with other strategies within the 
cell salvage programme it is impossible to segregate the impacts of the separate 
strategies on allogeneic blood usage. 
7.3.4 The impact of a shorter LOS on costs, in the short term, would be limited to the 
release of some marginal costs avoided. These would mainly relate to the cost of 
accommodation and patient meals. There is a wide expectancy that cost savings in 
reducing LOS will be higher. The Clinical Services Journal (January 2012), in an 
article on improvement on pre-operative Hb management in hip and knee 
replacement, stated “The average length of stay, which costs around £300 per day 
has fallen from 7.5 days to 6.5 days for hips..”. The intimation in this sentence is that 
significant savings could be achieved. In the short term this will not be the case given 
the majority of costs are fixed. Other articles e.g. Dixon et al (2005) and Freedman et 
al (2008) also imply fixed costs would be released quickly in comparisons on 
avoiding allogeneic blood transfusions. Para 6.5 (regression analysis) noted that there 
is unlikely to be any significant causational relationship between cell salvage and 
LOS, once other factors have been considered. Any resultant savings would therefore 
be minimal. 
It is likely that South Manchester could also improve on its low allogeneic 
transfusion rate if the rate of anaemia was nearer the rate of the other two sites. This 
however cannot be quantified and would benefit from more recent analysis. 
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7.3.5 Impact of Weekend Working. The cost impact of this area would need to be 
considered primarily in the context of the costs of length of stay. More weekend 
therapy support working would be likely to attract premium payments for staff in the 
short to medium term. This should contribute towards savings in the lower length of 
stay but only after an initial rise in overall costs as the new system would take time 
to establish. The evidence from this comparative study indicates that an allogeneic 
blood transfusion has little or no impact on LOS. As such no costs of LOS have been 
incorporated in this study. 
7.3.6 The early analysis and articles generally noted higher allogeneic transfusion 
rates in operations. Introduction of cell salvage systems would therefore be more 
likely to generate a greater fall in the rate of allogeneic blood usage. Cell salvage 
would therefore appear successful in decreasing the allogeneic transfusion rate 
however it was an expensive method to avoid a blood transfusion. In the English 
NHS, the price of a unit of red cells has been at a maximum of £140 (figure 10, page 
42) in 2008/09. The relatively high cost of the consumables for the OrthoPat machine 
(c. £170 per operation from a financial perspective, table 64) was offset by the high 
red cell price and high allogeneic blood volumes thereby allowing a surplus to be 
maintained. In reality, there were a number of patient blood management (PBM) 
techniques much cheaper than cell salvage that would, when utilised, bring down the 
blood usage and hence costs. The researcher discussed this issue with the teams in 
Pittsburgh and Swansea in 2014 and 2015. Independently both organisations had 
taken the decision to run down and phase out their use of the OrthoPat cell saver. Dr 
Jon Waters at Pittsburgh confirmed that the allogeneic transfusion rate at Pittsburgh 
for total hip replacement operations had fallen from 27.4% in 2009 to 19.5% in 2014 
and in October 2016 noted the rate was running at around 9.0%. This rate was 
achieved by focusing on PBM techniques, at the same time as withdrawing both intra 
and post-operative cell salvage from most total hip replacement patients. The Cell 
Salvage Coordinator for the Welsh Blood Service also confirmed that, since 2015, no 
hospital in Wales uses post-operative cell salvage. Dr Waters’ comments are 
especially relevant as the savings in blood avoidance are significantly higher when 
there is a high allogeneic transfusion. Decreasing the allogeneic rate via PBM 
methods and, at the same time, phasing out cell salvage will obviously enhance the 
continuing fall in overall blood related costs. 
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7.3.7 As highlighted in the literature review there have been few discussions relating 
to the cost of the donation process and the time taken to make the donation. 
Whatever blood avoidance technique is adopted there will be a corresponding 
decrease in the volume of allogeneic blood required. NHSBT’s variable costs are c. 
£18 per unit of allogeneic blood (table 71). A crude analysis (table 74 page 183) 
calculates the donor/societal cost at £8.72 per unit. As the £122 charge for an 
allogeneic unit is a transfer price from one NHS organisation to another this element 
can be excluded. The ‘saving’ of avoiding an allogeneic unit is therefore £26.72 (£18 
+ £8.72). Comparing this to the c. £83 cost of operating cell salvage per operation for 
the Electa salvage machine at the Royal Cornwall Hospitals (table 64 page 171) 
implies a shortfall of c. £55 per operation (£83 - £26.72). The corresponding shortfall 
for the OrthoPat cell saver (£213 per operation) would be c. £186. Using cell salvage 
therefore points to a significant loss and, from a cash perspective, it would be 
arguably cheaper to use allogeneic blood. 
 
7.3.8 Para 1.7 noted the disadvantages of allogeneic blood transfusions. Donors 
themselves perceive that their donation is the ‘gift of life’ (para 1.8) and Q5 of the 
donor survey highlighted that 90% felt “giving blood is important to me”. It could be 
argued that this “feel good factor” may be partially diminished if donors were aware 
that, potentially, their donation could be replaced by potentially more expensive 
blood avoiding initiatives such as cell salvage. Para 1.10 highlights the challenges on 
recruitment and retention of blood donors. Regular donors may balk at the idea that 
each donation does not save a person’s life, or their donation could be perceived as 
not being required by being replaced by a recycling machine. 
 
7.3.9 Costs at NHSBT (or any other blood collection organisation) rarely figure in 
the wider discussions. Davies et al (2006) noted the impact of the fall in demand for 
allogeneic blood in 2002/2003 and highlighted the impact on NHSBT’s fixed costs 
stating: “the average cost of fixed overheads per unit of blood will increase”. Davies 
et al (2006) implied this would put upward pressure on the allogeneic blood price, 
assuming that NHSBT would need to cover all these costs. In hindsight, this 
assumption did not consider the reaction by NHSBT to ‘downsize’ and remove fixed 
costs to reflect the lower level of activity. As noted in para 1.23 the transfer price of a 
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unit of allogeneic blood will be adjusted to reflect changing costs as annually agreed 
with the National Commissioning Group for Blood. 
 
7.3.10 Maintenance costs were calculated in table 63 (page 170). This was 
calculated at 25.1% of the total annual cell salvage maintenance cost of £10,000. 
This percentage was based on the apportionments of primary total hip replacement 
operations as a percentage of all orthopaedic operations (28.2%). The national split 
of primary to secondary total hip replacement surgery was then utilised (89.2%) to 
derive a proportion of primary total hip replacements. This derived estimate was 
required as the detailed data had been archived. There is no reason to think that the 
Royal Cornwall Hospitals resident profile is significantly different from the national 
average however there is a possibility that this percentage may be slightly 
understated. Any difference, however, is not likely to impact on the relative costs of 
the two types of cell salvage machines in use. 
7.3.11 The researcher had various ‘off the record’ discussions with blood bank 
managers and clinicians regarding the cost of a unit of allogeneic blood and volumes 
utilised in hospitals. The discussions elicited that a number of blood 
bank/haematology departments noted the lower volumes of allogeneic blood could 
be offered up annually as part of a savings programme within their respective 
hospital trust. The relative ease of decreasing the volumes of allogeneic blood with 
the relatively basic financial monitoring systems helped to avoid scrutiny within the 
hospital’s annual budgeting discussions. 
7.3.12 All the above comments are equally relevant irrespective of whether a 
financial or economic costing approach was undertaken. It was viewed that the 
calculation of the wider societal cost was justifiable since few studies considered 
these costs when calculating the financial impact of avoiding allogeneic blood 
transfusions. In particular; question 12 of the donor questionnaire asked if the donor 
had to make up work time spent donating. 69% of respondents stated they did not 
have to. This proportion was used to generate a cost of ‘lost production’ in the 
economy through blood donation. In hindsight, this figure is only a snapshot. The 
researcher can personally confirm that city centre pre-booked donations can be 
undertaken very quickly and his current employer encourages staff to donate where 
possible. A further questionnaire to research the employment background and 
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location (this data is not currently collected) of the employers would give some 
corroboration of this split. The average cost per unit relating to the donor/societal 
cost was calculated at £8.42 (table 73), when taxes are excluded. This is relatively 
small compared to the hospital-based costs. An associated issue is the ‘windfall' of 
additional tax revenues (excise duty and VAT) that relates to the journey to/from the 
donor centre by the donors. This is estimated at c. £0.55m on 2m donations p.a. To 
the best of the researcher’s knowledge this tax revenue has not been discussed or 
publicised. An additional cost is the associated CO2 emissions that were calculated at 
2,351 tonnes relating to the donor’s journey to/from the donation centre. 
 
7.3.13 Drummond et al (2015) developed a checklist to assess economic evaluations. 
Table 82 below summarises the questions with responses and notes any 
parallels/contradictions between financial and economic evaluations. 
  
Table 82. Drummond et al (2015) Economic Evaluation Checklist 
Question Response 
Para 
Ref(s) 
1. Was a well-defined 
question posed in answerable 
form? 
The research question sought to evaluate whether cell 
salvage was an appropriate technique to decrease 
allogeneic blood costs. It examined costs associated with 
allogeneic and salvaged blood and associated activity 
over a similar time frame in three sites covering one 
procedure; one of the sites used cell salvage. 
3.3 
2. Was a comprehensive 
description of the competing 
alternatives given? (i.e. can 
you tell who did what to 
whom, where and how 
often?) 
The choice was utilising allogeneic blood transfusions in 
two of the hospitals v an alternative combination of cell 
salvage/allogeneic blood transfusion in one hospital. In all 
three hospitals it was stated that there was an assiduous 
blood management programme in place in line with the 
‘Better Blood Transfusion’ initiatives. 
5.2 
3. Was the effectiveness of 
the programmes or services 
established? 
The study utilised information from a consecutive series 
of primary total hip replacement patients from late 2010 
to early 2011. Key datasets were utilised, based on 
previous studies and discussions with clinicians. HRG 
information was extracted separately by the relevant 
hospital information department. Patients with a length of 
stay > 14 days were excluded as there may have been 
significant associated comorbidities or other reasons for 
delaying discharge. 
6.2 
to 
6.7 
4. Were all the important and 
relevant costs and 
consequences for each 
alternative identified? 
Key relevant costs relating to allogeneic blood and cell 
salvage usage from both a financial and economic 
perspective were identified. 
 6.8 
5. Were unit costs and 
consequences measured 
accurately in appropriate 
physical units prior to 
valuation?  
Operating costs of cell salvage were identified and 
information on number of operations utilising cell salvage 
and units of allogeneic blood transfused supported the 
calculation of unit costs. Some shortcomings/limitations 
were identified. 
 6.8 
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Question Response 
Para 
Ref(s) 
6. Were costs and 
consequences valued 
credibly? 
Costs of providing allogeneic blood from NHSBT needed 
manipulation to isolate further detail. Transfer prices were 
extracted from the NHSBT charge by reference to the 
NHSBT audited accounts and an estimate for VAT was 
extracted from cell salvage operating costs. These were 
mainly from agreed supplier prices. Running costs were 
calculated by utilising estimated energy usage and price 
of KwH. 
 
Extraction of the transfer prices allowed analysis from 
both a financial and economic perspective. 
6.14 
 
 
 
 
 
 
 
 
6.8 
7. Were costs and 
consequences adjusted for 
differential timing? 
Not directly applicable. All activity information collected 
was within a six-month time frame, so no discounting 
required. Equivalent annualised costs were utilised for 
depreciation of equipment, these costs were not materially 
different between a financial and economic approach. 
 6.10 
8. Was an incremental 
analysis of costs and 
consequence of alternatives 
performed? 
Extensive statistical analysis to establish homogeneity of 
patient characteristics and treatment was utilised. Basic 
sensitivity analysis to check the alternative of cell salvage 
costs v allogeneic blood costs and units utilised was 
undertaken. An incremental analysis of costs was not 
explicitly calculated given the significant difference in 
costs between salvaged and allogeneic blood. 
6.3 
 
6.4 
 
6.15 
9. Was uncertainty in the 
estimates of costs and 
consequences adequately 
characterized? 
The information from NHSBT breaking down the unit 
cost/price of £122 has to be taken on face value and 
cannot be verified as this breakdown is relatively 
confidential and would need to be reworked. This price 
has remained relatively static since 2010. A reconciliation 
to the published, audited, accounts for 2010/11 was 
undertaken to generate reassurance 
 
It is likely, given the continuing redundancy programme, 
downsizing of the estate stock etc, that fixed costs are 
being removed, implying the profile of costs are 
changing. In real terms there has therefore been a price 
decrease. 
7.5 
 
 
 
 
 
 
 
1.23 
 
2.2 
10. Did the presentation and 
discussion of study results 
include all issues of concern 
to users? 
Conclusions were based on the assessment that this was a 
cost minimisation analysis. They were compared to the 
conclusions of other studies in the literature review and 
information on other sites' transfusion rates. 
It is not clear if any of the patients were Jehovah's 
Witnesses who explicitly rejected an allogeneic blood 
transfusion regardless of the clinical judgement. Given 
there are an estimated 138,000 JW followers in UK 
(0.21% of population-JW website accessed 4 March 
2018) it is likely that only 1 out of the 498 patients was a 
JW patient. 
 
Issues relating to LOS were addressed, however one 
cannot say with absolute certainty that cell salvage has 
avoided allogeneic transfusions at RCH 
The conclusions are likely to be relevant to other 
orthopaedic procedures (especially total knee replacement 
surgery) but not Cardiac procedures where the blood loss 
is generally higher and only intra-operative cell salvage is 
applicable. 
It is therefore recommended that a similar model is 
adopted to study Cardiac patients. 
2.4 
 
 
 
 
 
 
 
 
 
 
 
6.5 
& 
7.5 
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A summary of all the associated costs is reproduced from table 80 and shown in table 
83 below: 
 
Table 83. Unit Blood Costs for Primary Total Hip Replacement Surgery by Site by Operation 
Hospital 
\Category 
South 
Manchester 
Royal 
Cornwall 
without Cell 
Salvage 
Spec 
Orthopaedic 
Centre 
Royal 
Cornwall 
with Cell 
Salvage 
Unit Blood Cost per Operation 
Financial Analysis Method £22.25 £22.18 £41.85 £171.61 
Unit Blood Cost per Operation 
Cost Minimisation Method £19.11 £19.03 £35.94 £144.52 
  
From both a financial and economic assessment cell salvage is still showing that it is 
not cost effective in primary total hip replacement surgery. The costs of cell salvage 
consumables are increasing the overall blood costs considerably. Against an existing 
low allogeneic transfusion rate (without reinfusions or allogeneic transfusions) at the 
Royal Cornwall Hospitals, the allogeneic transfusion rate is unlikely to drop much 
lower; therefore, the use of cell salvage in primary total hip replacement surgery 
would only generate marginal savings. Cell salvage cannot therefore be viewed as 
cost effective in primary total hip replacement surgery. It is also likely that Patient 
Blood Management initiatives have lowered the ‘baseline’ allogeneic transfusion rate 
at South Manchester with the potential to decrease this for the SOC. 
7.4  Objective Three: Investigate Other Issues 
To the best of the researcher’s knowledge no study has been undertaken to gauge the 
views of blood donors regarding cell salvage or other blood avoiding techniques. It 
may be that donors feel their time is precious and, if some donations could be 
replaced by a machine, then the donor would not need to donate as often. This may 
alter the donor’s view point to one that believes allogeneic blood is only required to 
replace more expensive cell salvage rather than focusing on the ‘life-saving’ 
capabilities. The contrasting view would be that active donors need to be retained to 
meet potential increases in demand. This potential conflict would be best discussed 
away from the media. 
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The advent of on line bookings and larger venues can make the matching of donor 
supply to blood demand more effective. This is likely to encourage younger donors 
(including the ‘Class of 96’, para 1.10) to attend more frequently. There will 
obviously be an additional cost associated with this. 
Manufacturer’s Claims 
The investor discussions with the manufacturer Haemonetics in para 1.9 pointed to a 
decrease in usage and hence demand for the OrthoPat post-operative cell salvage 
machine and the associated consumables (disposables). The reference to costs of 
allogeneic blood in the OrthoPat brochure is shown in appendix 1 and can still (5 
April 2018) be viewed on the Haemonetics website.  The brochure still quotes that a 
unit of blood costs “more than $1,400”. The reference is to an article by Dr Aryeh 
Shander (Shander et al (2007)). Dr Shander was one of the authors of the “three-
pillar approach” (para 5.5), that was the foundation for the Patient Blood 
Management (PBM) initiative. The three-pillar approach explicitly recommended 
post-operative cell salvage and this recommendation was echoed in the UK PBM 
guidance issued in June 2014. There would obviously be differences in the exchange 
rate and relative purchasing power differences, but $1,400 would equate to a UK unit 
of allogeneic blood costing over £1,000. This is not realistic. Additionally, in 2009 
UPMC at Pittsburgh were paying c. $300 per unit of allogeneic blood. The 
indications are that the costings supporting the OrthoPat cell salvage machine are 
substantially overstated irrespective of whether these have been derived from a 
financial or economic approach. 
Length of Stay 
The longer LOS in South Manchester is likely to be associated with a number of key 
factors: 
• A higher incidence of pre-operative anaemia; highlighted by the higher 
proportion of patients below the WHO anaemia criteria (para 6.3). 
• The day of the week scheduled for primary total hip replacement surgery with 
recovery coinciding with the level of lower therapy support being available. 
This can prolong the overall recovery time for the patient and therefore 
impact on the time to discharge. 
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• The low number of discharges that actually occur on a weekend. 
The severity of the operation/comorbidities and the patients’ age have not been 
identified as contributors in the statistical analysis as these are not significantly 
different from the other two sites. The impact on the difference in LOS at South 
Manchester was estimated by regression with the R square value of 36.3% (para 6.5). 
This points to additional factors influencing the difference. However, the operating 
day should not be considered in isolation. As highlighted in table 47, operations 
undertaken on a Tuesday/Wednesday imply a correlation with a longer length of stay 
at South Manchester than the other two centres. 
The day of the week of surgery is therefore likely to be significant. 61% of patients at 
South Manchester have their operation on a Wednesday. These patients should be 
commencing their recovery programme with the therapy support commencing by the 
Friday. This is likely to be interrupted with little therapy support available on the 
weekend. 
Munoz et al (2012) highlighted that the line of causation was that if the patient’s Hb 
level was low this would slow the recovery. An allogeneic transfusion would 
therefore be required to increase the Hb level. Munoz et al (2012) noted the LOS for 
patients who had an allogeneic transfusion was a day longer. It was highlighted in the 
literature review that there was a (potentially unintended) view that the absence of an 
allogeneic transfusion was the reason for a lower LOS. The SOC has indicated this is 
not the case since their LOS is similar to the Royal Cornwall Hospitals. The 
allogeneic transfusion is likely to be an indicator that the patient needs further 
support in his/her comparatively slower recovery, not a cause of the increased LOS. 
The indication is therefore that the LOS is, in part, a function of the day of the week 
of the surgery coinciding with the associated availability of therapy support. 
Additionally, the rate of discharge on the weekend is significantly lower at South 
Manchester than the other two sites. This may point to a lower number of staff 
available at the weekend to manage the discharge process. 
There may be capacity (both space and clinical resource) issues in moving the theatre 
lists to another day. It seems, however, that if there was a shift towards the end of the 
week then the patients’ recovery would still be likely to fall foul of the lack of 
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therapy support on the weekend. Moving to a seven-day working week at South 
Manchester would circumvent the ‘weekend effect’ permitting more weekend 
therapy support for patients who had their operations later in the week and allowing 
more weekend discharges. More weekend therapy support is now in place at South 
Manchester and it would be useful to rework the analysis with more recent activity to 
verify this impact is now minimised and LOS has fallen. 
Variation in Severity of Cases and Comorbidities 
Discussions with the SOC staff pointed to their higher transfusion rate relating to 
more operations being undertaken at the higher end of the HB12B range with 
potentially more comorbidities and complications. This is a possible explanation, 
given that the centre deals with more specialist orthopaedic patients but there has 
been a significant time elapsed since the data was extracted all the information has 
been archived. It would take a lot of time and resource to drill down the old data 
beyond HRG level. As noted earlier the HRG analysis is already more detailed than 
any previous study on primary hip replacement surgery. It was also noted that the 
LOS was not significantly different between the Royal Cornwall Hospital and the 
Specialist Orthopaedic Centre where patients did not have an allogeneic transfusion. 
Arguably, the patients may have had similar comorbidities giving a similar LOS or, 
however, the Specialist Orthopaedic Centre patients could have had more 
comorbidities but the potentially more specialist service ensured a relatively quick 
recovery. This issue is highly subjective with no further evidence available to make a 
judgement. 
Table 57 (page 166) compared the least invasive HRG (HB12C) activity in the three 
sites where no allogeneic transfusions or Royal Cornwall Hospitals reinfusions was 
administered. The LOS is still significantly longer at South Manchester. The longer 
LOS cannot therefore be an issue relating to allogeneic transfusions or the utilising 
of cell salvage for these patients. 
The older a patient the generally longer s/he will take to recover from surgery and the 
effects of the anaesthetic. Given both the mean and standard deviation of patients’ 
ages are similar then the patients’ age should not be a distorting factor to LOS in this 
analysis. 
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Overall, adopting an approach to focus on comparative data relating to patients who 
did not have an allogeneic transfusion/reinfusion has established a baseline of patient 
data where it can be said 100% certainty that this data is not affected by cell salvage 
or allogeneic blood transfusions because these transfusions did not occur. The most 
striking aspects are that the LOS remained significantly longer in South Manchester 
and that there is a significantly higher proportion of patients presenting as anaemic. 
These patients are likely to take longer in their recovery and may therefore have an 
impact on lengthening the LOS. 
Allied to the HRG discussion is the view that cell salvage should be more targeted. 
All patients may not need salvaging. It is highly unlikely that a patient 
retrospectively identified as a HB12C HRG will require an allogeneic transfusion 
(table 53 page 161) therefore it would not be cost effective to aim to salvage all 
patients at the Royal Cornwall Hospitals. Likewise, with age and gender (table 34 
page 142), where only one male across the three sites under the age of 65 required an 
allogeneic transfusion. This would be the case from both a financial and an economic 
perspective. Tio et al (2016) point to the need to identify which patients to salvage. 
The challenging aspect is therefore to predict which patients are at a higher risk of 
requiring an allogeneic transfusion. The Royal Cornwall Hospitals are arguably 
salvaging too many patients and the overall costs of operating cell salvage would 
obviously be reduced if cell salvage utilisation was lower. Tio et al (2016) calculate, 
for total knee replacement surgery, post-operative cell salvage would be required in 
seven patients to avoid one allogeneic unit. The cell salvage cost would therefore be 
more than ten times the cost of one allogeneic unit.  
7.5 Limitations 
As noted previously the hospital systems do not have the level of sophistication to 
easily extract information relating to when the patients’ Hb readings were taken and 
when the allogenic donations were administered. As such, the summary information 
is limited to the number of allogeneic donations, if any, per patient and the lowest 
post-operative Hb level taken. It is highly likely that most of the allogeneic units 
were administered post-operatively. There is a level of reassurance that, if there was 
a significant post-operative blood loss, any associated co-morbidity would result in a 
higher resource HRG code being allocated. Similarly, there is a chance that the 
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patient’s post-operative Hb level was even lower than that recorded. If this happened 
it is likely that the patient was recovering more slowly and would have been attended 
to by a clinician. In these cases, an allogeneic blood transfusion may have been 
administered following an additional Hb reading being taken. 
Though the sample sizes were relatively large the HRG analysis needed to be 
grouped in order that non-parametric analysis did not violate the key assumptions on 
numbers of samples. The grouping ‘tight HRG’ was an amalgam of all HRG codes 
not classed as HB12B or HB12C. This accounted for c. 9.6% of the 498 patient 
records. This group included both less and greater ‘CC’ requirements hence the data 
could potentially distort the conclusions. Table 84 breaks down the activity by HRG. 
The Royal Cornwall Hospital has the highest proportion of the HB11 series of major 
HRGs (4.7% against 2.0% at South Manchester and 3.6% at the SOC); thus, there is 
little chance this issue affects any conclusions on the allogeneic transfusion rate. 
Table 84. Breakdown of HRGs by Site and Extraction of Major HRGs (HB11 Series) 
Row Labels Manchester 
Royal 
Cornwall 
Spec Orth 
Centre 
 
Total 
HB11A 1 1  - 2 
HB11B 2 6 4 12 
HB11C  - 3 1 4 
HB12A 8 12 8 28 
HB12B 108 137 95 340 
HB12C 27 54 29 110 
HB13Z 2  -  - 2 
 Total 148 213 137 498 
     
Major HRG 
(HB11s) % 2.0% 4.7% 3.6% 3.6% 
 
The development of tranexamic acid was highlighted in para 1.9. During the period 
when the data for this thesis was collected (2010/2011) tranexamic acid was 
becoming widely used in surgery across the NHS. At the time, most dosages would 
be dispensed orally immediately prior to surgery. The means of application has since 
progressed and both intravenous and a local wound spray application has been 
developed. Confirmation was received from the three sites that tranexamic acid was 
administered to all patients however this was not formally verified in the information 
provided to the researcher. As such there is a risk that some patients may have not 
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actually received a dosage of tranexamic acid, thereby potentially distorting the 
results. 
The socio-economic background of the patients was not considered in the study. 
Generally, the more affluent and higher educated people lead a healthier lifestyle, 
including a healthy diet and exercise. It would therefore be more likely for patients in 
higher socio-economic groups to ensure they listened to the advice in the pre-
operative assessments.  
Quality of surgery could potentially be a factor in influencing the requirement for an 
allogeneic blood transfusion leaving the researcher’s assertions open to criticism. 
Generally, one would expect the quality of surgery to be of a high standard. Primary 
total hip replacement surgery is a routine procedure and hospital quality control 
procedures would indicate deviations from the expected outcome. The researcher 
discussed this with the three sites and had not been made aware of any issues in 
quality. 
Similarly, the quality and level of post–operative therapy support may vary across 
sites. This has not been measured or clarified and therefore could impact on the 
patient’s recovery. Given the relevant institute professional standards for 
physiotherapists and occupational therapists, the overall impact of any variation is 
unlikely. What may be more likely in international comparisons are that the amount, 
day and timing of therapy support (Husted et al (2008)) may cause variations. 
The length of stay issues should not be taken in isolation for primary total hip 
replacement surgery. It may also be that other procedures exhibit a significantly 
shorter LOS at South Manchester than the Royal Cornwall Hospital because their 
recovery does not straddle a weekend. The indication in the statistics is that the LOS 
is likely to be a function of the day of the week of surgery for primary total hip 
replacement surgery only and not as a view of all specialties across the sites. 
The analysis also does not consider readmissions due to the operation not being 
successful. The National Joint Registry 10th Annual Report (2013) estimated a 
national readmission rate of 7.6% for primary total hip replacement operations using 
PROMS (Patient Reported Outcome Measures) data. The significant areas of post-
operative problems/complications highlighted in the report relate to wound problems 
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including bleeding, urinary problems and allergic reactions to drugs. It is reasonable 
to therefore assume that allogeneic blood/cell salvage has not had any significant 
adverse impact on the surgery thereby necessitating a readmission. 
Capital costs of cell salvage machines are estimated in the calculations. The 
acquisition cost of the capital items is ‘sunk’ and Horngren (1997) defines these as 
“Past costs that are unavoidable because they cannot be changed no matter what 
action is taken”. From an economic perspective Nechyba (2011) defines a sunk cost 
as “an expense that is unaffected by the economic choice at hand”. The choice to 
salvage is therefore not based on the capital cost of the acquired equipment. 
Depreciation and the opportunity cost relating to the cell salvage equipment was 
calculated in para 6.10. From both a financial and an economic perspective the 
amounts were immaterial, given the long forecast life of the equipment. These 
calculated costs were also notional given the equipment had been acquired and 
replaced on a piecemeal basis over the years. They may be more relevant if a 
decision was taken to buy a new machine; in which case the calculations could be 
used to support a ‘make v buy’ decision. This approach is also consistent with 
Horngren’s ‘concept of relevance’ where managers focus on future expected results 
(para 2.2). 
The transfer prices adjustment for the cost of an allogeneic blood unit was based on 
the annual published accounts for 2010/11 and was obviously an estimate. A more 
accurate calculation could have been derived using the NHSBT capital asset 
management system however this information was not available to the researcher. A 
crude estimate of the unit capital cost within the £122 price of an allogeneic unit 
would be to take 73.7% of the depreciation element of £13,892k (table 85 below) and 
divide by the 1,838k units of blood issued. The resultant estimate is therefore c. 
£5.57 per allogeneic unit. 
The associated maintenance and depreciation costs of the cell salvage machines were 
based on a mix of national and local activity. The machines were classed as a 
‘grouped asset’ and, at the time, the depreciation costs were not charged out to the 
relevant cost centres in the Royal Cornwall Hospitals. The machines were acquired 
over different dates and an acquisition cost of £15,000 (including VAT) was assumed, 
based on the approximate list prices at the time. It is likely that these costs were 
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over-estimated however they were not deemed to have skewed the overall cost 
comparison. The total amount of costs involved were not material (figure 26). 
The depreciation and the transfer price for a unit of allogeneic blood were extracted 
from the summary of the 2010/11 audited accounts from NHS Blood and Transplant 
(para 6.14). The various taxation elements extracted were based on apportionments 
along with an overall apportionment of the NHSBT ‘Group Costs’; these are 
primarily overhead costs. Complex areas such as NHS VAT accounting for 
contracted out services were estimated on the balances in the reported categories in 
the accounts. An actual assessment based on the detailed analysis of VAT returns was 
unavailable. In order to check the overall reasonableness of the derivation of the 
economic cost of an allogeneic unit of blood (table 76) the NHSBT depreciation 
element (reported as “capital charges” in the accounts) was added back into the 
calculations and apportioned on the basis of expenditure over the three management 
units. The elements of the transfer payments were also added back. Table 85 below 
estimates a total cost of £130 per unit. This is close to the £122 actual charge 
provided independently by the NHSBT Finance Department implying a level of 
accuracy of the methodology to derive the economic cost of an allogeneic unit from 
the limited published information available. A much more accurate calculation could 
be derived from having full access to NHSBT’s reporting systems however this 
access was not available. 
Table 85. Reworked NHSBT 2010/11 Annual Accounts Totals to Verify Internal Market Price of An 
Allogeneic Unit 
 
The overhead apportionment methodology was very basic in the extraction of an 
estimate of the economic costs from the published accounts. Additionally, there was 
a reluctance to share the information by former colleagues at NHSBT on the detail 
behind the breakdown of the £122 into the related activities. The implication is, 
Total
Blood 
Compone
nts
Spec 
Servs ODT
£'000 £'000 £'000 £'000
Overall Expenditure less Capital Charges 372,821 276,002 52,478 44,341
Apportion depreciation 18,765 13,892 2,641 2,232
Add back transfer payments 45,786 33,896 6,445 5,446
Sub total 437,372 323,789 61,565 52,018
At 73.7% to reflect red cell element 238,633
Divide by 1,838,000 units issued £130
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however, that the derived figures are reasonably verifiable against the published 
accounts totals. These are audited and therefore give an additional level of 
reassurance of independent verification. 
Further apportionments were required to estimate the maintenance costs and 
depreciation for the cell salvage machines. These were based on an overall split of 
the orthopaedic HRGs. 
A further limitation in this analysis is the calculations to derive the costs associated 
with the allogeneic blood donor. As highlighted in the literature review these costs 
are generally ignored. The donor survey indicated lost production time to donate was 
significant primarily because the majority of employers did not deduct pay for 
donors who donated in work time nor did they insist on the donors making up the 
lost time. The calculation is relatively subjective, based on Office for National 
Statistics median earnings 2011 final results, and this area would therefore benefit 
from an updated study. In hindsight one of the survey questions (Q 11) could have 
been made clearer but the overall estimate enabled a new complexion to be added 
into the discussion and allowed an overall cost of blood usage in operations to be 
calculated. 
The comparative prices of units of red cells, charged by NHSBT, are effectively 
averages. It was noted in para 6.12 that Horngren et al (2015) advises these average 
costs are treated “cautiously”. Given, however, that NHSBT is effectively reactive to 
activity decreases and needs to maintain a presence across England to supply 
hospitals the average costs are therefore useful as an indicative tool. Other forms of 
costing from a financial perspective may not be appropriate given the price of an 
allogeneic unit of blood is fixed over a time period and most consumables’ costs are 
also at negotiated fixed rates over a particular activity range. 
Most costs associated with cell salvage will therefore be similar between hospital 
trusts. There may be some variation in the local agreements struck with suppliers. 
These were viewed as more competitive than the NHS national framework prices. A 
comparison of costs between hospitals utilising cell salvage would be possible 
subject to any confidentiality clauses on prices imposed by the manufacturers. 
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Arguably the most significant limitation of this study is that since there is no 
significant difference between those patients salvaged and not salvaged (para 6.6 
page 160) at the Royal Cornwall Hospitals the researcher cannot be certain that 
reinfusing has avoided an allogeneic transfusion. The numbers of patients receiving 
an allogeneic transfusion was too low to undertake a statistical comparison. The 
potential allegations of bias would arise if patients were pre-selected to undergo or 
not have, cell salvage. The more restrictive blood management techniques (para 6.7 
page 163) adopted by the Royal Cornwall Hospitals imply a lower likelihood of a 
patient receiving an allogeneic transfusion. The implication is therefore that 
allogeneic transfusion rate differences between the sites are influenced by various 
factors and cannot be fully explained by using, or not using, cell salvage. 
7.6 Reflection and Assessment of Position at June 2018 
Allogeneic blood usage has continued to fall year on year. It is highly likely that the 
fall is due to less allogeneic blood being required in the surgical environment. The 
impact of the three Better Blood Transfusion initiatives (para 1.11 page 18) has 
prompted a reassessment of allogeneic blood requirements. This laid the foundation 
to the international Patient Blood Management (PBM) approach from 2014. Cell 
salvage was promoted as a means of supporting the avoidance of an allogeneic blood 
transfusion but its costs, both from a financial and economic viewpoint (para 6.15) 
seem prohibitive compared to a course of iron tablets (less than £1) or a dose of 
tranexamic acid (c £1-£2 per ampoule) prior to surgery. These options can 
significantly reduce the allogeneic transfusion rate. 
The researcher found universal acceptance that a lower allogeneic transfusion rate 
was more favourable for the patient. He would have liked to pursue the difference in 
viewpoint with the Bavarian/German Blood Service (para 1.15 page 26) however this 
was beyond the scope of the thesis and may be revisited in the future in the event of 
any collaborative work arising with NHSBT. 
Similarly, seeking explanations for the differing length of stay in response to various 
articles in the literature review was challenging. Previous studies did not undertake 
detailed work on developing a ‘background count’ where information on non-
transfused patients was compared. The researcher was pleased that he had devoted a 
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lot of time to this area. Given the length of stay was significantly longer at South 
Manchester for patients who did not have an allogeneic transfusion the researcher 
could say with confidence that the longer average length of stay was not a factor of 
allogeneic transfusions but of other issues such as the availability of staff on a 
weekend to provide therapy support and patient discharge procedures. Noting that 
the majority of total hip replacement patients have their operation at South 
Manchester on a Wednesday exacerbates the issue as patients should have been on 
their way to recovery by the weekend however the staff availability was a limiting 
factor. The researcher was satisfied that he was able to independently highlight this 
issue allowing South Manchester to go some way to addressing this challenge. 
The focus of the economic appraisal was finalised as a cost minimisation analysis. 
Cost benefit analysis was considered but was excluded (point 6, table 79, page 188) 
as the length of stay was not deemed to be a factor of having an allogeneic blood 
transfusion. As noted in para 2.4 the ‘output’ of the study is a successful primary total 
hip replacement operation and the focus is therefore on the ‘input’ of the 
management of blood (either allogeneic, salvaged or avoided totally). 
The researcher has had follow up discussions with the Royal Cornwall Hospitals and 
has shared his activity information with the cell salvage lead. As at April 2018 the 
Royal Cornwall Hospitals do not now use post-operative cell salvage (the OrthoPat 
machine) on the grounds of the cost of consumables and inflexibility since there is no 
‘collect first’ option. The researcher’s average cost comparison (para 6.8 page 172) 
supported the Royal Cornwall Hospitals in reaching this decision. 
The OrthoPat Advance (para 1.9, page 13) has still not come on the market and, in 
2017, the US manufacturers, Haemonetics, closed down their manufacturing and 
distribution plant near Glasgow. 270 jobs were shed, and the work was transferred to 
Malaysia. An additional plant was also closed in Italy. These closures are consistent 
with the lower demand for both blood donation and cell salvage equipment across 
Europe.  
The Royal Cornwall Hospitals are also now more selective on the patients they 
salvage. This decision was again based, in part, on the researcher’s findings. The cell 
salvage lead has also expanded his role to lead the Trust’s anaemia service, 
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acknowledging the significant interrelationships between the two elements of blood 
management. 
The Association of Anaesthetists of Great Britain and Ireland (AAGBI) guidelines 
still recommend intraoperative and post-operative cell salvage be “considered”, prior 
to orthopaedic surgery. In reality, it would be difficult for the AAGBI to specifically 
recommend adoption or non-adoption of cell salvage in specific applications e.g. 
primary total hip replacement surgery, given each patient will have different 
characteristics. The Royal Cornwall Hospitals approach therefore remains consistent 
with the guideline. 
Technology is also developing in areas such as wound closure technology with 
products being utilised to stem bleeding more quickly and hence reduce blood loss. 
Widespread use would be likely to decrease the demand for allogeneic blood. These 
technologies are currently still being developed but will be likely to add to the debate 
on potentially reducing the impact of cell salvage. 
In April 2018 the researcher had a discussion with the Chief Nurse at NHSBT. She 
highlighted that allogeneic transfusion rates are continuing to fall and are likely to 
have been a combination of all the blood avoidance methods in PBM. She confirmed 
that cell salvage is still promoted by the UK Cell Salvage Action Group (para 1.15 
page 25), but their utilisation studies and anecdotal evidence indicate activity is still 
at approximately the same rate across the UK as 2011. 
The National Comparative Audit of Blood Transfusion 2016 Repeat Audit was 
developed by NHSBT in conjunction with the Royal College of Surgeons and the 
Faculty of Intensive Care Medicine. It gathered information on the impact of Patient 
Blood Management on transfusion rates across 156 hospital sites in the UK and 
Ireland. The data is still being analysed as part of a wider study, reporting in 2019 
(the “AFFINITIE” Programme), however the interim conclusions to the report 
highlight that: 
• Hospital Transfusion Committees (HTCs) should ensure the use of 
tranexamic acid is the “standard of care for surgical patients expected to have 
moderate or more significant blood loss”. 
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• “The HTC should identify the need for intra-operative cell salvage and 
resource appropriately; this would normally be used in relevant high blood 
loss procedures”. 
These conclusions support the researcher’s view that the impact of tranexamic acid is 
a crucial part of the portfolio of blood avoidance techniques. The report is not as 
enthusiastic on cell salvage and leaves the door open for local interpretation on the 
need for cell salvage; being consistent with the AAGBI recommendations above. 
In terms of costs, cell salvage is at the highest end of the cost spectrum of allogeneic 
blood avoidance methods and, as noted above, iron tablets and tranexamic acid are 
much cheaper methods of avoiding an allogeneic transfusion. The future requirement 
for cell salvage in surgery is therefore likely to be in the more complex cases that 
involve a higher blood loss and associated steeper fall in Hb levels. These cases are 
more likely to be within Cardiac surgery. These cases may, in turn, be more likely to 
be in an emergency setting where obviously the pre-operative Hb levels have not 
been managed and the programme of preparatory iron tablets cannot be introduced 
prior to surgery. 
The utilisation of the HRG coding added a new dimension to the comparison and 
gave additional reassurance that the patients conditions were similar across the three 
sites. What was surprising was that this comparative analysis had not been 
undertaken previously. In part, it seems to be due to lack of knowledge by clinicians 
over the HRG process. Most of the studies in cell salvage are written by clinicians. 
Their ‘currency’ is the operation and view a total hip replacement operation as being 
the unit of measurement. In discussions most clinicians had not heard of the term 
‘HRG’. It is reassuring to see that the Royal Cornwall Hospitals systems can now 
generate monthly reports that analyse blood transfusions by HRG. Arguably the 
researcher could assert that this thesis adds an element of doubt to previous 
published studies that do not have this additional homogeneity check. It is refreshing 
that US studies have commenced work in this area (Frank et al (2014)). 
On reflection, the researcher made significant headway in reaching a baseline; 
allowing a ‘background count’ across the three sites to isolate any anomalies. It is 
likely that the gap between the transfusion rates at South Manchester and the Royal 
Cornwall Hospitals would be narrower if the pre-operative Hb levels at South 
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Manchester were addressed. All other things being equal; the narrower the apparent 
gap in allogeneic transfusion rates the weaker the assertion that cell salvage is 
delivering benefits. It is, frustratingly, this gap in allogeneic transfusion rates that the 
researcher cannot fully explain. A repeat study focusing on patients solely within the 
WHO Hb levels may eliminate the impact of pre-operative Hb disparities but leave 
the study open to allegations of bias in the cohort for selection. 
7.7 Summary of Chapter 7 
This thesis has segregated the activity into a number of distinct clusters (e.g. HRG, 
patients with/without cell salvage and reinfusions with/without transfusions etc) in 
order to achieve a baseline comparison of patients within three sites who did not 
have an allogeneic blood transfusion or utilise reinfused blood. The strong 
indications are that the Royal Cornwall Hospitals can manage to maintain a lower 
allogeneic transfusion rate without the requirement to salvage primary total hip 
replacement patients. 
The study has ensured the relevant costs are identifiable and quantifiable from both a 
financial and economic approach. These costs vary significantly but both sets are 
consistent with the view that cell salvage in primary total hip replacement surgery 
will not support a reduction in overall blood costs (allogeneic or salvaged). 
Given the relatively long duration to complete this study the recent discussions with 
the Royal Cornwall Hospitals and NHSBT bear out the researcher’s thoughts that 
cell salvage cannot be utilised in isolation. The continuing fall in the overall 
allogeneic blood usage is unlikely to be a product of cell salvage given national cell 
salvage activity has been relatively unchanged since 2011. It is therefore much more 
likely that the low cost and high impact recommendations from the 2014 Patient 
Blood Management guidance are having this effect. These include pre-operative Hb 
management, tranexamic acid and changes in administration of allogeneic blood to 
avoid administrating two allogeneic units at the same time. 
The researcher approached the study from a different angle than most other studies; 
using HRG coding and, initially, comparing data from patients who did not have an 
allogeneic transfusion or had salvaged blood reinfused. This approach gives more 
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confidence that the costs can be readily compared from both a financial and 
economic viewpoint. 
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Chapter 8. Conclusions 
8.1 Introduction 
This chapter summarises the research work and confirms whether, in the researcher’s 
view, the research question has been answered. 
Is cell salvage an appropriate method of blood conservation to support the reduction 
in costs associated with the collection and utilisation of allogeneic blood? 
8.2 Response to the Research Question 
A short answer to the research question would be that cell salvage is currently not an 
appropriate method to support the reduction in costs associated with the collection 
and utilisation of allogeneic blood in primary total hip replacement surgery. This 
conclusion is the same from both a financial and an economic approach. 
The main reason for coming to this conclusion is that only a small percentage of 
successful primary total hip replacement operations now require an allogeneic blood 
transfusion. This is due a combination of factors associated with the development of 
best practice in managing the use and application of allogeneic blood along with less 
invasive surgery causing lower blood loss. Cell salvage is one of an array of 
allogeneic blood avoidance techniques but is much more expensive than ensuring a 
patient is adequately prepared for surgery; this can be as simple as prescribing a 
course of iron tablets for the patient to take after the pre-operative assessment and 
prior to surgery. Additionally, clinicians now widely use antifibrinolytic drugs such 
as tranexamic acid that prevent blood clots breaking down and hence slow down 
blood loss. If these procedures are adopted the impact of cell salvage in primary total 
hip replacement surgery is marginal and the cell salvage costs compared to the costs 
of allogeneic blood avoided are prohibitive. This conclusion has been reached by 
initially comparing the costs associated with the NHS internal market for blood with 
cell salvage costs from both a financial and economic analysis. In both comparisons 
cell salvage was deemed more expensive and hence not cost effective. 
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The internal market for allogeneic blood and the associated high price is likely to 
have stimulated interest in alternatives to allogeneic blood such as cell salvage. The 
relative price of allogeneic blood is continuing to falling in real terms due to the 
continual fall in the demand for the product. This fall in demand has continued from 
2000 to the present. As the real term cost of utilizing allogeneic blood is falling (para 
1.23) the perceived ‘savings’ at hospital level by using cell salvage to avoid an 
allogeneic transfusion will also fall. 
The approach to the study was significantly different to traditional studies reviewed 
in chapter four, in that the study was able to secure a baseline position to compare 
sites by initially excluding data from patients who received allogeneic blood 
transfusions or had their own blood recycled. This, along with using HRG data, 
allowed any differences in patient profile and preparation to be tested. These 
differences were therefore isolated before the comparison extended to allogeneic 
transfusions and reinfusions of salvaged blood. The key differences identified were 
pre-operative Hb levels and the length of stay. 
The use of allogeneic blood was concluded not to have any significant impact on 
length of stay. Other factors such as availability of weekend therapy staff to support 
the recovery programme and staff available on the weekend to discharge the patients 
were considered more influential. It must be stressed that this analysis is not a 
criticism of South Manchester’s scheduling of most orthopaedic surgery on a 
Wednesday. The other two sites may have corresponding challenges with other 
specialties. Examining this issue in isolation is therefore unlikely to lead to any 
significant conclusions. It does, however, point to length of stay being an 
unnecessary distraction in the discussion on allogeneic blood and cell salvage. 
The US term ‘transfusion trigger’ was still apparent in the data with the Royal 
Cornwall Hospitals’ restrictive transfusion policy contributing towards the lower 
allogeneic transfusion rate. This, again, is another blood conservation measure 
working in tandem with cell salvage. The evidence points to these measures running 
concurrently at the Royal Cornwall Hospitals and their joint impact leads to a lower 
allogeneic transfusion rate. The difference, however, between the costs of the 
different measures is significant ranging from around £1 for a packet of iron tablets 
to over £200 (from a financial perspective) for post-operative cell salvage. 
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Further studies are therefore recommended to investigate the costs associated with 
cell salvage in operations with a higher predicted blood loss e.g. in various Cardiac 
procedures or more specialist elective surgery. 
8.3  Overall Conclusion 
In primary total hip replacement surgery, cell salvage has been found not to be 
effective in supporting the Patient Blood Management process and reducing costs 
associated with the collection and utilisation of allogeneic blood. Cheaper and easier 
to implement methods exist to minimise the potential requirements for an allogeneic 
blood transfusion and it is recommended that hospitals focus on these methods to 
minimise their allogeneic blood requirements for this branch of orthopaedic surgery. 
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Glossary 
Term Definition 
Alloimmunization An immune response to foreign bodies in 
allogeneic blood. 
Autologous 
Transfusion 
A transfusion involving the patient’s own 
blood. This includes cell salvage as  well as 
forms of pre-deposit blood 
Anticoagulant A substance that helps prevent blood clotting. 
This will be mixed in with the shed blood 
during the recycling process (see figure 6).  
Antifibrinolytic Drugs that prevent blood clots breaking down 
and hence slowing down blood loss. 
Arthroplasty Replacing or reconstructing a joint in the body. 
Cross Matching A check undertaken on a sample of the 
patient's blood to ensure the best match with 
allogeneic blood by minimising the level of 
antibodies. This is focused on the red cells in 
the blood. 
Group and Screen A wider cluster of tests than cross matching to 
determine the patient's blood group and 
antibodies. 
Haematocrit The volume of red cells in the blood expressed 
as a percentage of blood volume. 
Haemoglobin (Hb) The protein molecule in blood that carries 
oxygen around the body. This is measured in 
grams per litre (grams per decilitre is still a 
common measurement in the US). Generally, 
the higher the better as this implies oxygen will 
travel faster around the body and assist 
recovery. 
Haemopoiesis Where the body generates the production of its 
own blood and blood components. 
Haemostasis The situation where the body is losing blood. 
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Heteroscedasticity Where the size of the errors differs across the 
values of an independent variable. Taking the 
logarithm lowers the relative difference to a 
more manageable comparison. 
SAGM A preservative added to allogeneic blood. 
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Appendix 2 
Pricing of Allogeneic Unit of Blood 2017/18 Notification 
'''':;;1 
Blood and Transplant 
NHSBT Board 
September 2016 
NHSBT Pricing Proposals for 2017-18 
1. Status - Public 
2. Executive Summary 
This paper provides a summary of the pricing proposals for NHSBT's blood 
components and specialist services for 2017-18. Following approval by the 
Board, these will be discussed with the National Commissioning Group in 
November 2016 with a view to implementation in 2017-18. Hospitals and the 
National Blood Transfusion Committee were consulted on these proposals in 
mid-2016. In overall terms the cost of providing blood to the NHS will decrease 
by -1.7% in 2017/18. Taking Specialist Services into account (and associated 
demand increases) the total change in cost to the NHS will be -0.4%. 
3. Action Requested 
The Board is asked to approve the pricing proposals prior to the NCG meeting. 
4. Purpose 
4.1 Background: red blood cell and platelet demand 
Demand for red cells has declined steadily over the last 5 years, driven by a 
combination of medical advances such as laparoscopic surgery, 
pharmacological developments and educational initiatives such as NHSBT's 
"patient blood management" programme which encourages the safe and 
appropriate use of blood. Publications in medical journals have also 
demonstrated that patients can have a better outcome when less blood is 
used. Despite an increase in the population over 60 years old (Le. the age 
group which uses most blood), blood usage continues to decline. 
Since the end of 2011/12, NHSBT has seen a 17% reduction in the demand for 
blood (vs forecast demand for 2016/17). In the same period, the NHS's 
expenditure on blood (and hence NHSBT's income) has reduced from £300m 
in 2011/12 to a forecasted £261m in 2016/17, while the unit price of red cells 
has reduced from £125 to £120 despite increasing levels of safety and 
availability. 
Demand for red cells continues to be volatile and is proving challenging to 
predict, with for example the recent NHS "reset" being seen as a contributory 
factor to this ongoing uncertainty. The latest figures are suggesting a demand 
forecast for 2017/18 of 1.461m units. This is 4.3% lower than the plan agreed 
for this year with the NCG (1.527m units) and lower than the forecast of 
1.517m units for 2016/17. Demand for platelets is now also declining, for the 
first time, driven by factors such as the use platelet-sparing drugs in oncology. 
The platelet demand forecast for 2017/18 is 0.256m units compared with a 
plan of 0.275m agreed with the NCG for the current year. 
NHSBT has implemented substantial cost reduction programmes 
(approximately £80m since 2011/12) and has an ongoing cost improvement 
plan of c£16m in 2016/17. The cost reductions have included the 
rationalisation of manufacturing and testing facilities and a reduction in blood 
collection capacity leading to substantial decreases in headcount. However, 
NHSBT currently has a need for significant investment to replace an ageing IT 
infrastructure and to replace the critical operational application underpinning 
the blood supply chain. The ongoing provision of critical products and services 
is highly dependent on its successful replacement. The overall cost of this 
change will be substantial and is estimated to be in the range of £30m-£40m 
over 5 years. 
The plan for 2017/18 has generated a cost improvement target of c£15m, 
which combines cost pressures (those costs over which NHSBT has no 
control, e.g. staff grade increment increases; apprenticeship levy; capital 
charge adjustments etc.), inflation (prospective pay award 1 % and Treasury 
GDP Deflator 1.8%) and also the lost contribution to our costs from the 
demand reductions described above (£10.0m). Prices for 2017/18 have been 
set on the basis of planned cost improvements which will address c£g.8m of 
the overall target with the balance being made up from a price increase for red 
cells to NHS and private hospitals (£3.6m) and platelets (£1.6m). 
The cost improvement plan will be derived from the following: 
- Demand reduction and productivity improvements of £3.5m 
- Operational and support function efficiencies of £4.7m 
- Estate Management and Optimisation £1.2m 
- Procurement £O.4m. 
Category Blood (£m's) SpS (£m's) Total (£m's) 
Openmg position (closmg NCG position 2016/17) 265.3 56.2 321.5 
2017/18 Product and Service Demand Impact -0.1 1.8 1.7 
2017/18 Cost Reduction Programme -9.8 -0.2 -10.0 
2017/18 Cost Pressures and Developments 1.9 0.4 2.3 
2017/18 Inflation funding increase (Pay 1 %; Non-pay 
1.8% 3.5 1.1 4.6 
Total Impact -4.5 3.1 -1.4 
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4.2 Pricing: Red Cells 
The proposed cost improvement plan for 2017/18 (c£9.8m) has been 
extensively reviewed by the Executive Team and represents a balanced 
approach in the context of the significant organisational challenges facing 
NHSBT next year, in particular the ongoing level of resource and investment 
which is currently being focused on core systems. It is in this context that the 
most realistic approach would be to recommend an increase in the price of 
blood for 2017/18. It should be noted that a further increase to our prices in 
2018/19 can not be ruled out at this stage and would be largely dependent on 
the level of demand seen. 
It is therefore recommended that the price of red blood cells for 2017/18 should 
increase by 2% / £2.35 per unit, i.e. an increase from £120 to £122.35 per unit. 
NHSBT is mindful of the difficult financial status of many NHS hospitals, and it 
should be noted that despite this increase, NHS expenditure on blood will 
nevertheless reduce by around 1.7% next year. 
4.3 Provision of Hepatitis E virus (HEV) negative components 
In 2015, SaBTO recommended that HEV negative blood components should 
be provided for organ and stem cell transplant recipients. NHSBT implemented 
the change in early 2016. For blood components that were HEV negative as 
part oftheir standard manufacture (i.e. neonatal and paediatric packs), the 
costs were included in the price of red cells. For those units which ordered as 
HEV negative for adult solid organ or stem cell transplant recipients, an added 
value charge of £17.18 per unit was made. 
Demand for HEV-negative components is now stabilising. This allows a more 
accurate picture of the cost of testing, and the added-value charge will be 
reduced from £17.18 to £9.37 for 2017-18. In due course, should SaBTO 
recommend the universal screening of blood components, NHSBT would need 
to amend the price to cover the cost of the additional testing. . 
4.4 Platelets collected by apheresis 
There are a number of hospitals which only order platelets collected by 
apheresis. Clinical guidance indicates that apheresis and pooled platelets are 
functionally equivalent and should be used interchangeably, with the caveat 
that those recipients born on or after 1 st January 1996 should, when available, 
receive apheresis platelets. We will therefore introduce individual prices for 
platelets produced by apheresis and for platelets produced by pooling in 
2017/18 to reflect the differential cost of manufacture. It is proposed that the 
price of apheresis-derived platelets will increase be set at £219.30 compared 
with £ 178.19 for a pooled unit. 
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4.5 Diagnostic and Therapeutic Services Pricing 
Prices will be held flat for all specialist business units in 2017/18, with the 
exception being Red Cell Reference services, which will increase by £1 m (9%) 
next year. The additional income will be recovered through an increase to the 
fixed cost recharge element (a charge made to each hospital to secure the 
ongoing provision of a national reference service). This service is currently in 
deficit and will move the service to a balanced income and expenditure position 
next year. However, the charge per reference referral from hospitals will 
remain flat. 
In line with our strategic aim of continuous growth, DTS will see an increase of 
£2.2m in additional sales activity during 2017/18 of which Tissue and Eye 
Services will contribute £1.2m. In overall terms DTS income will rise by £3.1m 
(5.5%) and generate an improved contribution of £1.9m in 2017/18. 
4.6 Changes to NHSBT Transport Arrangements 
Hospitals are requesting that NHSBT develops its logistics services to reflect 
changing working patterns, e.g. weekend working. However, the increasing 
trend for the self-collection of blood by hospitals is significantly impacting our 
ability to manage the supply chain in an efficient manner and has markedly 
reduced NHSBT's income from ad hoc delivery charges, which since 2011/12 
has now resulted in a reduction to service income of c£0.8m per annum. 
NHSBT is therefore recommending a revision to its existing logistics model in 
2017/18 which will result in a fixed charge of £11 per order for the self- 
collection of blood by hospitals from NHSBT blood centres. This charge 
reflects the costs of preparing the order for collection and it is estimated that 
this will generate additional income of c£0.7m, depending on hospitals' future 
ordering behaviour. 
Ad-hoc and blue-light/emergency deliveries are currently charged at £52.15 
per order, regardless of distance from the supplying blood centre and will 
remain unchanged for 2017-18. The future provision and pricing of this service 
remains under review and we aim to submit further proposals for the 
commissioning round in 2018/19. 
4.7 Impact on hospitals and customer feedback 
In mid-2016 NHSBT undertook an extensive consultation exercise with 
hospitals to assess the impact of a range of potential pricing changes. These 
included the differential pricing of apheresis platelets, differential pricing of rare 
groups such as O negative red cells and A negative platelets, and changes in 
transport arrangements. A substantial response was received to the online 
survey from haematology, finance and operational staff in 116 Trusts. 
Feedback from the survey was supplemented by face-to-face meetings. 
In general, hospitals were not supportive of differential pricing of blood 
components or in the alternative prices for transport arrangements. One 
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particular area of concern was the differential pricing of O negative blood, 
where the concept of a 50% increase in price was tested in an attempt to 
reduce the demand for this rare blood group, which represents 13% of demand 
but only 8% of the donor base. NHS hospitals were particularly vocal in their 
opposition to the latter proposal (despite a compensatory reduction in the price 
of other blood groups) and this is not being recommended for 2017/18. 
That said, an increase in the price of O negative blood to £180 per unit for 
private hospitals will be implemented in late 2016/17, focusing on those which 
order predominantly O negative blood, do not have a transfusion laboratory 
partnership with a local NHS hospital, and often consequently have high 
wastage levels. Significant Patient Blood Management activity will continue in 
an attempt to reduce the demand for O negative blood, and a price rise to NHS 
hospitals cannot be ruled out in the future if usage patterns do not change. 
NHSBT estimates that the impact of the proposed pricing changes on NHS 
hospitals for 2017/18 is as follows: 
4.8 Summary 
Currently, NHSBT faces a difficult financial situation, with declining demand, 
substantial cost reduction programmes and a parallel need for investment in 
core systems. For this reason, an increase in the price of red cells is being 
recommended although the overall cost of blood to the NHS will continue to 
decline. NHSBT is also recommending the introduction of separate prices for 
pooled and apheresis platelets (reflecting the different cost of production) and 
the introduction of a "self-collect" charge. An increase in the price of O negative 
red cells and A negative platelets is currently not being recommended (despite 
rapidly increasing demand in the case of A negative platelets) but may need to 
be considered again in 2018/19. 
Authors 
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Appendix 1 - National Prices 
For the Financial Year 2017/18 
Blood Components 
Red Cell Components 
Standard Red Cells Other Groups 
Standard Red Ceil O Rh D neqative (Private Hospitals onlv) 
Neonatal Red Cells 
Frozen Red Cells, Thawed & Washed 
Red Cells for Exchanqe Transfusion 
Larae Volume Neonates & Infants 
Red Cells for Intra-Uterine Transfusion 
Red Cell Added Value Services 
Premium for CMV -ve Red Cells 
Premium for Irradiated Red Cells 
Premium for Cell Washing 
Premium HLA selected red cells 
Platelet Components 
Platelets (1.0 ATDI Pooled 
Platelets (1 . O A TD) CD 
Platelets (1.0 ATD\ Rh A neg Pooled 
Platelets (1.0 ATD) Rh A neg CD 
Neonatal Platelets 
Platelets for Intra-Uterine Transfusion 
Platelet Added Value Services 
Premium for CMV -ve Platelets 
Premium for Irradiated Platelets 
Premium for Cell Washing 
Premium for HLA Selected Platelets 
Premium for HPA Selected Platelets 
Plasma Components 
Clinical FFP (UK sourced) 
Paediatric MBFFP (non-UK Sourced) 
Neonatal MBFFP (non-UK Sourced) 
Crvoprecioitate 
Cryoprecipitate (UK Sourced) 
Pooled crvoorecioitate (UK Sourced) 
MB Cryoprecipitate-Neonatal (non-UK Sourced) 
MB Crvoorecioitate-Pooled (non-UK Sourced) 
Other Comnonents and Services 
Optimised Pooled Granulocyte 
Buffv Coats 
Premium for HEV neg 
Total (£m's) [price x volume issued] 
120.00 
120.00 
51.68 
792.53 
199.00 
158.80 
182.26 
8.80 
8.78 
121.75 
126.98 
193.15 
193.15 
193.15 
193.15 
90.16 
317.93 
8.80 
8.78 
33.37 
239.90 
239.90 
28.46 
178.03 
50.02 
31.63 
177.57 
187.50 
1080.48 
1104.65 
82.05 
17.18 
122.35 
180.00 
52.33 
806.49 
200.64 
159.60 
183.56 
8.98 
8.96 
124.28 
129.61 
178.19 
219.30 
178.19 
219.30 
91.04 
320.52 
8.98 
8.96 
34.06 
244.88 
244.88 
28.46 
183.53 
51.40 
31.63 
177.55 
192.99 
1113.45 
1127.58 
83.75 
9.37 
2.35 
60.00 
0.65 
13.96 
1.64 
0.80 
1.30 
0.18 
0.18 
2.53 
2.63 
-14.96 
26.15 
-14.96 
26.15 
0.88 
2.59 
0.18 
0.18 
0.69 
4.98 
4.98 
0.00 
5.50 
1.38 
0.00 
-0.02 
5.49 
32.97 
22.93 
1.70 
-7.81 
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NBS England Patient Blood Management Notification 
Letter Header 
National Blood Transfusion Committee 
Patient Blood Management 
An evidence-based approach to patient care 
Fore ward 
On behalf of NHS England, I am delighted to support the National Blood Transfusion Committee's 
Patient Blood Management recommendations. 
Blood components are used to save and improve thousands of lives each year. Red blood cell 
usage in England has decreased by over 20% in the last 14 years, but national and large regional 
audits consistently show that 15-20% of red blood cell transfusion is not compliant with national 
guidelines. Recent meta-analyses show that restrictive red blood cell transfusion reduces 
mortality and morbidity. Everyone involved in blood transfusion needs to take responsibility for 
ensuring that blood transfusion is used appropriately. 
Patient Blood Management is an evidence-based, multidisciplinary approach to optimising the 
care of patients who might need transfusion. It encompasses measures to avoid transfusion such 
as anaemia management without transfusion, cell salvage and the use of anti-fibrinolytic drugs to 
reduce bleeding as well as restrictive transfusion. It ensures that patients receive the optimal 
treatment, and that avoidable, inappropriate use of blood and blood components is reduced. 
Patient Blood Management needs leadership and support at every level, from trust management, 
health professionals in hospitals, NHS Blood & Transplant and the National and Regional Blood 
Transfusion Committees. I commend these guidelines to all, and offer our thanks to the many 
professionals involved in their development. 
Ja Martin 
Professar JE Martin MA MB BS PhD FRCPath 
National Clinical Director of Pathology, NHS England 
Date: Thursday, 26 June 2014 
Copies of this document are available on: 
http://www.transfusionguidelines. arg. ukluk-transfusion-committeeslnational-blood-transfusion-committee/patient-blood-management 
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Patient Blood Management 
An evidence-based approach to patient care 
Summary 
Patient Blood Management: The Future of Blood Transfusion conference was held on 18 June 
2012. The event was jointly hosted by the Department of Health, the National Blood Transfusion 
Committee (NBTC) and NHS Blood and Transplant (NHSBT) and supported. by Professor Sir 
Bruce Keogh, NHS Medical Director. 
The aim of the multi-disciplinary conference was to share views on how blood transfusion practice 
could be improved to: 
• Build on the success of previous Better Blood Transfusion initiatives and to further 
promote appropriate use of blood components. 
• Improve the use of routinely collected data to influence transfusion practice. 
• Provide practical examples of high quality transfusion practice and measures for the 
avoidance of transfusion, wherever appropriate. 
• Consider the resources needed to deliver better transfusion practice including support 
from NHSBT. 
• Understand the patient perspective on transfusion practice. 
This document provides initial recommendations from the National Blood Transfusion Committee 
about how the NHS should start implementing Patient Blood Management, which is a multi- 
disciplinary, evidence-based approach to optimising the care of patients who might need blood 
transfusion. 
A toolkit to assist NHS Trusts will be developed and posted on the NBTC website: 
http://www.transfusionguidelines. arg. uk/transfusion-practice 
Rationale 
Patient Blood Management is an evidence-based, multidisciplinary approach to optimising the 
care of patients who might need transfusion. It puts the patient at the heart of decisions made 
about blood transfusion to ensure they receive the best treatment and avoidable, inappropriate 
use of blood and blood components is reduced. It represents an international initiative in best 
practice for transfusion medicine. 
National, regional and local audits in England consistently show inappropriate use of all blood 
components; 15-20% of red cells and 20-30% of platelets/plasma. Evidence shows that the 
implementation of Patient Blood Management improves patient outcomes by focussing on 
measures for the avoidance of transfusion and reducing the inappropriate use of blood and 
therefore can help reduce health-care costs. 
Why does Patient Blood Management matter? 
Patient benefit 
Increases in the use of blood components are projected due to a number of factors such as 
medical advances and an ageing population. Only 4% of the eligible population give blood, and 
new donors are always needed to replace regular donors who can no longer donate. 
Patient Blood Management improves patient care by reducing inappropriate transfusion and also 
helps to ensure the availability of blood components for those patients where there are no 
transfusion alternatives. 
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Cost to the NHS 
Previous Better Blood Transfusion initiatives have been very successful, for example by reducing 
red cell usage by over 20% over the last ten years. Through sharing data on blood usage, 
providing examples of best practice and overcoming barriers to change, it should be possible to 
reduce the current high level of inappropriate use of blood components described above. NHS 
Blood and Transplant recovers the cost of collecting and processing blood from the hospitals that 
use it so the NHS will save money by using only the blood that patients need. 
Who needs to be involved? 
Everyone involved in blood transfusion needs to take responsibility for ensuring that blood 
components are used appropriately for the benefit of patients. Patient Blood Management needs 
leadership and support at every level, including national and regional leaders, hospital 
management, and health professionals. 
2013 Survey of Patient Blood Management 
In October 2013 all NHS Trusts in England were sent a form surveying their preparedness for 
Patient Blood Management (PBM) and their current activities. 
146/149 (98%) Trusts sent a response, and a summary of the key findings is provided below:- 
• 40% (59/146) of Hospital Transfusion Committees do not include PBM in their remit or 
mention the development of a PBM working group 
• 96% Trusts have a consultant haematologist responsible for transfusion but only 81 % 
provided information about the number of assigned programmed activities for transfusion; 
46% of those that did respond indicated their haematologists have no assigned programmed 
activities for transfusion 
• 17% Trusts have < 1 whole time Transfusion Practitioner 
• 75% of Transfusion Practitioners spend 30% or less of their time on PBM activities 
• Trusts responding to the survey have 36 different types of transfusion laboratory IT; many 
have poor functionality to support PBM e.g. only 24% of Trusts use electronic order 
communications for blood ordering and only 69% of blood transfusion laboratory systems 
record the reason for transfusion to facilitate audit 
• Only 43% of Trusts have a process for reporting blood usage to clinical t~ams 
• Only 53% of Trusts undertake local audits of blood use 
• Most Trusts offer training to the majority of clinicians, but 19% did not comment on the 
training of their FY doctors, and 23% did not send data on how they trained their Core or 
Specialist trainees. 
• Fewer than 65% of Trusts provide information about blood transfusion and document 
consent in the majority of their patients who might need transfusion 
• Only 68% of Trusts provide arrangements for the identification and management of anaemia 
before elective surgery 
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• Only 25% of Trusts use near patient haemostasis testing 
• Only 21 % of Trusts have a policy to minimise the volume and frequency of blood samples to 
minimise iatrogenic anaemia 
• 27% of Trusts are not using tranexamic acid for trauma patients, and 30% are not using 
tranexamic acid for surgical patients 
• There is patchy use of intraoperative cell salvage, for example 55% of Trusts use it for 
orthopaedic surgery 
• Only 29% of Trusts have implemented a policy of transfusing one unit of red cells at a time in 
non-bleeding patients followed by reassessment of further need for transfusion 
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Recommendations for the implementation of Patient Blood Management (PBM) 
A. General considerations 
Establishment of PBM E;!rogramme and raising awareness amongst clinicians and 
oatients 
• All NHS Trusts should establish a multidisciplinary PBM programme through the 
Hospital Transfusion Committee (HTC) or as a suborouo of the HTC 
• Education of all clinicians involved in the decision to transfuse blood components should 
be provided to enhance clinician awareness about good patient blood management 
includino avoidance of blood wherever possible 
• Education of patients for whom transfusion may be a treatment option about 
individualised blood management and blood avoidance should be an integral part of 
relevant care pathways 
Issues in oatient testina 
• The volume and frequency of blood samples should be minimised to prevent iatrogenic 
anaemia 
• Use of near patient haemostasis and haemoglobin (Hb) testing should be undertaken to 
guide blood component therapy in patients with haemorrhage in conjunction with the 
Trust Point of Care Testing (PaCT) committee/Patholoav laboratorv 
Use of aonroorlate dose and thresholds for transfusion 
• Use locally agreed triggers for transfusion based on national guidelines and use 
National Blood Transfusion Committee (NBTC) indication codes when requesting blood 
from the transfusion laboratory and when prescribing blood components 
• Develop systems and protocols that empower transfusion laboratory staff to question 
requests that do not conform with these triggers and where inadequate clinical 
explanation is given 
• Regularly audit transfusion requests against these triggers 
• Transfuse one dose of blood component at a time e.g. one unit of red cells or platelets 
in non-bleeding patients and reassess the patient clinically and with a further blood 
count to determine if further transfusion is needed 
B. Specific aspects of surgical PBM 
Preooerative Manaaement of Anaemia and Haemostasis 
• Provide arrangements for the timely identification and correction of anaemia before 
elective surgery which is likely to involve significant blood loss using WHO definitions of 
anaemia i.e. Hb in adult males <130a/L and adult females <120q/L 
• Develop and implement protocols for the management of patients taking anticoagulants 
and anti-platelet drugs that may increase the risk of bleedina 
• Avoid transfusion for managing anaemia if alternatives are available e.g. oral iron for 
iron deficiency anaemia and intravenous iron for functional iron deficiencv 
Intraooerative Manaaement 
• Use intraoperative cell salvage for appropriate procedures 
• Use pharrnacolooic, aqents to reduce blood loss e.o. tranexamic acid 
• Maintain physiologic homeostasis (normothermia, acid-base management, 
normocalcemia, avoid over-treatment with intravenous fluid) 
• Use controlled hypotension whenever indicated and safe 
• Position patients to minimise central venous pressure and caoillarv oozina 
• Minimise surgical blood loss through use of new technologies (argon beam coagulator, 
radiofrequency dissectinq sealer, etc.) 
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Postoj;!erative Management 
• Use postoperative blood salvage (washed, unwashed) where indicated 
• Consider alternatives to transfusion for postoperative anaemia management (volume 
expanders, intravenous iron) 
• Consider the effects of intra-operative fluid administration e.g. haemodilution leading to 
false Hb estimation 
C. Specific aspects of medical PBM 
Manaaement of abnormal haemostasis 
• Develop and implement a protocol for the management of reversal of warfarin, including 
the use of vitamin K and prothrombin complex concentrates 
• Develop and implement a protocol for the management of abnormal haemostasis in 
patients with major haemorrhaqe e.q. acute upper qastrointestinal haernorrhaqe 
• Develop and implement a protocol for the management of bleeding in patients taking 
novel anticoagulants (e.g. dabigatran, rivaroxaban and apixiban) and potent anti platelet 
aaents (e.a. orasuorel and ticaqrelor) 
• Use anti-fibrinolvtics, e.c. tranexamic acid, for major bleed ina 
• Develop and implement a protocol for the management of severe thrombocytopenia in 
patients undergoing stem cell transplantation or intensive chemotherapy for malignant 
disease 
Manaaement of anaemia 
• Identify and correct the underlying cause of the anaemia before considering transfusion, 
wherever possible 
• Avoid transfusion for managing anaemia if alternatives are available e.g. oral iron for 
iron deficiency anaemia, intravenous iron for functional iron deficiency 
• Make individualised plans for patients needing regular transfusion and consider the 
potential for complications of transfusion such as red cell alloimmunisation and iron 
overload and their manaaement 
D. Implementation of PBM 
Imolementation of aood oractice for blood avoidance and the use of blood 
• Analvse casemix and clinical services to determine the main tarqets for PBM 
• Identify PBM champions to help educate staff and patients 
• Establish a PBM committee (either stand-alone or within the Hospital Transfusion 
Committee) to oversee the PBM proqramme 
• Obtain a mandate for PBM from hospital manaqement 
• Educate clinicians about PBM and evidence-based transfusion practice 
• Adopt a PBM scorecard to share with senior NHS Trust members to monitor adherence 
to guidelines for blood avoidance and the use of blood, including the use of 
benchmarking to identify clinicians/clinical teams who are consistently well outside of 
averaae blood use for a specific procedure 
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Responsibilities of staff involved in Patient Blood Management (PBM) at hospital 
level 
1. Transfusion medicine physician 
• Have comprehensive knowledge of technical and clinical aspects of transfusion science 
and blood component preparation and storage 
• Be an expert in evidence-based utilisation guidelines, accreditation standards and policies 
• Develop constructive working relationships with hospital major blood users 
• Serve as clinical champion for PBM to peers and junior medical staff 
• Advise on appropriate management of anaemia and haemostatic disorders 
• Work with IT departments and others to develop IT systems to suooort PBM 
2. Surgery/Anaesthesia clinicians 
• Serve as clinical champions for PBM to peers and junior medical staff 
• Advise on implementing intra- and postoperative cell salvage and other blood sparing 
techniques 
• Identify and eliminate non-evidence based or wasteful transfusion practice 
• Assist with establishing preoperative haemoglobin and haemostasis optimisation clinics, 
point of care testinq and blood utilisation audit and benchmarkina 
3. Haematology/General Medicine physicians 
• Serve as clinical champions for PBM to peers and junior medical staff 
• Assist in establishing and maintaining haemoglobin and haemostasis optimisation clinics, 
and point of care testing 
• Assist in reducing the amount and frequency of blood sample collection both for laboratory 
and point of care testing 
• Advise on and implement appropriate manaaement of anaemia and haemostatic disorders. 
4. Transfusion nurse/practitioner 
• Provide and/or facilitate transfusion-related education including for PBM throughout the 
hospital 
• Ensure clinical transfusion incidents, transfusion reactions, specimen labelling errors are 
investigated 
• Submit data to haemovigilance programmes 
• Develop constructive working relationships with the many clinical users of blood products, 
and assist with the implementation of PBM programme 
• Support local, regional and national transfusion audits by involving appropriate 
stakeholders to undertake data collection and implement quality improvements arising from 
audits. 
5. Hospital management 
• Ensure awareness of transfusion-related hospital accreditation requirements (CPA, MHRA, 
NHSLA, CaC) 
• Identify ways of circumventing or eliminating barriers to change 
• Provide liaison with hospital executive committee when necessary 
• Provide information to support business cases for PBM including the expected savings of 
the implementation of PBM initiatives 
• Provide information to transfusion laboratory and blood services regarding major changes 
planned to services that may affect the amount of blood components used 
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• Provide support for the use of IT systems to provide sustainable data for blood transfusion 
key performance indicators. 
6. Transfusion Laboratory Manager 
• Have comprehensive knowledge of technical and clinical aspects of transfusion science 
and blood component preparation and storage 
• Be responsible for blood stock control and availability 
• Be the key contact for queries/issues in the blood transfusion laboratory 
• Support the provision of data for blood utilisation audit and benchmarking (and work with IT 
department/IT specialists) 
• Empower laboratory staff to challenge clinicians about apparently inappropriate requests 
for blood components. 
7. HTC/PBM subcommittee Chair 
• Establish and lead the committee to oversee the PBM programme. 
• Ensure en a ement and su ort from senior mana ement for PBM initiatives 
8. Other specialists who should participate in PBM include:- 
• Information technology specialists: Help with access to essential data for process 
improvement, assist in setting up computerised physician order entry programmes (CPOE) 
in with educational and reporting functions 
• Patient advocate/expert. 
• Clinical governance department/committee: Assist with the monitoring of quality standards 
and patient safety. 
• Trust Board representative: Be a champion for PBM. 
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Issues to consider when implementing Patient Blood Management (PBM), including 
what data should be collected and how to measure progress 
• Establish what PBM measures have already been implemented e.g. guidelines for 
appropriate use of blood in different clinical settings and pre-operative anaemia 
management. 
• Establish mechanisms for determining how blood components are used e.g. by major 
medical and surgical diagnostic groups and by clinical team and individual clinician. 
-. Audit the use of blood components against local and national guidelines and benchmark 
with other hospitals of similar size and case mix. 
• Develop the tools and opportunities for presenting blood usage and audit data back to 
clinical teams and individual clinicians. 
• Measure baseline data and establish mechanisms for monitoring parameters of PBM 
such as: 
- Proportion of red cell, platelet and plasma units with pre-transfusion blood 
countlhaemostasis testing and the clinical indication documented 
- Proportion of adult patients undergoing elective surgery where transfusion may be 
needed e.g. cardiac and orthopaedic surgery, and where preoperative anaemia 
screening was carried out at least 2 weeks before surgery 
- Proportion of adult patients undergoing elective surgery where transfusion may be 
needed e.g. cardiac and orthopaedic surgery, and where preoperative blood group and 
antibody screening was completed before surgery 
- Proportion of patients undergoing surgery where transfusion may be needed where 
intraoperative cell salvage and tranexamic acid were used 
- Proportion of medical staff trained in blood ordering 
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Work needed to support the implementation of Patient Blood Management (PBM) 
The need for further work to support the implementation of Patient Blood Management was 
highlighted at the Patient Blood Management: The Future of Blood Transfusion conference. 
Examples of the work needed include:- 
• The development of a minimum dataset for patients receiving blood transfusion 
• The development of standard terms for the collection of data on the reason for transfusion, 
as hospital coding information is not reliable for this purpose 
• The development of key performance indicators for hospital transfusion practice 
• Further development of electronic systems in hospitals for the collection of data to monitor 
the appropriate use of blood and measures for blood avoidance 
• The development of a central mechanism for benchmarking blood usage and transfusion 
practice in hospitals 
• The development of a tool to assess the resources, both staff and non-staff, required to 
implement Patient Blood Management at Trust level 
• The development of national training and educational materials for Patient Blood 
Management, including e-Iearning programmes 
• Continued development of patient information leaflets and transfusion awareness tools 
• The development of NICE guidelines for transfusion. 
• Commissioning of high quality clinical research (systematic reviews and clinical trials) on safe 
and effective transfusion practice- including alternatives to blood transfusion 
Several of these activities are already in initial development and will be placed on the Patient 
Blood Management Toolkit when progressed. 
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Appendix 4 
US AABB Patient Blood Management Poster 
Focus on Your Patient, 
Not the Transfusion 
PATIENT BLOOD MANAGEMENT 
IMPROVES PATIENT OUTCOMES LOWERS RISKS 
NATIONAL STATS 
WHAT'S YOUR BLOOD USAGE? 
jjil PATIENT BLOOD MANAGEMENT www.aabb.org/PBM 
Appendix 5 
European Blood Alliance Questionnaire Summary 
Schedule 
NHSBT Finance Directorate 
Cell Salvage Project 
Economic and Financial Impacts of an Expansion in Cell Salvage Utilisation 
1. Background 
There is continued interest in analysing the costs associated with cell salvage as a 
means of minimising the expenditure on allogeneic blood. The majority of studies 
emphasise the main savings as being the difference between the costs of setting up 
a cell salvage programme and the avoidance of expenditure on the (ever-increasing) 
cost of allogeneic blood. 
A recent study at the Cleveland Clinic Foundation, Cleveland, OH.1 cited potential 
savings of $1.5m utilising 5,500 cases on an initial capital outlay of $104,000. This is 
the most up to date study available and is written from an accountancy standpoint, 
focusing on the costs and benefits of a hospital operating within a market 
environment. 
2. UK Experience 
UK health provision operates in a different environment to the US in relation to the 
provision of allogeneic blood. Public sector hospitals are part of the National Health 
Service (NHS) with the blood collection agencies (NHS Blood and Transplant- 
NHSBT, being the body for England and North Wales) being part of the same 
organisation. 
An expansion in cell salvage would therefore require a focus on the cost structures of 
both the hospitals and NHSBT. An internal market exists for allogeneic blood with a 
transfer price of approximately €190 per unit. This transfer price will net off when 
analysing aggregated income and expenditure at a corporate NHS level. Thus, in the 
short term, an expansion in cell salvage at hospital level will result in lower 
expenditure at hospital level but disproportionately higher expenditure in NHSBT due 
to the differing cost structure of the two organisations. 
In economists' terms costs are more variable at the hospital level. In the short term 
therefore the combined costs of expanding cell salvage utilisation would lead to 
aggregated higher costs to the NHS as a whole. This may partly explain why the UK 
significantly lags behind Western Europe and North America in cell salvage 
utilisation. 
Few studies have focused on quantifying and analysing this, possibly unique, cost 
issue. Initial thoughts are that this is a potential disincentive for the NHS to 
encourage the expansion of cell salvage caused by the nature of the organisation of 
collection and provision of allogeneic blood in the UK health "mixed economy". 
3. International Dimension-Brief Questionnaire 
The author wishes to pursue further studies in the cost implications of cell salvage 
with the support of Swansea University's Department of Health Economics. An 
outline of the differing "markets" for allogeneic blood has been suggested as a start 
point to assess whether overseas experiences can be used to develop a model for a 
UK wide potential expansion in cell salvage. 
1119cell Page 1 of 2 
For your particular country: 
3.1. What organisation is responsible for the collection of blood from donors? 
3.2. Generally, what commercial relationships exist for hospitals to buy in 
allogeneic blood? 
3.3. Is this a public or private sector organisation? 
3.4. How much do hospitals pay for a unit of blood? 
3.5. Is there any recent study relating to the proportion of allogeneic blood 
replaced by cell salvage in your country? 
3.6. Is cell salvage equipment available for emergency admissions in hospitals? 
3.7. Are patients offered the choice of whether they wish to have their elective 
operation undertaken utilising cell salvage? 
Many studies potentially overstate the costs associated with operating cell salvage 
systems by e.g. assuming extra operating department staff are required. In your 
country: 
3.8. Do student-training programmes for work in operating theatres (medical, 
nursing or practitioner staff) include training in operating cell salvage 
equipment? 
My current thoughts are around the UK "mixed economy" model making the financial 
benefits of an expansion less obvious than for a hospital buying in blood like any 
other healthcare product. This would allow the hospital more short-term flexibility in 
choosing between the alternatives to an allogeneic blood transfusion. 
There seems therefore to be less obvious financial incentives for the UK NHS to 
expand the cell salvage programme. An international comparison would assist in 
developing a research question. 
I would be grateful for your responses to the above questions and any other 
information you feel is relevant. 
Thank you 
Bernard Crotty 
National Finance Manager-Capital Planning 
NHSBT UK 
5 October 2007 
bernard.crotty@nhsbt.nhs.uk 
Ref [1] Waters JR, Meier HH, Waters JH. An Economic Analysis of Costs Associated 
with Development of a Cell Salvage Program. Anesth Analg. 2007 Apr;104(4):869- 
75. 
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Appendix 6 
ABM Pre-Operative Assessments Questionnaire 
ABM 
Ymddiriedolaeth Prifysgoi GIG 
Abertawe Bra Morgannwg 
University NHS Trust 
~ e_"v I c:J\~ 
Anaesthetic I surgical fitness for elective surgery ---- 
Height Weight BMI 
Resp, rate Pulse BP 
Proposed operation: Addressograph. 
I Date of assessment: 
Telephone number . 
Available at short notice Y I N 
History of presenting complaint 
Past medical history 
Surgeon . 
Suitable for Day Surgery y I N 
Previous operations' illnesses No I Yes 
) 
Operation '_i_ll_ne_s_s --¡-_H_o_sp~i_ta_l---1 Date 
........................ • - It It ' •• 1 _... ••• .. . 
.................... , .. , .. 
• •••••••• •••• •••• ••• •• - •••••••••••••••••••••• " ••••••••• -, , •• '." •• , ,." •••• " ••••••••••• , I" •••••.••••••• II ·i , , •••••••• 
Details of problem (Refer unless nausea and vomiting) I 
I , 
I 
l 
Any previous problems with 
anaesthetic 
No' Yes 
Have any relatives has 
problems with anaesthetic 
Details I 
I 
I 
Cardiovascular assessment 
Refer if in last year Have ou had- a heart attack? 
No Yes Comments 
Do you have. a Pacemaker? 
Type . 
Last checked · Refer 
FlU out suppt~me~tary chest pain sheet 
Do you have Angina? Or chest 
~ain on exercJse/e>sertion 
,WihtA GraGe 1 Nq liniitatiôil of açtiVlty, no symptoms from ordInary 
r- __ __",""""""'C'"""',...,..-.....-------l--~~..;:._+ac :vl 
't'lYHA Gr3<1e 2 
lton òf actlVÌty 
sf or with mild exertion. 
I~YIiA Grade 3 
NYHA Grade 4 
Pp yeu (1~ve a heart murmur? 
lty brings on di¢orrifòrt, symptoms 
.. ~fer 
Details 
HoW m,any pillows do you need? 
Refer if !:las orthopnoea 
Réfer 
Re~piratory assessment NQ Yes Comments 
Do you have asthma? Well contròlled? Yes I no 
Do you have ehrenie bronchitis 
or emRhysema? 
DQ yoú !:lave ªny other chest 
prpbl~rnl>" o"t so what? 
Have you beèn ádmitted to hospital 
for YQl!r chest problems? 
Have you taken steroid tablets for 
your chest probtems? 
Do you ~et short of breath walking How far? 
on the flat? Refer if less than 200m 
Do you get short of breath and 
- 
Refer 
have to stop on a flight of stairs? 
Do you have sleep apnoea? 
Refer, and use Epworth Sleepiness Score 
sheet 
Do you currently smoke? 
How many per day? 
Woutd you like help to stop? No /Yes-reter 
When did you stop? 
Comments and mvestigations 
2 
No Yes Comments 
Refer jf within 12 months 
Refêr ff within last year or uncontrolled 
~ef~r if .still being treated 
Refer íf'uncontrotted 
• e~Ked within last 6 months . 
bloOd test , ~ 
. fiJe sickre cell trait, have they 
t~s.t~d? Refer if positive 
Eg wh~1il cut I with dental extractions 
Refer With ·Olotting screen 
Refer If neck movement restricted 
. Medication history. What medication or drugs do you take? 
Include over the j:ounter drugs, inhalers, HRT, eye drops, topical medication, recreational! 
iIIidt drugs, complimentªry medicine etc 
Drug name Route Dose Frequency 
....................................... ................................................................................................ ...................... 
..... .......................................................................................... ' . 
............... ....................... ' ' . 
.... ~ ..........•...... , , , ." " , , ,'.. . , , 
.................. ....................................................... ................................................................ .............. 
. , , '" , - . 
........... " ' , , , . 
................. ............................................... ' , . 
........................................................................................ ......... . 
Refer if taking warfarin, clopidogrel or other "blood thinning" medication 
Do you have allergies to No Yes To what? 
medications? Include rubber, 
latex, dressings, food etc. Refer if latex or anaesthetìc drugs 
Details of allergy: anaphalaxis, Have you given patient's own medication leaflet? 
swelling, wheeze, rash, etc. 
3 
.. 
Clinical examination 
Height Weight BMI 
BP Pulse Respiratory rate 
02 saturatfç>n Peak How (if indicated) 1 2 3 
Ño rIS .. --.''' .. 
Anaemia 
.launëlìce 
t¥êoosis 
.. '.0 
. ' 
L.yfflJ~n n(i)des" . 'e., . 
. 
. 'Ge(femª ... , 
;;;;,:':"", .. ;. 
'-t;\fS À6ñ9rÌiitsl hêart 'SQ!JOÒS Refer if muntíYT'ijëârd máy need écho. ~ . 
'. 
~S "À~~rmal rr~SPll!atory, Refer at ö~scr~tion 
~xamilila,tiöh 
~~ -.,', ~.~' ' "'<' • - 
~i .. ~ . ..;. .=-.~!. - ~ 
Refer 
. " !'WilY 
, ~~~th Q~ènir\~ < 3 ñngers 
·Manamp'~âtí sopre 3 or 4 Refer 
" _.', 
Réslfi~fèd',neêk movements Refer 
, 
PassfbiUty öf spfnal! epiQural 
discussed. Cheek for deformity and 
naeIJl!sl h.airy patch 
Abeto Vascular Vein R L, 
Groin 
, , 
Pop. Fossa. 
- - 
PR (if indicated) 
What is the ASA? 
Class I. 
Class II. 
Class IIJ. 
Class IV. 
Ctass V. 
Normal healthy individual. 
Systemic disease that does not limit activity. Eg hypertension 
, Severe systemic dîsease that limits activity, but not incapacitating. Eg CCF 
Severe systemic disease which is constantly life threatening. 
Moribund, not expected to survive 24 hours without surgery. 
ASA 3/4 are likely to be picked up from the above questions, but as a general 
rule, all ASA 3/4 should be discussed with an anaesthetist. 
All Gynae patients to have urine bottle. YES 
Written information given: Yes No Assessed by . 
I\,jAM{ 
S~5'~ 
-~ 
4 
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Literature Review-Summary of Comments to 2013  
Brief Summary of Articles to End 2013
Ref Author Year Country Specialty Summary
Reference 
to Costs Title
A43
Agostini V., Delucia M., Gagliardi S., Gasperoni A., Santarelli 
R. 2012 US Orthopaedics Not directly relevant Low
Preoperative Use Of Erythropoietin As An Alternative 
To Preoperative Blood Donation Programme In Elective 
Orthopedic Surgery
61 Allanki S 2009 India Liver Tx
Five and a half year study on 60 orthotopic liver tx patients. Unclear on the mix of gender, age, pre op assessments, Hb 
levels making the comparison difficult and open to criticism. No evidence that cell salvage is cost effective as stated in the 
conclusion. Low
Transfusion Alternatives in Liver Transplantation: 
Single Center Study
A46 Aluri S., Wrench I.J., Wilson M. 2012 UK Obstetrics
Pointed to Salvo study. Noted that txn rate fell in caesarean patients from 5.6% prior to CS to 4.4% after with 3.6% being 
salvaged. Did not, however, state how many of post CS implementation received both CS and allogeneic txns. Implication is 
that CS lowered the txn rate. Low
Cell Salvage During Caesarean Section Reduces 
Perioperative Allogeneic Red Cell Transfusion In 
Suitable Patients
30 Ambarkova Vilarova E.; Blagoevska M.; Kocovska E.; Mitrev Z. 2010 Macedonia AAA
Conference abstract. Txn trigger of 8 g/dL used. CS stopped the fall to the trigger. Noted subjective txn policy was "based 
mainly on clinical judgement, not only on Hb concentration but....other factors ..as well". States "these findings also have 
important financial implications". Does not elaborate. Low
Use of Red Cell Savage for Abdominal Aneurysm 
Repair and Transfusion Requirements
44 Anderson S; Panizza B 2010 Aus Surgery Found no articles in this specific area. Concentrated on a lit review of surgery in contaminated fields. Low
Are Cell Salvage and Autologous Blood Transfusion 
Safe in Endonasal Surgery?
39 Ashworth A; Hanison J; Klein AA 2010 UK Surgery
Debate on whether there is a risk of contamination of salvaged blood. Authors quote various references to back up their 
claim that there is no relationship between CS and adverse clinical outcomes in transnasal surgery. They suggest transnasal 
surgery is therefore "safe". Low Is Cell Salvage Safe in Transnasal Surgery?
14 Attaran S.; McIlroy D.; Fabri B.M.; Pullan M.D. 2011 UK Cardiac
Study designed to challenge the use of cell salvage in routine cardiac surgery. Notes the cost of the "collect first" where no 
reunfusion and classes this as a loss. Felt the difference in txn rate was not significant (35.6% v 30.3%  p=0.23, 
with/without cs). This was based on a transfusion trigger of 8g/dl. Not clear when Hb reading was taken-before or during 
the op? This would be a factor and CS use may, intraoperatively, be offsetting the fall in Hb levels. High
The Use of Cell Salvage in Routine Cardiac Surgery is 
Ineffective and Not Cost Effective and Should be 
Reserved for Selected Cases
76 Atwal NS, Bedi G, Lankester BJ, Campbell D, Gargan MF 2008 Orthopaedics Partially relevant-focused on PAD saying PAD was cost effective Low Management of Blood Loss in Periacetabular Osteotomy
A48 Baker, Robert A., Merry, Alan F. 2012 Australia Cardiac
Set out arguments to continue study to answer questions:
1. Should it be used for all cases?
2. When, during a case, should it be used? 
3. Should it be used after theatre? Overall argues a consensus needs to be reached. I could argue that an orthopaedics 
consensus may be easier to achieve due to the severity of the patients' conditions  being less. Low
Cell Salvage Is Benefi Cial For All Cardiac Surgical 
Patients: Arguments For And Against.
73 Berrizbeitia LD; Wry P; Fernandez J 2008 US Cardiac
No allogeneic blood used in a type A aortic dissection. Usual average is between 2.8 and 11 units. Experiences of one 
operation on a 29 year old male. Lowest Hb level was 5.34; 9 days after the operation. Every blood avoiding technique was 
adopted and, it seems, regular intervention and monitoring. It is not clear whether this involved additional staff, if this was a 
planned test and if the patient was selected at random. Low
Repair of Acute Type A Aortic Dissection Without the 
Use of Blood Products
98 Bess R.S.; Lenke L.G. 2006 US Orthopaedics
Brief reference to CS with far more space devoted to PAD. Quoted a study from 2004 on adult lumbar fusion surgery on 
100 patients. 24% of CS patients needed allogeneic txn v 20% w/out CS but with PAD needed 1 unit of allogeneic blood. 
Conclusion was that IOCS not cost effective for this operation. (Reitman CA, Waters WC, Sassard WR. The Cell Saver in 
Adult Lumbar Fusion Surgery: a cost-benefit outcomes study. Spine 2004;29:1580-4). Medium
Blood Loss Minimisation and Blood Salvage 
Techniques for Complex Spinal Surgery
A17
Bhangu, Aneel, Nepogodiev, Dmitri, Doughty, Heidi, Bowley, 
Douglas M 2013 UK Cross
Assessed the role of cell salvage in operations involving gun shot wounds and blast injury in Camp Bastion, Afghanistan. 
Concluded CS useful to avoid using allogeneic blood due to the logistical issues of getting the blood over from the UK. 
However, salvaged blood was often contaminated due to the nature of the wounds, the time to set up the CS equipment may 
be too long and often injuries would come in together. Allogeneic units were quicker, easier and cleaner. Low
Intraoperative Cell Salvage In A Combat Support 
Hospital: A Prospective Proof Of Concept Study.
A06 Bigsby E., Acharya M.R., Ward A.J., Chesser T.J. 2013 UK Orthopaedics
Two types of acetabular fracture: elementary fracture and associated fracture. Check if there's a HRG for this or where it 
may go. Retrospective review of case notes. Similar data assessed to mine except LOS and HRG. Used Sorin Electa. All 
patients were salvaged and McClelland's estimate (from handbook of txn med 2007) was used to convert to notional 
units of allogeneic blood avoided. They predicted what the post op Hb level would be without a txn and then the amount 
of rbcs to bring Hb up to 80g/l. The mechanism for the prediction is not clear. Ignored capital/running costs of the machines 
but made the point that increased utilisation would dilute these anyway. Ignored any discussion on LOS. High
The Use Of Blood Cell Salvage In Acetabular Fracture 
Internal Fixation Surgery
101 Bird C 2006 UK Cross
"Opinion" style article. Note the quote that most Trusts spend between £1m and £4m on blood. Ignores surgery/medical 
split. Very basic but useful section on "how does cell salvage work". High Cell Salvage
92
Blanchette C.M.; Wang P.F.; Joshi A.V.; Asmussen M.; 
Saunders W.; Kruse P. 2007 US Orthopaedics
Large scale retrospective multi site study. Assessed average costs and average usage. Very difficult to assess the detail and 
the rationale behind the conclusions in the tables. Concluded that utilising cell salvage resulted in a lower probability of an 
allogeneic txn. Potentially had the opportunity to assess LOS with or w/out a txn but this was not discussed. For all the data 
there were few concrete conclusions. High
Cost and Utilisation of Blood Transfusion Associated 
with Spinal Surgeries in the United States
49 Bouras I; Mingo O 2010 UK Oncology Opinion piece. Noted main advantages of CS. Highlighted theoretical risk of disseminating malignance. Low Should Cell Salvage be Used in Oncological Surgery?
47 Bowen RE; Gardner S; Scaduto AA; Eagan M; Beckstead J 2010 US Paeds
Analysis of 54 consecutive paed patients undergoing paediatric posterior spinal fusion. 33 CS and 21 non-CS.  Allogeneic 
txn rates markedly lower in CS group 6% v 55% intraop and 18% v 55 peroperative. Check defns of intraop and periop. No 
ref to costs; plenty to stats. Low
Efficacy of Intraoperative Cell Salvage Systems in 
Paediatric Idiopathic Scoliosis Patients Undergoing 
Posterior Spinal Fusion with Segmental Spinal 
Instrumentation
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Brief Summary of Articles to End 2013
Ref Author Year Country Specialty Summary
Reference 
to Costs Title
A29 Brearton C., Bhalla A., Mallaiah S., Barclay P. 2012 UK Obstetrics
Traditional cost comparison ignoring costs at NHSBT. Made the case for cell salvage over the period January 2006 to June 
2011; the equivalent of 83 units avoided generated a saving of £1,130 (£13.60 per unit; £1,130/83). £13.60/£123 per unit = 
11%. Allogeneic txn rates not stated; note the comment on "haemostatic effect" with the presence of CS altering behaviour 
and reinforcing the message about cell salvage. Approx 23% of patients had blood reinfused (137/587). Later in the study 
the patient selection is more selective and "the equivalent cost of blood salvaged for the first six months of 2011 is close to 
the cost of the disposable equipment". High
The Economic Benefits Of Cell Salvage In Obstetric 
Haemorrhage
93 Bridgens JP; Evans CR; Dobson PM; Hamer AJ 2007 UK Orthopaedics
Small scale study of 94 patients (47 with and 47 without CS) over 4 years for revision hips. Observed a 59% reduction in 
allogeneic blood. Volume of allogeneic blood transfused seemed high. Authors noted that the control group were operated 
on by less experienced staff. Medium
Intraoperative Red-Blood Cell Salvage in Revision Hip 
Surgery
27 Brown C.V.R.; Foulkrod K.H.; Sadler H.T.; Richards E.K.; 
Biggan D.P.; Czysz C.;
2010 US Trauma Retrospective study of  94 patients in Trauma unit. Half had CS (Electa) and other half did not. No difference in mortality 
between groups. Posed a potential ethical dilemma-if the salvaged blood is contaminated should it be reinfused if allogeneic 
blood is available? Usual question on staffing costs-in this study a perfusionist is externally supplied at a cost per 4 hour 
stint @ $375. High
Autologous Blood Transfusion During Emergency 
Trauma Operations
7 Buckley F.; O'Sullivan C.; Wolf B.; Lush C. 2011 UK AAA Summary of poster. Single site study on 204 patients. Average reduction of 1 unit of allogeneic blood where CS was 
utilised. Highlighted training was a key issue. Tie in with Hannah's work on costs of training. "Saving" of £122 for the unit 
v consumables and running costs etc. High
Examining the Efficiency of Use of Cell Salvage in 
Elective Aortic Surgery in a District General Hospital
17 Butchart A.G.; Abdy S. 2011 UK Orthopaedics Noted recs by AAGBI to utilise CS if blood loss >1 litre or 20% of circulating blood volume. Anecdotal evidence that 
theatre practitioners not happy with using the kit and usage tailing off. Data notes lower post op Hb if CS used in hip 
replacement. High Are We Using Cell Salvage Enough?
A45 Campbell, J, Holland, C, Richens, D, Skinner, H 2012 UK Cardiac
Small sample (20), 10 with CS and 10 without. Using CS may "dilute platelets and coagulation factors" which allogeneic 
blood may offset because no heparin would be used (cross ref to intro refs to heparin). Authors stressed weakness of sample 
size. No mention of costs. Low
Impact Of Cell Salvage During Cardiac Surgery On The 
Thrombelastomeric Coagulation Profile: A Pilot Study.
A16
Canan, Chelsea E, Myers, John A, Owens, Roger Kirk, 
Crawford 3rd, Charles H, Djurasovic, Mladen, Burke, Lauren O, 
Bratcher, Kelly R, McCarthy, Kathryn J, Carreon, Leah Y 2013 US Orthopaedics
Study of 180 patients (150 with CS and 30 without) in single level lumbar spine surgery. Txn trigger of 80 g/l used for 
allogeneic txns. Proportions requiring an allogeneic txn were 38.7% v 40% respectively. Very high costs of using CS 
machine were stated. Not broken down in detail; neither was the cost of an allogeneic unit. Incremental cost effectiveness 
ratio was calculated to give a cost of >$55,000 per allogeneic txn averted. Seemed unnecessary to undertake this analysis 
since the difference in txn rates was so slight. Not clear also why such a lobsided proportion of 150:30. This was not 
explained. High
Blood Salvage Produces Higher Total Blood Product 
Costs In Single-Level Lumbar Spine Surgery.
A42 Canniff E., McCarthy K.F., Iohom G. 2012 Ireland Cross
Focused on frequency of usage based on survey of anaesthetists. Note 95% agreed that CS had a role in blood conservation 
but significantly fewer had working knowledge or were able to set up and operate. Low The Use Of Cell Salvage During Anaesthesia
A33 Carey K., Paul A., MacLaughlin S., Garrido E. 2012 UK Orthopaedics
Service evaluation over 16 months on 23 consecutive patients recorded. Compared pre and post op Hb levels. Active 
intervention (100% cell salvage, hypotensive anaesthesia, aggressive temperature management, fibrinolytic therapy and near 
patient testing) reduces the requirement for allogeneic units to < half a unit per patient. It did not compare this against what 
would have been the allogeneic usage if the interventions were not as active.  If a patient has an allogeneic txn they cannot 
become blood donors. CS therefore would prevent the donor base being eroded. My conclusion rather than the authors. Low
Blood Conservation In Adult Scoliosis Surgery: A 
Report Of The First 15 Months Of The New Scottish 
National Adult Spine Deformity Correction Service
42
Carless PA, Henry DA, Moxey AJ, O'Connell D, Brown T, 
Fergusson DA 2010 UK Cross Classic coverage of issues. Note especially conclusions and recs on orthopaedics. Medium
Cell Salvage for Minimising Perioperative Allogeneic 
Blood Transfusion
89 Catling S 2007 UK Obstetrics
Assessment of main blood conservation methods. Quoted "Blood Matters" (16, 2004) estimate that, if CS was used in 
operations with forecast blood loss > 1,000 mls, then 160,000 allogeneic units would be avoided. Cannot  attribute this 
comment from Blood Matters to any study. Strong case for CS in obstetrics made, drawing on issues raised in ref "82" 
above. Low
Blood Conservation Techniques in Obstetrics: A UK 
Perspective
82 Catling S 2008 UK Obstetrics
Cited two main potential risks in CS. 1.Contraindications of re-infused blood containing amniotic fluid. 2. Mixing of blood 
groups from fetus to mother. Anti D can treat "2". The CS procedure can remove most of the amniotic fluid-there is no 
evidence that residual elements can cause harm. Low Intraoperative Cell Salvage in Obstetrics
68 Catling S; Williams S; Freites O; Rees M; Davies C; Hopkins L 2009 UK Gynaecology
Followed up a NICE review looking at the theoretical risk of re-transfusing malignant cancer cells in gynae-oncology 
patients. Using a leucocyte filter would remove this risk. The authors stress that the more significant risk is the risks 
associated with allogeneic txns. Low
Use of a Leucocyte Filter to Remove Tumour Cells from 
Intra-Operative Cell Salvage Blood
48 Catling S; Wrench I 2009 UK Obstetrics
Letter-Discussion on amniotic fluid embolus (AFE). Very low risk (1 in 8,000 to 80,000). Concern that this issue may 
dissuade centres from adopting CS. This was responding to 60 below. Most telling bit was the response to the letter that 
quoted "the ethics of randomising patients to receive donor blood when they could chose (sic) autologous blood should 
be considered". Response was that the ethics' c'ttee could decide. Low
Cell Salvage at Caesarean Section: the Need for an 
Evidence-Based Approach
A09 Che, J., Tian, M., Ding, G., Huai, Q., Dong, P., Li, Y., Li, S. 2013 China Cross
Not relevant. The term "cost" did not feature in the text. Focused on length of time before reinfusing and recommended 
maximum time elapsed of 6 hours. Seems strange since using the continuous autotxn CATS system. Low
Effects Of Cell Salvage On Erythrocyte 2,3-
Disphosphoglycerate And G-6- Pd Levels And 
Phosphatidylserine Expression.
36 Chieza J.T.; Sharafudeen S.; Skelton V.; Parry N. 2010 UK Obstetrics
Poster-No mention of machine type and whether a "collect first" system could be adopted. Small sample of patients using 
CS (31). Costs of consumables were c£50. Looked at the equivalent allogeneic volume of salvaged blood (7.5 units in the 
21 patients); converted this to c£1,100 and compared against the c£1,500 of consumables. Implied need to take care in CS 
use "to avoid wasting resources". Medium
Types of Abnormal Placentation and IOCS: DO They 
All Benefit?
A01
Choi, E S, Ahn, W S, Lee, J M, Jeon, J K, Kim, H C, Lim, Y J, 
Sim, J Y 2013 US Obstetrics Further discussion on debate over leucocyte filters in Obstetrics. No reference to costs. Low
A Laboratory Study Of The Effects Of Processing 
Blood Through A Cell Salvage Device And Leucocyte 
Depletion Filter On Levels Of Pro-Inflammatory 
Cytokines And Bradykinin.
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A35
Clement R.C., Kamath A.F., Derman P.B., Garino J.P., Lee G.-
C. 2012 US Orthopaedics
Not relevant. Compared two types of wound sealant in revision hip surgery and attempted to ensure CS was used in both 
groups in order to minimise it's impact on allogeneic blood requirements. Note that CS is not an option if the site is infected 
QUOTE; this may be the reason for the revision hip surgery. Low
Bipolar Sealing In Revision Total Hip Arthroplasty For 
Infection. Efficacy And Cost Analysis
A14
Colomina M.J., Cassinello C., Diez-Lobo A., Hidalgo F., 
Aragon S., Duran L. 2013 Spain Cross Survey of PBM in 82 anaesthesia departments in Spain. 75% used tranexamic acid and 67% used CS. Low
Implementation Of Patient Blood Management Program 
In Spain: Evaluation Survey
A03
Courtemanche K., Elkouri S., Dugas J.-P., Beaudoin N., 
Bruneau L., Blair J.-F. 2013 US Cardiovascular
Retrospective study comparing 38 patients with IOCS from the start to 174 patients who either had IOCS commence during 
surgery (because of higher blood loss) or no IOCS at all.
Concluded that LOS did not vary but patients with IOCS spent less time in ICU. No reference to costs. May be useful to 
follow the heading la out in my "results" chapter. Low
Reduction In Allogeneic Blood Products With Routine 
Use Of Autotransfusion In Open Elective Infrarenal 
Abdominal Aortic Aneurysm Repair
45 Cowlishaw PJ; Belavy D 2010 Aus Surgery
Letter focusing on the presence of bacteria in salvaged blood in transnasal surgery. Even with the  filtration and washing of 
salvaged blood there is no guarantee of the sterility. Match the risk of sepsis with the risk of allogeneic txn. Low Is Cell Salvage Safe in Transnasal Surgery?
105 Crotty B 2006 UK Cross
Overtaken by events. Relied on the NHS internal market, included depreciation. Ignored any element of prediction as to the 
likelihood of an alogeneic transfusion being required. High Recycling Blood: Sharing the Benefits of Cell Salvage
103
Davies L; Brown TJ; Haynes S; Payne K; Elliott RA; McCollum 
C 2006 UK Cross Large scale study noting, inter alia, the financial impacts on NHS Blood & Transplant. High
Cost Effectiveness of Cell Salvage and Alternative 
Methods of Minimising Perioperative Allogeneic Blood 
Transfusion: a Systematic Review and Economic Model
A11
Debois, William, Prata, Jessica, Elmer, Barbara, Liu, Junli, 
Fominyam, Edward, Salemi, Arash 2013 US Cross
Not directly relevant. The study focused on waste disposal of "regulated waste". Noted in passing that additional cell 
salvage would mean less waste because there was less shed blood to be disposed. Low
Improved Environmental Impact With Diversion Of 
Perfusion Bypass Circuit To Municipal Solid Waste.
A47
Dhawale AA, Shah SA, Sponseller PD, Bastrom T, Neiss G, 
Yorgova P, Newton PO, Yaszay B, Abel MF, Shufflebarger H, 
Gabos PG, Dabney KW, Miller F 2012 #N/A Paeds Not directly relevant Low
Are Antifibrinolytics Helpful In Decreasing Blood Loss 
And Transfusions During Spinal Fusion Surgery In 
Children With Cerebral Palsy Scoliosis?
43
Dunn J.J.; Aning J.J.; Sprott H.H.; McGrath J.S.; Pocock R.D.; 
Thompson J.F.; Ridler B.M.F.; Daugherty M.O. 2010 UK Surgery
Centralised urological cancer surgery now centred regionally. With specialist surgery and enhanced CS the "before" and 
"after" centralisation resulted in allogeneic txn rates going from 66% before to 34% after. Poster-noted LOS decreased by 3 
days. Looked also at age and pre/post Hb. Medium
Centralisation of Urological Cancer Surgery-Is Cell 
Salvage Still Effective?
9 Edelstein S.B.; Shipp C.; Kang J.; Jarosz C.; DeChristopher P.J. 2011 US Cross Summary of poster. CS is one of the elements in the armoury on a T/E programme. Since implementation there has been a 
fall in red cell usage of 8%. Stressed the change in culture required. Medium
Successful Implementation of a Blood Management 
Program at an Academic Health Center
65 Effa Heap G 2009 UK Policy Discusses the implications of treating a JW patient. Nothing really relevant to costs. Low
Blood Transfusion: Implications of Treating a Jehovah's 
Witness Patient.
100
Everts PAM; Knape JTA; Weibrich G; Schonberger JPA; 
Hoffmann J; Overdevest EP; Box HAM; van Zundert A 2006 Netherlands Cross
Not directly relevant; focus is on platelets and studies on autologous techniques that are in their early stages. One quote 
worth highlighting "not many well-designed scientific studies are available, and many anecdotic stories exist". Low Platelet-Rich Plasma and Platelet Gel: A Review
56 Folkersen L.; Grunnet N.; Jakobsen C.-J. 2009 Denmark Cardiac
Poster-study looked at 624 consecutive patients. 200 with CS then 180 w/out then 244 with CS. Significant fall in txn rates 
with CS. Overall average red cell requirement fell by c1.27 units where CS was adopted. This equated to c€300 units per 
case. Not clear if this had factored in the costs of CS. Also not clear how "a retrospective study was made of 624 
consecutive cardiac patients from 3 successive periods" can be undertaken with then without and then with again. Low
Transfusion of Shed Mediastinal Blood Reduces the Use 
of Allogeneic Blood Transfusion Without Increasing 
Complications
3 Frank S M. 2011 US Cross Critique of Waters article not picked up in search-attached in file as hard copy. Points to wider savings but uses average 
costs to make the point. Critical of the stand by set up costs not being included. Cites the hazards of allogeneic blood and 
CS minimising these. Note Pittsburgh notes re readmission. High
Who Benefits from Red Blood Salvage?-Utility and 
Value if Intraoperative Autologous Transfusion
81 Freedman J; Luke K; Escobar M; Vernich L; Chiavetta JA 2008 Canada Cross
Appointment of Transfusion Co-ordinators achieved a fall in the amount of allogeneic blood at 23 Canadian hospitals. 
Focused on pre-deposit, epo and cell salvage. Noted variability and lack of "buy in" from some physicians. The lack of a 
local "champion" made it difficult to achieve change. On the positive side there were reductions in the amount of allogeneic 
blood used. Very little detail on operating costs were included. Average costs by in-patient day were used. It is not clear 
whether CS operating costs were used. Total savings were estimated at $15m v costs of $2m. LOS savings were estimated at 
$5.3m. Difficult to assess the costs as there was no breakdown and no way of pulling out e.g. the financial impact of PAD v 
CS. High
Experience of a Network of Transfusion Coordinators 
for Blood Conservation (Ontario Transfusion 
Coordinators [ONTraC]
A15
Garratt C., Sharafudeen S., Skelton V., Parry N., Groves P., 
Fleming I. 2013 UK Obstetrics
Lean study focusing on eliminating wasteage of consumables in lower segment caesarean section (LSCS). Prospective audit: 
59 women, 17 had sufficient blood loss. Only 1/17 needed an allogeneic txn. Did not state the proportion of the 42 others 
who had a txn. Emphasis was that they had been selective on which type of LSCS would utilise CS. Argued that it saved 27 
units of blood by assessing how much autotransfused blood was reinfused. No mention of running costs or training etc. Medium
Lean Transformation Of Intra-Operative Cell Salvage 
(Iocs) Practice In A Teaching Hospital Birth Centre: An 
Audit Of Efficacy And Cost
60
Geoghegan J; Daniels J; Moore P; Thompson P; Khan K; 
Gülmezoglu A 2009 UK Obstetrics
Cites paucity of studies in caesarean sections. Limited evidence either way even though CS has been approved. How does 
this tie up with NICE guidelines? Was there some politics here with the suggestion for a large multicentre RCT preempting 
the SALVO study? Low
Cell Salvage at Caesarean Section: the Need for an 
Evidence-Based Approach
77
Ging AL; St. Onge JR; Fitzgerald DC; Collazo LR; Bower LS; 
Shen I 2008 US Cardiac
Case study of paediatric patient who's parents were JW. A surgical correction of a ventricular septal defect was 
undertaken.Used the whole range of blood sparing techniques which are now standard in the hospital. In the US c20% of all 
blood txns associated with cardiac surgery. Still use ANH as a norm. Focused on hematocrit rather than HB and mention of 
lots of staff involvement-is this realistic? Low
Bloodless Cardiac Surgery and the Pediatric Patient: a 
Case Study
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72
Golab H.D.; Scohy T.V.; de Jong P.L.; Takkenberg J.J.M.; 
Bogers A.J.J.C. 2008 US Cardiac
Study of elective paediatric cardiac surgery. Successive cohorts of 122-one with one without CS. Less allogeneic blood used 
in CS group but the operating cost of the CS equipment was greater than the cost of blood avoided. Noted a habitual 
transfusion of allogeneic blood regardless of whether salvaged blood was available. Also the provision of a 2nd unit of 
allogeneic blood in ICU after one given in the OR. There was often 2 units given instead of 1. Consistent with discussion in 
UK. No reference was made to training costs and no LOS info. General point-need the training model to be more dynamic-
if it's on training syllabus and training is undertaken over a period then there will come a point when everyone is trained 
so this overhead will tail off. Medium
Intraoperative Cell Salvage in Infants Undergoing 
Elective Cardiac Surgery: A Prospective Trial
11 Grainger H, Catling S. 2011 UK Obstetrics Examines the concerns over potential cross infection and potential contamination of fetal blood-mainly with, but not 
exclusively, caesarean delivery. Little reference to cost. Notes that, in the UK, if you receive allogeneic blood you cannot 
then donate. This cuts off potential future supply. Medium Intraoperative Cell Salvage in Obstetrics
69 Grainger H; Jones J; McGee D 2008 UK Cross Overview of the standardised training material available. Low
Education, Training and Competency Assessment for 
Intraoperative Cell Salvage
A08 Grainger, H., Howell, C., Jones, J. 2013 UK Cross Not directly relevant Low
Update On The UK Cell Salvage Action Group 
Autologous Transfusion Label.
62 Gray M.; Gowrie-Mohan S.; Harvey D. 2009 UK AAA Not directly relevant Medium
Six Year Experience Of Intraoperative Red Cell Salvage 
In One District General Hospital
16 Hansen 2011 Ger Cross German article-can't get hold of this. Abstract looks fairly general. Low
6 Hassan N.; Halanski M.; Wincek J.; Reischman D.; Sanfilippo 
D.; Rajasekaran S.; Wells C.; Tabert D.; Kurt B.; Mitchell D.; 
Huntington J.; Cassidy J.
2011 US Paeds Cites the hazards of allogeneic txns. Points to an article in paed patients on allogeneic txns in paed sciolosis (curvature of 
spine) implying longer LOS (ref 21). Mentions CS through the article but does not highlight any detail e.g were there 
reinfusions, collect first in operation etc. Medium
Blood Management in paediatric spinal deformity 
surger: review of a 2-year experience.
A13
Herd J.M., Joseph J., McGarvey M., Tsimbouri P., Bennett A., 
Meek R.M.D., Morrison A. 2013 UK Orthopaedics
Same machines and same surgeons on a study that covered three groups: pre 2005, 2006-2008 and 2008-2010. Found that 
3.5 v 1.4 v 0.8 allogeneic units were required in the respective groups. Same machine type (CS 5) used for 2nd and 3rd 
group. Useful comparator but noted the variability in the type of revision hip operation. Highlighted different types of 
revision hip surgery that the studies did not differentiate between. Similar to primary hips! Medium Intra-Operative Cell Salvage In Revision Hip Surgery
85 Hill B 2007 UK Cross
General overview, glossed over any downsides and highlighted PAD in addition to CS. Emphasis on JW's. No reference to 
costs. Low Bloodless Surgery
63 Holt DW, McMullen B, Ask AM 2009 US Cardiac Use of ultrafiltration rather than centrifuging in CS. Very short conference abstract; no evidence provided. Low
Ultrafiltration is an Effetive Substitute for Cell 
Centrifutation in Perioperative Blood Management 
Techniques
33 Hulatt LJ; Fisher W 2010 UK Sickle Cell
Highlighted issues relating to patients with sickle cell carrier status. Effectively "proceed with caution" in order that further 
research in this area can be undertaken. Low
Intra-operative Cell Salvage and Sickle Cell Carrier 
Status.
29 Hussain S; Clyburn P 2010 UK Obstetrics
Cross refs to Waldron/Ralph 20/21. Note, though there is a potential risk, there is an easy solution. Stop the cell salvage 
and give allogeneic txn. CS is not a 100% replacement for allogeneic txn. Low Cell Salvage-Induced Hypotension and London Buses
23 Jaben E.A.; Bryant S.C.; Winters J.L. 2010 US Cross Studied long term survival rates following surgery when a txn was required. Effectively the lower the txn volume the longer 
the survival. High
Long Term Survival After Transfusion Among 
Olmstead County, MN Residents 1991-2009
A49 Junkin R., Ziarkowski A. 2012 UK Cross Noted low utilisation of CS "may represent a barrier to usage". Ties in with the "flying hours" argument. No costs included. Low
Impact And Experiences Of Introducing Intraoperative 
Cell Salvage In A District General Hospital
35
Kelleher A.; Davidson S.; Gohil M.; Machin M.; Kimberley P.; 
Hall J.; Tillyer L. 2010 UK Cardiac
Poster-QA testing on Hb levels pre and post processing. Deceiving as this extracts the concentration of the blood collected 
and takes the Hb level of this rather than the patients overall Hb level. Compares two types of machine (COBE BRAT 2 and 
Heamonetics CS 5). Difficult to assess consecutively given the advances in systems. Low
Red Cell Salvage in Cardiac Surgery-The Role of 
Quality Assurance in Providing Evidence to Support a 
Change of Cell Saver Device
2 Kelleher A; Davidson S; Gohil M; Machin M; Kimberley P; 
Hall J; Banya W.
2011 UK Cardiac Cites Davies and Carless stating CS cost effective and decrease requirement for allogeneic blood. Focuses on QA issues and 
a change in procedures that increased the proportion of free haemoglobin. The lower the better. The prop of free 
haemoglobin increases with the age of allogeneic blood. The fresher the blood the better. Cross ref to Koch on duration on 
ref to more complications the older the blood. High
A Quality Assurance Programme for Cell Salvage in 
Cardiac Surgery
71
Klein A.A.; Nashef S.A.M.; Sharples L.; Bottrill F.; Dyer M.; 
Armstrong J.; Vuylsteke A. 2008 UK Cardiac
213 pats, 102 selected for CS. Routine cardiac surgery (elective CABG, valve surgery or a combination). Study noted little 
difference in txn rates between the two groups. Txn rate c32%. Costs are unclear and the cost differences between the two 
groups are not itemised e.g. why OR costs $435 different with CS-there is a separate heading for CS equipment-would this 
be training? Note post op allogeneic usage significantly higher for non-CS group. OR blood requirements are the same 
across both groups. Was this expected? If CS used this would imply the HB levels s/b higher. This is not measured. See 
quote on pg 1494. High
A Randomised Controlled Trial of Cell Salvage in 
Routine Cardiac Surgery
18 Knels 2011 Ger Cross
Another German article, fairly descriptive, charting the development of autologous techniques since the early 1990's Low
10 Konstantinou E; Brady J; Soultati, A. 2011 Greece AAA Retrospective study of 62 patients over a four year period who had undergone a AAA utilising cell salvage. Used a 
simplistic cost model assuming the volume of blood reinfused was a direct substitute for allogeneic blood. Note the high 
price of allogeneic blood in Greece. This makes CS more attractive. Is 62 patients over such a long period to calculate an 
average reinfusion of 2.52 units a sufficient estimate? Same maintained machines used? Same surgeons/techniques? 
Concluded that salvaging <2 units was not cost effective. NB look at Pittsburgh notes re concentrations-was this taken into 
account? Medium
Intraoperative Use of Cell Saver on Patients Undergoing 
Open Abdominal Aortic Aneurysm Surgical Repair: A 
Greek Hospital Experience
A40 Kumar N., Chen Y., Nath C., Liu E.H. 2012 Singapore Orthopaedics
Focused on Spine surgery. Useful summary of autologous techniques. Unfavourable summary of PAD; not enthusiastic on 
ANH but keen on both ICS and POCS. Quoted costs in Savvidou (2009) but these did not tie to those in Savidou et al's 
article. Kumar et al had converted fron euros into dollars and concluded the cost of allogeneic txns was 12 times greated 
than salvaged. Bit disconcerting. Did not find any retraction/clarification. Medium
What Is The Role Of Autologous Blood Transfusion In 
Major Spine Surgery?
H:\My Documents\PhD 2017 h Drive\Submission\Appendices\20171116contents excel.xlsx
Brief Summary of Articles to End 2013
Ref Author Year Country Specialty Summary
Reference 
to Costs Title
4 Liumbruno GM; Liumbruno C; Rafanelli D 2011 US Obstetrics Again cites the hazards of allogeneic; notes the increased risk of alloimmunisation-where the patient's blood effectively 
becomes immune to the benefits of the allogeneic blood. Vague on costs, points to Waters (91) and ignores the stand by 
costs. High
Intraoperative Cell Salvage in Obstetrics: is it a Real 
Therapeutic Option?
52 MacIvor D; Nelson J; Triulzi D 2009 US Urology
Study of radical prostatectomy by one surgeon at UPMC between April-Jun 2005 (Gp 1) and Apr-Jun 2006 (Gp 2). Data 
taken included txn rates, volumes, pre/post op Hb rates and LOS. Gp 1 was exclusively PAD and Gp 2 CS. Typical levels 
of wasteage in Gp 1 but no  allogeneic txn. 2/63 had allogeneic txn in Gp2. Note the significantly higher Hb levels pre-op 
for Gp2. Expect this as PAD will reduce Hb levels. No real focus on outcomes since timings are too short. No focus on 
costs. Conclusion was that PAD associated with higher risks e.g. mix ups, older product, so CS avoids these risks. No 
mention of risks associated with CS. Low
Impact of Intraoperative Red Blood Cell Salvage on 
Transfusion Requirements and Outcomes in Radical 
Prostatectomy
38 Mackenzie M.J.; Yentis S.M.; Sooranna S.; Johnson M.R. 2010 UK Obstetrics
Filtration of amniotic fluid with call salvage without washing. This is early days on research and a sample of 8 patients were 
studied. Not really convincing-"cell salvage...(may)..prove to be useful in dire situations". Low Passage of Amniotic Fluid Through Leucocyte Filters
66
Markovic M.; Davidovic L.; Savic N.; Sindjelic R.; Ille T.; 
Dragas M. 2009 Serbia Cardiovascular
Prospective study of 90 consecutive patients (2004/2005) against a consecutive listing (2002) of 90 patients that did not 
undergo CS. Noted that RAAA (Ruptured) has high immediate blood loss. CS can commence immediately while there was 
an average wait of 30 minutes to an hour for allogeneic blood to be cross matched and supplied from the blood bank. Cited 
TRALI and other side effects. There were a number of older references quoted. Concluded CS is more cost effective when 
>3 units of allogeneic blood are required. Costs were allogeneic blood v consumable costs (the kit was provided foc). No 
mention of training costs. High
Intraoperative Cell Salvage versus Allogeneic 
Transfusion During Abdominal Aortic Surgery: Clinical 
and Financial Outcomes.
A34
Michael AL, Loughenbury PR, Rao AS, Dunsmuir RA, Millner 
PA 2012 UK Orthopaedics
Highlighted variations in practice in scoliosis surgery. High proportion of cell salvage/blood recycling routine usage (78%); 
16% stated never used it. May be useful to QUOTE in intro. Low
A Survey Of Current Controversies In Scoliosis Surgery 
In The United Kingdom.
A31 Morris S., Robinson M., Uncles D.R. 2012 UK Obstetrics
Large sample (675) operated in collect first (£19.50) on Sorin Electa. Reinfused 75 (£40.50). Interesting to see how they got 
their costs. Results were £160 for CS  v £162 for allogeneic. However how did they calculate the substitution of salvaged v 
allogeneic. Worthwhile asking. Compare costs with John's at RCH. Very similar. Medium
An Analysis Of The Use Of Routine Cell Salvage For 
Caesarean Section In A South Coast District General 
Hospital
A41 Munoz M., Ariza D., Campos A., Martin-Montanez E. 2012 Spain Orthopaedics
Traditional study assessing txn rate and LOS; assigning an average cost of €320 per in patient day. Calculated that the LOS 
is one day longer when a patient had an allogeneic txn. High
Cost-Effectiveness Of Postoperative Shed Blood 
Reinfusion After Major Orthopedic Surgery: An 
Analysis Of 1093 Consecutive Total Knee 
Arthroplasties
A12 Murthy N., Uchil D. 2013 UK Obstetrics
Thought provoking. Two machines at the hospital (Lewisham), 7 patients identified (changed then to 8) over 26 months. 
Not useful but what were the machines doing for the rest of the time? Had any staff been trained? Low
Saving Mothers' Lives-Have We Caught Up With 
Intraoperative Cell Salvage In Obstetrics?
A20 Nathwani R., Price J., Kaur J. 2013 UK Orthopaedics
Another traditional study that generates a "loss". Insufficient detail on e.g. pre and post op Hbon which to base any 
conclusions. Pointed out deficiencies in theatre staff experience and lack of effective clinical audit contributed to lower take 
up. Medium
Intra-Operative Cell Salvage Use In A Tertiary 
Orthopaedic Centre
A25 None stated 2012 UK Cross Not directly relevant Low Grant For Cell Salvage Research During Normal Births.
A10 None stated 2013 UK Cross Not directly relevant Low
Update On The UK Cell Salvage Action Group 
Autologous Transfusion Label.
A28 Oberhofer D., Sakic K., Jankovic S., Tonkovic D., Vrgoc G. 2012 Croatia Orthopaedics Noted high txn rates in THR (63%, n =30) and pointed to the requirements to introduce blood conservation programmes. Low
[How To Improve Perioperative Blood Management In 
Patients Undergoing Total Hip Or Knee Replacement 
Surgery?] [Croatian] Kako Poboljsati Transfuzijsko 
Lijecenje Bolesnika Podvrgnutih Ugradnji Totalnih 
Endoproteza Kuka I Koljena?
A23 Odak S., Raza A., Shah N., Clayson A. 2013 UK Orthopaedics
"Traditional" comparison of costs in pelvic acetabular injuries giving an average saving in blood costs by using CS costs of 
£87 per patient. Worked out the mean blood loss was 1.32 litres from the stats on the machine and weighing the swabs. 
Using McClelland HB increase of 10g/l with one allogeneic unit;  a  250ml (1 allogeneic unit) equates to a notional 50 g/l 
fall in Hb level (1,320 ml/250ml). The pre-op mean was 118 g/l; less 50 g/l requirement equates to needing 2 allogeneic 
units over the 80 g/l threshold. With 30 patients this is 2 x 30 = 60 units less the actual units required of 26 to give 34 units 
avoided.
This is all very theoretical; we do not know actually how much would have been actually avoided. The average age of the 
patient is 41 years' old; chances are they're fairly fit and could withstand a temporary fall to below 80g/l anyway. High
Clinical Efficacy And Cost Effectiveness Of 
Intraoperative Cell Salvage In Pelvic Trauma Surgery
A19 Offierski C.M., Gagne S., Bishop C. 2013 Canada Orthopaedics
Poster. Looked at a "gradual adoption" of tranexamic acid (TA) in orthopaedics in Niagara Hospital. Saw significant fall in 
rate of blood txn (19% to 11%) once TA utilised. The number of units required also fell when a patient had a txn. Actual 
patient numbers were fairly significant as number of patients not requiring a txn fell by 65; saving 130 units (often the usual 
2 units); this equated to potential cost savings of $160,000 and saving of 72 bed days (not explained). Post op Hb levels 
were higher using TA though this rate was not separated out between hips and knees. High
Efficacy Of Tranexamic Acid For Blood Conservation 
In Primary Total Joint Arthroplasty
34 Olshove 2010 US Paeds
Introduced a programme of blood management, utilising ANH as well as CS from 2006. Showed in  2006-2008 the txn rate 
had fallen from 70% in 2003-2005 to 57%. Difficulty in making the comparison but this is always an issue with cardiac. Low
Perfusion Techniques Toward Bloodless Paediatric 
Open Heart Surgery
32 Osaro E.; Njemanze C. 2010 UK Cross
Summary of main issues relating to autologous issues overall rather than cell salvage. Stressed that all autologous techniques 
should be used to minimise pressure on allogeneic requirements. Useful to consider the cost-effectiveness of this assertion 
but this was not pursued. Low
Chalenges of Meeting the Future Blood Transfusion 
Requirement in England & Wales. Autologous Blood 
Transfusion Could Become an Adjunct to the UK Blood 
Transfusion Program in the Future
99 Ostrowsky J; Henderson M; Hennein H 2006 US Cardiothoracic
Described a specialist technique for paediatric heart surgery. Extracorporeal circuit (the tubes etc) need priming. Cell 
salvage can work but, given the size of the patient, an arterial pump can be used to start the process. This is highly 
specialised. No mention of costs/LOS. Useful to note generally that CS would only really be useful when the kit is used a lot 
in "common" operations. Low
Autologous Priming Technique to Reduce Blood 
Transfusion in Pediatric Cardiopulmonary Bypass
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90 Pape A.; Habler O. 2007 Cross General overview. Low Alternatives to Allogeneic Blood Transfusions
37 Pathak D.; McDonald A.; Barclay P.; Mallaiah S. 2010 UK Obstetrics
CS during C section. Poster looks at "moderate" risk of txn. Supported by Sorin. If full bowl then re-infused. Only 2 
patients out of 100 required an allogeneic txn. 17 of these underwent cell salvage (i.e. they were not at minimal risk of 
needing a txn). Av fall in pre to post op Hb was 1.28 g/dl for CS against 1.57 for non-CS. Rem CS used in higher risk group 
so difference is effectively exacerbated. Only one noted with a declaration of interest (Sorin) Medium Use of Cell Salvage in Caesarean Section
A27 Peacock L., Clark V., Catling S. 2012 UK Obstetrics
Concluded that there is "currently no evidence base that CS in obstetrics reduces allogeneic txns or is cost effective". See 
page 70 highlighted "the reservoir …". Useful to quote. Noted that there may be some benefit in targeting "situations" where 
"bleeding could could be predicted and worthwhile volumes of blood were likely to be collected". Useful, however, to quote 
this article to exclude Obstetrics in preference to Orthopaedics for my analysis. Low
Recent Developments In The Obstetric Use Of Cell 
Salvage
102
Phillips S.D.; Maguire D.; Deshpande R.; Muiesan P.; Bowles 
M.J.; Rela M.; Heaton ND. 2006 UK Liver Tx
Study of 660 patients who had a liver tx between Jan 1997 and July 2002. Blood loss recorded; inc salvaged, suctioned and 
swabs.65% had CS. Cost of CS operation was £138. Very high txn volumes-median was 3260 mls. Associated low pre op 
Hb with higher txn volumes-no other factor correlated (e.g. age, gender). Large volumes of blood salvaged. Calculations are 
unclear but the methodology is to calculate a notional total cost if no CS was used (£503,443) and subtract the blood and 
CS related costs of actual usage (£371,542). This gives a 26% saving. It is not clear how these figures were derived. Key 
assumption was that the allogeneic units and recycled units were of the same concentration. This is not the case and implies 
the "saving" is understated. Concluded CS is cost effective if >80 cases are undertaken per year. High
A Prospective Study Investigating the Cost 
Effectiveness of Intraoperative Blood Salvage During 
Liver Transplation
97
Phillips SJ; Chavan R; Porter ML; Kay PR; Hodgkinson JP; 
Purbach B; Reddick AH; Frayne JM 2006 UK Orthopaedics
Retrospective study of 80 patients using both cell salvage and tranexamic acid on 40 (group A) v 40 (group B) in a control 
group that had neither. 22 needed an allogeneic txn in group A v 37 in group B. Cannot isolate whether the tranexamic 
acid or the cell salvage (or both) caused the favourable movement. Identified £70k of savings due to allogeneic blood 
avoidance and lower LOS of 2.8 days if no allogeneic txn was undertaken. Savings were sketch and seemed to be based 
partly on an in patient day occupancy rate of £270. Medium
Does Salvage and Tranexamic Acid Reduce the Need 
for Blood Transfusion in Revision Hip Surgery
5 Portsmore S.; Jarman H.; Jaiganesh T. 2011 UK Emergency
Focus on trauma/massive haemorrhage. Indicates CS cost effective from vols of >250-500 ml blood loss. High
Autologous Cell Salvage Within an Emergency 
Department-A Feasibility Study
57 Powell E.; Osborn N. 2009 UK Obstetrics
Poster-retrospective study of cesaerean activity at Heartland's Hospital. Reluctance to have the ODP using the CS equipment 
in emergency situations because few ODPs trained. Ones who were trained were deployed mainly on elective surgery. 
Where CS not used (20 ops) 16 were emergency and av allogeneic blood required was >3.5 units per op. Corresponding 
info for elective surgery  was not complete but, of 34 cases (28 elective)  using CS, 12 required txns. Conclusion was that 
CS would generate the bigger savings in the emergency setting and the training of ODPS was the limiting factor. Medium
Audit of Autologous and Allogeneic Blood Use in 
Obstetrics
88 Rahman IA; Hoth T; Doughty H; Bonser RS 2007 UK Cardiothoracic
Rare event in a patient with a thoraco-abdominal aneurysm repair in JW patient. Highly likely to require a txn. Conclusion 
sums up "....full repairs are possible in highly selected patients, provided that there is meticulous planning and utilisation of 
an array of blood conservation methods". Low
Thoraco-Abdominal Aneurysm Repair in a Jehovah's 
Witness: Maximising Blood Conservation
21 Ralph C; Faulds J; Sullivan I 2010 UK Obstetrics Follow up to "20". Inconclusive. Note as a side effect. Medium Cell salvage and leucocyte depletion filters
1 Rando K.; Niemann C.U.; Taura P.; Klinck J. 2011 Multi Nat Liver Tx
Focus on developing countries. CS is one of many categories reviewed in Liver Tx. Recommends ancillary attendants to be 
trained in CS.The conclusion is that "reduced cost and risk are likely in proportion to blood loss". Low
Optimizing Cost Effectiveness in Perioperative Care for 
Liver Transplantation:A model for Low to Medium-
Income Countries
A36 Rao VK, Dyga R, Bartels C, Waters JH 2012 US Orthopaedics
Compared notional costs between salvaged and allogeneic blood by converting the volumes reinfused and then comparing 
the cost of cell salvage with the allogeneic units. Did not include cost of storing the allogeneic blood. Converted the volumes 
salvaged into "therapeutically equivalent units of allogeneic RBCs". This study therefore worked on notional savings; 
similar to many studies. One key point was raised around the majority of blood loss in THR is intraoperatively and the 
therapeutically equivalent unit is <1. This calls into question whether the Orthopat usage was necessary. Highlight this 
with Haemonetics telecon. High
A Cost Study Of Postoperative Cell Salvage In The 
Setting Of Elective Primary Hip And Knee Arthroplasty.
A24 Raval JS, Nelson JB, Woldemichael E, Triulzi DJ 2012 US Oncology Not relevant. Compared PAD with CS with no discussion on costs. ICS now used "in lieu of PAD". Low
Intraoperative Cell Salvage In Radical Prostatectomy 
Does Not Appear To Increase Long-Term Biochemical 
Recurrence, Metastases, Or Mortality.
A26 Roberts H., Carroll C. 2012 Australia Neurosurgery Not relevant. No guidelines for CS in Neuro therefore uncharted territory. Low Use Of Intraoperative Cell Salvage In Neurosurgery
A51
Rollins, Ke, Trim, Nl, Luddington, Rj, Colah, S, Klein, A, 
Besser, Mw, Nair, Sk 2012 US Cardiac
Extreme example. One cardiac patient who lost 18 litres of blod in the first 24 hours post surgery. Various conslicts between 
high levels of heparin because of continuing salvaging. Low
Coagulopathy Associated With Massive Cell Salvage 
Transfusion Following Aortic Surgery.
A04
Samnaliev M, Tran CM, Sloan SR, Gasior I, Lightdale JR, 
Brustowicz RM 2013 US Paeds
Analysis of 478 paediatric patients; 90% were orthopaedic. All had CS and 50% received allogeneic blood. Concluded that 
CS cheapest and then combined with allogeneic txn. Allogeneic txn alone came next then finally pre-deposit. Could not use 
a control group so utilised a decision tree model of "hypothetical identical control group of patients". High
Economic Evaluation Of Cell Salvage In Pediatric 
Surgery.
A44
Samnaliev M., Tran C., Gasior I., Sloan S.R., Lightdale J., 
Brustowicz R. 2012 US Paeds Used average costs to compare CS v allogeneic costs. No workings but stated "CS resulted in savings of =<$556 per patient. Medium Cost Analysis Of Cell Salvage In Pediatric Surgery
51
Savvidou C.; Chatziioannou S.N.; Pilichou A.; Pneumaticos 
S.G. 2009 Greece Orthopaedics
Study on adult lumbar fusion. 50 patients randomised to 25 with CS and 25 without. Used "local" price of unit of allogeneic 
blood (€450). Concluded that the cost of cell salvage  was cheaper than using allogeneic blood even where allogeneic blood 
was required in the CS group. One concern was that the average age of the CS group (gp A) was 56 years v 61 years in gp 
B. No mention of this in the text. Also no mention of "collect first" for gp A. Note though that txn rate is high. All gp B 
were txd v 48% in gp A. Pre op Hbs were similar. High
Efficacy and Cost-Effectiveness of Cell Saving Blood 
Autotransfusion in Adult Lumbar Fusion
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58 Scannell BP; Loeffler BJ; Bosse MJ; Kellam JF; Sims SH 2009 US Orthopaedics
Study looked at 186 patients treated for acetabular fracture (where femur is forced into pelvis). There are basic costs; flat 
transfusion fee of $542.50 plus $404.50 per allogeneic unit. CS has a flat rate fee of $976.73. LOS significantly higher 
when CS not used. Consistent with my analysis. Note comments on inability to assess and predict the patients who woul 
dbenefit from CS. This mainly boils down to clinician judgement. One of the clinicians never used CS-not expalined why 
this is the case or the potential distortions this can cause. Note CS cheaper if >= 2 units required. Article points to these 
costs being small in relation to overall bill. However relate blood costs to the HRG tariff price in the UK-will be significant. 
Reference to "no formal protocol for blood txn". Pre op assessments not really relevant given the time between trauma and 
surgery is around 5 days. Note pp 344 the general signs/reasons for txn. High
Efficacy of Intraoperative Red Blood Cell Salvage and 
Autotransfusion in the Treatment of Acetabular 
Fractures
59 Schill DM 2009 US Cardiac
Two case studies quoted. Obviously not sufficient to base any firm conclusions. Their conclusion is that it is possible to 
eliminate the need for allogeneic blood. This is nothing new. Low
Bloodless Aortic Valve and Ascending Aorta 
Replacement Surgery Requiring Circulatory Arrest: Two 
Case Studies
A50 Shander A, Javidroozi M 2012 US Cross
Highlighted concept of PBM (see pp 51). Noted minimising blood loss as one of the three strands of PBM. Uses the term 
"restrictive txn practices" on pp 54. Autotxn strategies can be a "pre-emptive" element of PBM. Low
Strategies To Reduce The Use Of Blood Products: A US 
Perspective.
40 Sharma S; Gunning P 2010 UK Surgery
Snapshot survey of Sp Regs and Clin Fellows in North West Thames. 72% responded. Low CS utilisation primarily due to 
lack of familiarity with the process. The medic has overall responsibility for the operation but "85% of Registrars had never 
set up a cell saver device themselves and were not confident at doing so and operating it". Note comment on Royal college 
of Anaesthetists-always use CS in emergency surgery where blood loss > 1 litre. Low
The Need for Intra-Operative Cell Salvage training to 
reduce the Use of Allogeneic "bank" Blood During 
Surgery. Is the Routine Adoption of a Competency-
Based Assessment in Intra-Operative Cell Salvage 
Required?
67 Sinclair KC; Clarke HD; Noble BN 2009 US Orthopaedics
Transfusion trigger of 9g/dL adopted on TKR. Three way comparison between PAD, CS using an Orthopat and allogeneic 
blood, if required. Concluded that PAD and CS gave similar results in avoiding allogeneic blood (25 % of CS  required 
allogeneic blood with 18% for PAD) the costs were significantly higher with CS. No costs were, however, included. Low
Blood Management in Total Knee Arthroplasty: A 
Comparison of Techniques
83 Singh K.; Kaur A.; Singh A.; Singh R. 2007 India Cardiothoracic
Very basic study of a variant of cell salvage with a drainage system used to collect shed blood in a bag. The blood was 
immediately reinfused via  a filter. No mention of costs or allogeneic units avoided. Low
Intraoperative Autotransfusion-A Simple and Cost 
Effective Method
A05 Solomon L, von Rahden RP, Allorto NL 2013 South AfricaObstetrics
Analysed all blood salvaged and reinfused between July 2012 to June 2013 and converted this to equivalent units of 
allogeneic blood. Little difference in the costs of either. Note the optical sensors to assess haematocrit rather than the 
"smoothie" approach at RCH. Focused mainly on trauma and Obstetrics. Noted the instantaneous aspect of having the 
salvaged blood available imediately rather than having to wait for allogeneic blood that can be in short supply. Highlighted 
the relatively low volumes of salvaged blood and implied that more effective usage would increase the savings. No alloeneic 
txn rates were given nor was it stated that the patient would have actually needed the salvaged blood. High
Intra-Operative Cell Salvage In South Africa: Feasible, 
Beneficial And Economical.
25 Spahn DR 2010 Multi Nat Orthopaedics Highlighted HB levels of F <12 and M <13 as "unmet medical need". Large analysis of studies whittled down to 49. 
Compared various factors on e.g. age, anaemia defn, pre and post op Hb, txn rate. Difficult to undertake the comparisons as 
they were not a standard set of factors to analyse e.g. some did not differentiate between age of M/F. Did highlight LOS 
being associated with low Hbs. CS conclusion was that CS "generally reduced the need for an allogeneic blood txn" (p 
489). Overall conclusion was around anaemia treatments requiring allogeneic txns. Should look further at patient blood 
management initiatives. High
Anemia and Patient Blood Management in Hip and 
Knee Surgery
26 Sreelakshmi T.R.; Eldridge J. 2010 UK Obstetrics
Detail that initiated the discussion in 20 and 21 above. Recommends if hypotension then remove the filter as " the washing 
process alone is very effective at removing fetal tissue". Medium
Acute Hypotension Associated With Leucocyte 
Depletion Filters During Cell Salvaged Blood 
Transfusion
55 Staber M.; Junkin R.; Watson T. 2009 UK Orthopaedics
Mix of elective and emergency. Where an allogeneic txn then 2.8 units transfused. Used the £140 per unit cost of blood. 
Assessed CS was cost effective at the equivalent of 0.5 units (post op) and 1 unit (intraop). High
Blood Transfusions in Orthopaedics and Blood Salvage-
A Cost Consideration
70 Steffens TG; Kohmoto T; Edwards N; Wolman RL; Holt DW 2008 US Cardiac
Study on modified ultrafiltration ( a technique able to remove the fluid overload and inflammatory mediators associated 
with use of cardiopulmonary bypass). This technique is used a lot on paediatrics but less so in adults. The study was 
terminated early because of a practice change and a move to ANH. Only 19 subjects went through the trial. It was arguably 
pointless to pursue the trial with a small sample and, effectively, no management support. Low
Effects of Modified Ultrafiltration on Coagulation as 
Measured by the Thrombolelastograph
A30 Tan N.L., Corbineau H., Phu B.D., Verhoye J.-P. 2012 Vietnam Cardiac
Study of 68 patients; 21 of whom underwent CS. Decision on whether to salvage was based on three criteria when Hb 
<100g/l. These were age, haemodilution (based on serum protein level) and how impaired the left ventricular function was 
performing. This seemed very subjective. Their conclusion was that the use of a cell saver was "useless" in most cases. Low
Is A Cell Saver Necessary In Off-Pump Coronary Artery 
Bypass Surgery?
46 Tanqueray T; Allam J; Norman B; Cox M 2010 UK Obstetrics
Letter-Similar to issues of hypotension and using LDF's (see 20 above). In massive obstetric haemmorhage may be safer to 
remove the filter. There would be more amniotic fluid contaminants but this is a lower risk. What about "top up" of 
allogeneic blood? Low
Leucocyte Depletion Filter and a Second Suction Circuit 
During Intra-Opertive Cell Salvage in Obstetrics
80 Tawfick W.A.; O'Connor M.; Hynes N.; Sultan S. 2008 Ireland Cardiovascular
AAA study. Assessed 187 patients over nine years with 101 using Fresenius CATS salvage machine. "Traditional style" 
study comparing allogeneic blood usage, LOS and using average costs to demonstrate the shorter LOS meant significant 
savings in overhead costs. Patients allocated to CATS if there was a skilled operative available. No mention of significantly 
higher proportion of elective patients in CATS rather than the control group. With such a wide period of study (9 years) 
other techniques may have developed, training may have improved etc. These issues were not addressed. Very optimistic. High
Implementation of the Continuous Autotransfusion 
System (CATS) in Open Abdominal Aortic Aneurysm 
Repair: An Observational Comparative Cohort Study.
A39 Thomas D.W. 2012 UK Cross
Assessed the pros and cons of CS. Noted the disadvantages were "mainly organisational" such as enthusiasm of clinical 
lead, training and a minimum level of activity in order to generte operator competencies (use this reference to my "flying 
hours"). Noted that CS can be expensive but no detail provided. Highlighted "there remains a reluctance to use (CS) in all 
surgical situations due to clinical objections about the likelihood of contamination". Low
Surgical And Anaesthetic Management Of Anaemia: 
Pros And Cons Of Cell Salvage Devices
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8 Thurer R.L.; Parce P.; Parrell S.; Popovsky M.A. 2011 US Cross Summary of poster. Author is on the Haemonetics payroll. CS reduced txn rate by 43% to 5%. However Orthopat cannot 
benefit from the just incurring stand by costs-all or nothing because of the one price for consumables. Useful conclusion 
on the idea that more than one blood avoidance tool, being used together, can make it difficult to isolate what tool 
contributes to the lower blood requirement. High
How Effective are Educational Programs as Part of a 
Comprehensive Strategy to Limit Stored Blood 
Transfusion?
22.2 Thurer R.L.; Parrell S.; Dowling W.J.; Parce P.; Popovsky M.A. 2010 US Orthopaedics Knee surgery. Note the post-operative bleeding. Ideal for the Orthopat. Compared, with same surgeons at same hospital 370 
TKR ops in 2007 with 400 patients in 2009, all utilising the Orthopat. PAD was also used extensively. 2009-allogeneic 
transfusion fell by 33% and requirements to undertake PAD txn fell by 45%. Discharge Hb level was virtually unchanged. 
Note nothing about age/gender. High
Postoperative Blood Salvage with Cell Washing 
Reduces Transfusion Requirements for Patients Having 
Total Knee Replacement Surgery
12 Tse EY; Cheung WY; Ng KF; Luk KD 2011 China Orthopaedics Covers a wide range of blood avoidance techniques. Notes the 2 unit estimate for cost saving (quotes Gause PR et al in 
Spine 2008; 33:571-5). Highlights the difficulties in isolating the effectiveness of individual techniques when a 
number of them will be used together (one of the points frequently raised by the RCH). Medium
Reducing Perioperative Blood Loss and Allogeneic 
Blood Transfusion in Patients Undergoing Major Spine 
Surgery
28
Ubee S.S.; Manikandan R.; Gudimetla A.R.; Singh G 2010 India Urology Unclear where the study was hosted-may have been in Southport, Lancashire. See "19" above. Another small sample with 
no split over M/F. Points to lower RBC requirements if CS is used but how valid given you are only looking at sample of 2 
x 15 patients. ANH and PAD referred to but seems like not utilised. Medium Cost Benefits of Cell Salvage in Radical Cystectomy
19 Ubee S; Kumar M; Athmanathan N; Singh G; Vesey S 2011 UK Urology Txn threshold of 9 g/dl used. 6 patients out of the 25 in the allogeneic group had blood given interoperatively. Small 
samples.CS group had allogeneic txns on ward. LOS in gp A was 7 days and 5 days in group B. With £135 per unit authors 
felt it cost-effective. High
Intraoperative Red Blood Cell Salvage and Autologous 
Transfusion During Open Radical Retropubic 
Prostatectomy: a Cost Benefit Analysis
24 Vassili M. 2010 US Cardiac Poster. Just a list of blood avoidance techniques summarising recent literature (three references included). Low Intraoperative Blood Salvage
64
Venkatachalam KL; Fanning LJ; Willis EA; Beinborn DS; 
Bradley DJ; Cha Y; Shen W; Asirvatham SJ; Sinak LJ; Packer 
DL; Munger TM; Santrach PJ; Friedman PA 2008 US Cardiovascular
Small scale pilot study of nine consecutive Periocardiocentesis (fluid aspirated from the sac round the heart). All were cell 
salvaged and 4/9 did not need allogeneic txn. Striking that this evidence was used to partly justify the establishment of a 
"rapid response" team to permit cell salvage. Tie this in with the view from Jon Waters that extra resources are needed and 
John F's view that CS in part is a motivator and focal point for all the other blood avoidance techniques. Low
Use of an Autologous Blood Recovery System During 
Emergency Pericardiocentesis in the Electrophysiology 
Laboratory
50
Vieira S.D.; Dourado D.A.; Amaral E.V.; Souza L.C.; Buffolo 
E.; Arrais M.; Carballo M.T.; Berwanger O.; Colella R. 2009 Brazil Cardiac
Short conference abstract. Stressed that minority of cardiac patients consume >80% of intraoperative allogeneic blood. 
Recommended targeting the patients who were in the highest risk group. This group included age >70 and renal 
insufficiency. It noted three other common surgical procedures that had a higher risk of a txn being required. High
Risk Factors for Increased Blood Transfusion in Patients 
Submitted to Cardiac Surgery with Intraoperative 
Autologous Transfusion: A Cohort Study
A02
Vonk, Alexander B A, Meesters, Michael I, Garnier, Robert P, 
Romijn, Johannes W A, van Barneveld, Lerau J M, Heymans, 
Martijn W, Jansen, Evert K, Boer, Christa 2013 Netherlands Cardiac
No focus or mention of costs. This was a large scale single site study that used the Euroscore (European system for cardiac 
operative risk evaluation). This calculates the expected risk of death and therefore was used to select low to medium risk 
patients. Statistical analysis assessed patient demographics and surgical characteristics were similar between the two groups. 
Conclusion was that CS significantly avoided the need for an allogeneic txn both intra-op and post op. USEFUL to quote.
Woud have been useful to assess costs of programme and operational costs of CS. Median number of allogeneic units in non-
CS was 2 units v 1 unit for CS patients. 39% of patients needed allogeneic txns in non-CS v 20% in CS. Low
Intraoperative Cell Salvage Is Associated With Reduced 
Postoperative Blood Loss And Transfusion 
Requirements In Cardiac Surgery: A Cohort Study.
20 Waldron S 2010 UK Obstetrics Hypotension-low blood pressure. Noted there may be a link with the leucocyte depletion filters (LDFs) that remove the the 
white cells  prior to reinfusion. Medium
Hypotension Associated with Leucocyte Depletion 
Filters Following Cell Salvage in Obstetrics
15 Waldron S.; Chadwick S.; Parkes A.; Kirk P. 2011 UK Obstetrics Poster assessing costs in caesarean sections. Cross refs to the NICE guidance stating IPG144 "endorsed". Took 100 
consecutive patients and undertook "collect first" with a Fresenius CATS. Showed a "saving" of £2,200 on the 100 patients-
very basic-did not include training costs. Noted difficulties in transvaginal blood and recommended further studies. 
Catherine Ralph undertaking a study in this area at the moment. High A Cost Assessment of Cell Salvage in Obstetrics
54 Waldron-Lynch F; Herold KC 2009 US Diabetes Not relevant Low
Advances in Type 1 Diabetes 
Therapeutics:Immunomodulation and Beta-Cell Salvage
91 Waters J.R.; Meier H.H.; Waters J.H. 2007 US Cross
Confusing analysis of costs. Includes costs for staff that are viewed as a necessity. Omits e.g. maintenance costs. Calculates 
a notional unit of salvaged blood and compares this against the estimated allogeneic blood usage that would have been 
required. These costs may or may not have been incurred and consequently the conclusions are sweeping. High
An Economic Analysis of Costs Associated with 
Development of a Cell Salvage Program
22.1 Waters J; Dyga R; Wisniewski M; Yazer M 2010 US Orthopaedics THR surgery. Significant variation between txn rates per surgeon. Overall txn rate is 47%; massively higher than RCH or S 
Manc. LOS higher where txn but still lower than my averages. High
RBC Transfusion Practice in Total Hip Replacement 
Surgery is Highly Variable
22.3 Waters J; Dyga R; Wisniewski M; Yazer M 2010 US Orthopaedics Looked at transfusion practice in Orthopaedic surgery. Concluded "extensive variation in practice exists between 
orthopaedic surgeons doing equivalent surgical procedures". Crucially "cell salvage might not be beneficial in THR". Useful 
to highlight in intro to thesis that pre-operative autologous donations are still popular in the US. This could decrease the pre-
op Hb level but then there is sufficient non-allogeneic blood to infuse into the patient. Look at the last sentence "cell salvage 
might not be beneficial in THR". High Transfusion Practice in Orthopedic Surgery
74 Wise A, Clark V 2008 UK Obstetrics
Not much detail. Noted (inter alia) cell salvage has made its debut in the past 10 years. No reference to cost except cost of 
allogeneic blood. Low Strategies to Manage Major Obstetric Haemorrhage
13 Yarham, G; Clements, A Oliver, M; Morris, C; Cumberland, T; 
Bryan, M; Jekler, S; Johns, K; Mulholland, J
2011 UK Evaluation Evaluation of the Sorin Xtra (the updated Electa, in use at RCH) at the Essex Cardiothoracic Centre. Inflates the cost of a 
unit of allogeneic blood for cost of group & screen (determine ABO and Rh) and cross match (check for antibodies). These 
techniques would have been undertaken anyway. Emphasises the downsides of txns quoting higher mortality in cardiac if a 
patient has a txn. Also quotes the age of blood study by Koch. Conclusion that this machine is the "next generation" and the 
outputs are mainly what the manufacturer claims. High
Evaluating the "Next Generation" of Cell Salvage-Will 
it Make a Difference
75
Yazer MH; Waters JH; Elkin KR; Rohrbaugh ME; Kameneva 
MV 2008 US Cross
Keeping suction pressure down reduces the damage to the RBCs. Compared COBE Brat with Haemonetics SmartSuction. 
Tests undertaken in lab environment. Concluded that varying (and speeding up) the suction does not significantly increase 
the yield of salvaged blood. Low
A Comparison of Hemolysis and Red Cell Mechanical 
Fragility in Blood Collected with Different Cell Salvage 
Suction Devices
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96 Kulej J; Wall A; Dragan S; Krawczyk A; Romaszkiewicz P 2006 Cross Eastern European. Focused on PAD Low
The Value of Autotransfusion in the Management of 
Intraoperative Blood Loss During Orthopaedic Surgery
87 Boulton F; James V; Stainsby D 2007 Cross Not relevant-All PAD Low
Guidelines to Policies on Alternatives to Allogeneic 
Blood Transfusion. Predeposit Autologous Blood 
Donation and Transfusion
95 Gomez M; Vives E; Garcia-Erce J; Sanchez C; Llach X 2007 Spain Orthopaedics
Spanish article. Only summary translated, Calculates POCS with Orthopat cheaper than allogeneic transfusion. Used 
average costs from a database. Low
Economic Assessment of OrthoPat in Postoperative 
Recovery Compared to Standard Therapy in Knee 
Arthroplasty
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Lit Review Notes for Recent Articles 2014-16 
 
1. Background 
 
1.1. A search was performed on NHS Athens on 3 January 2017 using the same search 
criteria as for the previous searches. 71 articles including 16 duplicates. 29 were 
considered to be at least partially relevant. Key articles are listed below. 
 
2. Key Articles 
 
Ref 1st 
Author 
Spec Information 
1 Tio M et al Ortho Post op CS in TKA. CS would avoid allogeneic txn in 1 in 7 patients. 
Costs 10 x greater. Difficulty in spotting/predicting the “right” patients to 
salvage. 
2 So-Osman 
C et al 
Ortho Implied greater post-operative complications when patient salvaged. 
Likely to impact on LOS but not seemingly the case at RCH where the 
LOS is similar to SOC. 
3 Cote et al Cardiac ICS “associated with a cost benefit of $116 per patient”. Cardiac. 
4 Stone N Ortho Scoliosis-twisting of the spine-rarely emergency. CS reduces the demand 
for allogeneic txns-one unit less per operation. Not clear if this is an 
average of one unit over every patient. 
9 Lemke et 
al 
Liver Liver resection. Worked up a model-ICS cost minimising  
11 Yeung S et 
al 
Obs Volume of blood salvage not sufficient to increase Hb levels but regular 
use of cell savers keeps “the team up to date with the skills required”. 
Need further studies. 
12 Pawasker 
A et al 
Orth TKA. Meta-analysis. Concluded auto txn cost effective. 
13 Elmalky M 
et al 
Orth IOCS with leucodepletion filter cost effective in metastatic spine tumour 
surgery.  
14 Theusinger 
O et al 
Orth Pointed to joint impacts of other PBM techniques 
17 Guzel et al Orth TKA compared TXA with POCS and routine drainage. TXA more cost 
effective. Philosophical-if you combine CS and TXA then this is best for 
the patient but the separate benefits cannot be isolated unless you 
separate like in this study. Would you want to use both in targeted 
patients? 
20 Kelly P et 
al 
Orth Another spine. Same conclusion that CS not cost effective but may do so 
if it’s usage is targeted.  
24 Crossland 
C et al 
Obs CS more expensive. May be “untold benefits in keeping staff trained for 
unexpected haemorrhages, avoiding risks of allogeneic txn and improved 
patient outcomes”. Sledgehammer to crack the nut? 
29 Goucher et 
al 
Obs CS cost effective where high blood loss predictable. 
33 Taylor et al Obs Titled “too much blood”. Txns undertaken with Hb>100 g/l. Note one of 
the co-authors was Paula Joy who undertook the highly critical 
orthoaedics study in Royal Gloucs. Useful back up for RCH restrictive 
blood practice. 
34 Rajkumar 
A 
Orth CS increased in PHR. Allogeneic txns fell markedly. Get copy of article. 
Any other contributors (e.g. TXA). 
35 Pendry K 
et al 
Cross PBM. Useful to note how everything is being brought together under the 
PBM umbrella. 
36 Xie Y et al Cardiac ICS generally safe in cardio by pass and cost effective in developed 
countries but not in China 
41 Li J et al Trauma Seemed to pinch Carless et al’s conclusion on “large, multicentre…” etc. 
45 Dhariwal S Obs Inconclusive. Pointed to SALVO study. 
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Ref 1st 
Author 
Spec Information 
46 Nemani V 
et al 
Orth Spine surgery. Concluded POCS kept Hb levels higher in early post op 
period but does not significantly reduce requirements for allogeneic 
blood. May be useful to quote in the LOS issue in that higher Hb may well 
point to lower LOS. 
49 Albright et 
al 
Obs Consider when “predictability high probability” of transfusion or when “a 
massive transfusion is reasonably likely”. 
50 Ratcliffe A 
et al 
Orth Revision hips at RCH. 13 day LOS with txn v 7 days without. “Believe” 
level of causation between allogeneic blood and LOS. 
52 England E 
et al 
Orth Noted national average txn rate of 25%. Seems very high. Track down 
the article. May be useful to quote. Increased cost associated with LOS 
looks like average costs. Noted TXA reduced Hb drop but not LOS. 
Causation and impact/influence of CS. 
53 Grainger H 
et al 
Cross Referred to Welsh database. Implied more “prudent” use of resources 
needed. 
57 Son M Gynae CS only cost effective when reinfused. This is stating the obvious but 
useful to stress. Noted the difficulty in predicting which patient will require 
reinfusion to avoid allogeneic txn. 
60 Font Gaul 
A et al 
Ortho Review of PBM one year on. Slight translation issue but txn rates fell with 
the implementation of PBM. 
61 Vigna-
Taglianti F 
et al 
Ortho Highlighted beneficial impact of TXA and high pre-op Hb levels. Note a 
limitation of my study is that I only have the word of the leads that TXA 
was administered in all cases. 
64 Bellam S Obs Equivalent unit calculation used. Low consumables costs but may not 
have VAT on them.  
65 Herd J Orth Traditional study over long period comparing against early control group. 
Noted techniques had changed and fall in txn rate may not just be in 
relation to CS. 
 
 
Bernard Crotty 
6 January 2017 
Appendix 8 
Donor Questionnaire Results 2013 
Survey Results Page l of6 
PAGE: RECENT ATTENDANCE 
1. Have you attended ~ Ofood donation session or cl'inic: In (he laEi( four mondls? 
Response Response 
Percent Gount 
Yes 76.7% 891 
No - 23.3% 270 
answered question 1,161 
skipped question O 
PAGE: REASON NOT A TIENDED 
2. lJIIhiCh of reasons below best explains why you haven't attende<! a blood donallon session in Ille last rour 
months (Tick aH that apply)? 
Response Response 
Percent Count 
I was too busy on the donation 
day. - 169% 50 
Haven't thought about îtJ 
forgot. • 4.2"10 11 
Location of the donation 
session was not convenient for 
me. - 9.4% 25 
Moved hamel work. 3.8% 10 
Lifestyle reason (E.g. have 
recently been to malarial 
country). • 5.3% 14 
No appointments available 
when I wanted to donate! 
session full. - 17.0% 46 
The timas of the donation 
session were not convenient 
for me. - 14.7% 39 
Health reason (E .. g medication, 
had operation that prevents me 
from giving). - 29.8"4 79 
Had bad experience at previous 
donation session. • 5.3% 14 
Other (please specify) 
Sho ..... répfies - 24.9% 66 
answered question 265 
Skipped questIon 896 
PAGE: REASON ATTENDED 
3. VVhich of the statements below appffes to you and your reasons for attending your last donation session (T;CX 
all that apply lo you)? 
Response Response 
Percent Count 
I always give blood when I'm 
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due. 64.9% 573 
I had an appointment 71.5% 631 
I had been meaning to give - 10.3% 91 blood for a while. 
I was able to give blood after a • 6.3% 56 period of being unable to. 
Someone I knew needed blOod. 1.6% 16 
Someone I knew was going 
was going to the donation 2.5% 22 
session. 
The location of the clonation 
61.6% 544 
sessicn was convenient for me. 
The time of the donation 
.50.1% 442 
session was convenient fOT me. 
It was a work-based donation 
32% 28 
session. 
Other (please specify) 30 
Show¡(lpI!l":o 
answered question 883 
skipped question 278 
PAGE: GIVE BLOOD AGAIN 
4. How ilkely are you lo gl"" bleod in lI1e funrre? 
I definitely will give blood in the 
future. 
Response Response 
Percent Count 
31% 36 
0.6% 7 
1.9% 22 
• 6.0% 69 
8S.3% 1,012 
answered question 1,146 
skipped question 15 
I definitely will not give blood In 
the future. 
I probably will noi give blood in 
the future. 
I am not sure whether I WIll give 
blood in tha future or not. 
I probablV will give blood in the 
future. 
PAGE: COMMITMENT QUESTIONS 
5. On a scare of one to ten, where one IS strongly disagree and ten is strongly agree, please say how strongly you agree with the followîng statements 
- -- --------_. 
Rating Rating 
2 3 4 5 6 7 8 9 io 
Average Count 
'Giving blood is very 1.2% 0,4% 0.5% 0.3% 1.2% 2.5% 5.9% 13.3% 14.0% 60.6% 
9.06 1,134 
important to me'. (14) (5) (6) (3) (14) (2S) (67) (151) (159) (687) 
'I have so many 28.2% 12.1% 9.7% 5.2% 93% 6.3% 8.9% 10.8% 4.7% 4.7% 4.25 1,134 
commitments it is (32tH (137) (110) (59) (106) (72) (101) (123) (53) (53) 
sometimes hard to give 
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blood'. 
'I reallv enjoy giving 
blood'. 
2.3% 
(26) 
4.2% 
(48) 
5.8% 
(66) 
4.9% 
(55) 
15.6% 
(177) 
6.4% 
(73) 
10.6% 
(120) 
14.9% 
(169) 
10.8% 
(123) 
24.4% 
(277) 
6.99 1,134 
answered question 1,134 
skipped question 7:T 
PAGE: 
6. How many minutes did you spend travelling to your last donation session from your 'taning poln!? 
Response Response 
Percent Count 
less than 5 minutes - 15.S% 178 
5-10 minutes 33.4% 377 
11-15 minutes - 21.2% 240 
16-20 minutes - 14.5% 164 
21-25 minutes • 5.0% 57 
26-30 minutes • 4.2% 48 
More lhan 30 minutes • 5.8% 66 
answered question 1,130 
skipped question 31 
PAGE: 
7 HOW many minutes did you spend travelling from your last donation session to your desënation? 
Response Response 
Percent Count 
less than 5 minutes - 15.9% 
5-10 minutes 34.3% 
11-15 minutes - 215% 
16-20 minutes - 14.2% 
21-25 minutes • 5.3% 
26-30 minutes • 3.7% 
More than 30 minutes • 4.9% 
179 
385 
242 
160 
60 
42 
55 
answered question 1,123 
Skipped question 38 
PAGE: 
8_ Wlat was your main mode of transport to your last donation session? 
Respoose Response 
" 
Percent Count 
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Bike 3.4% 38 
Bus 3.5% 39 
Car-solo 52.9% 598 
Car-shared - 9.6% 108 
Motorbike 0,4% 4 
Train 10% 11 
Tram 0.0% a 
Underground 15% 17 
Walk - 279% 315 
answered question 1,130 
skipped question 31 
PAGE: 
9. Which of the following best describes yoo (Uck as many as relevant)? 
Response Response 
Percent Count 
Homemaker - 9.0% 102 
In employment 63.3% 717 
Retired - 18.4% 209 
Self employoo - 10.1% 114 
Student • 4.7% 53 
Unemployed 2.9% 33 
answered question 1,133 
skipped questton 28 
PAGE: 
10. Which of the following best describes your emptoyrnent (lick as many as relevanl)? 
Response Response 
Percent Count 
Full-time 81.5% SSO 
Part-time - 17.9% 121 
In the public sector - 20.6% 139 
In the private sector - 23.7% 160 
answered question 675 
skipped. question 486 
PAGE: 
11 Does your employer deduct pay because you attend a blood donation session? 
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No 
Response Response 
Percent Count 
• 4.5% 30 
86.0% 573 
- 9.5% 63 
answered question 666 
skipped questícn 495 
Yes 
Not applicable· I donate in my 
awn time 
PAGE: 
12. Am you expected to make up the lime in your work for attending a blood donation session? 
Response Response 
Percent Count 
Yes - 309% 201 
No 69.1% 449 
answered question 650 
skipped question 511 
PAGE: 
, 3. 'Mlat actuat costs did you incur in order to allow you lO donale at your last donation session (Tick as many 
as relevant) ? 
Other (please specify) 
Show replie$ 
Response Response 
Percent Caunt 
0.3% 2 
3.2% 19 
- 13.4% 81 - 8.6% 52 
79.1% 477 
answered question 603 
skipped question 558 
Specific child care 
Lost pay 
Parking ticket 
Magazinel newspaper to amuse 
myself 
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